<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Europace</journal-id><journal-id journal-id-type="iso-abbrev">Europace</journal-id><journal-id journal-id-type="publisher-id">europace</journal-id><journal-title-group><journal-title>Europace</journal-title></journal-title-group><issn pub-type="ppub">1099-5129</issn><issn pub-type="epub">1532-2092</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35373836</article-id><article-id pub-id-type="pmc">PMC9435643</article-id><article-id pub-id-type="doi">10.1093/europace/euac030</article-id><article-id pub-id-type="publisher-id">euac030</article-id><article-categories><subj-group subj-group-type="heading"><subject>Position Paper</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00200</subject></subj-group></article-categories><title-group><article-title>European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases<sup><xref rid="euac030-FM4" ref-type="author-notes">&#x000a0;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Wilde</surname><given-names>Arthur A M</given-names></name><aff>
<institution>Heart Centre, Department of Cardiology, Amsterdam Universitair Medische Centra</institution>, <addr-line>Amsterdam, location AMC</addr-line>, <country country="NL">The Netherlands</country></aff><xref rid="euac030-cor1" ref-type="corresp"/><!--a.a.wilde@amsterdamumc.nl--><xref rid="euac030-FM1" ref-type="author-notes"/><xref rid="euac030-FM2" ref-type="author-notes"/><role>(EHRA Chair)</role></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Semsarian</surname><given-names>Christopher</given-names></name><aff>
<institution>Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, University of Sydney</institution>, <addr-line>Sydney</addr-line>, <country country="AU">Australia</country></aff><xref rid="euac030-cor1" ref-type="corresp"/><!--Christopher.semsarian@sydney.edu.au--><xref rid="euac030-FM3" ref-type="author-notes"/><role>(APHRS Co-Chair)</role></contrib><contrib contrib-type="author"><name><surname>M&#x000e1;rquez</surname><given-names>Manlio F</given-names></name><aff>
<institution>Instituto Nacional de Cardiolog&#x000ed;a Ignacio Ch&#x000e1;vez, Ciudad de M&#x000e9;xico</institution>, <country country="MX">Mexico</country></aff><aff>
<institution>Member of the Latin American Heart Rhythm Society (LAHRS)</institution>
</aff><xref rid="euac030-cor1" ref-type="corresp"/><!--manlio.marquez@gmail.com--><xref rid="euac030-FM1" ref-type="author-notes"/><role>(LAHRS Co-Chair)</role></contrib><contrib contrib-type="author"><name><surname>Shamloo</surname><given-names>Alireza Sepehri</given-names></name><aff>
<institution>Department of Electrophysiology, Heart Center at University of Leipzig</institution>, <addr-line>Leipzig</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Ackerman</surname><given-names>Michael J</given-names></name><aff>
<institution>Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology &#x00026; Experimental Therapeutics; Divisions of Heart Rhythm Services and Pediatric Cardiology; Windland Smith Rice Genetic Heart Rhythm Clinic and Windland Smith Rice Sudden Death Genomics Laboratory</institution>, <addr-line>Mayo Clinic, Rochester, MN</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name><surname>Ashley</surname><given-names>Euan A</given-names></name><aff>
<institution>Department of Cardiovascular Medicine, Stanford University</institution>, <addr-line>Stanford, California</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name><surname>Sternick</surname><given-names>Eduardo Back</given-names></name><aff>
<institution>Arrhythmia and Electrophysiology Unit, Biocor Institute</institution>, <addr-line>Minas Gerais</addr-line>, <country country="BR">Brazil</country>; and Member of the Latin American Heart Rhythm Society (LAHRS)</aff></contrib><contrib contrib-type="author"><name><surname>Barajas-Martinez</surname><given-names>H&#x000e9;ctor</given-names></name><aff>
<institution>Cardiovascular Research, Lankenau Institute of Medical Research</institution>, <addr-line>Wynnewood, PA</addr-line>, <country country="US">USA</country>; and Member of the Latin American Heart Rhythm Society (LAHRS)</aff></contrib><contrib contrib-type="author"><name><surname>Behr</surname><given-names>Elijah R</given-names></name><aff>
<institution>Cardiovascular Clinical Academic Group, Institute of Molecular and Clinical Sciences, St. George&#x02019;s, University of London; St. George&#x02019;s University Hospitals NHS Foundation Trust</institution>, <addr-line>London</addr-line>, <country country="GB">UK</country>; Mayo Clinic Healthcare, London</aff><xref rid="euac030-FM3" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name><surname>Bezzina</surname><given-names>Connie R</given-names></name><aff>
<institution>Amsterdam UMC Heart Center, Department of Experimental Cardiology</institution>, <addr-line>Amsterdam</addr-line>, <country country="NL">The Netherlands</country></aff><xref rid="euac030-FM2" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name><surname>Breckpot</surname><given-names>Jeroen</given-names></name><aff>
<institution>Center for Human Genetics, University Hospitals Leuven</institution>, <addr-line>Leuven</addr-line>, <country country="BE">Belgium</country></aff><xref rid="euac030-FM2" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name><surname>Charron</surname><given-names>Philippe</given-names></name><aff>
<institution>Sorbonne Universit&#x000e9;, APHP, Centre de R&#x000e9;f&#x000e9;rence des Maladies Cardiaques H&#x000e9;r&#x000e9;ditaires</institution>, <addr-line>ICAN, Inserm UMR1166, H&#x000f4;pital Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re, Paris</addr-line>, <country country="FR">France</country></aff><xref rid="euac030-FM2" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name><surname>Chockalingam</surname><given-names>Priya</given-names></name><aff>
<institution>Cardiac Wellness Institute</institution>, <addr-line>Chennai</addr-line>, <country country="IN">India</country></aff></contrib><contrib contrib-type="author"><name><surname>Crotti</surname><given-names>Lia</given-names></name><aff>
<institution>Center for Cardiac Arrhythmias of Genetic Origin</institution>, <addr-line>Istituto Auxologico Italiano, IRCCS, Milan</addr-line>, <country country="IT">Italy</country></aff><aff>
<institution>Cardiomyopathy Unit and Cardiac Rehabilitation Unit, San Luca Hospital, Istituto Auxologico Italiano, IRCCS</institution>, <addr-line>Milan</addr-line>, <country country="IT">Italy</country></aff><aff>
<institution>Department of Medicine and Surgery, University of Milano-Bicocca</institution>, <addr-line>Milan</addr-line>, <country country="IT">Italy</country></aff><xref rid="euac030-FM2" ref-type="author-notes"/><xref rid="euac030-FM3" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name><surname>Gollob</surname><given-names>Michael H</given-names></name><aff>
<institution>Inherited Arrhythmia and Cardiomyopathy Program, Division of Cardiology, University of Toronto</institution>, <addr-line>Toronto, ON</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Lubitz</surname><given-names>Steven</given-names></name><aff>
<institution>Cardiac Arrhythmia Service, Massachusetts General Hospital and Harvard Medical School</institution>, <addr-line>Boston, MA</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name><surname>Makita</surname><given-names>Naomasa</given-names></name><aff>
<institution>National Cerebral and Cardiovascular Center, Research Institute</institution>, <addr-line>Suita</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Ohno</surname><given-names>Seiko</given-names></name><aff>
<institution>Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center</institution>, <addr-line>Suita</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Ortiz-Genga</surname><given-names>Mart&#x000ed;n</given-names></name><aff>
<institution>Clinical Department</institution>, <addr-line>Health in Code, A Coru&#x000f1;a</addr-line>, <country country="ES">Spain</country>; and Member of the Latin American Heart Rhythm Society (LAHRS)</aff></contrib><contrib contrib-type="author"><name><surname>Sacilotto</surname><given-names>Luciana</given-names></name><aff>
<institution>Arrhythmia Unit, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo</institution>, <addr-line>Sao Paulo</addr-line>, <country country="BR">Brazil</country>; and Member of the Latin American Heart Rhythm Society (LAHRS)</aff></contrib><contrib contrib-type="author"><name><surname>Schulze-Bahr</surname><given-names>Eric</given-names></name><aff>
<institution>Institute for Genetics of Heart Diseases, University Hospital M&#x000fc;nster</institution>, <addr-line>M&#x000fc;nster</addr-line>, <country country="DE">Germany</country></aff><xref rid="euac030-FM2" ref-type="author-notes"/><xref rid="euac030-FM3" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name><surname>Shimizu</surname><given-names>Wataru</given-names></name><aff>
<institution>Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School</institution>, <addr-line>Bunkyo-ku, Tokyo</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Sotoodehnia</surname><given-names>Nona</given-names></name><aff>
<institution>Cardiovascular Health Research Unit, Division of Cardiology, Department of Medicine, University of Washington</institution>, <addr-line>Seattle, WA</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name><surname>Tadros</surname><given-names>Rafik</given-names></name><aff>
<institution>Cardiovascular Genetics Center, Department of Medicine, Montreal Heart Institute, Universit&#x000e9; de Montr&#x000e9;al</institution>, <addr-line>Montreal</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Ware</surname><given-names>James S</given-names></name><aff>
<institution>National Heart and Lung Institute and MRC London Institute of Medical Sciences, Imperial College London</institution>, <addr-line>London</addr-line>, <country country="GB">UK</country></aff><aff>
<institution>Royal Brompton &#x00026; Harefield Hospitals</institution>, <addr-line>Guy&#x02019;s and St. Thomas&#x02019; NHS Foundation Trust, London</addr-line>, <country country="GB">UK</country></aff></contrib><contrib contrib-type="author"><name><surname>Winlaw</surname><given-names>David S</given-names></name><aff>
<institution>Cincinnati Children's Hospital Medical Centre, University of Cincinnati</institution>, <addr-line>Cincinnati, OH</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kaufman</surname><given-names>Elizabeth S</given-names></name><aff>
<institution>Metrohealth Medical Center, Case Western Reserve University</institution>, <addr-line>Cleveland, OH</addr-line>, <country country="US">USA</country></aff><xref rid="euac030-cor1" ref-type="corresp"/><!--ekaufman@metrohealth.org--><xref rid="euac030-FM1" ref-type="author-notes"/><role>(HRS Co-Chair)</role></contrib></contrib-group><contrib-group><contrib contrib-type="author"><collab>Document Reviewers</collab></contrib><contrib contrib-type="author"><name><surname>Aiba</surname><given-names>Takeshi</given-names></name><aff>
<institution>Department of Clinical Laboratory Medicine and Genetics, National Cerebral and Cardiovascular Center</institution>, <addr-line>Suita, Osaka</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Bollmann</surname><given-names>Andreas</given-names></name><aff>
<institution>Department of Electrophysiology, Heart Center Leipzig at University of Leipzig</institution>, <addr-line>Leipzig</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>Leipzig Heart Institute</institution>, <addr-line>Leipzig Heart Digital, Leipzig</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Jong Il</given-names></name><aff>
<institution>Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine</institution>, <addr-line>Seoul</addr-line>, <country country="KR">Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Dalal</surname><given-names>Aarti</given-names></name><aff>
<institution>Department of Pediatrics, Division of Cardiology, Vanderbilt University School of Medicine</institution>, <addr-line>Nashville, TN</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name><surname>Darrieux</surname><given-names>Francisco</given-names></name><aff>
<institution>Arrhythmia Unit, Instituto do Cora&#x000e7;&#x000e3;o, Hospital das Cl&#x000ed;nicas HCFMUSP, Faculdade de Medicina, Universidade de S&#x000e3;o Paulo</institution>, <addr-line>S&#x000e3;o Paulo</addr-line>, <country country="BR">Brazil</country></aff></contrib><contrib contrib-type="author"><name><surname>Giudicessi</surname><given-names>John</given-names></name><aff>
<institution>Department of Cardiovascular Medicine (Divisions of Heart Rhythm Services and Circulatory Failure and the Windland Smith Rice Genetic Heart Rhythm Clinic)</institution>, <addr-line>Mayo Clinic, Rochester, MN</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name><surname>Guerchicoff</surname><given-names>Mariana</given-names></name><aff>
<institution>Division of Pediatric Arrhythmia and Electrophysiology, Italian Hospital of Buenos Aires</institution>, <addr-line>Buenos Aires</addr-line>, <country country="AR">Argentina</country></aff></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Kui</given-names></name><aff>
<institution>Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University</institution>, <addr-line>Nanchang</addr-line>, <country country="CN">China</country></aff></contrib><contrib contrib-type="author"><name><surname>Krahn</surname><given-names>Andrew D</given-names></name><aff>
<institution>Division of Cardiology, University of British Columbia</institution>, <addr-line>Vancouver</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>MacIntyre</surname><given-names>Ciorsti</given-names></name><aff>
<institution>Department of Cardiovascular Medicine, Division of Heart Rhythm Services</institution>, <addr-line>Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, MN</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name><surname>Mackall</surname><given-names>Judith A</given-names></name><aff>
<institution>Center for Cardiac Electrophysiology and Pacing, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine</institution>, <addr-line>Cleveland, OH</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name><surname>Mont</surname><given-names>Llu&#x000ed;s</given-names></name><aff>
<institution>Institut d&#x02019;Investigacions Biom&#x000e8;diques August Pi Sunyer (IDIBAPS)</institution>
<addr-line>Barcelona</addr-line>, <country country="ES">Spain</country></aff><aff>
<institution>Centro de Investigacion Biomedica en Red en Enfermedades Cardiovasculares (CIBERCV)</institution>, <addr-line>Madrid</addr-line>, <country country="ES">Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Napolitano</surname><given-names>Carlo</given-names></name><aff>
<institution>Molecular Cardiology, Istituti Clinici Scientifici Maugeri</institution>, <addr-line>IRCCS, Pavia</addr-line>, <country country="IT">Italy</country></aff><aff>
<institution>Department of Molecular Medicine, University of Pavia</institution>, <addr-line>Pavia</addr-line>, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Ochoa</surname><given-names>Juan Pablo</given-names></name><aff>
<institution>Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)</institution>, <addr-line>Madrid</addr-line>, <country country="ES">Spain</country></aff><aff>
<institution>Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro</institution>, <addr-line>Madrid</addr-line>, <country country="ES">Spain</country></aff><aff>
<institution>Centro de Investigacion Biomedica en Red en Enfermedades Cariovasculares (CIBERCV)</institution>, <addr-line>Madrid</addr-line>, <country country="ES">Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Peichl</surname><given-names>Petr</given-names></name><aff>
<institution>Department of Cardiology, Institute for Clinical and Experimental Medicine</institution>, <addr-line>Prague</addr-line>, <country country="CZ">Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Alexandre C</given-names></name><aff>
<institution>Laboratory of Genetics and Molecular Cardiology, Heart Institute, University of S&#x000e3;o Paulo Medical School</institution>, <addr-line>S&#x000e3;o Paulo 05403-000</addr-line>, <country country="BR">Brazil</country></aff><aff>
<institution>Hipercol Brasil Program</institution>, <addr-line>S&#x000e3;o Paulo</addr-line>, <country country="BR">Brazil</country></aff></contrib><contrib contrib-type="author"><name><surname>Schwartz</surname><given-names>Peter J</given-names></name><aff>
<institution>Center for Cardiac Arrhythmias of Genetic Origin</institution>, <addr-line>Istituto Auxologico Italiano, IRCCS, Milan</addr-line>, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Skinner</surname><given-names>Jon</given-names></name><aff>
<institution>Sydney Childrens Hospital Network, University of Sydney</institution>, <addr-line>Sydney</addr-line>, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Stellbrink</surname><given-names>Christoph</given-names></name><aff>
<institution>Department of Cardiology and Intensive Care Medicine, University Hospital Campus Klinikum Bielefeld</institution>, <addr-line>Bielefeld</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Tfelt-Hansen</surname><given-names>Jacob</given-names></name><aff>
<institution>The Department of Cardiology, the Heart Centre, Copenhagen University Hospital</institution>, <addr-line>Rigshopitalet, Copenhagen</addr-line>, <country country="DK">Denmark</country></aff><aff>
<institution>Section of genetics, Department of Forensic Medicine, Faculty of Medical Sciences, University of Copenhagen</institution>, <country country="DK">Denmark</country></aff></contrib><contrib contrib-type="author"><name><surname>Deneke</surname><given-names>Thomas</given-names></name><aff>
<institution>Heart Center Bad Neustadt</institution>, <addr-line>Bad Neustadt a.d. Saale</addr-line>, <country country="DE">Germany</country></aff><role>(Reviewer Coordinator)</role></contrib></contrib-group><contrib-group><contrib contrib-type="author"><collab>Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), a branch of the European Society of Cardiology (ESC), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).</collab></contrib></contrib-group><author-notes><corresp id="euac030-cor1">Corresponding authors. <italic toggle="yes">E-mail address</italic>: <email>a.a.wilde@amsterdamumc.nl</email> (A.W.); <italic toggle="yes">E-mail address</italic>: <email>Christopher.semsarian@sydney.edu.au</email> (C.S.); <italic toggle="yes">E-mail address</italic>: <email>manlio.marquez@gmail.com</email> (M.F.M.); <italic toggle="yes">E-mail address</italic>: <email>ekaufman@metrohealth.org</email> (E.K.)</corresp><fn id="euac030-FM1"><p>Arthur A. M. Wilde, Manlio F. M&#x000e1;rquez and Elizabeth S. Kaufman are co-shared first/last author and corresponding authors.</p></fn><fn id="euac030-FM2"><p>Member of the European Reference Network for rare, low prevalence and complex diseases of the heart: ERN GUARD-Heart.</p></fn><fn id="euac030-FM3"><p>Member of the European Cardiac Arrhythmia Genetics (ECGen) Focus Group of the European Heart Rhythm Association (EHRA).</p></fn><fn id="euac030-FM4" fn-type="COI-statement"><p>
<bold>Conflict of interest:</bold> none declared.</p></fn></author-notes><pub-date pub-type="collection"><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub" iso-8601-date="2022-04-04"><day>04</day><month>4</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>4</month><year>2022</year></pub-date><volume>24</volume><issue>8</issue><fpage>1307</fpage><lpage>1367</lpage><permissions><copyright-statement>The article has been co-published with permission in <italic toggle="yes">EP Europace, Journal of Arrhythmia</italic>, and <italic toggle="yes">Heart Rhythm</italic>. All rights reserved. &#x000a9; the European Society of Cardiology, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society, 2022. The articles are identical except for minor stylistic and spelling differences in keeping with each journal s style. Either citation can be used when citing this article.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="euac030.pdf"/><related-article related-article-type="companion" ext-link-type="doi" id="RA1" xlink:href="10.1093/europace/euac106"/><funding-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>FWO &#x02013; Flanders</institution></institution-wrap>
</funding-source></award-group></funding-group><counts><page-count count="61"/></counts></article-meta></front><body><sec><title>Table of Contents</title><p>
<bold>Introduction</bold>&#x02002;&#x02002;3</p><p>&#x02003;Purpose&#x02002;&#x02002;3</p><p>&#x02003;Organization of the writing committee&#x02002;&#x02002;3</p><p>&#x02003;Methodology and evidence review&#x02002;&#x02002;3</p><p>&#x02003;Document review and approval&#x02002;&#x02002;4</p><p>&#x02003;Scope of the document&#x02002;&#x02002;4</p><p>
<bold>Genetic influences on disease and modes of inheritance</bold>&#x02002;&#x02002;4</p><p>
<bold>Different methods of genetic testing</bold>&#x02002;&#x02002;8</p><p>&#x02003;Methods to interrogate genetic variation&#x02002;&#x02002;8</p><p>&#x02003;Genome-wide association study and polygenic risk scores&#x02002;&#x02002;9</p><p>
<bold>Choice of genetic tests and interpretation of variants</bold>&#x02002;&#x02002;12</p><p>&#x02003;Background&#x02002;&#x02002;13</p><p>
<bold>State of genetic testing for inherited arrhythmia syndromes</bold>&#x02002;&#x02002;14</p><p>&#x02003;Long QT syndrome&#x02002;&#x02002;14</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;15</p><p>&#x02003;&#x02003;Summary of the major long QT syndrome genes&#x02002;&#x02002;15</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications of long QT syndrome genetic testing&#x02002;&#x02002;16</p><p>&#x02003;&#x02003;Acquired long QT syndrome&#x02002;&#x02002;17</p><p>&#x02003;Catecholaminergic polymorphic ventricular tachycardia&#x02002;&#x02002;18</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;18</p><p>&#x02003;&#x02003;Diagnostic implications of catecholaminergic polymorphic ventricular tachycardia genetic testing&#x02002;&#x02002;18</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications of catecholaminergic polymorphic ventricular tachycardia genetic testing&#x02002;&#x02002;19</p><p>&#x02003;Brugada syndrome&#x02002;&#x02002;20</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;20</p><p>&#x02003;&#x02003;Diagnostic implications of Brugada syndrome genetic testing&#x02002;&#x02002;20</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications of Brugada syndrome genetic testing&#x02002;&#x02002;22</p><p>&#x02003;(Progressive) cardiac conduction disease&#x02002;&#x02002;22</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;22</p><p>&#x02003;&#x02003;Diagnostic implications of genetic testing in cardiac conduction disease/progressive cardiac conduction disease&#x02002;&#x02002;22</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications of genetic testing&#x02002;&#x02002;25</p><p>&#x02003;Short QT syndrome&#x02002;&#x02002;25</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;25</p><p>&#x02003;&#x02003;Diagnostic implications of short QT syndrome genetic testing&#x02002;&#x02002;25</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications of short QT syndrome genetic testing&#x02002;&#x02002;27</p><p>&#x02003;Atrial fibrillation&#x02002;&#x02002;27</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;27</p><p>&#x02003;&#x02003;Genetic forms of atrial fibrillation&#x02002;&#x02002;27</p><p>&#x02003;Sinus node disease&#x02002;&#x02002;28</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;29</p><p>&#x02003;&#x02003;Diagnostic implications of genetic testing in sinus node dysfunction&#x02002;&#x02002;29</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications of genetic testing&#x02002;&#x02002;30</p><p>&#x02003;Early repolarization syndrome&#x02002;&#x02002;31</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;31</p><p>&#x02003;Wolff&#x02013;Parkinson&#x02013;White syndrome&#x02002;&#x02002;31</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;31</p><p>&#x02003;&#x02003;Genetics of Wolff&#x02013;Parkinson&#x02013;White&#x02002;&#x02002;31</p><p>
<bold>State of genetic testing for cardiomyopathies</bold>&#x02002;&#x02002;32</p><p>&#x02003;Hypertrophic cardiomyopathy&#x02002;&#x02002;32</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;32</p><p>&#x02003;&#x02003;Diagnostic implications of genetic testing&#x02002;&#x02002;33</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications of genetic testing&#x02002;&#x02002;35</p><p>&#x02003;Dilated cardiomyopathy&#x02002;&#x02002;35</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;36</p><p>&#x02003;&#x02003;Diagnostic implications of dilated cardiomyopathy genetic testing&#x02002;&#x02002;36</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications of dilated cardiomyopathy genetic testing&#x02002;&#x02002;37</p><p>&#x02003;Arrhythmogenic cardiomyopathy&#x02002;&#x02002;37</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;38</p><p>&#x02003;&#x02003;Diagnostic implications of arrhythmogenic cardiomyopathy genetic testing&#x02002;&#x02002;38</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications of arrhythmogenic cardiomyopathy genetic testing&#x02002;&#x02002;39</p><p>&#x02003;Left ventricular non-compaction cardiomyopathy&#x02002;&#x02002;40</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;40</p><p>&#x02003;&#x02003;Diagnostic implications of left ventricular non-compaction genetic testing&#x02002;&#x02002;41</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications&#x02002;&#x02002;41</p><p>&#x02003;Restrictive cardiomyopathy&#x02002;&#x02002;41</p><p>&#x02003;&#x02003;Background&#x02002;&#x02002;42</p><p>&#x02003;&#x02003;Diagnostic implications of restrictive cardiomyopathy genetic testing&#x02002;42&#x02002;</p><p>&#x02003;&#x02003;Prognostic and therapeutic implications&#x02002;&#x02002;42</p><p>
<bold>State of genetic testing for sudden cardiac death or survivors of unexplained cardiac arrest</bold>&#x02002;&#x02002;42</p><p>&#x02003;Background&#x02002;&#x02002;43</p><p>
<bold>State of genetic testing for congenital heart disease</bold>&#x02002;&#x02002;44</p><p>&#x02003;Background&#x02002;&#x02002;45</p><p>&#x02003;Antenatal testing&#x02002;47&#x02002;</p><p>&#x02003;Antenatal screening&#x02002;47&#x02002;</p><p>&#x02003;Neonates and infants requiring investigation or procedures for congenital heart disease&#x02002;&#x02002;47</p><p>&#x02003;Patients with congenital heart disease and extracardiac anomalies&#x02002;&#x02002;47</p><p>&#x02003;Familial forms of congenital heart disease&#x02002;&#x02002;47</p><p>&#x02003;Sporadic non-syndromic congenital heart disease&#x02002;&#x02002;47</p><p>&#x02003;Heterotaxy&#x02002;&#x02002;47</p><p>
<bold>State of genetic testing for coronary artery disease and heart failure</bold>&#x02002;&#x02002;48</p><p>
<bold>Conclusion and future directions</bold>&#x02002;&#x02002;48</p></sec><sec><title>&#x02003;</title><p>
<bold>Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), a branch of the European Society of Cardiology (ESC), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).</bold>
</p></sec><sec sec-type="intro"><title>Introduction</title><sec><title>Purpose</title><p>Genetic testing has advanced significantly since the publication of the 2011 HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies.<sup><xref rid="euac030-B1" ref-type="bibr">1</xref></sup> In addition to single-gene testing, there is now the ability to perform whole-exome sequencing (WES) and whole-genome sequencing (WGS). There is growing appreciation of oligogenic disorders,<sup><xref rid="euac030-B2" ref-type="bibr">2</xref>,</sup><sup><xref rid="euac030-B3" ref-type="bibr">3</xref></sup> the role of modifier genes,<sup><xref rid="euac030-B2" ref-type="bibr">2</xref></sup> and the use of genetic testing for risk stratification, even in common cardiac diseases such as coronary artery disease or atrial fibrillation (AFib), including a proposal for a score awaiting validation.<sup><xref rid="euac030-B4" ref-type="bibr">4</xref></sup> This document reviews the state of genetic testing at the present time, and addresses the questions of what tests to perform and when to perform them. It should be noted that, as articulated in a 1999 Task Force Document by the European Society of Cardiology (ESC) on the legal value of medical guidelines,<sup><xref rid="euac030-B5" ref-type="bibr">5</xref></sup> &#x02018;The guidelines from an international organization, such as the ESC, have no specific legal territory and have no legally enforcing character. Nonetheless, in so far as they represent the state-of-the-art, they may be used as indicating deviation from evidence-based medicine in cases of questioned liability&#x02019;. In the case of potentially lethal and treatable conditions such as catecholaminergic polymorphic ventricular tachycardia (CPVT) or long QT syndrome (LQTS), it is the responsibility of the physician, preferably in conjunction with an expert genetics team, to communicate to the patient/family the critical importance of family screening, whether this be facilitated by cascade genetic testing or by broader clinical family screening.</p></sec><sec><title>Organization of the writing committee</title><p>The writing committee included chairs and representatives nominated and approved by European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS). Chairs and authors had no relevant relationship with industry (RWI). Details are available in <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>.</p></sec><sec><title>Methodology and evidence review</title><p>Writing committee members were assigned topics, compiled tables of recommendations supported by appropriate text and references, and attended periodic virtual meetings. Writing committee members without relevant RWI drafted recommendations. In the arena of genetic testing, there are few if any randomized trials to provide the strongest level of scientific evidence. Recommendations were associated with a green heart symbol (&#x02018;should do this&#x02019;) if supported by at least strong observational evidence and author consensus. A yellow heart (&#x02018;may do this&#x02019;) was used if there was some evidence and general agreement. A red heart (&#x02018;do not do this&#x02019;) indicated evidence or general agreement not to perform this testing (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T1" ref-type="table">1</xref></italic>). Writing committee consensus of 80% was required. The recommendations were approved by an average of 93% of the writing committee members.</p><table-wrap position="float" id="euac030-T1"><label>Table 1</label><caption><p>Scientific rationale of consensus statements<sup><xref rid="tblfn1" ref-type="table-fn">a</xref></sup></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Definitions related to a treatment or procedure</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Symbol</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Supported by strong observational evidence and authors&#x02019; consensus</td><td rowspan="1" colspan="1">&#x02018;Should do this&#x02019;</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">Some evidence and general agreement favour the usefulness/efficacy of a test</td><td rowspan="1" colspan="1">&#x02018;May do this&#x02019;</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td></tr><tr><td rowspan="1" colspan="1">There is evidence or general agreement not to recommend a test</td><td rowspan="1" colspan="1">&#x02018;Do not do this&#x02019;</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p>The categorization for our consensus document should not be considered directly similar to the one used for official society guideline recommendations which apply a classification (I&#x02013;III) and level of evidence (A, B, and C) to recommendations.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Document review and approval</title><p>After review by the writing committee, the recommendations were opened for public comment. The document was then reviewed by the scientific documents committees of EHRA, HRS, APHRS, and LAHRS. After revision, the document was sent to external reviewers nominated by the participating societies. After further revision, the document was endorsed by the collaborating societies and presented for publication.</p></sec><sec><title>Scope of the document</title><p>This document addresses essential principles of genetic testing including modes of inheritance, different testing methodologies, and interpretation of variants. Additionally, the document presents the state of genetic testing for inherited arrhythmia syndromes, cardiomyopathies, sudden cardiac death (SCD), congenital heart disease (CHD), coronary artery disease, and heart failure. A discussion of aortopathies and hyperlipidaemia is beyond the scope of this document. The authors discuss diagnostic, prognostic, and therapeutic implications of genetic testing in each of these syndromes, as far as these are known. The writing committee recognizes that the feasibility of genomic testing by gene panel testing or by WES or WGS depends on the availability of genomic technology and on regional reimbursement policy. Therefore, the recommendation &#x02018;should do this&#x02019; can be read as &#x02018;should do this when available&#x02019;.</p><p>
<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T2" ref-type="table">2</xref></italic> lists previous guidelines and consensus statements that are considered pertinent for this document as they all include relevant information for the diagnosis of patients with inherited cardiovascular conditions (ICCs) and the need for genetic testing. The terms and abbreviations used in consensus statement are summarized in <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T3" ref-type="table">3</xref></italic>.</p><table-wrap position="float" id="euac030-T2"><label>Table 2</label><caption><p>Relevant clinical practice documents or guidelines</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Title</th><th rowspan="1" colspan="1">Publication year</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Consensus documents/guidelines of scientific societies</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families<sup><xref rid="euac030-B6" ref-type="bibr">6</xref></sup></td><td rowspan="1" colspan="1">2021</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Catheter Ablation of Ventricular Arrhythmias<sup><xref rid="euac030-B7" ref-type="bibr">7</xref></sup></td><td rowspan="1" colspan="1">2020</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association<sup><xref rid="euac030-B8" ref-type="bibr">8</xref></sup></td><td rowspan="1" colspan="1">2020</td></tr><tr><td rowspan="1" colspan="1">&#x02003;European Recommendations Integrating Genetic Testing into Multidisciplinary Management of Sudden Cardiac Death<sup><xref rid="euac030-B9" ref-type="bibr">9</xref></sup></td><td rowspan="1" colspan="1">2019</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pre-participation Cardiovascular Evaluation for Athletic Participants to Prevent Sudden Death: Position Paper from the EHRA and the EACPR, Branches of the ESC<sup><xref rid="euac030-B22" ref-type="bibr">22</xref></sup></td><td rowspan="1" colspan="1">2019</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HRS Expert Consensus Statement on Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy<sup><xref rid="euac030-B11" ref-type="bibr">11</xref></sup></td><td rowspan="1" colspan="1">2019</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death<sup><xref rid="euac030-B12" ref-type="bibr">12</xref></sup></td><td rowspan="1" colspan="1">2017</td></tr><tr><td rowspan="1" colspan="1">&#x02003;ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death<sup><xref rid="euac030-B13" ref-type="bibr">13</xref></sup></td><td rowspan="1" colspan="1">2015</td></tr><tr><td rowspan="1" colspan="1">&#x02003;EHRA/HRS/APHRS Expert Consensus on Ventricular Arrhythmias<sup><xref rid="euac030-B14" ref-type="bibr">14</xref></sup></td><td rowspan="1" colspan="1">2014</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes<sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup></td><td rowspan="1" colspan="1">2013</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies<sup><xref rid="euac030-B1" ref-type="bibr">1</xref></sup></td><td rowspan="1" colspan="1">2011</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases<sup><xref rid="euac030-B16" ref-type="bibr">16</xref></sup></td><td rowspan="1" colspan="1">2010</td></tr><tr><td rowspan="1" colspan="1">
<bold>NIH-Clinical Genome Resource Consortium (ClinGen) documents</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;A Multi-Centred, Evidence-Based Evaluation of Gene Validity in Sudden Arrhythmic Death Syndromes: CPVT and The Short QT Syndrome<sup><xref rid="euac030-B17" ref-type="bibr">17</xref></sup></td><td rowspan="1" colspan="1">2022</td></tr><tr><td rowspan="1" colspan="1">&#x02003;International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework<sup><xref rid="euac030-B18" ref-type="bibr">18</xref></sup></td><td rowspan="1" colspan="1">2021</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Evidence-Based Assessment of Genes in Dilated Cardiomyopathy<sup><xref rid="euac030-B19" ref-type="bibr">19</xref></sup></td><td rowspan="1" colspan="1">2021</td></tr><tr><td rowspan="1" colspan="1">&#x02003;An International, Multicentred Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome<sup><xref rid="euac030-B20" ref-type="bibr">20</xref></sup></td><td rowspan="1" colspan="1">2020</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Reappraisal of Reported Genes for Sudden Arrhythmic Death: An Evidence-Based Evaluation of Gene Validity for Brugada Syndrome<sup><xref rid="euac030-B21" ref-type="bibr">21</xref></sup></td><td rowspan="1" colspan="1">2018</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes<sup><xref rid="euac030-B10" ref-type="bibr">10</xref></sup></td><td rowspan="1" colspan="1">2017</td></tr></tbody></table></table-wrap><table-wrap position="float" id="euac030-T3"><label>Table 3</label><caption><p>Definitions and abbreviations</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Term (abbreviation)</th><th align="left" rowspan="1" colspan="1">Definition</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sudden cardiac arrest (SCA)</td><td rowspan="1" colspan="1">Sudden cessation of cardiac activity with haemodynamic collapse, typically due to sustained ventricular arrhythmia</td></tr><tr><td rowspan="1" colspan="1">Sudden cardiac death (SCD)</td><td rowspan="1" colspan="1">Death that occurs within 1&#x02009;h of onset of symptoms in witnessed cases, and within 24&#x02009;h of last being seen alive when it is unwitnessed</td></tr><tr><td rowspan="1" colspan="1">Sudden unexplained death (syndrome) [SUD(S)]</td><td rowspan="1" colspan="1">Unexplained sudden death occurring in an individual older than 1&#x02009;year</td></tr><tr><td rowspan="1" colspan="1">Sudden unexplained death in infancy (SUDI)<sup><xref rid="tblfn2" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">Unexplained sudden death occurring in an individual younger than 1&#x02009;year with negative pathological and toxicological assessment</td></tr><tr><td rowspan="1" colspan="1">Sudden arrhythmic death (syndrome) [SAD(S)]<sup><xref rid="tblfn3" ref-type="table-fn">b</xref></sup></td><td rowspan="1" colspan="1">Unexplained sudden death occurring in an individual older than 1&#x02009;year with negative pathological and toxicological assessment</td></tr><tr><td rowspan="1" colspan="1">
<bold>Abbreviation</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">ASO</td><td rowspan="1" colspan="1">Allele-specific oligonucleotide</td></tr><tr><td rowspan="1" colspan="1">ACMG</td><td rowspan="1" colspan="1">American College of Medical Genetics &#x00026; Genomics</td></tr><tr><td rowspan="1" colspan="1">aCGH</td><td rowspan="1" colspan="1">Array comparative genomic hybridization</td></tr><tr><td rowspan="1" colspan="1">ACM</td><td rowspan="1" colspan="1">Arrhythmogenic cardiomyopathy</td></tr><tr><td rowspan="1" colspan="1">ALVC</td><td rowspan="1" colspan="1">Arrhythmogenic left ventricular cardiomyopathy</td></tr><tr><td rowspan="1" colspan="1">ARVC</td><td rowspan="1" colspan="1">Arrhythmogenic right ventricular cardiomyopathy</td></tr><tr><td rowspan="1" colspan="1">AFib</td><td rowspan="1" colspan="1">Atrial fibrillation</td></tr><tr><td rowspan="1" colspan="1">ASD</td><td rowspan="1" colspan="1">Atrial septal defect</td></tr><tr><td rowspan="1" colspan="1">ASS</td><td rowspan="1" colspan="1">Atrial stand still</td></tr><tr><td rowspan="1" colspan="1">AD</td><td rowspan="1" colspan="1">Autosomal dominant</td></tr><tr><td rowspan="1" colspan="1">AR</td><td rowspan="1" colspan="1">Autosomal recessive</td></tr><tr><td rowspan="1" colspan="1">BrS</td><td rowspan="1" colspan="1">Brugada syndrome</td></tr><tr><td rowspan="1" colspan="1">CRDS</td><td rowspan="1" colspan="1">Calcium release deficiency syndrome</td></tr><tr><td rowspan="1" colspan="1">CCD</td><td rowspan="1" colspan="1">Cardiac conduction disease</td></tr><tr><td rowspan="1" colspan="1">RyR2</td><td rowspan="1" colspan="1">Cardiac ryanodine receptor</td></tr><tr><td rowspan="1" colspan="1">CMR</td><td rowspan="1" colspan="1">Cardiovascular magnetic resonance</td></tr><tr><td rowspan="1" colspan="1">CPVT</td><td rowspan="1" colspan="1">Catecholaminergic polymorphic ventricular tachycardia</td></tr><tr><td rowspan="1" colspan="1">CVS</td><td rowspan="1" colspan="1">Chorionic villous sample</td></tr><tr><td rowspan="1" colspan="1">CMA</td><td rowspan="1" colspan="1">Chromosomal microarray</td></tr><tr><td rowspan="1" colspan="1">CHD</td><td rowspan="1" colspan="1">Congenital heart disease</td></tr><tr><td rowspan="1" colspan="1">CNV</td><td rowspan="1" colspan="1">Copy number variant</td></tr><tr><td rowspan="1" colspan="1">DCM</td><td rowspan="1" colspan="1">Dilated cardiomyopathy</td></tr><tr><td rowspan="1" colspan="1">ERP</td><td rowspan="1" colspan="1">Early repolarization pattern</td></tr><tr><td rowspan="1" colspan="1">ECA</td><td rowspan="1" colspan="1">Extracardiac anomaly</td></tr><tr><td rowspan="1" colspan="1">GWAS</td><td rowspan="1" colspan="1">Genome-wide association studies</td></tr><tr><td rowspan="1" colspan="1">GRS</td><td rowspan="1" colspan="1">Genomic risk scores</td></tr><tr><td rowspan="1" colspan="1">HCM</td><td rowspan="1" colspan="1">Hypertrophic cardio-myopathy</td></tr><tr><td rowspan="1" colspan="1">IVF</td><td rowspan="1" colspan="1">Idiopathic ventricular fibrillation</td></tr><tr><td rowspan="1" colspan="1">ICD</td><td rowspan="1" colspan="1">Implantable cardioverter-defibrillator</td></tr><tr><td rowspan="1" colspan="1">ICC</td><td rowspan="1" colspan="1">Inherited cardiovascular conditions</td></tr><tr><td rowspan="1" colspan="1">JLNS</td><td rowspan="1" colspan="1">Jervell and Lange-Nielsen Syndrome</td></tr><tr><td rowspan="1" colspan="1">LCSD</td><td rowspan="1" colspan="1">Left cardiac sympathetic denervation</td></tr><tr><td rowspan="1" colspan="1">LV</td><td rowspan="1" colspan="1">Left ventricular</td></tr><tr><td rowspan="1" colspan="1">LVH</td><td rowspan="1" colspan="1">Left ventricular hypertrophy</td></tr><tr><td rowspan="1" colspan="1">LVNC</td><td rowspan="1" colspan="1">Left ventricular non-compaction cardiomyopathy</td></tr><tr><td rowspan="1" colspan="1">LB</td><td rowspan="1" colspan="1">Likely Benign</td></tr><tr><td rowspan="1" colspan="1">LP/P</td><td rowspan="1" colspan="1">Likely pathogenic/pathogenic</td></tr><tr><td rowspan="1" colspan="1">LQTS</td><td rowspan="1" colspan="1">Long QT syndrome</td></tr><tr><td rowspan="1" colspan="1">MAF</td><td rowspan="1" colspan="1">Minor allele frequency</td></tr><tr><td rowspan="1" colspan="1">MLPA</td><td rowspan="1" colspan="1">Multiplex ligation-dependent probe amplification</td></tr><tr><td rowspan="1" colspan="1">NGS</td><td rowspan="1" colspan="1">Next-generation sequencing</td></tr><tr><td rowspan="1" colspan="1">PRS</td><td rowspan="1" colspan="1">Polygenic risk scores</td></tr><tr><td rowspan="1" colspan="1">PCR</td><td rowspan="1" colspan="1">Polymerase chain reaction</td></tr><tr><td rowspan="1" colspan="1">PNP</td><td rowspan="1" colspan="1">Polyneuropathy</td></tr><tr><td rowspan="1" colspan="1">PCCD</td><td rowspan="1" colspan="1">Progressive cardiac conduction disease</td></tr><tr><td rowspan="1" colspan="1">RCM</td><td rowspan="1" colspan="1">Restrictive cardiomyopathy</td></tr><tr><td rowspan="1" colspan="1">siRNA</td><td rowspan="1" colspan="1">Short interfering RNA</td></tr><tr><td rowspan="1" colspan="1">SQTS</td><td rowspan="1" colspan="1">Short QT syndrome</td></tr><tr><td rowspan="1" colspan="1">SNP</td><td rowspan="1" colspan="1">Single-nucleotide polymorphism</td></tr><tr><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">Single-nucleotide variant</td></tr><tr><td rowspan="1" colspan="1">SND</td><td rowspan="1" colspan="1">Sinus node dysfunction</td></tr><tr><td rowspan="1" colspan="1">SCA</td><td rowspan="1" colspan="1">Sudden cardiac arrest</td></tr><tr><td rowspan="1" colspan="1">SCD</td><td rowspan="1" colspan="1">Sudden cardiac death</td></tr><tr><td rowspan="1" colspan="1">TOF</td><td rowspan="1" colspan="1">Tetralogy of Fallot</td></tr><tr><td rowspan="1" colspan="1">TdP</td><td rowspan="1" colspan="1">Torsades de pointes</td></tr><tr><td rowspan="1" colspan="1">TKOS</td><td rowspan="1" colspan="1">Triadin knockout syndrome</td></tr><tr><td rowspan="1" colspan="1">UCA</td><td rowspan="1" colspan="1">Unexplained cardiac arrest</td></tr><tr><td rowspan="1" colspan="1">UTRs</td><td rowspan="1" colspan="1">Untranslated regions</td></tr><tr><td rowspan="1" colspan="1">VUS</td><td rowspan="1" colspan="1">Variants of uncertain clinical significance</td></tr><tr><td rowspan="1" colspan="1">VF</td><td rowspan="1" colspan="1">Ventricular fibrillation</td></tr><tr><td rowspan="1" colspan="1">VSD</td><td rowspan="1" colspan="1">ventricular septal defect</td></tr><tr><td rowspan="1" colspan="1">WES</td><td rowspan="1" colspan="1">Whole-exome sequencing</td></tr><tr><td rowspan="1" colspan="1">WGS</td><td rowspan="1" colspan="1">Whole-genome sequencing</td></tr><tr><td rowspan="1" colspan="1">WPW</td><td rowspan="1" colspan="1">Wolff&#x02013;Parkinson&#x02013;White syndrome</td></tr><tr><td rowspan="1" colspan="1">X-chr</td><td rowspan="1" colspan="1">X-chromosomal</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><label>a</label><p>Synonymous with &#x02018;sudden unexplained infant death&#x02019; (SUID).</p></fn><fn id="tblfn3"><label>b</label><p>Synonymous with &#x02018;autopsy-negative sudden unexplained death&#x02019;.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>Genetic influences on disease and modes of inheritance</title><p>Research conducted, over the last three decades, has provided considerable insights into the modes of inheritance of cardiovascular disorders and into the underlying genes and pathways. These insights were fuelled by developments in technologies for DNA sequencing and genotyping, statistical genetic approaches, and our increased understanding of the wide spectrum of genetic variation in the general population. Two broad categories of cardiovascular disorders are recognized: Mendelian disorders that are caused by the inheritance of one or two genetic variants and that typically cluster in families, and disorders with complex inheritance, wherein multiple genetic variants contribute and for which familial clustering is less pronounced. In both categories non-genetic factors also contribute to the ultimate phenotypic expression.</p><p>Inheritance patterns for monogenic disorders include autosomal dominant (AD), autosomal recessive (AR), and sex-linked. In AD disorders, the inheritance of a single defective copy of a gene, either the maternal or the paternal copy, is sufficient to cause the disorder. In some cases, an AD condition may result from a <italic toggle="yes">de novo</italic> variant in the gene and occurs in individuals with no history of the disorder in their family. In AR disorders, both the maternal and paternal copies need to be defective to produce the disorder. X-linked disorders are caused by pathogenic variants in genes on the X chromosome. Two types of X-linked disorders are recognized, X-linked dominant and X-linked recessive. In females with an X-linked dominant condition, a pathogenic variant in one of the two copies of the gene is sufficient to cause the condition. In males, who have only one X chromosome, a pathogenic variant in the only copy of the gene causes the disorder. In X-linked recessive inheritance, in males, one defective copy of the gene is sufficient to cause the condition, whereas females are mildy affected or unaffected if only one copy of the gene is aberrant. A characteristic of both types of X-linked inheritance is that males cannot pass on the disorder to their sons. Besides Mendelian inheritance, single-gene disorders may exhibit mitochondrial inheritance. Because mitochondrial DNA is inherited from the mother, only females can pass on genetic defects residing on mitochondrial DNA. In rare cases, disease-causing variants may arise post-zygotically (during development), leading to mosaicism (the occurrence of genetically distinct cell populations). Mosaicism may be limited to somatic cells, where there would be no risk of passing the disease-variant to the offspring, or it may also affect the germ line cell population and in this way the disease variant may be passed to the offspring.</p><p>Disease-associated genetic variants likely lie on a spectrum of population frequency and phenotype effect size. Mendelian variants, when dominant, are usually characterized by an ultra-low minor allele frequency (MAF, typically &#x0003c;0.01%) in the population and have large effect sizes (<italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F1" ref-type="fig">1</xref></italic>). Classically, genes underlying Mendelian disorders were identified by linkage studies that tracked chromosomal regions that are co-inherited with the condition in multiple affected individuals in families, followed by Sanger sequencing of the linked chromosomal interval. More recently, next-generation sequencing (NGS) and WES have been successful in identifying novel genes underlying Mendelian disorders. It is estimated that there are about 7000 single-gene inherited disorders of which causative genes have been discovered for over 4000.<sup><xref rid="euac030-B23" ref-type="bibr">23</xref></sup> Accordingly, many genes for hereditary cardiomyopathies, including dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and arrhythmogenic cardiomyopathy (ACM); hereditary arrhythmias, such as LQTSs, Brugada syndrome (BrS), short QT syndromes (SQTSs), and CPVT; and cardiac conduction defects have been identified.<sup><xref rid="euac030-B24" ref-type="bibr">24</xref></sup></p><fig position="float" id="euac030-F1"><label>Figure 1</label><caption><p>The genetic aetiology of cardiovascular diseases. Mendelian disease variants (upper left panel) are ultra-rare in the population and have large effect sizes, though often not sufficient in isolation to yield a disease phenotype. Mendelian genes and variants can be identified through analysis of family pedigrees or burden analysis in case&#x02013;control studies and further validated with functional assays. Common variants (upper right panel) with individually small effect sizes may collectively contribute to disease burden or modulate the effects of Mendelian variants. Intermediate effect variants (upper middle panel) are emerging variant classes that usually have population frequencies and effect sizes between rare Mendelian and common variants and may act to increase severity and penetrance. Such variants can be identified by demonstrating enrichment in case cohorts and deleterious effects in established functional assays. These different variant classes can combine to reach the threshold of disease in patients with rare cardiovascular diseases and contribute to the variable severity observed in patients. Diseases such as HCM and LQTS are often Mendelian [1] or near-Mendelian where Mendelian variants of large effect sizes can combine with other variant classes to cause disease [2] or act as protective modifiers (e.g. regulatory variants affecting the expression ratio of the mutant vs. non-mutant alleles) [3]. In contrast, diseases such as BrS and DCM may exhibit a more complex aetiology where substantial non-Mendelian genetic and non-genetic factors are required to reach disease threshold in the presence of a low penetrance rare variant [4] or in a non-Mendelian disease model [5]. blue &#x02212;, individual does not harbour the familial rare pathogenic variant; blue +, individual harbours the familial rare pathogenic variant; green &#x02212;, individual does not harbour that intermediate effect variant; green +, individual harbours a given intermediate effect variant; GWAS, genome-wide association study; MAF, minor allele frequency; PRS, polygenic risk score; SNP, single-nucleotide polymorphism. Adapted from Walsh <italic toggle="yes">et al</italic>.<sup><xref rid="euac030-B3" ref-type="bibr">3</xref></sup></p></caption><graphic xlink:href="euac030f1" position="float"/></fig><p>In Mendelian cardiovascular disorders with potentially devastating initial manifestations, such as SCD or aortic dissection, appropriate and prompt identification of individuals at risk is imperative.<sup><xref rid="euac030-B25" ref-type="bibr">25</xref></sup> Genetic testing has been recommended for a number of inherited cardiac conditions for several years and has become a standard aspect of clinical management in affected families. The primary benefit of genetic testing is to identify at-risk carriers of the familial pathogenic variant (and non-carriers who are unlikely to develop disease) through cascade screening, assuming a genetic variant is identified that can be predicted with confidence to cause the disease. Such clinical genetic testing for these single-gene disorders has been shown to be cost-effective<sup><xref rid="euac030-B26" ref-type="bibr">26</xref></sup> and can be considered as a success story in the application of genetics into clinical practice.</p><p>Although pathogenic Mendelian genetic variants are characterized by a large effect size, they may not in isolation be sufficient to yield a disease phenotype. This is evidenced by incomplete disease penetrance where only a proportion of individuals in the same family carrying a particular genetic variant shows the disease. Another feature that characterizes Mendelian disorders is the phenomenon of variable expressivity, where different disease severity is observed among individuals carrying the same underlying genetic predisposition. What this means is that, even within pedigrees sharing the same pathogenic variant, the clinical presentation can vary from a patient having no clinical manifestation of the disease to another having severe disease. A clearly pathogenic variant can, therefore, have high diagnostic value, but low prognostic utility.<sup><xref rid="euac030-B27" ref-type="bibr">27</xref></sup> Besides non-genetic (such as environmental) factors, penetrance and expressivity of Mendelian genetic defects are influenced by the co-inheritance of other genetic factors alongside the Mendelian genetic defect, that act to exacerbate or attenuate the effect of the latter on the phenotype (often referred to as &#x02018;genetic modifiers&#x02019;, <italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F1" ref-type="fig">1</xref></italic>).</p><p>Contrary to Mendelian disorders, where a single large-effect variant primarily determines susceptibility to the disorder, susceptibility to disorders with complex inheritance rests on the co-inheritance of multiple variants. Such variants are identified by means of genome-wide association studies (GWAS) that compare the prevalence of millions of genetic variants genome-wide between affected individuals and controls. Non-Mendelian genetic risk variants that contribute to cardiovascular disease risk and that are detectable with current approaches and study sample sizes can be broadly grouped into two categories. These comprise common variants, typically defined as having a MAF of &#x0003e;1&#x02013;5%, which have individually small effect sizes, and intermediate effect variants (MAF &#x0003c;1&#x02013;2%) with effect sizes and frequencies between common and Mendelian variants (<italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F1" ref-type="fig">1</xref></italic>).</p><p>It is likely that a continuum of genetic complexity exists where at one end of the spectrum are Mendelian disorders determined primarily by the inheritance of an ultra-rare large-effect genetic defect, and at the other end are highly polygenic disorders determined by many genetic variants with additive effect (<italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F1" ref-type="fig">1</xref></italic>). While some disorders present primarily with one form of inheritance, different inheritance patterns may exist for the same disorder.<sup><xref rid="euac030-B28" ref-type="bibr">28</xref></sup> Emerging data suggest that common variants of small effect and intermediate effect variants may, to varying extents, influence penetrance in individuals with Mendelian genetic defects by pushing the genetic burden towards the threshold of disease, as well as influence severity of disease.<sup><xref rid="euac030-B29" ref-type="bibr">29</xref>,</sup><sup><xref rid="euac030-B30" ref-type="bibr">30</xref></sup> While their incorporation into genetic testing approaches is expected to increase the sensitivity of genetic testing, the identification of such modulatory variants is still a matter of intense research and therefore currently not clinically applicable.</p></sec><sec><title>Different methods of genetic testing</title><sec><title>Methods to interrogate genetic variation</title><p>Genomic technology has enabled efficient and comprehensive assessment of genetic variation within individuals. We each carry millions of variants in our genome, ranging in size from substitutions of a single-nucleotide (single-nucleotide variant; SNV, sometimes termed SNP) to deletions or duplications of an entire chromosome. Smaller variants, such as SNVs, are more prevalent in our genomes. We each carry about 100 SNVs that have arisen <italic toggle="yes">de novo</italic> during our development and are private to us,<sup><xref rid="euac030-B31" ref-type="bibr">31</xref></sup> and thousands of other rare SNVs.<sup><xref rid="euac030-B32" ref-type="bibr">32</xref></sup> The largest structural variants are much less prevalent, for example aneuploidy (the presence of an abnormal number of chromosomes in a cell), affects about 1 in 300 live births.<sup><xref rid="euac030-B33" ref-type="bibr">33</xref></sup> Though <italic toggle="yes">individually</italic> smaller variants are less likely to cause disease than larger changes that are more likely to disrupt genome function, <italic toggle="yes">collectively</italic> they probably account for the majority of phenotypic variability and inherited disease.<sup><xref rid="euac030-B34" ref-type="bibr">34</xref>,</sup><sup><xref rid="euac030-B35" ref-type="bibr">35</xref></sup></p><p>The largest genetic variants were the first to be detectable and associated with disease, with an extra copy of chromosome 21 detectable by microscopy, and recognized as causing Down&#x02019;s syndrome in 1959.<sup><xref rid="euac030-B36" ref-type="bibr">36</xref></sup> In 1977, <italic toggle="yes">Sanger sequencing</italic> was developed as a method for directly reading the sequence of DNA,<sup><xref rid="euac030-B37" ref-type="bibr">37</xref></sup> with the resolution to discover SNVs. It was the most widely used DNA sequencing technology for more than 30&#x02009;years, underpinning the human genome project (1990&#x02013;2003),<sup><xref rid="euac030-B38" ref-type="bibr">38</xref></sup> and remains an important tool today as it is fast, flexible, and remains the gold-standard for accuracy. However, it is prohibitively costly and laborious for large scale genomics, or diagnostics of ICCs at scale. The human genome, for example, is made up of &#x0223c;3 billion base pairs, with about 20&#x000a0;000 distinct protein-coding genes. One sequencing reaction reads out up to &#x0223c;1000 base pairs of sequence (equivalent to 1000 base pairs), so that typically one reaction is required per exon of a gene. Large genes require many reactions (e.g. <italic toggle="yes">RYR2</italic> has 105 exons, <italic toggle="yes">TTN</italic> has 364 exons). Furthermore, ICCs are genetically heterogeneous, so that it is often necessary to sequence many genes in an individual patient.</p><p>A &#x02018;next generation&#x02019; of sequencing technologies became available in the early 2000s that used diverse strategies to make the sequencing process massively parallel, and therefore vastly more scalable.<sup><xref rid="euac030-B39" ref-type="bibr">39</xref>,</sup><sup><xref rid="euac030-B40" ref-type="bibr">40</xref></sup> Several <italic toggle="yes">high-throughput sequencing</italic> technologies are now available, each with different strengths and weaknesses (e.g. emphasizing cost, speed, accuracy or read-length), and high-throughput sequencing now is the mainstay for first-line sequencing in most diagnostic contexts.</p><p>High-throughput sequencing allows WGS, or with additional sample preparation, restriction to specific genomic regions of interest: <italic toggle="yes">targeted sequencing</italic>. The choice of target represents a trade-off of cost vs. completeness of genetic characterization. The region of interest may be restricted by gene, and/or by functional annotation (e.g. coding sequence, promotor region, cis-regulatory element, intron, etc.). Since protein-coding regions represent about 1% of the genome, but harbour &#x0223c;85% of disease-causing variants,<sup><xref rid="euac030-B41" ref-type="bibr">41</xref></sup> targeted sequencing often prioritises these regions. Typical approaches are to sequence the protein-coding regions of all &#x0223c;20&#x000a0;000 annotated genes (<italic toggle="yes">WES</italic>),<sup><xref rid="euac030-B42" ref-type="bibr">42</xref></sup> or a pre-specified set of genes of interest, such as genes related to a particular clinical condition (a &#x02018;gene panel&#x02019;; usually exons only). Data can also be generated for a large panel of genes, or indeed all genes, but with downstream <italic toggle="yes">in silico</italic> analysis restricted to a more focused subset&#x02014;sometimes described as a &#x02018;virtual panel&#x02019;. In practice there is usually also a trade-off between depth and breadth of sequencing, with broader targets (e.g. WES) leading to reduced sequencing depth and reduced sensitivity in some areas. That is for a given amount of sequencing, as the number of genes sequenced increases, the amount of data from each gene decreases. We can focus sequencing on a narrow region for maximum accuracy, or can spread across a larger region, accepting that sensitivity will decrease if sequencing is spread too thinly. Currently, more targeted sequencing often provides more complete data for the selected region. <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T4" ref-type="table">4</xref></italic> summarizes the strengths and limitations of the various genetic testing methods.</p><table-wrap position="float" id="euac030-T4"><label>Table 4</label><caption><p>Different methods of genetic testing</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Technology</th><th align="left" rowspan="1" colspan="1">Strengths</th><th align="left" rowspan="1" colspan="1">Limitations</th><th align="left" rowspan="1" colspan="1">Example diagnostic application</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">
<bold>Sequencing approaches</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<bold>Sanger sequencing</bold></td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Accuracy</p></list-item><list-item><p>Low cost per reaction</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Not scalable</p></list-item><list-item><p>Insensitive to large SVs</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Single gene test</p></list-item><list-item><p>Single variant testing&#x02014;for a pre-specified variant during cascade family evaluation</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<bold>Panel sequencing</bold></td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Balances reasonably comprehensive coverage (e.g. all genes associated with a particular phenotype) against cost</p></list-item><list-item><p>Often highly optimized for complete and uniform capture of region of interest</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Usually exonic only</p></list-item><list-item><p>Needs updating as knowledge changes (e.g. new gene-disease associations discovered)</p></list-item></list>
</td><td rowspan="1" colspan="1">First line diagnostic test for proband</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<bold>WES</bold></td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Comprehensive coverage of all genes</p></list-item><list-item><p>Off-the-shelf design</p></list-item><list-item><p>Can run a single wet-lab workflow, and introduce specificity at analysis stage</p></list-item><list-item><p>Can update analysis to incorporate new knowledge without regenerating data&#x02014;adaptable</p></list-item><list-item><p>Enables analyses for secondary findings</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Larger target requires more sequencing (c.f. panels)</p></list-item><list-item><p>May be less optimized than more focused panel</p></list-item><list-item><p>More costly and complex to store and process data (c. 10&#x02013;100&#x000d7; more data than panel)</p></list-item><list-item><p>Will not detect non-coding variants</p></list-item><list-item><p>May not detect all variant classes</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Diagnosis in proband for very heterogeneous conditions (e.g paediatric and syndromic cardiomyopathies)</p></list-item><list-item><p>Second line test if panel negative in specific circumstances, for example with informative family structure</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<bold>WGS</bold></td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Comprehensive genetic characterization&#x02014;all genes, all elements, all variant types</p></list-item><list-item><p>Will also detect common variants for PRS, pharmacogenetics and other applications</p></list-item><list-item><p>Enables analyses for secondary findings</p></list-item></list>
</td><td rowspan="1" colspan="1">More costly and complex to store and process data (&#x0223c;100&#x000d7; more data than WES)</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Diagnosis in proband for very heterogeneous conditions</p></list-item><list-item><p>Second line test if panel negative</p></list-item><list-item><p>Definitive and future-proof genetic characterization if funds permit&#x02014;e.g. hold data in medical record for iterative targeted interpretation according to clinical needs</p></list-item></list>
</td></tr><tr><td colspan="4" rowspan="1">
<bold>Non-sequencing approaches</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<bold>Allele-specific PCR</bold></td><td rowspan="1" colspan="1">Quick, cheap, accurate</td><td rowspan="1" colspan="1">Pre-specified variants only</td><td rowspan="1" colspan="1">Testing a single variant in a large family (more likely Sanger sequencing now)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<bold>Array comparative genomic hybridization</bold></td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Cheap screening for SVs/CNVs</p></list-item><list-item><p>High-resolution (compared with cytogenetic approaches)</p></list-item></list>
</td><td rowspan="1" colspan="1">Insensitive to other variant classes</td><td rowspan="1" colspan="1">Screening for structural variants, including aneuploidy, e.g. in structural congenital heart disease</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<bold>Droplet digital PCR</bold></td><td rowspan="1" colspan="1">Low cost, high-sensitivity, detection of genome dose for SV/CNV detection at a pre-specified locus</td><td rowspan="1" colspan="1">Scalability limited by multiplexing of pre-specified PCR amplicons targeting regions of interest</td><td rowspan="1" colspan="1">Confirmation of putative CNVs detected in high-throughput sequence data</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<bold>DNA SNP arrays</bold></td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Genome wide</p></list-item><list-item><p>Relatively cheap</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Pre-specified variants only</p></list-item><list-item><p>Accuracy poor for many rarer variants</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Recreational ancestry analysis</p></list-item><list-item><p>Polygenic risk</p></list-item><list-item><p>Pharmacogenetics</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p>CNV, copy number variant; PCR, polymerase chain reaction; PRS, polygenic risk score; SNP, single-nucleotide polymorphism; SV, structural variant; WES, whole-exome sequencing; WGS, whole-genome sequencing.</p></fn></table-wrap-foot></table-wrap><p>While exon sequencing typically also targets sufficient immediately adjacent sequence to detect non-coding variants disrupting known splice sites, it will not detect variants that create new splice sites at a distance from the usual coding sequence, and usually omits 5&#x02032;- and 3&#x02032;-untranslated regions and other regulatory elements which can harbour important disease-associated variants.<sup><xref rid="euac030-B43" ref-type="bibr">43</xref>,</sup><sup><xref rid="euac030-B44" ref-type="bibr">44</xref></sup></p><p>Sequencing methods also differ in their sensitivity for different variant types. All methods are able to detect the small variants that account for the majority of the burden of ICCs (SNVs, small insertions and deletions). Larger and more complex variants, such as deletion of a whole exon, or a complex genomic rearrangement, are often harder to detect, especially if sequencing does not cover the boundary of the variant (the breakpoint). They may nonetheless be detectable in high-throughput sequence data through a change in the number of DNA reads coming from a particular region, or through a change in allele balance (loss of heterozygosity). Whole-genome sequencing offers the most comprehensive sensitivity across all variant classes, but development in computational tools continues to improve detection of structural and copy number variants (CNVs) from WES and panel sequencing.<sup><xref rid="euac030-B45" ref-type="bibr">45</xref>,</sup><sup><xref rid="euac030-B46" ref-type="bibr">46</xref></sup> However, alternative non-sequencing quantification approaches such as multiplex ligation-dependent probe amplification (MLPA) or array comparative genomic hybridization may be more sensitive as discussed below.</p><p>All sequencing approaches directly read out the DNA sequence(s) present in a sample, allowing analysis of any variation present, and can be used for both <italic toggle="yes">discovery</italic> and <italic toggle="yes">detection</italic> of variants. There are some notable additional technologies that can determine the presence or absence of a pre-specified variant, i.e. <italic toggle="yes">detection only</italic>, that have important clinical applications.</p><p>Polymerase chain reaction (PCR) methods can be used for variant detection. <italic toggle="yes">Allele-specific PCR</italic> is cheap and scalable for the detection of a specific variant and quantification of alleles in a sample, but must first be optimized for each variant to be studied. <italic toggle="yes">Digital PCR</italic> (including droplet digital PCR) allows precise quantification of the number of copies of a target DNA sequence relative to a single-copy reference locus.<sup><xref rid="euac030-B47" ref-type="bibr">47</xref></sup> It is cheap and sensitive to small differences in dose and is an important approach to confirm the presence of potential new CNVs identified by sequencing.</p><p>Other important methods are based on competitive hybridization of DNA to oligonucleotide probes with a known sequence. <italic toggle="yes">DNA single-nucleotide polymorphism (SNP) arrays</italic> can detect millions of variants in parallel, but each variant must be pre-specified and the hybridization optimized, and not all variants can be assayed accurately. These have minimal utility for identification of rare variants for Mendelian diagnosis but are widely used where common variants are important, for example in GWAS, calculating polygenic risk scores as detailed below, and in pharmacogenetics.<sup><xref rid="euac030-B48" ref-type="bibr">48</xref></sup><italic toggle="yes">Array comparative genomic hybridization</italic> (aCGH) is another genome-wide hybridization-based approach used to detect copy-number changes, of particular importance in congenital structural heart disease and individuals with syndromic ICCs. MLPA combines PCR and hybridization methods to quantify specific nucleic acid sequences quickly and efficiently, and may be used to detect many variant types, but particularly copy number changes.<sup><xref rid="euac030-B46" ref-type="bibr">46</xref></sup></p><p>These diverse and complementary methods can then be deployed for different types of clinical genetic testing. <italic toggle="yes">Confirmatory testing</italic> refers to genetic analysis of an individual with a diagnostic clinical phenotype to identify the underlying genetic cause. In a proband (the first presenting person in a family), there is no pre-specified variant to search for, so a direct sequencing approach is used to discover any genetic variation in the genes associated with that condition. For many ICCs, the first line test will be a high-throughput sequencing gene panel relevant to a specific disease, or a virtual panel using WES with targeted analysis. If this analysis does not identify an underlying cause, then more comprehensive genetic characterization, such as WES or WGS, may be used to interrogate additional genes, look for variant types not examined by the first line test, or assess for non-coding variants. This kind of comprehensive testing is appropriate only in experienced centres and with cautious interpretation of any variants identified. Having established the causative variant in one family member, it is appropriate to look only for this specific variant in cascade testing of subsequent family members, using Sanger sequencing or a non-sequencing approach, unless there is reason to suspect additional genetic contributors.</p><p>
<italic toggle="yes">Predictive (or cascade) testing</italic> refers to testing of individuals with or without a phenotype, often unaffected relatives of an affected proband, with the aim of targeting clinical surveillance to individuals with the genetic predisposition. Sanger sequencing to detect the known familial variant is often used here.</p><p>WES and WGS also enable <italic toggle="yes">opportunistic screening</italic>. The American College of Medical Genetics &#x00026; Genomics (ACMG) recommend that a pre-specified panel of well-characterized disease-associated genes be interrogated whenever clinical exome or genome sequencing is undertaken, irrespective of the primary indication for genomic analysis.<sup><xref rid="euac030-B49" ref-type="bibr">49</xref></sup> This panel currently includes 73 genes (&#x02018;ACMG SF v3.0&#x02019;), many of which are ICC genes (<xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S1</xref></italic>).<sup><xref rid="euac030-B50" ref-type="bibr">50</xref></sup> The costs and benefits of actively seeking secondary findings remain under evaluation, and these recommendations have not been widely adopted outside the USA. Several companies also offer direct-to-consumer sequencing that includes analysis of ICC genes for individuals without symptoms or signs of disease. The costs and benefits of actively seeking secondary findings remain under evaluation, and a consensus has not been reached about these recommendations.</p></sec><sec><title>Genome-wide association study and polygenic risk scores</title><p>Genome-wide association study is used to test associations between genetic variants and human traits or disease phenotypes (<italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F2" ref-type="fig">2</xref>A</italic>).<sup><xref rid="euac030-B51" ref-type="bibr">51</xref></sup> Typically, in a GWAS, each study individual is genotyped by means of a DNA SNP (SNV) array for 200&#x000a0;000 to 1&#x000a0;000&#x000a0;000 known SNVs, although, increasingly, whole-genome sequence data may be used. Array-based genotyping is almost invariably followed by imputation, a process of using the known linkage disequilibrium (correlation) between SNVs in order to predict (impute) unobserved genotypes that are not directly assayed on the array. This permits examination of a greater number of variants (up to 10s of millions). Each variant is then tested for association with the trait or phenotype of interest. Since the positions of the SNVs are known in the genome, the results of a GWAS in one study may be combined with others in a meta-analysis to improve statistical power. Variants with an association <italic toggle="yes">P</italic>-value &#x0003c;5 &#x000d7; 10<sup>&#x02212;8</sup> are generally considered statistically significant, based on multiple testing correction for the roughly 1&#x000a0;000&#x000a0;000 independent common variant tests (haplotype blocks) in the human genome.<sup><xref rid="euac030-B52" ref-type="bibr">52</xref></sup></p><fig position="float" id="euac030-F2"><label>Figure 2</label><caption><p>Genome-wide association studies (GWAS) test the association of common genetic variants with traits or diseases. Results are shown as a Manhattan plot (<italic toggle="yes">A</italic>) where the <italic toggle="yes">P</italic>-value (<italic toggle="yes">y</italic>-axis) is plotted against the genomic position (<italic toggle="yes">x</italic>-axis) for millions of common variants across the genome (blue markers). Polygenic risk scores (<italic toggle="yes">B</italic>) are generally derived from GWAS and calculated for an individual <italic toggle="yes">i</italic> (<italic toggle="yes">PRS<sub>i</sub></italic>) as the sum of the products of allelic dosage (<italic toggle="yes">dosage<sub>ij</sub></italic>) by the regression coefficient/weight (<italic toggle="yes">bj</italic>) for all <italic toggle="yes">M</italic> genetic variants (<italic toggle="yes">j</italic>). Created with Biorender.com.</p></caption><graphic xlink:href="euac030f2" position="float"/></fig><p>Similar analytic methods can be used to examine WGS and WES data. Since 2006, the GWAS approach has been successfully implemented across a broad range of phenotypes in cardiovascular genetics. It has been widely applied to identify common variants that modulate interindividual variability of quantitative cardiophysiologic traits, such as electrocardiogram (ECG) parameters,<sup><xref rid="euac030-B53" ref-type="bibr">53</xref></sup> cardiovascular magnetic resonance (CMR) parameters<sup><xref rid="euac030-B54" ref-type="bibr">54</xref></sup> and blood pressure,<sup><xref rid="euac030-B55" ref-type="bibr">55</xref></sup> with the premise that the genetic variants that impinge on such traits also contribute to disease. Genome-wide association study has also been widely applied for identification of susceptibility variants for common multifactorial disorders such as coronary artery disease,<sup><xref rid="euac030-B56" ref-type="bibr">56</xref></sup> heart failure,<sup><xref rid="euac030-B57" ref-type="bibr">57</xref></sup> and AFib.<sup><xref rid="euac030-B58" ref-type="bibr">58</xref></sup> An analytic technique referred to as Mendelian randomization uses genetic information as an instrumental variable to assess for the causal relations between risk factors and diseases. For example, using this approach, GWAS studies of SCD have suggested a genetic correlation between SCD and coronary disease, traditional coronary artery disease risk factors, and electrical instability traits (QT and AFib).<sup><xref rid="euac030-B59" ref-type="bibr">59</xref></sup></p><p>Genome-wide association studies are increasingly being used to identify common variants that contribute to susceptibility to rare/less common cardiovascular disorders such as BrS,<sup><xref rid="euac030-B60" ref-type="bibr">60</xref></sup> LQTS,<sup><xref rid="euac030-B28" ref-type="bibr">28</xref></sup> DCM,<sup><xref rid="euac030-B61" ref-type="bibr">61</xref></sup> and HCM.<sup><xref rid="euac030-B29" ref-type="bibr">29</xref>,</sup><sup><xref rid="euac030-B30" ref-type="bibr">30</xref></sup> Notably, GWAS enable the identification of many genetic variants associated with a given trait or disease, which can be used to &#x02018;score&#x02019; a specific individual for their aggregate genetic predisposition to that specific trait or disease. Such scores are referred to as <italic toggle="yes">polygenic risk scores (PRS)</italic> or genomic risk scores. Polygenic risk scores result in numeric estimates that represent the cumulative burden of genetic predisposition to a specific phenotype. The phenotype can be a disease such as DCM, or a trait such as left ventricular (LV) systolic dysfunction. The scores are typically calculated by combining the effects of many genetic variants in a mathematical framework to derive a single numeric value for an individual. The number of variants included in a PRS may range from a few to several million. The genetic variants chosen for inclusion in a PRS, and the importance or weight given to each variant, are typically derived from large-scale genetic association studies (i.e. GWAS) with the disease or trait of interest.</p><p>Since genotypes vary at each genomic position across individuals, PRS follow a distribution in the population (<italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F2" ref-type="fig">2</xref>B</italic>). Typically, individuals in the lower tails of a polygenic risk score have a lower risk of developing the disease or trait of interest, whereas those in the upper tails have a higher risk. Polygenic risk scores have been calculated for many conditions including cardiovascular diseases.<sup><xref rid="euac030-B62" ref-type="bibr">62</xref></sup> Both the number of conditions for which they have been calculated and the mathematical methods for selecting and weighing variants are rapidly evolving. Polygenic risk scores have been largely utilized for research purposes to date, but scores are increasingly being applied to clinical trial settings<sup><xref rid="euac030-B63" ref-type="bibr">63&#x02013;65</xref></sup> indicating the potential clinical utility of using these risk markers in the management and prevention of common diseases. The potential utility of PRS in less common conditions such as inherited arrhythmias and cardiomyopathies is also being explored.<sup><xref rid="euac030-B28" ref-type="bibr">28&#x02013;30</xref>,</sup><sup><xref rid="euac030-B66" ref-type="bibr">66&#x02013;68</xref></sup> In the coming years, we anticipate that PRS are likely to enter the clinical practice landscape and become more widely utilized. At present, it seems too early, however. Eventually, PRS may hopefully be able to provide information not only on disease risk but also disease mechanism and therapeutic efficacy.</p><table-wrap position="float" id="T20"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Genetic testing in patients with a potential cardiogenetic condition is performed only with appropriate genetic counselling.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">In patients with a clear specific phenotype, it is appropriate to perform genetic testing analysing genes with definite or strong evidence supporting disease causation.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B17" ref-type="bibr">17</xref>,</sup>
<sup>
<xref rid="euac030-B20" ref-type="bibr">20</xref>,</sup>
<sup>
<xref rid="euac030-B21" ref-type="bibr">21</xref>,</sup>
<sup>
<xref rid="euac030-B69" ref-type="bibr">69</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In patients with a clear specific phenotype, it may be appropriate to analyse genes with moderate evidence supporting disease causation.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B17" ref-type="bibr">17</xref>,</sup>
<sup>
<xref rid="euac030-B20" ref-type="bibr">20</xref>,</sup>
<sup>
<xref rid="euac030-B21" ref-type="bibr">21</xref>,</sup>
<sup>
<xref rid="euac030-B69" ref-type="bibr">69</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In selected cases with a definite phenotype and no genetic diagnosis after testing of the genes with definite or strong evidence supporting disease causation, broader genetic testing may be considered. Such selected cases may include familial cases, those with atypical features, such as extracardiac manifestations and those with unusual early disease onset.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B17" ref-type="bibr">17</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant interpretation in the clinical setting is greatly enhanced by the use of disease-specific, multi-disciplinary teams that could include clinical disease experts, clinical geneticists, or genetic counsellors and molecular geneticists.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B70" ref-type="bibr">70&#x02013;75</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant interpretation is best performed using standard guidelines for interpretation and can be enhanced by gene-specific rule specifications tailored for the gene and disease under consideration.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B17" ref-type="bibr">17</xref>,</sup>
<sup>
<xref rid="euac030-B76" ref-type="bibr">76</xref>,</sup>
<sup>
<xref rid="euac030-B77" ref-type="bibr">77</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Reported Variants of Uncertain Clinical Significance (VUS) may be reclassified, i.e. &#x02018;upgraded&#x02019; [Likely Pathogenic/Pathogenic (LP/P)] or &#x02018;downgraded&#x02019; (Likely Benign/Benign), in multi-disciplinary clinics with access to molecular genetics laboratories, according to robustness of clinical phenotype and/or familial segregation evidence.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B70" ref-type="bibr">70&#x02013;75</xref>,</sup>
<sup>
<xref rid="euac030-B78" ref-type="bibr">78</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Genetic testing for genes with (i) limited, (ii) disputed, or (iii) refuted evidence should not be performed in patients with a weak (non-definite) phenotype in the clinical setting.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B17" ref-type="bibr">17</xref>,</sup>
<sup>
<xref rid="euac030-B20" ref-type="bibr">20</xref>,</sup>
<sup>
<xref rid="euac030-B21" ref-type="bibr">21</xref>,</sup>
<sup>
<xref rid="euac030-B69" ref-type="bibr">69</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In families where a LP/P variant has been identified, detailed genetic counselling and guidance regarding inheritance patterns, variant penetrance, and risk should be offered, and cascade testing facilitated.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">In patients with a high probability of a specific inherited cardiac disease and a molecular screening performed in a pre-NGS era or with an incomplete NGS panel, repetition of the testing should be considered.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Choice of genetic tests and interpretation of variants</title><p>&#x000a0;</p><sec><title>Background</title><p>A basic tenet of clinical genetic testing is that the genes evaluated should have strong scientific evidence supporting their disease association.<sup><xref rid="euac030-B69" ref-type="bibr">69</xref></sup> Given the challenge of variant interpretation,<sup><xref rid="euac030-B79" ref-type="bibr">79</xref></sup> there is risk of inaccurate information being provided to patients and families when genes with limited evidence for disease causality are tested. In the context of life-changing diagnoses which may provoke significant anxiety or aggressive treatment interventions, optimizing methods for best practice of genetic variant interpretation is essential. Recent collaborative projects involving clinical disease experts, genetic counsellors, and clinical/molecular geneticists have provided detailed evidence-based gene classifications for Mendelian arrhythmia and cardiomyopathy disorders, highlighting genes with moderate, strong or definitive evidence for disease causation, and others with limited or disputed evidence<sup><xref rid="euac030-B12" ref-type="bibr">12&#x02013;15</xref>,</sup><sup><xref rid="euac030-B17" ref-type="bibr">17</xref>,</sup><sup><xref rid="euac030-B22" ref-type="bibr">22</xref></sup> (for definitions of these classifications see page 7 in: <ext-link xlink:href="https://clinicalgenome.org/site/assets/files/5391/gene_curation_sop_pdf-1.pdf" ext-link-type="uri">https://clinicalgenome.org/site/assets/files/5391/gene_curation_sop_pdf-1.pdf</ext-link>).</p><p>In 2015, the ACMG provided a standard, criteria-based approach for the interpretation of genetic variants in clinical testing.<sup><xref rid="euac030-B69" ref-type="bibr">69</xref></sup> Criteria include the frequency of the allele in people with and without disease, the degree of familial segregation with other affected family members, topological location within relevant functional domains of the protein, and functional analysis of the variant. Importantly, no single criterion alone, including abnormal functional assay, is sufficient to conclude the pathogenicity of a genetic variant. A summation of the evidence leads to a provisional classification of the variant along a probabilistic range of categories: Pathogenic (P), Likely Pathogenic (LP), Variant of Uncertain Clinical Significance (VUS), Likely Benign (LB), Benign (B). Although challenging to quantify, according to ACMG guidelines the terms LP and LB suggest a &#x0003e;90% certainty of a variant being disease-causing or benign, highlighting the significant range of probability for variants classified as VUS.</p><p>The VUS classification represents the &#x02018;Achilles Heel&#x02019; of genetic variant interpretation in the clinical arena. At times, high-volume, multi-disciplinary clinics may have sufficient clinical expertise or evidence that may allow for an upgrading or downgrading of the variant to pathogenic or benign, respectively.<sup><xref rid="euac030-B74" ref-type="bibr">74</xref>,</sup><sup><xref rid="euac030-B77" ref-type="bibr">77</xref>,</sup><sup><xref rid="euac030-B78" ref-type="bibr">78</xref></sup> In contrast, the absence of segregation of a VUS interpreted variant with a robust familial phenotype may lead to re-classifying to likely benign. These examples highlight that most laboratory-based variant interpretation is done in the absence of detailed clinical phenotyping knowledge available in a multidisciplinary clinic. To minimize the burden of VUS classifications, collaborative expert teams have proposed ACMG-modified, gene-specific rules which take in to account the specific knowledge accumulated for certain genes in specific conditions.<sup><xref rid="euac030-B76" ref-type="bibr">76</xref>,</sup><sup><xref rid="euac030-B80" ref-type="bibr">80</xref></sup> Where possible, this approach may enhance variant interpretation classification.<sup><xref rid="euac030-B77" ref-type="bibr">77</xref></sup></p><p>Genes that do not have sufficient evidence to date as single-gene causes for disease should not receive variant interpretations. Clinical testing laboratories that continue to offer these genes on their panels should clearly label their limited evidence, but may consider providing unclassified, identified variants to clinics in support of ongoing research on candidate genes.</p><sec><title>Use of the obtained genetic knowledge</title><p>After genetic testing, a clinically actionable result (LP/P) can provide diagnostic clarification in the proband (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T5" ref-type="table">5</xref></italic>). It also provides information relevant to prognosis and relevant to therapeutic choices in many but not all disease entities (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T5" ref-type="table">5</xref></italic>). In addition, it offers the potential for cascade (predictive) testing of at-risk family members.<sup><xref rid="euac030-B81" ref-type="bibr">81&#x02013;85</xref></sup> Cascade testing involves targeted testing of first-degree relatives for the LP/P variant found in the proband (&#x02018;appropriate relatives&#x02019;). When cascade testing is performed in an at-risk relative, those who are found not to carry the disease-causing gene variant can be released from further clinical surveillance in the vast majority of conditions. Some exceptions exist and are discussed at the individual disease level. In general, cascade screening is recommended when results will affect clinical management. When the results are &#x02018;only&#x02019; useful for family planning, cascade screening may be considered. Recommendations for cascade screening and the age at which this should be performed are disease- and sometimes gene-specific. Those who are found to carry the disease-causing gene variant should undergo clinical screening at regular intervals. Family members of a patient where genetic testing is not done or is negative (no likely-pathogenic or pathogenic variant is identified) also require clinical screening at regular intervals because there is considerable phenotypic heterogeneity in age of onset and disease progression within members of the same family. That being said, in some diseases, there is emerging evidence that a negative genetic test in the proband or the affected individual may indicate lower probability of monogenic disease.</p><table-wrap position="float" id="euac030-T5"><label>Table 5</label><caption><p>Impact of genetic testing for the proband</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Arrhythmia syndromes</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Long QT syndrome</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">+++</td></tr><tr><td rowspan="1" colspan="1">&#x02003;CPVT</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Brugada syndrome</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Progressive cardiac conduction disease</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Short QT syndrome</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Sinus node disease</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Atrial fibrillation</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Early repolarization syndrome</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">
<bold>Cardiomyopathies</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Hypertrophic cardiomyopathy</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">++</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dilated cardiomyopathy</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">++</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Arrhythmogenic cardiomyopathy</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">++</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Left ventricular non-compaction</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Restrictive cardiomyopathy</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1">
<bold>Congenital heart disease</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Syndromic CHD</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Non-syndromic CHD</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Familial CHD</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><label>+++</label><p>: is recommended/is indicated or useful.</p></fn><fn id="tblfn6"><label>++</label><p>: can be recommended/can be useful.</p></fn><fn id="tblfn7"><label>+</label><p>: may be considered/may be useful.</p></fn><fn id="tblfn8"><label>&#x02013;</label><p>: is not recommended/is not indicated nor useful.</p></fn></table-wrap-foot></table-wrap><p>In the event that a VUS is reported, a disease-specific multidisciplinary team can help to further classify the variant as LP or LB, based on the criteria outlined in detail above. A VUS that has not been upgraded to LP should not be used to facilitate cascade screening; rather, clinical screening is required. When multiple family members exhibit a characteristic phenotype, robust co-segregation of the variant with the affected family members can contribute to classification of the variant as LP or even P.</p><p>A pathogenic variant can also be identified at postmortem testing (i.e. after the usually SCD of a family member) using blood or tissue collected at autopsy. Postmortem testing is especially useful in instances where the family variant is unknown and no other affected family members are still living.<sup><xref rid="euac030-B86" ref-type="bibr">86&#x02013;88</xref></sup> Access to a molecular autopsy as well as considerations related to costs and insurance coverage for this testing can vary between countries and jurisdictions. Nevertheless, identification of a LP/P variant may confirm or establish a familial diagnosis and allow cascade genetic testing of other at-risk relatives as outlined previously.</p><p>In addition, detailed genetic counselling and guidance is recommended and should start before a genetic test is performed. Families should be informed of the mode of inheritance of disease, most commonly AD inheritance whereby there is a 50% chance the variant will be passed on to offspring, regardless of sex. Families should be informed that carrying the LP/P variant does not necessarily mean development of clinical disease, reflecting variable penetrance, e.g. some gene variant carriers may never develop clinical disease (genotype positive, phenotype negative) or may only develop very mild disease and therefore be at low risk of disease complications. In all families and couples (with most conditions) where pregnancy is being planned, the above factors need to be discussed, as well as reproduction options such as prenatal genetic testing and preimplantation genetic diagnosis.</p></sec></sec></sec><sec><title>State of genetic testing for inherited arrhythmia syndromes</title><p>&#x000a0;</p><sec><title>Long QT syndrome</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T21"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">LQTS</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">+++</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T22"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendations</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Molecular genetic testing for definitive disease associated genes (currently <italic toggle="yes">KCNQ1, KCNH2, SCN5A, CALM1, CALM2</italic>, and <italic toggle="yes">CALM3</italic>) should be offered to all index patients with a high probability diagnosis of LQTS, based on examination of the patient&#x02019;s clinical history, family history, and ECG characteristics obtained at baseline, during ECG Holter recording and exercise stress test (Schwartz Score &#x02265; 3.5, <xref rid="sup1" ref-type="supplementary-material">Supplementary</xref><italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S2</xref></italic>).<sup><xref rid="tblfn9" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B20" ref-type="bibr">20</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Analysis of specific genes should be offered to patients with a specific diagnosis as follows: <italic toggle="yes">KCNQ1 and KCNE1</italic> in patients with Jervell and Lange-Nielsen syndrome, <italic toggle="yes">CACNA1C</italic> in Timothy syndrome, <italic toggle="yes">KCNJ2</italic> in Andersen&#x02013;Tawil syndrome, and <italic toggle="yes">TRDN</italic> in patients suspected to have triadin knockout syndrome.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B20" ref-type="bibr">20</xref>,</sup>
<sup>
<xref rid="euac030-B89" ref-type="bibr">89&#x02013;93</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">An analysis of <italic toggle="yes">CACNA1C</italic> and <italic toggle="yes">KCNE1</italic> may be performed in all index patients in whom a cardiologist has established a diagnosis of LQTS with a high probability, based on examination of the patient&#x02019;s clinical history, family history, and ECG characteristics obtained at baseline, during ECG Holter recording and exercise stress test (Schwartz Score &#x02265; 3.5).<sup><xref rid="tblfn9" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B20" ref-type="bibr">20</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant-specific genetic testing is recommended for family members and appropriate relatives following the identification of the disease-causing variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children is recommended from birth onward (any age).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table><table-wrap-foot><fn id="tblfn9"><label>a</label><p>The Schwartz score can be found in <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S2</xref></italic>.</p></fn></table-wrap-foot></table-wrap><sec><title>Background</title><p>The congenital LQTS is a genetically transmitted channelopathy, characterized by prolongation of the QT interval on the baseline ECG, usually associated with T-wave abnormalities (i.e. notched T waves, biphasic T waves).<sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup> To make a diagnosis of congenital LQTS it is essential to exclude secondary causes, i.e. QT-prolonging drugs or electrolyte imbalances.<sup><xref rid="euac030-B94" ref-type="bibr">94</xref></sup> Prolongation of action potential duration favours early afterdepolarizations and torsades de pointes (TdP) is the typical arrhythmia in this disease.<sup><xref rid="euac030-B95" ref-type="bibr">95&#x02013;98</xref></sup> Torsades de pointes, frequently triggered by pauses and/or adrenergic stimulation,<sup><xref rid="euac030-B98" ref-type="bibr">98</xref></sup> can cause self-terminating dizziness or syncopal events or can degenerate into ventricular fibrillation (VF) and SCD. Electrocardiogram characteristics associated with high risk of life-threatening arrhythmias, include T wave alternans and functional 2:1 atrioventricular block, which are frequently present in patients who present perinatally. To make a diagnosis of LQTS, it may be important to evaluate not only basal ECG but also the behaviour of QTc during exercise stress test and 24-h, preferably 12-lead, Holter recording.<sup><xref rid="euac030-B99" ref-type="bibr">99</xref>,</sup><sup><xref rid="euac030-B100" ref-type="bibr">100</xref></sup> Diagnostic criteria have been developed to support the diagnosis of the disease, i.e. the &#x02018;Schwartz score&#x02019;.<sup><xref rid="euac030-B101" ref-type="bibr">101</xref></sup></p><p>Long QT syndrome has a prevalence of at least 1:2500 people<sup><xref rid="euac030-B102" ref-type="bibr">102</xref></sup> and clinical manifestations tend to occur during childhood or teenage years. Among symptomatic index cases, the untreated 10-year mortality is &#x0223c;50%.<sup><xref rid="euac030-B103" ref-type="bibr">103</xref>,</sup><sup><xref rid="euac030-B104" ref-type="bibr">104</xref></sup></p></sec><sec><title>Summary of the major long QT syndrome genes</title><p>
<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T6" ref-type="table">6</xref></italic> (and <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S3</xref></italic>) summarize all genes associated with LQTS and their ClinGen classification.<sup><xref rid="euac030-B20" ref-type="bibr">20</xref></sup> Long QT syndrome genes can be divided in three main groups: those genes in which pathogenic variants reduce potassium outward currents, those in which pathogenic variants increase sodium inward current, and those in which pathogenic variants increase calcium inward current.</p><table-wrap position="float" id="euac030-T6"><label>Table 6</label><caption><p>Genes implicated in long QT syndrome (LQTS)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<italic toggle="yes">Gene</italic>
</th><th align="left" rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Phenotype&#x02014;syndrome</th><th align="left" rowspan="1" colspan="1">Protein (functional effect)</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNQ1</italic>
</td><td rowspan="1" colspan="1">11p15.5</td><td rowspan="1" colspan="1">LQTS, JLNS</td><td rowspan="1" colspan="1">Loss-of-<italic toggle="yes">I</italic><sub>Ks</sub> channel function</td><td rowspan="1" colspan="1">40&#x02013;55%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNH2</italic>
</td><td rowspan="1" colspan="1">7q35-36</td><td rowspan="1" colspan="1">LQTS</td><td rowspan="1" colspan="1">Loss-of-<italic toggle="yes">I</italic><sub>Kr</sub> channel function</td><td rowspan="1" colspan="1">30&#x02013;45%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">SCN5A</italic>
</td><td rowspan="1" colspan="1">3p21-p24</td><td rowspan="1" colspan="1">LQTS</td><td rowspan="1" colspan="1">Increase in <italic toggle="yes">I</italic><sub>Na1.5</sub> channel function</td><td rowspan="1" colspan="1">5&#x02013;10%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CALM1</italic>
</td><td rowspan="1" colspan="1">14q32.11</td><td rowspan="1" colspan="1">LQTS</td><td rowspan="1" colspan="1">L-type calcium channel (&#x02191;)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CALM2</italic>
</td><td rowspan="1" colspan="1">2p21</td><td rowspan="1" colspan="1">LQTS</td><td rowspan="1" colspan="1">L-type calcium channel (&#x02191;)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CALM3</italic>
</td><td rowspan="1" colspan="1">19q13.32</td><td rowspan="1" colspan="1">LQTS</td><td rowspan="1" colspan="1">L-type calcium channel (&#x02191;)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TRDN</italic>
</td><td rowspan="1" colspan="1">6q22.31</td><td rowspan="1" colspan="1">Recessive LQTS</td><td rowspan="1" colspan="1">L-type calcium channel (&#x02191;)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Strong</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNE1</italic>
</td><td rowspan="1" colspan="1">21q22.1</td><td rowspan="1" colspan="1">LQTS, JLNS, a-LQTS</td><td rowspan="1" colspan="1">Loss-of-<italic toggle="yes">I</italic><sub>K</sub> channel function</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Strong in aLQTS, definitive in JLNS</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNE2</italic>
</td><td rowspan="1" colspan="1">21q22.1</td><td rowspan="1" colspan="1">a-LQTS</td><td rowspan="1" colspan="1">Loss-of-<italic toggle="yes">I</italic><sub>K</sub> channel function</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Strong in aLQTS</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNJ2</italic>
</td><td rowspan="1" colspan="1">17q23</td><td rowspan="1" colspan="1">ATS</td><td rowspan="1" colspan="1">Loss-of-<italic toggle="yes">I</italic><sub>K1</sub> channel function</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definitive in ATS</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CACNA1C</italic>
</td><td rowspan="1" colspan="1">12p13.3</td><td rowspan="1" colspan="1">TS, LQTS</td><td rowspan="1" colspan="1">L-type calcium channel (&#x02191;)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definitive in TS, moderate in LQTS</td></tr></tbody></table><table-wrap-foot><fn id="tblfn10"><p>Functional effect: (&#x02193;) loss-of-function or (&#x02191;) gain-of-function at the cellular <italic toggle="yes">in vitro</italic> level.</p></fn><fn id="tblfn11"><p>a-LQTS, acquired-long QT syndrome; ATS, Andersen&#x02013;Tawil syndrome; JLNS, Jervell and Lange-Nielsen syndrome; RWS, Romano&#x02013;Ward syndrome; TS, Timothy syndrome.</p></fn></table-wrap-foot></table-wrap><p>
<italic toggle="yes">Potassium channel-related LQTS</italic>:<sup><xref rid="euac030-B95" ref-type="bibr">95</xref>,</sup><sup><xref rid="euac030-B96" ref-type="bibr">96</xref></sup> pathogenic variants in potassium channels genes are responsible for the vast majority of LQTS cases and <italic toggle="yes">KCNQ1</italic> and <italic toggle="yes">KCNH2</italic>, encoding for the alpha subunit of potassium channels conducting the <italic toggle="yes">I</italic><sub>Ks</sub> and <italic toggle="yes">I</italic><sub>Kr</sub> currents, respectively, account for 80% of all genetically explained LQTS cases.<sup><xref rid="euac030-B95" ref-type="bibr">95</xref>,</sup><sup><xref rid="euac030-B96" ref-type="bibr">96</xref></sup> Homozygous or compound heterozygous pathogenic variants in <italic toggle="yes">KCNQ1</italic> and <italic toggle="yes">KCNE1</italic> cause the recessive Jervell and Lange-Nielsen syndrome (JLNS), in which the cardiac phenotype is combined with congenital deafness.<sup><xref rid="euac030-B105" ref-type="bibr">105</xref></sup><italic toggle="yes">KCNE1</italic> is strongly associated with acquired-LQTS (aLQTS),<sup><xref rid="euac030-B94" ref-type="bibr">94</xref></sup> as is <italic toggle="yes">KCNE2</italic>, and it also causes an uncommon subtype usually associated with low penetrance and with a mild phenotype.<sup><xref rid="euac030-B106" ref-type="bibr">106</xref></sup> Finally, in this subgroup, the Andersen&#x02013;Tawil syndrome (ATS), caused by pathogenic variants in the <italic toggle="yes">KCNJ2</italic> gene, is generally included,<sup><xref rid="euac030-B95" ref-type="bibr">95</xref>,</sup><sup><xref rid="euac030-B96" ref-type="bibr">96</xref>,</sup><sup><xref rid="euac030-B107" ref-type="bibr">107</xref></sup> although it should be questioned whether ATS is actually a subform of LQTS.<sup><xref rid="euac030-B74" ref-type="bibr">74</xref>,</sup><sup><xref rid="euac030-B107" ref-type="bibr">107</xref></sup> Patients with ATS frequently also present with extra cardiac features, including skeletal myopathy (periodic muscular weakness) and several skeletal and facial dysmorphic features.<sup><xref rid="euac030-B95" ref-type="bibr">95</xref>,</sup><sup><xref rid="euac030-B96" ref-type="bibr">96</xref></sup></p><p>
<italic toggle="yes">Sodium channel-related LQTS</italic>: pathogenic variants in <italic toggle="yes">SCN5A</italic>, causing an increase of sodium inward current, are the third most frequent cause of LQTS and have a predominant role in forms with malignant perinatal presentation.<sup><xref rid="euac030-B108" ref-type="bibr">108</xref>,</sup><sup><xref rid="euac030-B109" ref-type="bibr">109</xref></sup> Overlapping phenotypes (LQTS, BrS, and cardiac conduction defects) are described.<sup><xref rid="euac030-B110" ref-type="bibr">110</xref></sup> Other components of the Na channel complex have been proposed as candidate genes for LQTS, but there is insufficient evidence to confirm an association.<sup><xref rid="euac030-B20" ref-type="bibr">20</xref></sup></p><p>
<italic toggle="yes">Calcium channel-related LQTS</italic>: pathogenic variants causing an increase of calcium inward current are associated with rare but malignant forms of LQTS, some with associated syndromic features. Specifically, Timothy syndrome, caused by the pathogenic G406R variant in <italic toggle="yes">CACNA1C</italic><sup><xref rid="euac030-B89" ref-type="bibr">89</xref></sup> is characterized by a perinatal presentation of life-threatening arrhythmias frequently associated with syndactyly, CHDs, cognitive abnormalities, and autism. Long QT syndrome caused by any of the three <italic toggle="yes">CALM</italic> genes<sup><xref rid="euac030-B90" ref-type="bibr">90</xref>,</sup><sup><xref rid="euac030-B111" ref-type="bibr">111</xref></sup> represents another malignant form of the disease and data from the International Calmodulinopathy Registry show life-threatening arrhythmias in 78% of the cases, mean QTc of almost 600&#x02009;ms and a perinatal presentation in 58%.<sup><xref rid="euac030-B91" ref-type="bibr">91</xref></sup> Some of these cases show neurological features unrelated to cardiac arrest, and cardiac structural abnormalities.<sup><xref rid="euac030-B91" ref-type="bibr">91</xref></sup> The triadin knockout syndrome (TKOS)<sup><xref rid="euac030-B92" ref-type="bibr">92</xref>,</sup><sup><xref rid="euac030-B93" ref-type="bibr">93</xref></sup> is a recessive syndrome caused by pathogenic variants in <italic toggle="yes">TRDN</italic>; data from the International Registry show that cardiac arrest is the first clinical manifestation in 71% of patients, and transient QT prolongation, sometimes with T-wave inversion in V1&#x02013;V3/V5 is frequently observed.<sup><xref rid="euac030-B93" ref-type="bibr">93</xref></sup> Patients in this category also frequent present with neuromuscular involvement. All these forms, which cause QT prolongation secondary to abnormal calcium handling, have in common an early malignant presentation and a poor response to conventional medical therapies.</p><sec><title>Index cases (proband)</title><p>In LQTS patients with a high probability of LQTS, based on examination of the patient&#x02019;s clinical history, family history, and ECG characteristics obtained both in baseline, during ECG, Holter recording and exercise stress test (Schwartz Score &#x02265; 3.5), molecular testing is recommended with a different level of strength depending of the type of gene. In genes with definitive evidence, currently <italic toggle="yes">KCNQ1, KCNH2, SCN5A, CALM1, CALM2</italic>, and <italic toggle="yes">CALM3</italic>, the testing is strongly recommended in all probands<sup><xref rid="euac030-B20" ref-type="bibr">20</xref></sup> (<italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F3" ref-type="fig">3</xref></italic>), including an analysis of CNV, and a disease-causing variant is identified in around 70&#x02013;85% of cases.<sup><xref rid="euac030-B95" ref-type="bibr">95</xref>,</sup><sup><xref rid="euac030-B112" ref-type="bibr">112</xref></sup> A possible exception is an active athlete with a prolonged QTc. Indeed, not rarely athletes develop significant QT prolongation which is fully reversible on detraining.<sup><xref rid="euac030-B113" ref-type="bibr">113</xref></sup> In such cases the diagnosis of LQTS should not be made.<sup><xref rid="euac030-B113" ref-type="bibr">113</xref></sup> Another strong recommendation is provided in the context of specific syndromes for causative genes, i.e. <italic toggle="yes">KCNE1</italic> in patients with JLNS,<sup><xref rid="euac030-B105" ref-type="bibr">105</xref></sup><italic toggle="yes">CACNA1C</italic> in patients with Timothy syndrome,<sup><xref rid="euac030-B89" ref-type="bibr">89</xref></sup><italic toggle="yes">KCNJ2</italic> in patients with ATS,<sup><xref rid="euac030-B95" ref-type="bibr">95</xref></sup> and <italic toggle="yes">TRDN</italic> in patients with Triadin Knock-out syndrome<sup><xref rid="euac030-B92" ref-type="bibr">92</xref>,</sup><sup><xref rid="euac030-B93" ref-type="bibr">93</xref></sup> (<italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F3" ref-type="fig">3</xref></italic>). <italic toggle="yes">CACNA1C</italic> and <italic toggle="yes">KCNE1</italic> that have a moderate evidence in the context of LQTS, the testing may be considered in patients with a high probability of diagnosis. Only in this subgroup of patients with high probability of LQTS may a broader genetic testing be considered if no disease-causing variant is identified in established genes, and only in experienced centres and with a careful interpretation of the variant identified. However, in these cases a negative genetic test does not exclude the disease, already established clinically. In patients with an intermediate probability of LQTS (e.g. prolonged QTc with a Schwartz score 1.5&#x02013;3.0), testing of genes with limited, disputed and refuted evidence should not be performed, while testing of the established genes may be considered, mostly to help rule out the diagnosis after extensive phenotypic investigation.</p><fig position="float" id="euac030-F3"><label>Figure 3</label><caption><p>Clinical algorithm for genetic testing and family screening in long-QT syndrome.</p></caption><graphic xlink:href="euac030f3" position="float"/></fig></sec><sec><title>Family screening</title><p>Cascade screening in family members is indicated whenever a disease-causing variant is identified in the index case. Indeed, low penetrance and variable expressivity, do not allow one to exclude the diagnosis only on the basis of a normal baseline ECG.<sup><xref rid="euac030-B114" ref-type="bibr">114</xref>,</sup><sup><xref rid="euac030-B115" ref-type="bibr">115</xref></sup> Early identification of affected family members is important to establish preventive measures, as the risk of life-threatening arrhythmias is not negligible even among those with a normal baseline QTc.<sup><xref rid="euac030-B116" ref-type="bibr">116</xref></sup></p></sec></sec><sec><title>Prognostic and therapeutic implications of long QT syndrome genetic testing</title><p>In LQTS, the identification of a disease-causing variant contributes to risk stratification. Indeed, the identification of a pathogenic variant in <italic toggle="yes">KCNQ1, KCNH2</italic>, or <italic toggle="yes">SCN5A</italic> has a role together with the length of the QTc in identifying the risk of life-threatening arrhythmias in asymptomatic subjects.<sup><xref rid="euac030-B117" ref-type="bibr">117</xref></sup> Also, the location of the variant across the protein is important. In fact, location in the pore region of <italic toggle="yes">KCNH2</italic>,<sup><xref rid="euac030-B118" ref-type="bibr">118</xref></sup> the transmembrane location,<sup><xref rid="euac030-B118" ref-type="bibr">118</xref></sup> the S6 segment specifically,<sup><xref rid="euac030-B119" ref-type="bibr">119</xref></sup> and dominant-negative effect for <italic toggle="yes">KCNQ1</italic>, are independent risk factors for cardiac events.<sup><xref rid="euac030-B120" ref-type="bibr">120</xref></sup> Furthermore, some specific pathogenic variants are associated with unusually high clinical severity (high penetrance, long QTc, high incidence of SCD), such as the <italic toggle="yes">KCNQ1</italic>-A341V<sup><xref rid="euac030-B121" ref-type="bibr">121</xref></sup> or the <italic toggle="yes">SCN5A</italic>-G1631D.<sup><xref rid="euac030-B108" ref-type="bibr">108</xref></sup> Others, such as <italic toggle="yes">SCN5A-</italic>D1790G and the E1784K, that not only causes LQTS, but it is also associated with BrS and sinus node dysfunction (SND)<sup><xref rid="euac030-B110" ref-type="bibr">110</xref></sup> are relatively benign.<sup><xref rid="euac030-B122" ref-type="bibr">122</xref></sup> Thus, when managing families with the latter pathogenic variant, the possibility of an overlap syndrome should be considered. In the recessive JLNS, it matters whether there are two pathogenic variants in <italic toggle="yes">KCNE1</italic> or in <italic toggle="yes">KCNQ1</italic>, with the former presenting with a more benign disease course in terms of risk of life-threatening arrhythmias.<sup><xref rid="euac030-B105" ref-type="bibr">105</xref></sup> Finally, there are some specific genetic subtypes that are at particular high risk of SCD in paediatric age, as patients carrying a pathogenic variant in one of the <italic toggle="yes">CALM</italic> genes<sup><xref rid="euac030-B90" ref-type="bibr">90</xref>,</sup><sup><xref rid="euac030-B91" ref-type="bibr">91</xref></sup> and despite no systematic studies, the available data suggest that whenever the variants affect the calcium current, the phenotype tends to be more complex and severe.<sup><xref rid="euac030-B89" ref-type="bibr">89&#x02013;93</xref>,</sup><sup><xref rid="euac030-B111" ref-type="bibr">111</xref></sup> The role of SNVs as genetic modifier has also been documented, but its evaluation has not yet entered clinical practice in a standardized manner.<sup><xref rid="euac030-B2" ref-type="bibr">2</xref>,</sup><sup><xref rid="euac030-B123" ref-type="bibr">123</xref></sup></p><p>The amazing progress in understanding the genotype-phenotype correlation has allowed LQTS to become the first disease for which initial steps for gene-specific management have become possible and are already usefully implemented. Patients with a pathogenic variant in <italic toggle="yes">KCNQ1</italic> are at higher risk during sympathetic activation (e.g. during exercise, swimming and emotional stress), and antiadrenergic intervention such as beta-blockers<sup><xref rid="euac030-B124" ref-type="bibr">124</xref>,</sup><sup><xref rid="euac030-B125" ref-type="bibr">125</xref></sup> and left cardiac sympathetic denervation (LCSD)<sup><xref rid="euac030-B126" ref-type="bibr">126</xref>,</sup><sup><xref rid="euac030-B127" ref-type="bibr">127</xref></sup> are particularly effective. An implantable cardioverter-defibrillator (ICD) is rarely needed and certainly not for primary prevention, in contrast to the other subtypes where the predicted risk in patients with very long QTc may lead to an earlier primary ICD implantation.<sup><xref rid="euac030-B116" ref-type="bibr">116</xref></sup> In <italic toggle="yes">KCNH2</italic>-LQTS patients, it is essential to preserve adequate potassium levels, and oral potassium may help.<sup><xref rid="euac030-B128" ref-type="bibr">128</xref></sup> Also, these patients are at higher risk when aroused from sleep or rest by a sudden noise<sup><xref rid="euac030-B129" ref-type="bibr">129</xref>,</sup><sup><xref rid="euac030-B130" ref-type="bibr">130</xref></sup> and in the post-partum phase.<sup><xref rid="euac030-B131" ref-type="bibr">131</xref></sup> Removal of telephones and alarm clocks from their bedrooms is recommended. The realization that <italic toggle="yes">SCN5A</italic> variants producing LQTS have a &#x02018;gain-of-function&#x02019; support the use of late sodium current blockers, in particular mexiletine, in those patients with a QTc &#x0003e;500&#x02009;ms, if their QTc shortens by more than 40&#x02009;ms after oral loading test.<sup><xref rid="euac030-B132" ref-type="bibr">132&#x02013;134</xref></sup> Recently, mexiletine was shown to shorten QTc also in a significant percentage of <italic toggle="yes">KCNH2</italic> patients<sup><xref rid="euac030-B135" ref-type="bibr">135</xref></sup> opening the possibility of its clinical use also in this genetic subgroup. Finally, very preliminary data, showed that a drug combining lumacaftor and ivacaftor, already in clinical use for cystic fibrosis, could have a role in patients carrying <italic toggle="yes">KCNH2</italic> variants causing a trafficking defect, but data on more patients are still needed.<sup><xref rid="euac030-B136" ref-type="bibr">136</xref>,</sup><sup><xref rid="euac030-B137" ref-type="bibr">137</xref></sup> All LQTS patients should avoid QT-prolonging drugs (see <ext-link xlink:href="http://www.crediblemeds.org" ext-link-type="uri">www.crediblemeds.org</ext-link>).</p></sec><sec><title>Acquired long QT syndrome</title><table-wrap position="float" id="T23"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendations</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Molecular genetic testing for definitive disease associated genes (currently <italic toggle="yes">KCNQ1, KCNH2, SCN5A, KCNE1</italic>, and <italic toggle="yes">KCNE2</italic>) should be offered to all patients with acquired LQTS who experienced drug-induced TdP, are aged below 40&#x02009;years and have a QTc &#x0003e;440&#x02009;ms (males) and &#x0003e;450&#x02009;ms (females) in the absence of culprit drug</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B20" ref-type="bibr">20</xref>,</sup>
<sup>
<xref rid="euac030-B94" ref-type="bibr">94</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Cascade family screening for the presence of pertinent variants should be considered when QT prolonging drugs are or could be prescribed</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table></table-wrap><p>The acquired LQTS, is a clinical condition characterized by QT prolongation (usually defined as &#x0003e;500&#x02009;ms or &#x0003e;60&#x02013;70&#x02009;ms drug-induced change from baseline) sometimes associated with TdP, which is induced by QT-prolonging drugs and more rarely hypokalaemia or bradycardia.<sup><xref rid="euac030-B94" ref-type="bibr">94</xref></sup> The probability of developing an acquired LQTS depends on two major factors: (i) the intrinsic risk conferred by a given drug, which is provided by CredibleMeds website (<ext-link xlink:href="https://crediblemeds.org" ext-link-type="uri">https://crediblemeds.org</ext-link>); (ii) the repolarization reserve of a subject in which genetic factors play a role.<sup><xref rid="euac030-B2" ref-type="bibr">2</xref></sup> The genetic predisposition to acquired LQTS includes both ultra-rare,<sup><xref rid="euac030-B138" ref-type="bibr">138</xref></sup> rare,<sup><xref rid="euac030-B139" ref-type="bibr">139</xref></sup> and common genetic variants.<sup><xref rid="euac030-B140" ref-type="bibr">140</xref></sup> The role of molecular testing in the isolated setting of drug-induced LQTS requires individualized consideration. In the study by Itoh <italic toggle="yes">et al.</italic>,<sup><xref rid="euac030-B94" ref-type="bibr">94</xref></sup> the probability of identifying a LP/P variant in patients with acquired LQTS was mainly dependent on three variables, i.e. age below 40&#x02009;years, QTc (at baseline) &#x0003e;440&#x02009;ms and presence of TdP/symptom. When all three variables were present, a LP/P variant was identified in more than 60% of the patients.<sup><xref rid="euac030-B94" ref-type="bibr">94</xref></sup> Molecular genetic screening in older individuals has a much lower yield and can therefore not be recommended on a standard basis.<sup><xref rid="euac030-B94" ref-type="bibr">94</xref></sup></p><p>Variants which are unequivocally associated with drug-induced LQTS (e.g. D85N in <italic toggle="yes">KCNE1</italic>) should be reported as a relevant result.<sup><xref rid="euac030-B73" ref-type="bibr">73</xref></sup> Active family screening for the presence of these variants should be considered when QT prolonging drugs are or could be prescribed (expert opinion).</p></sec></sec><sec><title>Catecholaminergic polymorphic ventricular tachycardia</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T24"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">CPVT</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T25"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">In any patient satisfying the diagnostic criteria for CPVT (such as Class 1 clinical diagnosis<sup><xref rid="tblfn12" ref-type="table-fn">a</xref></sup> or CPVT diagnostic score <underline>&#x0003e;</underline>3.5<sup><xref rid="tblfn13" ref-type="table-fn">b</xref></sup>), molecular genetic testing is recommended for the currently established definite/strong evidence CPVT-susceptibility genes: <italic toggle="yes">RYR2, CASQ2, CALM1-3, TRDN</italic>, and <italic toggle="yes">TECRL</italic>.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B91" ref-type="bibr">91</xref>,</sup>
<sup>
<xref rid="euac030-B141" ref-type="bibr">141&#x02013;145</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In phenotype-positive CPVT patients (definition: see rec. 1) who are negative for those established CPVT-susceptibility genes, genetic testing may be considered for CPVT phenocopies resulting from pathogenic variants in the <italic toggle="yes">KCNJ2, SCN5A</italic>, and <italic toggle="yes">PKP2</italic> genes.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B17" ref-type="bibr">17</xref>,</sup>
<sup>
<xref rid="euac030-B146" ref-type="bibr">146&#x02013;148</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In patients with a modest phenotype for CPVT (i.e. CPVT diagnostic score &#x02265; 2 but &#x0003c; 3.5<sup><xref rid="tblfn13" ref-type="table-fn">b</xref></sup>), genetic testing may be considered for the established definite/strong evidence CPVT-susceptibility genes: <italic toggle="yes">RYR2, CASQ2, CALM1-3, TRDN</italic>, and <italic toggle="yes">TECRL.</italic></td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B17" ref-type="bibr">17</xref>,</sup>
<sup>
<xref rid="euac030-B91" ref-type="bibr">91</xref>,</sup>
<sup>
<xref rid="euac030-B141" ref-type="bibr">141&#x02013;145</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant-specific genetic testing is recommended for family members and appropriate relatives following the identification of the disease-causative variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B149" ref-type="bibr">149</xref>,</sup>
<sup>
<xref rid="euac030-B150" ref-type="bibr">150</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children at risk of inheriting a P/LP variant is recommended from birth onward (any age).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table><table-wrap-foot><fn id="tblfn12"><label>a</label><p>Adapted from HRS/EHRA/APHRS Expert consensus recommendations on diagnosis of CPVT.<sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup></p></fn><fn id="tblfn13"><label>b</label><p>Adapted from Giudicessi <italic toggle="yes">et al</italic>.,<sup><xref rid="euac030-B151" ref-type="bibr">151</xref></sup> see <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S4</xref></italic>.</p></fn></table-wrap-foot></table-wrap><sec><title>Background</title><p>Catecholaminergic polymorphic ventricular tachycardia (VT) is an uncommon inherited arrhythmia syndrome with an unknown prevalence [estimated to be in the 1:20&#x000a0;000 range (personal guess, AW)]. It is characterized by polymorphic (rarely documented but typically bidirectional) ventricular arrhythmias in young individuals with structurally normal hearts. Catecholaminergic polymorphic ventricular tachycardia-associated arrhythmias are mediated adrenergically (i.e. occur during exercise or emotional stress), are often asymptomatic but may also cause syncope, syncope followed by generalized seizures, sudden cardiac arrest, and SCD.<sup><xref rid="euac030-B17" ref-type="bibr">17</xref>,</sup><sup><xref rid="euac030-B152" ref-type="bibr">152</xref>,</sup><sup><xref rid="euac030-B153" ref-type="bibr">153</xref></sup> Importantly, the occurrence of exercise-induced arrhythmias may be variable, so with a strong clinical suspicion more than one exercise test is warranted. CPVT is less common than other conditions causing SCD, yet disproportionately accounts for a high percentage (10&#x02013;15%) of SCD cases in the young,<sup><xref rid="euac030-B154" ref-type="bibr">154&#x02013;156</xref></sup> in &#x000b1;6% of those labelled as idiopathic ventricular fibrillation (IVF)<sup><xref rid="euac030-B157" ref-type="bibr">157</xref></sup> and in &#x000b1;1% of sudden infant death syndrome,<sup><xref rid="euac030-B158" ref-type="bibr">158</xref></sup> although the latter association is hard to confirm.</p></sec><sec><title>Diagnostic implications of catecholaminergic polymorphic ventricular tachycardia genetic testing</title><p>Catecholaminergic polymorphic ventricular tachycardia usually segregates as an AD trait but AR segregation is also possible (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T7" ref-type="table">7</xref></italic>). Compared to LQTS, there is also a higher frequency of sporadic <italic toggle="yes">de novo</italic> variants, particularly with the most common CPVT-causative gene, <italic toggle="yes">RYR2.</italic><sup><xref rid="euac030-B159" ref-type="bibr">159</xref>,</sup><sup><xref rid="euac030-B160" ref-type="bibr">160</xref></sup> This gene encodes the cardiac ryanodine receptor (RyR2), also called the calcium release channel and is responsible for release of calcium from the sarcoplasmic reticulum into the cytosol. Catecholaminergic polymorphic ventricular tachycardia 1-associated gain-of-function pathogenic variants in <italic toggle="yes">RYR2</italic> lead to a leaky RyR2 protein by various mechanisms. This in turn leads to increased diastolic cytosolic calcium levels with arrhythmic consequences, in particular under adrenergic circumstances. <italic toggle="yes">RyR2</italic> variants associated with a loss-of-function cellular phenotype are associated with the calcium release deficiency syndrome (CRDS), a newly described disease entity with specific electrophysiological characteristics distinguishable from CPVT.<sup><xref rid="euac030-B161" ref-type="bibr">161</xref>,</sup><sup><xref rid="euac030-B162" ref-type="bibr">162</xref></sup></p><table-wrap position="float" id="euac030-T7"><label>Table 7</label><caption><p>Genes implicated in catecholamine polymorphic ventricular tachycardia (CPVT)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<italic toggle="yes">Gene</italic>
</th><th align="left" rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Phenotype&#x02014;syndrome</th><th align="left" rowspan="1" colspan="1">Protein (functional effect)</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">RyR2</italic>
</td><td rowspan="1" colspan="1">1q43</td><td rowspan="1" colspan="1">CPVT/AD</td><td rowspan="1" colspan="1">RyR2 (&#x02191;); inappropriate Ca<sup>2+</sup> release from the SR</td><td rowspan="1" colspan="1">60&#x02013;70%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CASQ2</italic>
</td><td rowspan="1" colspan="1">1p13.1</td><td rowspan="1" colspan="1">CPVT/AR</td><td rowspan="1" colspan="1">Inappropriate Ca<sup>2+</sup> release from the SR</td><td rowspan="1" colspan="1">&#x000b1;5%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CASQ2</italic>
</td><td rowspan="1" colspan="1">1p13.1</td><td rowspan="1" colspan="1">CPVT/AD</td><td rowspan="1" colspan="1">Inappropriate Ca<sup>2+</sup> release from the SR</td><td rowspan="1" colspan="1">&#x000b1;5%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CALM 1&#x02013;3</italic>
</td><td rowspan="1" colspan="1">14q32.11<break/>2p21<break/>19q13.32</td><td rowspan="1" colspan="1">CPVT/AD</td><td rowspan="1" colspan="1">&#x02191; RyR2 binding affinity resulting in inappropriate Ca<sup>2+</sup> release from the SR</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Strong</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TECRL</italic>
<sup>
<xref rid="tblfn15" ref-type="table-fn">a</xref>
</sup>
</td><td rowspan="1" colspan="1">4q13.1</td><td rowspan="1" colspan="1">CPVT/AR</td><td rowspan="1" colspan="1">Altered Ca<sup>2+</sup> homeostasis, possibly linked to fatty acid/lipid metabolism</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TRDN</italic>
<sup>
<xref rid="tblfn15" ref-type="table-fn">a</xref>
</sup>
</td><td rowspan="1" colspan="1">6q22.31</td><td rowspan="1" colspan="1">CPVT/AR</td><td rowspan="1" colspan="1">&#x02193; expression leading to remodelling of the cardiac dyad/calcium release unit</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNJ2</italic>
</td><td rowspan="1" colspan="1">17q24.3</td><td rowspan="1" colspan="1">ATS/AD</td><td rowspan="1" colspan="1">Loss-of-<italic toggle="yes">I</italic><sub>K1</sub> channel function</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr></tbody></table><table-wrap-foot><fn id="tblfn14"><p>AD, autosomal dominant; AR, autosomal recessive.</p></fn><fn id="tblfn15"><label>a</label><p>
<italic toggle="yes">TECRL</italic> and <italic toggle="yes">TRDN</italic> may result in a CPVT-LQTS overlap phenotype consisting of modest QTc-prolongation and adrenergically triggered ventricular arrhythmia.</p></fn></table-wrap-foot></table-wrap><p>Other genes with an AD inheritance pattern are the 3 <italic toggle="yes">CALM</italic> genes, which also associate with other phenotypes, e.g. LQTS and IVF.<sup><xref rid="euac030-B91" ref-type="bibr">91</xref></sup> Those with a CPVT phenotype present at early age.<sup><xref rid="euac030-B91" ref-type="bibr">91</xref></sup> Genes with a predominant AR trait are <italic toggle="yes">CASQ2, TRDN</italic>, and <italic toggle="yes">TECRL</italic>.<sup><xref rid="euac030-B93" ref-type="bibr">93</xref>,</sup><sup><xref rid="euac030-B141" ref-type="bibr">141&#x02013;144</xref></sup> As expected, recessive CPVT is more severe than dominant CPVT.</p><p>A phenotype closely resembling CPVT is ATS, caused by functional loss-of-function variants in the gene <italic toggle="yes">KCNJ2</italic> encoding for the Kir2.1 inwardly rectifying potassium channel (<italic toggle="yes">I</italic><sub>K1</sub>).<sup><xref rid="euac030-B163" ref-type="bibr">163</xref></sup> Also the <italic toggle="yes">SCN5A</italic> associated phenotype Multifocal Purkinje-related Premature Contractions (MEPPC) can mimic CPVT although usually the ectopy burden is, as in ATS, also high in the resting state.<sup><xref rid="euac030-B146" ref-type="bibr">146</xref>,</sup><sup><xref rid="euac030-B147" ref-type="bibr">147</xref></sup> Finally, the <italic toggle="yes">PKP2</italic> gene, may in an earlier stage manifest as a disease without structural alterations but with adrenergically-mediated arrhythmias.<sup><xref rid="euac030-B148" ref-type="bibr">148</xref></sup> These genes might be tested in those patients with a CPVT-like phenotype, who are genotype negative for the strong CPVT genes (<xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S5</xref></italic>).</p><sec><title>Index cases</title><p>The yield of genetic testing in CPVT is highest (60%) in patients with a strong phenotype, i.e. a typical exercise test (occasionally including bi-directional VT).<sup><xref rid="euac030-B145" ref-type="bibr">145</xref>,</sup><sup><xref rid="euac030-B151" ref-type="bibr">151</xref>,</sup><sup><xref rid="euac030-B164" ref-type="bibr">164</xref></sup> In patients with a less typical clinical presentation [adrenergically induced syncope, IVF or isolated extrasystoles during the exercise test) the yield is much lower (15&#x02013;20%)].<sup><xref rid="euac030-B145" ref-type="bibr">145</xref>,</sup><sup><xref rid="euac030-B164" ref-type="bibr">164</xref></sup> This is not trivial because the &#x02018;background noise&#x02019; in the <italic toggle="yes">RYR2</italic> gene, i.e. the presence of benign variants, is a little over 3%. This raises the likelihood of a false-positive result in patients with a non-typical phenotype to 1 in 6 (compared to 1:20 in cases with a strong phenotype).<sup><xref rid="euac030-B164" ref-type="bibr">164</xref></sup> The latter findings have actually been used to propose a phenotype enhanced variant readjudication approach.<sup><xref rid="euac030-B151" ref-type="bibr">151</xref></sup> This approach significantly reduced the number of VUS by either promoting or demoting specific variants.<sup><xref rid="euac030-B151" ref-type="bibr">151</xref></sup> Specifically, akin to the &#x02018;Schwartz score&#x02019; for LQTS, Wilde and Ackerman introduced the analogous CPVT diagnostic score to improve the clinical veracity of the diagnosis of CPVT.<sup><xref rid="euac030-B151" ref-type="bibr">151</xref></sup> In patients with a CPVT diagnostic score of <underline>&#x0003e;</underline> 3.5 (without the genetic test result), the likelihood of CPVT1 (i.e. <italic toggle="yes">RYR2-</italic>mediated CPVT) is at least 60%. Furthermore, given that genetic test companies currently designate almost every novel missense variant in <italic toggle="yes">RYR2</italic> as a VUS because of the <italic toggle="yes">in silico</italic> challenges of assessing the pathogenicity of variants in the 4967 amino acid-containing protein, incorporation of this clinical score can assist physicians with decoding the genetic test result more accurately. For example, in a patient with a robust clinical score for CPVT but a VUS test result in <italic toggle="yes">RYR2,</italic> the genetic test ordering physician (the phenotyper) can upgrade that test with result to at least a &#x02018;likely pathogenic variant&#x02019; designation with 95% confidence.<sup><xref rid="euac030-B151" ref-type="bibr">151</xref></sup></p></sec><sec><title>Family screening</title><p>An active family screening approach is important in all CPVT families. Family-specific, cascade genetic testing for the identified CPVT-causative, pathogenic variant should be pursued regardless of symptom status and stress test expressivity. Even asymptomatic, normal stress test individuals who are genotype positive (i.e. genotype positive/phenotype negative) may require active therapy.<sup><xref rid="euac030-B149" ref-type="bibr">149</xref>,</sup><sup><xref rid="euac030-B150" ref-type="bibr">150</xref></sup></p><p>For many cases of CPVT2 stemming from homozygous variants in <italic toggle="yes">CASQ2</italic>, consanguinity is present. An alternative explanation is compound heterozygosity which is often the case for <italic toggle="yes">TRDN</italic>-mediated CPVT. The latter is part of the phenotypic spectrum of TKOS.<sup><xref rid="euac030-B93" ref-type="bibr">93</xref></sup> Heterozygous carriers of the relevant variants in <italic toggle="yes">TRDN</italic> and <italic toggle="yes">TECRL</italic> normally have no phenotype and do not need active treatment. This may not be true for family members heterozygous for a variant in <italic toggle="yes">CASQ2-</italic>encoded calsequestrin, which seems to suggest AD segregation.<sup><xref rid="euac030-B165" ref-type="bibr">165</xref></sup> In a more recent study, one-third of the heterozygous patients fulfil the diagnostic criteria for CPVT and some of them even presented with a cardiac arrest or exercise-related syncope.<sup><xref rid="euac030-B166" ref-type="bibr">166</xref></sup> These data were not considered sufficient to upscale the monoallelic gene status beyond the moderate level.<sup><xref rid="euac030-B17" ref-type="bibr">17</xref></sup> Yet, exercise-test-guided treatment is probably warranted in these patients.</p></sec></sec><sec><title>Prognostic and therapeutic implications of catecholaminergic polymorphic ventricular tachycardia genetic testing</title><p>While there is strong and obvious impact diagnostically with respect to CPVT genetic testing, the prognostic impact is less and the therapeutic impact is negligible currently. Prognostically, there are data to suggest that specific locations within the RyR2 (i.e. the C-terminal channel forming domain) may confer increased susceptibility to CPVT-triggered arrhythmias.<sup><xref rid="euac030-B167" ref-type="bibr">167</xref></sup> More importantly, patients with <italic toggle="yes">CALM</italic>-mediated CPVT are at increased risk,<sup><xref rid="euac030-B91" ref-type="bibr">91</xref></sup> and AR disease presents more often at earlier age and with more malignant arrhythmias. Therapeutically, in all CPVT genotypes, &#x000df;-adrenoceptor blockade (preferably with the non-selective beta blockers nadolol or propranolol) is the cornerstone of therapy, with upscaling therapy dependent on the (persistent) presence of symptoms and/or of ventricular arrhythmias during an exercise test, available in the form of combination drug therapy with the addition of Flecainide,<sup><xref rid="euac030-B168" ref-type="bibr">168</xref></sup> and LCSD.<sup><xref rid="euac030-B169" ref-type="bibr">169</xref></sup> Implantable cardioverter-defibrillator therapy should whenever possible be avoided in CPVT patients.<sup><xref rid="euac030-B170" ref-type="bibr">170</xref></sup> Patients satisfying a clinical diagnosis of CPVT but who are negative for both the established CPVT-causative genes and the genes underlying the CPVT phenocopies (i.e. genotype negative/phenotype positive) should also be treated similarly.<sup><xref rid="euac030-B149" ref-type="bibr">149</xref>,</sup><sup><xref rid="euac030-B167" ref-type="bibr">167</xref></sup></p></sec></sec><sec><title>Brugada syndrome</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T26"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Brugada syndrome</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T27"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Genetic testing with sequencing of <italic toggle="yes">SCN5A</italic> is recommended for an index case diagnosed with BrS with a type I ECG in standard or high precordial leads occurring either (i) spontaneously, or (ii) induced by sodium-channel blockade in presence of supporting clinical features or family history.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B21" ref-type="bibr">21</xref>,</sup>
<sup>
<xref rid="euac030-B171" ref-type="bibr">171</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Rare variants in genes with a disputed or refuted gene-disease clinical validity should not be reported routinely<sup><xref rid="tblfn16" ref-type="table-fn">a</xref></sup> for BrS genetic testing in a diagnostic setting.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B21" ref-type="bibr">21</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Targeted sequencing of variant(s) of unknown significance in <italic toggle="yes">SCN5A</italic> with a population allele frequency &#x0003c;1 &#x000d7; 10<sup>&#x02212;5</sup> identified in an index case can be considered concurrently with phenotyping for family members, following genetic counselling, to assess variant pathogenicity through co-segregation analysis.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B172" ref-type="bibr">172</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant-specific genetic testing is recommended for family members and appropriate relatives following the identification of the disease-causative variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing (of pathogenic <italic toggle="yes">SCN5A</italic> variants) in related children is recommended from birth onward (any age).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table><table-wrap-foot><fn id="tblfn16"><label>a</label><p>Unless in a research setting.</p></fn></table-wrap-foot></table-wrap><sec><title>Background</title><p>Brugada syndrome is an inherited arrhythmogenic disorder characterized by ST-segment elevation in the right precordial leads and malignant ventricular arrhythmias, sometimes associated with conduction disease and atrial arrhythmias. The prevalence of BrS is estimated to be 1 in 2000 worldwide, with higher prevalence in Asia.<sup><xref rid="euac030-B173" ref-type="bibr">173</xref></sup> Symptomatic patients are typically males presenting in their fourth decade of life.<sup><xref rid="euac030-B174" ref-type="bibr">174</xref>,</sup><sup><xref rid="euac030-B175" ref-type="bibr">175</xref></sup> Brugada syndrome may be involved in &#x0223c;18&#x02013;28% of unexplained sudden deaths/arrests.<sup><xref rid="euac030-B176" ref-type="bibr">176</xref>,</sup><sup><xref rid="euac030-B177" ref-type="bibr">177</xref></sup></p><p>According to the 2013 HRS/EHRA/APHRS expert consensus statement,<sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup> BrS is diagnosed in patients with ST-segment elevation with type I morphology &#x02265;2&#x02009;mm in &#x02265;1 lead among the right precordial leads V1, V2 positioned in the 4th intercostal space (standard ECG) or the 2nd and 3rd intercostal spaces (high parasternal leads),<sup><xref rid="euac030-B178" ref-type="bibr">178</xref></sup> observed either spontaneously or after provocative drug testing with a class I antiarrhythmic drug. In light of data highlighting the limited specificity of provocative testing,<sup><xref rid="euac030-B179" ref-type="bibr">179</xref></sup> the Shanghai scoring system was proposed whereby the diagnosis of definite BrS in presence of type I ECG that is only manifested with provocative testing also requires supporting clinical features (<xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S6</xref></italic>).<sup><xref rid="euac030-B180" ref-type="bibr">180</xref></sup> Brugada syndrome phenocopies such as myocardial ischaemia, electrolyte disturbances and drug intoxications should be excluded before a diagnosis of BrS can be made.<sup><xref rid="euac030-B181" ref-type="bibr">181</xref></sup> Drug-induced and fever-induced Brugada ECG pattern is not considered a BrS phenocopy and in both conditions genetic testing with sequencing of <italic toggle="yes">SCN5A</italic> may be considered.</p><p>Risk stratification in BrS relies primarily on symptoms and the ECG. Patients with suspected arrhythmic syncope with a spontaneous type I ECG are at high risk of malignant arrhythmic events (&#x0223c;2.3%/year<sup><xref rid="euac030-B182" ref-type="bibr">182</xref></sup>) and should consider ICD implantation.<sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup> Asymptomatic patients with drug-induced type I ECG are at low risk (&#x02264;0.4%/year<sup><xref rid="euac030-B183" ref-type="bibr">183</xref></sup>) and should be managed conservatively. All BrS patients should be counselled to (i) avoid drugs that impair cardiac sodium channels (brugadadrugs.org<sup><xref rid="euac030-B184" ref-type="bibr">184</xref></sup>), (ii) avoid alcohol intoxication, (iii) immediately treat fever with antipyretic drugs, and (iv) seek urgent medical attention following a syncope. The role of invasive electrophysiological testing for risk stratification remains controversial.</p></sec><sec><title>Diagnostic implications of Brugada syndrome genetic testing</title><p>Disease-causing rare genetic variants in <italic toggle="yes">SCN5A</italic> that result in loss of function of the cardiac sodium channel are identified in &#x0223c;20% of cases (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T8" ref-type="table">8</xref></italic>). In families with pathogenic <italic toggle="yes">SCN5A</italic> variants, penetrance is incomplete and non-carriers of the <italic toggle="yes">SCN5A</italic> variant may show a positive provocative drug challenge,<sup><xref rid="euac030-B185" ref-type="bibr">185</xref></sup> in line with the complex heritability of BrS. Case&#x02013;control GWAS in BrS identified several genetic loci harbouring common variants associated with the disease.<sup><xref rid="euac030-B60" ref-type="bibr">60</xref></sup> Polygenic scores derived from GWAS (PRS<sub>BrS</sub>) could underlie variable disease expressivity in carriers of <italic toggle="yes">SCN5A</italic> pathogenic variants.<sup><xref rid="euac030-B67" ref-type="bibr">67</xref></sup> Brugada syndrome in the absence of rare <italic toggle="yes">SCN5A</italic> variants is largely polygenic. PRS<sub>BrS</sub> are strongly associated with response to provocative drug testing.<sup><xref rid="euac030-B66" ref-type="bibr">66</xref></sup> For instance, a PRS<sub>BrS</sub> comprised of three common variants (rs11708996, rs10428132, and rs9388451) below the 10th percentile provides a sensitivity of 99% and a negative predictive value of 93% for drug-induced type I ECG, based on a population of 1368 patients that underwent ajmaline testing for suspected BrS.<sup><xref rid="euac030-B66" ref-type="bibr">66</xref></sup> Assessment of PRS<sub>BrS</sub> that include more genetic variation associated with BrS is ongoing.</p><table-wrap position="float" id="euac030-T8"><label>Table 8</label><caption><p>Gene implicated in Brugada syndrome</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<italic toggle="yes">Gene</italic>
</th><th rowspan="1" colspan="1">Locus</th><th rowspan="1" colspan="1">Phenotype&#x02014;syndrome</th><th rowspan="1" colspan="1">Protein (functional effect)</th><th rowspan="1" colspan="1">Frequency</th><th rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">SCN5A</italic>
</td><td rowspan="1" colspan="1">3p22.2</td><td rowspan="1" colspan="1">BrS/AD</td><td rowspan="1" colspan="1">Loss of <italic toggle="yes">I</italic><sub>Na1.5</sub> channel function</td><td rowspan="1" colspan="1">15&#x02013;30%</td><td rowspan="1" colspan="1">Definite</td></tr></tbody></table></table-wrap><p>Other genes have been implicated in BrS (<xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S7</xref></italic>). However, the gene-disease validity of most of those genes (other than <italic toggle="yes">SCN5A</italic>) has been <italic toggle="yes">disputed</italic> following rigorous assessment of available data using the ClinGen framework.<sup><xref rid="euac030-B21" ref-type="bibr">21</xref></sup> Although a <italic toggle="yes">disputed</italic> ClinGen status does not challenge a role of the gene product in BrS pathophysiology, it strongly argues against reporting those genes in the diagnostic setting. An algorithm for genetic testing of index cases with BrS and family members is shown in <italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F4" ref-type="fig">4</xref></italic>.</p><fig position="float" id="euac030-F4"><label>Figure 4</label><caption><p>Clinical algorithm for genetic testing and family screening in Brugada syndrome.</p></caption><graphic xlink:href="euac030f4" position="float"/></fig><sec><title>Index cases</title><p>The presence of a LP/P <italic toggle="yes">SCN5A</italic> variant confirms the diagnosis of BrS in probands with a type I ECG, but the absence of such variant does not exclude the diagnosis. In drug-induced type I BrS pattern in the absence of supporting clinical context and family history, it can be considered to perform <italic toggle="yes">SCN5A</italic> testing for the purpose of risk prediction, management and family screening. Interestingly, according to the Shanghai score, adding an <italic toggle="yes">SCN5A</italic> P/LP variant to a patient with &#x02018;isolated&#x02019; drug-induced type 1 would increase his score from 2.0 to 2.5 which remains insufficient for &#x02018;probable/definite BrS&#x02019;.<sup><xref rid="euac030-B169" ref-type="bibr">169</xref></sup></p></sec><sec><title>Family screening</title><p>Genetic testing should be offered to family members regardless of age<sup><xref rid="euac030-B186" ref-type="bibr">186</xref></sup> when a LP/P <italic toggle="yes">SCN5A</italic> variant is identified in a relative with BrS. Carriers of such variants should be instructed to take the same precautions as those with BrS (see above). Asymptomatic relatives who do not carry the <italic toggle="yes">SCN5A</italic> variant and have a completely normal resting ECG (also in the higher placed leads) can be discharged. Although phenotype positive-genotype negative family members have been described in genotype positive families,<sup><xref rid="euac030-B173" ref-type="bibr">173</xref></sup> standard provocative testing in these individuals is not supported by current data. Screening of relatives of <italic toggle="yes">SCN5A</italic> negative BrS probands should be done clinically using an ECG (also with high parasternal leads). Provocative testing can be considered based on patient&#x02019;s symptoms, resting ECG and personal preference, for the sake of prevention (treatment of fever, avoidance of drugs (brugadadrugs.org), and avoidance of alcohol intoxication). It should be noted and discussed with the patient prior to provocative testing that a positive provocative test in the absence of symptoms and <italic toggle="yes">SCN5A</italic> (P/LP) variant is diagnostic for BrS but is associated with a very low arrhythmic event rate, and should therefore be managed conservatively. In a large study from a single centre<sup><xref rid="euac030-B66" ref-type="bibr">66</xref></sup> which included relatives of <italic toggle="yes">SCN5A</italic> negative BrS probands, PRS<sub>BrS</sub> was significantly associated with drug-induced BrS, highlighting its potential in clinical practice. Yet, further studies in other cohorts are needed before widespread use of polygenic scores in BrS.</p><p>Of note, several pathogenic <italic toggle="yes">SCN5A</italic> variants are associated with a phenotype with both right precordial ST-segment elevation as well as QTc prolongation.<sup><xref rid="euac030-B187" ref-type="bibr">187</xref></sup> Clearly, in the family screening process the QTc should also carefully be evaluated and affected individuals should also avoid drugs from the <ext-link xlink:href="http://www.crediblemeds.org" ext-link-type="uri">www.crediblemeds.org</ext-link> list.</p></sec></sec><sec><title>Prognostic and therapeutic implications of Brugada syndrome genetic testing</title><p>Brugada syndrome patients with pathogenic <italic toggle="yes">SCN5A</italic> variants exhibit more conduction abnormalities,<sup><xref rid="euac030-B188" ref-type="bibr">188</xref>,</sup><sup><xref rid="euac030-B189" ref-type="bibr">189</xref></sup> and have worse arrhythmic outcomes.<sup><xref rid="euac030-B171" ref-type="bibr">171</xref>,</sup><sup><xref rid="euac030-B189" ref-type="bibr">189</xref>,</sup><sup><xref rid="euac030-B190" ref-type="bibr">190</xref></sup> The presence of <italic toggle="yes">SCN5A</italic> pathogenic variants does not, by itself, justify prophylactic ICD implantation, but should trigger an aggressive management in presence of clinical risk markers such as (arrhythmic) syncope. Because of the risk of conduction disturbance, the presence and type of <italic toggle="yes">SCN5A</italic> pathogenic variants should also be considered when selecting an implantable device, in addition to the baseline ECG and arrhythmia documentation.</p></sec></sec><sec><title>(Progressive) cardiac conduction disease</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T28"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cardiac conduction disease</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T29"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Targeted genetic testing is recommended as part of the diagnostic evaluation for index patients with isolated cardiac conduction disease (CCD/PCCD) or with concomitant structural heart disease or extracardiac disease, when there is early age of diagnosis or a suspicion of laminopathy, especially when there is documentation of a positive family history of CCD/PCCD.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Targeted genetic testing may be considered as part of the diagnostic evaluation for index patients with isolated cardiac conduction disease (CCD/PCCD) or with concomitant structural heart disease or extracardiac disease, especially in the setting of a positive family history.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Variant-specific genetic testing is recommended for family members and appropriate relatives following the identification of the disease-causative variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children may be considered from birth onward (any age) in specific settings.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table></table-wrap><sec><title>Background</title><p>Cardiac conduction disease (CCD) is a heterogeneous and often age-dependent, progressive cardiac conduction disease (PCCD) disorder characterized by a disturbed electrical impulse propagation in the atrioventricular (AV) node and His-Purkinje system. On the surface ECG, prolonged P-wave duration, AV block, and different degrees of bundle branch block (manifested as QRS fragmentation or QRS widening with normal or abnormal axis deviation) are typical features. Syncope or even cardiac arrest can occur from severe sinus node disease (manifested with sinus bradycardia or significant sinus pauses) of from complete AV block.<sup><xref rid="euac030-B191" ref-type="bibr">191</xref>,</sup><sup><xref rid="euac030-B192" ref-type="bibr">192</xref></sup></p><p>Fibrotic degeneration, ischaemia, infiltrative processes, valve calcifications, tumours, or thyroid dysfunction may lead to acquired dysfunction and CCD. However, in idiopathic or familial forms heritable factors significantly contribute to CCD/PCCD (Len&#x000e8;gre&#x02019;s disease). Isolated forms (&#x02018;primary electrical heart diseases&#x02019;) can be distinguished from CCD/PCCD in the setting of cardiomyopathies (typically DCM) or of syndromic disorders, e.g. with CHD or neurological phenotypes (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T9" ref-type="table">9</xref></italic>). Clinical disease expression may vary between pathogenic variant carriers within the family, but also between different families and often has an age-dependent course.</p><table-wrap position="float" id="euac030-T9"><label>Table 9</label><caption><p>Genes implicated in CCD/PCCD</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<italic toggle="yes">Gene</italic>
</th><th align="left" rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Phenotype&#x02014;syndrome</th><th align="left" rowspan="1" colspan="1">Protein (functional effect)</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td colspan="6" rowspan="1">
<bold>Genes for isolated SND</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">SCN5A</italic></td><td rowspan="1" colspan="1">3p22.2</td><td rowspan="1" colspan="1">BrS1, SND, ASS, (LQT3)<sup><xref rid="euac030-B194" ref-type="bibr">194&#x02013;196</xref>,</sup><sup><xref rid="euac030-B203" ref-type="bibr">203</xref>,</sup><sup><xref rid="euac030-B204" ref-type="bibr">204</xref></sup></td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Cardiac Na channel &#x003b1; subunit (Nav1.5)</p></list-item><list-item><p>Loss-of-function, <italic toggle="yes">I</italic><sub>Na</sub> &#x02193;</p></list-item></list>
</td><td rowspan="1" colspan="1">&#x0003e;10%</td><td rowspan="1" colspan="1">NA/major gene; definite for LQTS, BrS1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">TRPM4</italic></td><td rowspan="1" colspan="1">19q13.33</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B205" ref-type="bibr">205</xref>,</sup>
<sup>
<xref rid="euac030-B206" ref-type="bibr">206</xref>
</sup>
</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Transient receptor potential melastatin 4 channel</p></list-item><list-item><p>Gain-of-function</p></list-item></list>
</td><td rowspan="1" colspan="1">1&#x02013;10%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td colspan="6" rowspan="1">
<bold>Genes for syndromal disorders with CCD/PCCD</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">LMNA</italic></td><td rowspan="1" colspan="1">1q22</td><td rowspan="1" colspan="1">DCM (CMD1A), AFib, SND (Emery-Dreifuss muscular dystrophy 2/3, congenital muscular dystrophy, limb-girdle myopathy, familial lipodystrophy type 2, Hutchinson-Gilford progeria, and various other disorders)<sup><xref rid="euac030-B197" ref-type="bibr">197</xref>,</sup><sup><xref rid="euac030-B199" ref-type="bibr">199</xref>,</sup><sup><xref rid="euac030-B200" ref-type="bibr">200</xref></sup></td><td rowspan="1" colspan="1">Lamin A/C</td><td rowspan="1" colspan="1">&#x0003e;10%</td><td rowspan="1" colspan="1">NA/major gene; definite for DCM</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">DES</italic></td><td rowspan="1" colspan="1">2q35</td><td rowspan="1" colspan="1">DCM (CMD1I), ACM, Myofibrillar myopathy (MFM1)</td><td rowspan="1" colspan="1">Desmin</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>NA/rare gene;</p></list-item><list-item><p>Definite for DCM, moderate for ACM</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">DMD</italic></td><td rowspan="1" colspan="1">Xp21.2-p21.1</td><td rowspan="1" colspan="1">DCM (CMD3B), muscular dystrophy (Becker or Duchenne type)<sup><xref rid="euac030-B207" ref-type="bibr">207</xref></sup></td><td rowspan="1" colspan="1">Dystrophin</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#x02003;DMPK</italic>
</td><td rowspan="1" colspan="1">19q13.32</td><td rowspan="1" colspan="1">DCM, myotonic dystrophy (DM1)<sup><xref rid="euac030-B208" ref-type="bibr">208</xref></sup></td><td rowspan="1" colspan="1">Myotonic dystrophy protein kinase</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">EMD</italic></td><td rowspan="1" colspan="1">Xq28</td><td rowspan="1" colspan="1">DCM, LVNC, SND, Emery-Dreifuss muscular dystrophy (EMD)<sup><xref rid="euac030-B209" ref-type="bibr">209</xref>,</sup><sup><xref rid="euac030-B210" ref-type="bibr">210</xref></sup></td><td rowspan="1" colspan="1">Emerin</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#x02003;LAMP2</italic>
</td><td rowspan="1" colspan="1">Xq24</td><td rowspan="1" colspan="1">HCM, DCM, LVNCDanon disease (glycogen storage disease), skeletal muscle involvement, mental retardation<sup><xref rid="euac030-B211" ref-type="bibr">211</xref></sup></td><td rowspan="1" colspan="1">Lysosomal-associated membrane protein 2</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>NA/rare gene;</p></list-item><list-item><p>Definite for HCM</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">ZNF9</italic></td><td rowspan="1" colspan="1">3q21.3</td><td rowspan="1" colspan="1">DCM, myotonic dystrophy (DM2)<sup><xref rid="euac030-B212" ref-type="bibr">212</xref></sup></td><td rowspan="1" colspan="1">Zink finger protein 9 (CZNP)</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">GLA</italic></td><td rowspan="1" colspan="1">Xq22.1</td><td rowspan="1" colspan="1">Fabry disease (HCM, RCM, acral paresthaesia, PNP, kidney insufficiency, angio-keratoma, anhydrosis, cornea verticillata, etc.)</td><td rowspan="1" colspan="1">Galactosidase &#x003b1;</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene; definite for HCM</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">PRKAG2</italic></td><td rowspan="1" colspan="1">7q36.1</td><td rowspan="1" colspan="1">Cardiac preexcitation (WPW), LVH/HCM,<sup><xref rid="euac030-B213" ref-type="bibr">213</xref></sup></td><td rowspan="1" colspan="1">AMP-activated protein kinase &#x003b3;2-subunit</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene; definite for HCM</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">TNNI3K</italic></td><td rowspan="1" colspan="1">1p31.1</td><td rowspan="1" colspan="1">DCM, AFIB<sup><xref rid="euac030-B214" ref-type="bibr">214</xref></sup></td><td rowspan="1" colspan="1">Troponin I-interacting MAP kinase</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">NKX2-5</italic></td><td rowspan="1" colspan="1">5q35.1</td><td rowspan="1" colspan="1">ASD7, (VSD7, TOF)</td><td rowspan="1" colspan="1">Transcription factor Nkx2.5</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">GJC1</italic></td><td rowspan="1" colspan="1">&#x000a0;17q21.31</td><td rowspan="1" colspan="1">Bone malformations (brachyfacial pattern, finger deformity, and dental dysplasia)<sup><xref rid="euac030-B215" ref-type="bibr">215</xref></sup></td><td rowspan="1" colspan="1">Connexin 45</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">TBX5</italic></td><td rowspan="1" colspan="1">12q24.21</td><td rowspan="1" colspan="1">Holt-Oram syndrome (HOS) (hand-heart syndrome): ASD, hand and limb malformation (e.g., triphalangeal thumb), other CHD</td><td rowspan="1" colspan="1">Transcription factor TBX5</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">MYL4</italic></td><td rowspan="1" colspan="1">17q21.32</td><td rowspan="1" colspan="1">AFib/conduction disease</td><td rowspan="1" colspan="1">atrial-specific myosin light chain</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">mtDNA</italic></td><td rowspan="1" colspan="1">Mitochondrial DNA</td><td rowspan="1" colspan="1">Kearns-Sayre syndrome (KSS): Ptosis, progressive external ophthalmoplegia, ataxia, retinitis pigmentosa; Chronic progressive external ophthalmoplegia (CPEO), ptosis<sup><xref rid="euac030-B216" ref-type="bibr">216</xref></sup></td><td rowspan="1" colspan="1">(37 mitochondrial genes)</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr></tbody></table><table-wrap-foot><fn id="tblfn17"><p>Frequency: refers to mutation detection rate;<sup><xref rid="euac030-B25" ref-type="bibr">25</xref></sup> core genes: major (&#x0003e;10%) or minor (1&#x02013;10%); rare gene (&#x0003c;1%); (): mutation rate unknown and/or single reports.</p></fn><fn id="tblfn18"><p>Other phenotypes: [&#x02026;], phenotype associated with gene, but unlinked with CCD/PCCD.</p></fn><fn id="tblfn19"><p>ClinGen: Clinical Genome Resource of NCBI; <ext-link xlink:href="https://clinicalgenome.org" ext-link-type="uri">https://clinicalgenome.org</ext-link>, NA: not available = not yet curated.</p></fn><fn id="tblfn20"><p>ACM, arrhythmogenic cardiomyopathy; AFib, atrial fibrillation; ASD, atrial septal defect; ASS, atrial stand still; BrS, Brugada syndrome, CHD, congenital heart disease, DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LQT, long-QT syndrome subtype; LVH, left ventricular hypertrophy; LVNC, left ventricular non-compaction cardiomyopathy; PNP, polyneuropathy; WPW, Wolff&#x02013;Parkinson&#x02013;White syndrome; RCM, restrictive cardiomyopathy; SND, sinus node dysfunction; TOF, Tetralogy of Fallot; VSD, ventricular septal defect; X-chr., X-chromosomal.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Diagnostic implications of genetic testing in cardiac conduction disease/progressive cardiac conduction disease</title><p>Cardiac conduction disease/PCCD is genetically heterogeneous;<sup><xref rid="euac030-B193" ref-type="bibr">193</xref></sup> in the majority of CCD families an AD mode of inheritance is pertinent, whereas CCD/PCCD in the setting of some neuromuscular disorders is X-chromosomal linked and severely affects male patients. A <italic toggle="yes">de novo</italic> or recessive occurrence is rare.<sup><xref rid="euac030-B194" ref-type="bibr">194</xref>,</sup><sup><xref rid="euac030-B195" ref-type="bibr">195</xref></sup> Most pathogenic variants are non-synonymous or truncating pathogenic variants; so far, the frequency of small indels and CNV has not been addressed systematically.</p><p>Susceptible genes for each CCD subgroup are listed below (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T9" ref-type="table">9</xref></italic>, <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S8</xref></italic>). The overall and gene-specific mutation yield (sensitivity) is unknown and also for each gene; however, recent studies using targeted or WES suggested a pathogenic variant detection rate of &#x0003e;50% in index cases, with <italic toggle="yes">SCN5A</italic> and <italic toggle="yes">LMNA</italic> as core genes,<sup><xref rid="euac030-B196" ref-type="bibr">196</xref>,</sup><sup><xref rid="euac030-B197" ref-type="bibr">197</xref></sup> accounting for &#x0223c;20% each (<italic toggle="yes">TRPM4</italic>: 5&#x02013;10%). This also implies that in a measurable fraction of cases, including family clusterings of diseases, investigations of associated known heart disease genes are still insufficient to reveal the underlying substrate, suggesting that new causal genes have yet to be discovered.</p><sec><title>Index case</title><p>Upon the ECG diagnosis of CCD/PCCD and without evidence for acquired causes, an inherited form appears likely. However, cardiac sarcoidosis is a relatively common diagnosis in isolated AV block and should be systematically excluded before a genetic diagnosis is considered in sporadic isolated AV block. Screening for cardiac sarcoidosis (using CMR or positron emission tomography&#x02013;fluorodeoxyglucose) in patients younger than 60&#x02009;years with unexplained second-degree (Mobitz II) or third-degree AV block can be useful.<sup><xref rid="euac030-B198" ref-type="bibr">198</xref></sup> Further routine work-up includes exercise ECG, Holter ECG and echocardiography to address presence of a cardiomyopathy or CHD. Cardiac magnetic resonance imaging (MRI) (with gadolinium enhancement) may be considered, in particular for <italic toggle="yes">LMNA</italic> pathogenic variant carriers.<sup><xref rid="euac030-B193" ref-type="bibr">193</xref>,</sup><sup><xref rid="euac030-B199" ref-type="bibr">199</xref>,</sup><sup><xref rid="euac030-B200" ref-type="bibr">200</xref></sup> Early-onset or idiopathic forms of CCD/PCCD should prompt consideration of genetic testing, especially if the family history is indicative (CCD/PCCD, pacemaker implants, cardiomyopathy, etc.).</p><p>For the major genes associated with CCD, specialized cardiogenetic services have established targeted gene panels for CCD/PCCD testing. Four genes (<italic toggle="yes">SCN5A, LMNA, GLA</italic>, and <italic toggle="yes">PRKAG2</italic>; <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T9" ref-type="table">9</xref></italic>) are therefore recommended to be investigated.<sup><xref rid="euac030-B50" ref-type="bibr">50</xref></sup> The identification of a pathogenic variant in a disease-validated gene confirms not only the suspected diagnosis of CCD/PCCD, but also allows its classification as a genetic (and potentially heritable) disorder with or without additional clinical features.</p></sec><sec><title>Family investigation</title><p>A careful clinical and, if suitable [i.e. with knowledge of the pathogenic (ACMG class 4/5 i.e. LP/P) variant in a validated CCD/PCCD gene], genetic investigation is recommended and therefore indicated in family members as a part of a directed &#x02018;family cascade screening&#x02019;. This includes a comprehensive assessment of the family pedigree. In relatives testing negative for this pathogenic variant, monitoring for CCD/PCCD or its development and downstream investigations in the family branch are not further needed. In contrast, pathogenic variant-positive family members should be evaluated carefully for the presence of isolated or syndromic forms of CCD/PCCD with regard to typical phenotypic features of the underlying gene (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T9" ref-type="table">9</xref></italic>). In addition, genotype-dependant recommendations will be similar to those for the index case. Asymptomatic children in the first decade of life do not strictly needed to be investigated for their genetic status, although in specific settings an earlier evaluation may be pertinent.</p></sec></sec><sec><title>Prognostic and therapeutic implications of genetic testing</title><p>Genotype may not clearly stratify risk of CCD progression, but different underlying inherited aetiologies for CCD do give prognostic information, e.g. LMNA for SCD risk. In addition, pathogenic variants in distinct genes (e.g. <italic toggle="yes">LMNA, TNNI3K</italic>) may be associated with development of heart failure, whereas other genes may exhibit extracardiac features, such as myopathy, which require additional, specialized treatment. Patients with <italic toggle="yes">LMNA</italic> pathogenic variants may develop atrial and ventricular arrhythmias as well as progressive (end-stage) heart failure and the potential need for ICD or cardiac resynchronization therapy defibrillator therapy (upon the development of phenotypic expression) or heart transplantation.<sup><xref rid="euac030-B200" ref-type="bibr">200&#x02013;202</xref></sup> A risk stratification scheme has recently been proposed.<sup><xref rid="euac030-B200" ref-type="bibr">200</xref></sup> Patients with <italic toggle="yes">SCN5A</italic> pathogenic variants may also develop BrS, so avoidance of particular drugs and fever is recommended to reduce ventricular arrhythmias.</p></sec></sec><sec><title>Short QT syndrome</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T30"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SQTS</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T31"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">In any patient satisfying the diagnostic criteria for SQTS (such as Class 1 clinical diagnosis<sup><xref rid="tblfn21" ref-type="table-fn">a</xref></sup> or SQTS diagnostic score <underline>&#x0003e;</underline>4<sup><xref rid="tblfn22" ref-type="table-fn">b</xref></sup>), molecular genetic testing is recommended for the definitive disease associated genes (currently <italic toggle="yes">KCNH2, KCNQ1</italic>).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B17" ref-type="bibr">17</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Testing of <italic toggle="yes">KCNJ2</italic> and <italic toggle="yes">SLC4A3</italic> may be performed in all index patients in whom a cardiologist has established with a high probability a diagnosis of SQTS, based on examination of the patient&#x02019;s clinical history, family history, and ECG characteristics obtained at baseline or during ECG Holter recording and exercise stress test (SQTS diagnostic score &#x02265;4).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B17" ref-type="bibr">17</xref>,</sup>
<sup>
<xref rid="euac030-B217" ref-type="bibr">217</xref>,</sup>
<sup>
<xref rid="euac030-B218" ref-type="bibr">218</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant-specific genetic testing is recommended for family members and appropriate relatives following the identification of the disease-causative variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children may be considered in specific settings.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table><table-wrap-foot><fn id="tblfn21"><label>a</label><p>Adapted from HRS/EHRA/APHRS Expert consensus recommendations on diagnosis of SQTS.<sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup></p></fn><fn id="tblfn22"><label>b</label><p>Adapted from Gollob <italic toggle="yes">et al</italic>.,<sup><xref rid="euac030-B219" ref-type="bibr">219</xref></sup> see <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S9</xref></italic>.</p></fn></table-wrap-foot></table-wrap><sec><title>Background</title><p>Short QT syndrome is a very rare channelopathy, characterized by a short QT interval on the basal ECG and by an increased risk of both atrial and ventricular arrhythmias.<sup><xref rid="euac030-B15" ref-type="bibr">15</xref>,</sup><sup><xref rid="euac030-B96" ref-type="bibr">96</xref></sup> The QT evaluation should be performed not only in basal condition but also during ECG Holter recording and exercise stress test, as typical of this disease is the reduced rate-adaptation of QT during exercise<sup><xref rid="euac030-B220" ref-type="bibr">220</xref></sup> and the evidence of a short QTc at different heart rates and not only during bradycardia.<sup><xref rid="euac030-B96" ref-type="bibr">96</xref></sup> The cut-off value of &#x02018;short&#x02019; QT interval for defining SQTS remains a matter of debate as there is an overlap between healthy subjects and patients with SQTS. Short QT syndrome is usually diagnosed in the presence of a QTc consistently below 330&#x02013;340&#x02009;ms; while between 340 and 360&#x02009;ms additional criteria are needed and specifically, the presence of a pathogenic variant, family history of SQTS, family history of SCD below age 40 or survival after an episode of VT/VF in the absence of heart disease.<sup><xref rid="euac030-B15" ref-type="bibr">15</xref>,</sup><sup><xref rid="euac030-B96" ref-type="bibr">96</xref></sup> No specific triggers for life-threatening arrhythmias have been recognized and age at presentation is quite variable.</p></sec><sec><title>Diagnostic implications of short QT syndrome genetic testing</title><p>Short QT syndrome is a genetically heterogeneous AD disease. Four SQTS-susceptibility potassium channel genes, <italic toggle="yes">KCNH2</italic>,<sup><xref rid="euac030-B221" ref-type="bibr">221</xref></sup><italic toggle="yes">KCNQ1</italic>,<sup><xref rid="euac030-B222" ref-type="bibr">222</xref></sup><italic toggle="yes">KCNJ2</italic>,<sup><xref rid="euac030-B217" ref-type="bibr">217</xref></sup> and <italic toggle="yes">SLC4A3</italic><sup><xref rid="euac030-B223" ref-type="bibr">223</xref></sup> have been identified (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T10" ref-type="table">10</xref></italic>). Only the first two genes have a definite or strong disease association.<sup><xref rid="euac030-B17" ref-type="bibr">17</xref></sup> Pathogenic variants in the first three genes yield a gain-of-function to their encoded potassium channel. A missense mutation in <italic toggle="yes">SLC4A3</italic><sup><xref rid="euac030-B223" ref-type="bibr">223</xref></sup> encoding the anion exchange protein 3 (AE3) has been identified in two large families with SQTS by WES. Although the functional change of the mutation supports a contribution to the accelerated repolarization, further study will be necessary. Loss of function type mutations in L-type calcium channel related genes, <italic toggle="yes">CACNA1C, CACNA2b</italic>,<sup><xref rid="euac030-B224" ref-type="bibr">224</xref></sup> and <italic toggle="yes">CACNA2D1</italic><sup><xref rid="euac030-B218" ref-type="bibr">218</xref></sup> have been linked to SQTS<sup><xref rid="euac030-B17" ref-type="bibr">17</xref></sup> (<xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S10</xref></italic>), frequently showing overlapping BrS features.<sup><xref rid="euac030-B224" ref-type="bibr">224</xref></sup> However, the evidence of these genes is limited at most.</p><table-wrap position="float" id="euac030-T10"><label>Table 10</label><caption><p>Genes implicated in short QT syndrome (SQTS)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<italic toggle="yes">Gene</italic>
</th><th rowspan="1" colspan="1">Locus</th><th rowspan="1" colspan="1">Phenotype&#x02014;syndrome</th><th rowspan="1" colspan="1">Protein (functional effect)</th><th rowspan="1" colspan="1">Frequency</th><th rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNH2</italic>
</td><td rowspan="1" colspan="1">7q35-36</td><td rowspan="1" colspan="1">SQTS/AD</td><td rowspan="1" colspan="1">Increase in <italic toggle="yes">I</italic><sub>Kr</sub> channel function</td><td rowspan="1" colspan="1">&#x0003c;10%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNQ1</italic>
</td><td rowspan="1" colspan="1">11p15.5</td><td rowspan="1" colspan="1">SQTS/AD</td><td rowspan="1" colspan="1">Increase in <italic toggle="yes">I</italic><sub>Ks</sub> channel function</td><td rowspan="1" colspan="1">5%</td><td rowspan="1" colspan="1">Strong</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNJ2</italic>
</td><td rowspan="1" colspan="1">17q23</td><td rowspan="1" colspan="1">SQTS/AD</td><td rowspan="1" colspan="1">Increase in <italic toggle="yes">I</italic><sub>K1</sub> channel function</td><td rowspan="1" colspan="1">&#x000b1;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">SLC4A3</italic>
</td><td rowspan="1" colspan="1">2q35</td><td rowspan="1" colspan="1">SQTS/AD</td><td rowspan="1" colspan="1">pH (&#x02191;) and Cl&#x02212; (&#x02193;)</td><td rowspan="1" colspan="1">&#x0003c;1%<sup><xref rid="tblfn25" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">Strong&#x02013;moderate<sup><xref rid="tblfn26" ref-type="table-fn">b</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn24"><p>Functional effect: (&#x02193;) loss-of-function or (&#x02191;) gain-of-function at the cellular <italic toggle="yes">in vitro</italic> level.</p></fn><fn id="tblfn25"><label>a</label><p>Might be significantly higher (personal communication AAMW and MG).</p></fn><fn id="tblfn26"><label>b</label><p>Classification discussed between members of the Clin Gen curation panel. Maybe become strong based on new data (personal communication AAMW and MG).</p></fn><fn id="tblfn23"><p>BrS, Brugada syndrome; SQTS, short QT syndrome.</p></fn></table-wrap-foot></table-wrap><sec><title>Index cases</title><p>Short QT syndrome is diagnosed clinically in index patients<sup><xref rid="euac030-B13" ref-type="bibr">13</xref>,</sup><sup><xref rid="euac030-B15" ref-type="bibr">15</xref>,</sup><sup><xref rid="euac030-B219" ref-type="bibr">219</xref></sup> and the presence of a disease-causing variant is a key finding to support the diagnosis above all in cases in which the QTc is short, but not below 330&#x02013;340&#x02009;ms.<sup><xref rid="euac030-B13" ref-type="bibr">13</xref>,</sup><sup><xref rid="euac030-B15" ref-type="bibr">15</xref>,</sup><sup><xref rid="euac030-B219" ref-type="bibr">219</xref></sup> Genetic screening for two potassium channel genes (<italic toggle="yes">KCNQ1</italic> and <italic toggle="yes">KCNH2</italic>) is recommended and for two other genes (<italic toggle="yes">KCNJ2</italic> and <italic toggle="yes">SLC4A3</italic>) may be considered for index cases<sup><xref rid="euac030-B17" ref-type="bibr">17</xref></sup> (<italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F5" ref-type="fig">5</xref></italic>). Compared to loss-of function mutations identified in LQTS, the reported number of mutations in SQTS is very small.<sup><xref rid="euac030-B225" ref-type="bibr">225</xref></sup> All other genes should be screened in patients with a high probability of the disease and only in experienced centres as variant interpretation may be critical. If a SQTS patient shows an overlapping phenotype with BrS, mutations in L-type calcium channel related genes may be involved.</p><fig position="float" id="euac030-F5"><label>Figure 5</label><caption><p>Clinical algorithm for genetic testing and family screening in short-QT syndrome. <sup>a</sup>Adapted from HRS/EHRA/APHRS Expert consensus recommendations on diagnosis of SQTS.<sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup><sup>b</sup>Adapted from Gollob <italic toggle="yes">et al.</italic>,<sup><xref rid="euac030-B219" ref-type="bibr">219</xref></sup> see <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S9</xref></italic>.</p></caption><graphic xlink:href="euac030f5" position="float"/></fig><p>A short QTc is also found in patients with the AR primary systemic carnitine deficiency syndrome, which is characterized by hypoketotic hypoglycaemia, hyperammonaemia, liver dysfunction, hypotonia, and cardiomyopathy and caused by variants in <italic toggle="yes">SLC22A5</italic>.<sup><xref rid="euac030-B226" ref-type="bibr">226</xref></sup> Indeed, homozygote or compound heterozygote variants have been identified in unexplained SCD or resuscitated cardiac arrest cases without overt extra-cardiac manifestations.<sup><xref rid="euac030-B227" ref-type="bibr">227</xref>,</sup><sup><xref rid="euac030-B228" ref-type="bibr">228</xref></sup> The QT interval in these patients is responsive to carnitine supplementation treatment.<sup><xref rid="euac030-B227" ref-type="bibr">227</xref>,</sup><sup><xref rid="euac030-B228" ref-type="bibr">228</xref></sup></p></sec><sec><title>Family screening</title><p>Cascade screening in family members is indicated whenever a definite disease-causing variant is identified in the index case. However, results should be managed carefully.</p></sec></sec><sec><title>Prognostic and therapeutic implications of short QT syndrome genetic testing</title><p>Implantation of an ICD with/without hydroquinidine is recommended for high-risk patients independent of genetic status. In the long-term follow-up of SQTS patients, hydroquinidine prevented events, and the QT prolongation effect was more relevant in KCNH2-based patients.<sup><xref rid="euac030-B229" ref-type="bibr">229</xref></sup> In asymptomatic patients and family members with pathogenic variants, hydroquinidine prolonged QT intervals, though its efficacy for preventing life-threatening arrhythmias still needs to be proved.<sup><xref rid="euac030-B230" ref-type="bibr">230</xref>,</sup><sup><xref rid="euac030-B231" ref-type="bibr">231</xref></sup> There are some phenotypic differences among different genotypes. The onset of arrhythmias in <italic toggle="yes">KCNH2</italic>-based patients seems to occur later in life than in other subtypes,<sup><xref rid="euac030-B232" ref-type="bibr">232</xref></sup> while the occurrence of AFib is more frequent in this subtype.<sup><xref rid="euac030-B233" ref-type="bibr">233</xref></sup> However, life-threatening arrhythmias are equally frequent among different genotypes.<sup><xref rid="euac030-B232" ref-type="bibr">232</xref></sup></p></sec></sec><sec><title>Atrial fibrillation</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T32"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Atrial fibrillation</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T33"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">An analysis of <italic toggle="yes">SCN5A, KCNQ1, MYL4</italic> and truncating <italic toggle="yes">TTN</italic> variants may be performed in all index patients in whom the diagnosis of familial (young = age&#x02009;&#x0003c;&#x02009;60) AF, is established, based on examination of the patient&#x02019;s clinical history, family history, and ECG characteristics.</td><td rowspan="2" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B234" ref-type="bibr">234&#x02013;243</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Variant-specific genetic testing may be recommended for family members and appropriate relatives following the identification of the disease-causative variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children may be considered in specific settings.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table></table-wrap><sec><title>Background</title><p>Atrial fibrillation is the most common cardiac arrhythmia worldwide, and it may be associated with an unfavourable prognosis, depending on the clinical profile and access to treatment. Atrial fibrillation is characterized by uncoordinated electrical activity in the atria. This causes a rapid and irregular heartbeat and increases the risk of stroke and sudden death. Its prevalence is around 0.4% in the general population and increases to approximately 6% in those over 65&#x02009;years of age. The incidence of the familial form of AFib is unknown. The incidence of AFib increases together with the numbers of affected individuals with early onset AFib in the family.<sup><xref rid="euac030-B244" ref-type="bibr">244</xref></sup> Today, familial AFib is more commonly diagnosed. In a cohort study of 914 patients with AF, 36% had lone AFib. A positive family history for AFib was present in 15% of those lone AFib patients (5% of all AFib patients).<sup><xref rid="euac030-B245" ref-type="bibr">245</xref></sup> Atrial fibrillation is also commonly related to dilated or hypertrophic cardiomyopathies,<sup><xref rid="euac030-B246" ref-type="bibr">246</xref></sup> LQTS,<sup><xref rid="euac030-B247" ref-type="bibr">247</xref></sup> or SQTS,<sup><xref rid="euac030-B230" ref-type="bibr">230</xref>,</sup><sup><xref rid="euac030-B248" ref-type="bibr">248</xref></sup> BrS,<sup><xref rid="euac030-B234" ref-type="bibr">234</xref></sup> CPVT,<sup><xref rid="euac030-B249" ref-type="bibr">249</xref>,</sup><sup><xref rid="euac030-B250" ref-type="bibr">250</xref></sup> familial amyloidosis,<sup><xref rid="euac030-B251" ref-type="bibr">251</xref></sup> congenital cardiac abnormalities,<sup><xref rid="euac030-B252" ref-type="bibr">252</xref></sup> and pre-excitation syndromes.<sup><xref rid="euac030-B213" ref-type="bibr">213</xref>,</sup><sup><xref rid="euac030-B253" ref-type="bibr">253</xref></sup></p><p>The prognosis for AFib patients is determined by assessing associated cardiovascular disease and identifying patients with genetic predisposition to AFib may have important clinical implications. Furthermore, testing to identify genes that play a role in the initiation of AFib may provide new understanding and new therapeutic options. Also, early recognition of AFib patients at risk may reduce morbidity and mortality.<sup><xref rid="euac030-B254" ref-type="bibr">254</xref></sup></p></sec><sec><title>Genetic forms of atrial fibrillation</title><p>There has not yet been a consensus curation for isolated familial AFib (despite the fact that AFib is a well-established feature of many inherited cardiac syndromes, and the existence of some monogenic forms of isolated AFib). <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T11" ref-type="table">11</xref></italic> summarizes the existing evidence for genes implicated in AF. Evidence supporting AFib as a single-gene disease has emerged over the last decade. Genetic forms of AFib may be observed in association with other phenotypes (Brugada, conduction disease, cardiomyopathy), or may be isolated, probably particularly in young individuals.<sup><xref rid="euac030-B242" ref-type="bibr">242</xref>,</sup><sup><xref rid="euac030-B243" ref-type="bibr">243</xref></sup> Genes involved include those encoding both ion channels and sarcomere-related proteins.</p><table-wrap position="float" id="euac030-T11"><label>Table 11</label><caption><p>Genes implicated in atrial fibrillation</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Phenotype&#x02014;syndrome</th><th align="left" rowspan="1" colspan="1">Protein (functional effect)</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">SCN5A</italic>
</td><td rowspan="1" colspan="1">3p22.2</td><td rowspan="1" colspan="1">AFib/conduct.</td><td rowspan="1" colspan="1">Decrease in <italic toggle="yes">I</italic><sub>Na1.5</sub> channel function</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNQ1</italic>
</td><td rowspan="1" colspan="1">11p15.5</td><td rowspan="1" colspan="1">AFib/SQTS</td><td rowspan="1" colspan="1">Increase in <italic toggle="yes">I</italic><sub>Ks</sub> channel function</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCNH2</italic>
</td><td rowspan="1" colspan="1">7q35-36</td><td rowspan="1" colspan="1">AFib/SQTS</td><td rowspan="1" colspan="1">Increase in <italic toggle="yes">I</italic><sub>Kr</sub> channel function</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TBX5</italic>
</td><td rowspan="1" colspan="1">12q24.21</td><td rowspan="1" colspan="1">AFib/Holt Oram syndr.</td><td rowspan="1" colspan="1">T-Box transcription factor 5</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">GJA5</italic>
</td><td rowspan="1" colspan="1">1q21.1</td><td rowspan="1" colspan="1">AFib/atrial standstill</td><td rowspan="1" colspan="1">Decrease in Connexin 40 function</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MYL4</italic>
</td><td rowspan="1" colspan="1">17q21.32</td><td rowspan="1" colspan="1">AFib/conduction disease</td><td rowspan="1" colspan="1">atrial-specific myosin light chain</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TTN</italic>
</td><td rowspan="1" colspan="1">2q31.2</td><td rowspan="1" colspan="1">AFib/DCM</td><td rowspan="1" colspan="1">Titin</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">KCN5A</italic>
</td><td rowspan="1" colspan="1">12p13.32</td><td rowspan="1" colspan="1">AFib</td><td rowspan="1" colspan="1">Decrease in Ultrarapid component of the atrial-specific delayed rectifier potassium current (<italic toggle="yes">I</italic><sub>kur</sub>)</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">GJC1</italic>
</td><td rowspan="1" colspan="1">17q21.31</td><td rowspan="1" colspan="1">AFib</td><td rowspan="1" colspan="1">decrease in Connexin 45 function</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">NPPA</italic>
</td><td rowspan="1" colspan="1">1p36.22</td><td rowspan="1" colspan="1">AFib</td><td rowspan="1" colspan="1">Atrial naturetic protein (ANP), loss of interaction with the ANP receptor</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA, rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">LMNA</italic>
</td><td rowspan="1" colspan="1">1q22</td><td rowspan="1" colspan="1">AFib/conduction disease DCM (CMD1A), (Emery-Dreifuss muscular dystrophy 2/3, congenital muscular dystrophy, limb-girdle myopathy, familial lipodystrophy type 2, Hutchinson-Gilford progeria, and various other disorders)<sup><xref rid="euac030-B197" ref-type="bibr">197</xref>,</sup><sup><xref rid="euac030-B199" ref-type="bibr">199</xref>,</sup><sup><xref rid="euac030-B200" ref-type="bibr">200</xref></sup></td><td rowspan="1" colspan="1">Lamin A/C</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene &#x02018;Definitive&#x02019; for DCM</td></tr></tbody></table><table-wrap-foot><fn id="tblfn27"><p>(): mutation rate unknown and/or single reports.</p></fn></table-wrap-foot></table-wrap><p>From a purely electrical or ion channel perspective, loss-of-function genetic variants in the <italic toggle="yes">SCN5A</italic> gene may provoke an AFib phenotype, commonly in patients who also manifest BrS and/or conduction system disease.<sup><xref rid="euac030-B234" ref-type="bibr">234&#x02013;236</xref></sup> Additionally, gain-of-function mutations in <italic toggle="yes">SCN5A</italic> may cause AFib in isolation.<sup><xref rid="euac030-B237" ref-type="bibr">237</xref></sup> In a large Chinese family with AFib segregating as an AD trait, a gain-of<italic toggle="yes">-</italic>function variant in <italic toggle="yes">KCNQ1</italic> (S140G) was identified.<sup><xref rid="euac030-B238" ref-type="bibr">238</xref></sup> Similarly, a loss-of-function variant in the <italic toggle="yes">KCN5A</italic> gene encoding the ultrarapid component of the atrial-specific delayed rectifier potassium current (Ikur) has been described in a large pedigree with familial AFib.<sup><xref rid="euac030-B255" ref-type="bibr">255</xref></sup> Two additional potassium channels, <italic toggle="yes">KCNJ2</italic> and <italic toggle="yes">KCNH2</italic>, have been reported to cause AFib in patients with associated SQTS.<sup><xref rid="euac030-B256" ref-type="bibr">256</xref>,</sup><sup><xref rid="euac030-B257" ref-type="bibr">257</xref></sup> Lastly, genetic defects effecting gap junction function (<italic toggle="yes">GJA5, GJC1</italic>) may also provoke AFib.<sup><xref rid="euac030-B258" ref-type="bibr">258</xref></sup> The association of AFib with variants in other genes like <italic toggle="yes">KCNE2, RYR2</italic>, and <italic toggle="yes">SCN1B</italic> are not yet strong enough to warrant routine genetic screening outside a research setting.</p><p>Genes encoding sarcomeric proteins may also provoke AFib in the absence of ventricular involvement. The <italic toggle="yes">MYL4</italic> gene, encoding the atrial-specific myosin light chain, has been described as a cause of early-onset AFib and conduction system disease.<sup><xref rid="euac030-B239" ref-type="bibr">239</xref></sup> Similarly, mutations in <italic toggle="yes">LMNA</italic> and <italic toggle="yes">TTN</italic> (in particular A-band localizing variants) commonly provoke atrial arrhythmias.<sup><xref rid="euac030-B240" ref-type="bibr">240</xref>,</sup><sup><xref rid="euac030-B241" ref-type="bibr">241</xref>,</sup><sup><xref rid="euac030-B243" ref-type="bibr">243</xref></sup></p><p>Finally, a more rare and unique form of familial AFib has been reported secondary to a genetic defect in the NPPA gene, which encodes the atrial naturetic peptide, implicating neurohormonal dysregulation in provoking AFib.<sup><xref rid="euac030-B259" ref-type="bibr">259</xref></sup></p></sec></sec><sec><title>Sinus node disease</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T34"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sinus node disease</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T35"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendations</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">(Targeted) Genetic testing may be considered as part of the diagnostic evaluation for index patients with familial or isolated, but otherwise unexplained sinus node dysfunction (SND) or with SND and concomitant atrial fibrillation, cardiac conduction disease (CCD), structural heart disease or with SND and extracardiac disease (syndromal forms), especially in the setting of a positive family history.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Interrogation for a putative family history and family cascade screening including clinical screening and variant-specific genetic testing, are recommended for appropriate relatives.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table></table-wrap><sec><title>Background</title><p>Sinus node dysfunction (for diagnostic criteria, see ref.<sup><xref rid="euac030-B260" ref-type="bibr">260</xref></sup>) is an aetiologically and thereby clinically heterogeneous, often age-dependent disorder. Sinus node dysfunction is commonly acquired; inherited (&#x02018;idiopathic&#x02019; or familial) forms are less common, in particular in elder patients where ischaemia or age-related degeneration of the sinoatrial (SA) node occur. Infiltrative disorders (e.g. sarcoidosis, amyloidosis, hemochromatosis, collagen vascular disease or metastatic cancer), cardiac procedures, infections (e.g. bacterial endocarditis and Chagas disease), and obstructive sleep apnoea commonly result in SND. External causes are abnormally increased vagal tone, autonomic dysfunction, hypothyroidism, hyperkalaemia, hypokalaemia, hypocalcaemia, hypoxia and hypothermia, cardiac surgery, as well as increased intracranial pressure or medications.</p><p>Isolated (i.e. otherwise unexplained) or familial forms (&#x02018;primary electrical heart diseases&#x02019;) can be distinguished from syndromal forms (heritability of SND and heart rate is meanwhile noted from several large studies).<sup><xref rid="euac030-B261" ref-type="bibr">261&#x02013;264</xref></sup> In the surface ECG, sinus bradycardia (&#x0003c;50 b.p.m.) is a typical feature; significant bradycardia or pauses may result in dizziness, syncope or rarely cardiac arrest.<sup><xref rid="euac030-B192" ref-type="bibr">192</xref>,</sup><sup><xref rid="euac030-B265" ref-type="bibr">265</xref></sup> Other ECG signs are chronotropic incompetence, sinus pause (&#x0003e;3&#x02009;s) or sinus arrest, various degrees of SA exit block, atrial fibrillation, and AV node blockade.</p></sec><sec><title>Diagnostic implications of genetic testing in sinus node dysfunction</title><p>Sinus node dysfunction is genetically heterogeneous. There has not yet been a consensus curation for sinus node disease. The overall variant detection rate (sensitivity) for &#x02018;idiopathic&#x02019; or familial forms is unknown, but currently estimated &#x0003c;25%. The majority of SND patients have an AD mode of inheritance; <italic toggle="yes">de novo</italic> occurrence and other modes (X-chromosomal, recessive occurrence, digenic traits, or CNVs) are rare. Susceptible genes for each SND subgroup are listed below (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T12" ref-type="table">12</xref></italic> and <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S11</xref></italic>). Core genes for SND include <italic toggle="yes">SCN5A, HCN4</italic>, and <italic toggle="yes">LMNA</italic>.</p><table-wrap position="float" id="euac030-T12"><label>Table 12</label><caption><p>Genes implicated in sinus node disease (SND)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<italic toggle="yes">Gene</italic>
</th><th rowspan="1" colspan="1">Locus</th><th rowspan="1" colspan="1">Phenotype/syndrome</th><th rowspan="1" colspan="1">Protein (functional effect)</th><th rowspan="1" colspan="1">Frequency</th><th rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td colspan="6" rowspan="1">
<bold>Genes for isolated SND</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">SCN5A</italic></td><td rowspan="1" colspan="1">3p22.2</td><td rowspan="1" colspan="1">BrS1, SND, ASS, LQT3<sup><xref rid="euac030-B195" ref-type="bibr">195</xref>,</sup><sup><xref rid="euac030-B266" ref-type="bibr">266</xref>,</sup><sup><xref rid="euac030-B267" ref-type="bibr">267</xref></sup></td><td rowspan="1" colspan="1">Cardiac Na<sup>+</sup> channel &#x003b1; subunit (Nav1.5) (loss-of-function, <italic toggle="yes">I</italic><sub>Na</sub>&#x02193;)</td><td rowspan="1" colspan="1">1&#x02013;10%</td><td rowspan="1" colspan="1">NA/major gene &#x02018;Definitive&#x02019; for LQTS, BrS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">HCN4</italic></td><td rowspan="1" colspan="1">15q24.1</td><td rowspan="1" colspan="1">Familial SND, ST, left ventricular non-compaction.<sup><xref rid="euac030-B268" ref-type="bibr">268</xref>,</sup><sup><xref rid="euac030-B269" ref-type="bibr">269</xref></sup></td><td rowspan="1" colspan="1">Hyperpolarization-activated cyclic nucleotide-gated K<sup>+</sup> channel 4 (loss-of-function, <italic toggle="yes">I</italic><sub>f</sub> &#x02193;)</td><td rowspan="1" colspan="1">1&#x02013;10%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#x02003;GNB2</italic>
</td><td rowspan="1" colspan="1">7q22.1</td><td rowspan="1" colspan="1">Familial SND<sup><xref rid="euac030-B270" ref-type="bibr">270</xref></sup></td><td rowspan="1" colspan="1">G-protein &#x003b2; subunit 2 (gain-of-function, <italic toggle="yes">I</italic><sub>K</sub>, <sub>ACh</sub>&#x02191;)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">KCNQ1</italic></td><td rowspan="1" colspan="1">11p15.4</td><td rowspan="1" colspan="1">SQTS, [LQT1], AFib, SND<sup><xref rid="euac030-B271" ref-type="bibr">271</xref>,</sup><sup><xref rid="euac030-B272" ref-type="bibr">272</xref></sup></td><td rowspan="1" colspan="1">K<sup>+</sup> voltage-gated channel (subfamily Q, 1) (Kv7.1) (Gain-of-function, I<sub>Ks</sub>&#x02191;)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">NA/rare gene. &#x02018;Definitive&#x02019; for LQTS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">KCNJ5</italic></td><td rowspan="1" colspan="1">11q24.3</td><td rowspan="1" colspan="1">Familial SND<sup><xref rid="euac030-B273" ref-type="bibr">273</xref>,</sup><sup><xref rid="euac030-B274" ref-type="bibr">274</xref></sup></td><td rowspan="1" colspan="1">G-protein gated inwardly rectifying K<sup>+</sup> (GIRK) channel 5 (Kv3.4) (Gain-of-function, <italic toggle="yes">I</italic><sub>K, ACh</sub>&#x02191;)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">RYR2</italic></td><td rowspan="1" colspan="1">1q43</td><td rowspan="1" colspan="1">CPVT, SND<sup><xref rid="euac030-B249" ref-type="bibr">249</xref>,</sup><sup><xref rid="euac030-B275" ref-type="bibr">275</xref></sup></td><td rowspan="1" colspan="1">Ryanodine receptor 2 (gain-of-function)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">NA/rare gene &#x02018;Definitive&#x02019; for CPVT</td></tr><tr><td colspan="6" rowspan="1">
<bold>Genes for syndromal disorders with SND</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">LMNA</italic></td><td rowspan="1" colspan="1">1q22</td><td rowspan="1" colspan="1">DCM (CMD1A), Afib (Emery-Dreifuss muscular dystrophy 2/3, congenital muscular dystrophy, limb-girdle myopathy, familial lipodystrophy type 2, Hutchinson-Gilford progeria, and various other disorders)<sup><xref rid="euac030-B197" ref-type="bibr">197</xref>,</sup><sup><xref rid="euac030-B199" ref-type="bibr">199</xref>,</sup><sup><xref rid="euac030-B200" ref-type="bibr">200</xref></sup></td><td rowspan="1" colspan="1">Lamin A/C</td><td rowspan="1" colspan="1">1&#x02013;10%</td><td rowspan="1" colspan="1">NA/rare gene &#x02018;Definitive&#x02019; for DCM</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">CACNA1D</italic></td><td rowspan="1" colspan="1">3p21.1</td><td rowspan="1" colspan="1">+ Inner ear deafness<sup><xref rid="euac030-B276" ref-type="bibr">276</xref>,</sup><sup><xref rid="euac030-B277" ref-type="bibr">277</xref></sup> (neurodevelopmental disorders, autisms spectrum disorder with epilepsy; primary aldosteronism)</td><td rowspan="1" colspan="1">L-type calcium voltage-gated channel subunit alpha 1-D (Cav1.3)</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">GNB5</italic></td><td rowspan="1" colspan="1">15q21.2</td><td rowspan="1" colspan="1">+ Developmental delay, speech defects, severe hypotonia, pathological gastro-oesophageal reflux, retinal disease<sup><xref rid="euac030-B278" ref-type="bibr">278</xref></sup></td><td rowspan="1" colspan="1">G-protein &#x003b2; subunit 5, (inhibitory G-protein signaling)</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">SGOL1</italic></td><td rowspan="1" colspan="1">3p24.3</td><td rowspan="1" colspan="1">CAID syndrome; cohesinopathy with chronic atrial and intestinal dysrhythmia<sup><xref rid="euac030-B279" ref-type="bibr">279</xref></sup></td><td rowspan="1" colspan="1">Nuclear protein for chromosome segregation</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic toggle="yes">EMD</italic></td><td rowspan="1" colspan="1">Xq28</td><td rowspan="1" colspan="1">DCM, LVNC, AFib, Emery-Dreifuss muscular dystrophy (EMD)<sup><xref rid="euac030-B209" ref-type="bibr">209</xref>,</sup><sup><xref rid="euac030-B280" ref-type="bibr">280</xref></sup></td><td rowspan="1" colspan="1">Emerin</td><td rowspan="1" colspan="1">()</td><td rowspan="1" colspan="1">NA/rare gene</td></tr></tbody></table><table-wrap-foot><fn id="tblfn28"><p>Frequency: refers to mutation detection rate<sup><xref rid="euac030-B29" ref-type="bibr">29</xref></sup>; core genes: major (&#x0003e;10%) or minor (1&#x02013;10%); rare gene (&#x0003c;1%); (): mutation rate unknown and/or single reports.</p></fn><fn id="tblfn29"><p>Other Phenotypes: [&#x02026;], phenotype associated with gene, but unlinked with SND.</p></fn><fn id="tblfn30"><p>ClinGen: Clinical Genome Resource of NCBI; <ext-link xlink:href="https://clinicalgenome.org" ext-link-type="uri">https://clinicalgenome.org</ext-link>.</p></fn><fn id="tblfn31"><p>ASS, atrial stand still; AFib, atrial fibrillation; ASD, atrial septal defect; BrS, Brugada syndrome, CPVT, catecholaminergic polymorphic ventricular tachycardia; DCM, dilated cardiomyopathy; LQT, long-QT syndrome type; LVNC, left ventricular non-compaction cardiomyopathy; SND, sinus node dysfunction; ST, sinus tachycardia; X-chr., X-chromosomal.</p></fn></table-wrap-foot></table-wrap><sec><title>Index case with sinus node dysfunction</title><p>Upon the ECG diagnosis of SND and without evidence for acquired causes, an inherited form appears likely, particularly when it is found in younger individuals (&#x0003c;age 60). Routine work-up includes exercise ECG, Holter ECG, and echocardiography to address presence of a cardiomyopathy or CHD. Cardiac MRI (with gadolinium application) may be considered, in particular for <italic toggle="yes">LMNA</italic> pathogenic variant carriers.<sup><xref rid="euac030-B193" ref-type="bibr">193</xref>,</sup><sup><xref rid="euac030-B199" ref-type="bibr">199</xref>,</sup><sup><xref rid="euac030-B200" ref-type="bibr">200</xref></sup></p><p>For the major genes associated with SND (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T12" ref-type="table">12</xref></italic>), specialized cardiogenetic services have established targeted gene panels for SND and/or CCD/PCCD testing. Two genes (<italic toggle="yes">SCN5A</italic> and <italic toggle="yes">LMNA</italic>) are part of the medically actionable gene list (currently 73 genes) of the ACMG and are therefore recommended to be investigated.<sup><xref rid="euac030-B49" ref-type="bibr">49</xref></sup> The identification of a pathogenic variant in a disease-validated gene confirms not only the (suspected) diagnosis of SND, but also allows its classification as a genetic (and potentially heritable) disorder with or without additional clinical features.</p></sec><sec><title>Family investigation</title><p>A careful clinical and, if suitable [i.e. with knowledge of the pathogenic (ACMG class 4/5) variant in a validated SND], genetic investigation (testing for the relevant variant) is recommended and therefore indicated in family members as a part of a directed &#x02018;family cascade screening&#x02019;. This includes a comprehensive assessment of the family pedigree.</p><p>In relatives without this pathogenic variant, monitoring for SND or its development and downstream investigations in the family branch are not further needed. In contrast, pathogenic variant-positive family members shall be carefully evaluated for presence of isolated or syndromal forms of SND with regard to typical phenotypic features of the underlying gene (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T12" ref-type="table">12</xref></italic>). In addition, genotype-depending recommendations will be similar as for the index case. Asymptomatic children in the first decade of life are not strictly needed to be investigated for their genetic status (in the presence of normal findings during routine cardiological investigation).</p></sec></sec><sec><title>Prognostic and therapeutic implications of genetic testing</title><p>There is no genotype-based risk stratification for patients with SND. However, mutations in distinct genes (e.g. <italic toggle="yes">LMNA, SCN5A, KCNQ1</italic>) may be associated with other overlapping phenotypes (e.g. BrS, SQTS) or with the development of heart failure and arrhythmias (i.e. <italic toggle="yes">LMNA</italic>), whereas other genes may exhibit particular extracardiac features. This has impact for the mode of monitoring during follow-up (which should include regular imaging studies in families with f.e. <italic toggle="yes">LMNA</italic> and <italic toggle="yes">SCN5A</italic> variants).</p><p>Patients with <italic toggle="yes">LMNA</italic> variants may develop atrial and ventricular arrhythmias as well as progressive (end-stage) heart failure and the potential need for ICD therapy or heart transplantation. A risk stratification scheme has recently been proposed.<sup><xref rid="euac030-B200" ref-type="bibr">200</xref></sup> Patients with <italic toggle="yes">SCN5A</italic> pathogenic variants may also develop BrS; avoidance of particular drugs and fever are recommended to reduce ventricular arrhythmias.</p></sec></sec><sec><title>Early repolarization syndrome</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T36"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Early repolarization syndrome</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T37"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">In unexplained cardiac arrest survivors diagnosed clinically with ERS, molecular genetic testing may be appropriate.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">In asymptomatic individuals with only an ECG-based early repolarization pattern, genetic testing should not be performed.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table></table-wrap><sec><title>Background</title><p>The presence of a J wave, a positive deflection immediately following the QRS complex, in f.e. the inferolateral ECG leads is known as early repolarization pattern (ERP). Early repolarization pattern is a common ECG finding (estimated incidence 1&#x02013;13%), usually considered innocent amongst healthy asymptomatic young individuals and athletes.<sup><xref rid="euac030-B281" ref-type="bibr">281</xref></sup> Case&#x02013;control and epidemiological studies have, however, described an association between J waves and unexplained cardiac arrest (UCA).<sup><xref rid="euac030-B282" ref-type="bibr">282&#x02013;284</xref></sup></p><p>Ha&#x000ef;ssaguerre <italic toggle="yes">et al</italic>. found that ERP was present in 31% of 206 case subjects with IVF cases and 5% of 412 matched subjects without heart disease.<sup><xref rid="euac030-B284" ref-type="bibr">284</xref></sup> The link between ERP and malignant arrhythmias is also supported by the accentuation of the J wave before the onset of VF, an association with VF storms and the observation of triggering PVCs coincident with the J wave.<sup><xref rid="euac030-B284" ref-type="bibr">284&#x02013;286</xref></sup> The term early repolarization syndrome (ERS) has since been used to identify UCA survivors with an ECG with a suggestive/suspicious ERP.<sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup></p><p>According to animal models and an early ECG imaging study, an imbalance in myocyte currents in favour of enhanced outward currents (<italic toggle="yes">I</italic><sub>to</sub> and <italic toggle="yes">I</italic><sub>KATP</sub>) during phase 2 of the action potential causes premature myocardial repolarization and variable loss of the action potential dome, which is most marked in the epicardial myocardium. In turn, epicardial heterogeneity in repolarization duration and transmural heterogeneity is most marked in the inferior LV wall resulting in localized steep gradients of repolarization and inferior J point elevation.<sup><xref rid="euac030-B287" ref-type="bibr">287</xref>,</sup><sup><xref rid="euac030-B288" ref-type="bibr">288</xref></sup> Increasing evidence supports an alternative hypothesis, according to which the J point elevation typical of ERP could be an expression of delayed depolarization.<sup><xref rid="euac030-B289" ref-type="bibr">289&#x02013;291</xref></sup></p><p>Early repolarization pattern shows at least moderate heritability in nuclear families<sup><xref rid="euac030-B292" ref-type="bibr">292</xref></sup> and across general population studies.<sup><xref rid="euac030-B293" ref-type="bibr">293</xref></sup> It is over-represented in families of UCA survivors<sup><xref rid="euac030-B294" ref-type="bibr">294</xref></sup> and autopsy negative SCD families.<sup><xref rid="euac030-B295" ref-type="bibr">295</xref>,</sup><sup><xref rid="euac030-B296" ref-type="bibr">296</xref></sup> There has not yet been a consensus curation for ERS. <italic toggle="yes">SCN5A</italic> variants with loss-of-function (determined by patch clamping expression studies) have been identified in 2&#x02013;10% of patients with ERS, the patients showed signs of conduction slowing, supporting a depolarization phenotype.<sup><xref rid="euac030-B297" ref-type="bibr">297&#x02013;299</xref></sup> Two paediatric ERS cases have been identified with a duplication and a <italic toggle="yes">de novo</italic> missense variant in <italic toggle="yes">KCND3</italic> responsible for <italic toggle="yes">I</italic><sub>TO</sub>.<sup><xref rid="euac030-B300" ref-type="bibr">300</xref>,</sup><sup><xref rid="euac030-B301" ref-type="bibr">301</xref></sup> Furthermore, a recent general population GWAS has associated ERP with a genome-wide significant SNP tagging the <italic toggle="yes">KCND3</italic> locus (encoding the <italic toggle="yes">I</italic><sub>To</sub> current alpha subunit), suggesting the possibility of polygenic heritability.<sup><xref rid="euac030-B302" ref-type="bibr">302</xref></sup> There is, however, absence of other highly penetrant, reproducible and truly rare single gene causes of ERS. For example, the p.S422L variant in <italic toggle="yes">KCNJ8</italic> responsible for <italic toggle="yes">I</italic><sub>KATP</sub>, has been implicated frequently in ERS but has too high a population frequency to cause a rare monogenic disorder.<sup><xref rid="euac030-B303" ref-type="bibr">303</xref>,</sup><sup><xref rid="euac030-B304" ref-type="bibr">304</xref></sup><xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S12</xref></italic> summarizes all genes which have been associated with ERS.</p></sec></sec><sec><title>Wolff&#x02013;Parkinson&#x02013;White syndrome</title><sec><title>Background</title><p>WPW is a condition where an extraconnection in the heart, called an accessory pathway (AP), is present, resulting in a pattern of pre-excitation during sinus rhythm. The most common arrhythmia associated with WPW is a paroxysmal supraventricular tachycardia, where the impulse uses the AP either from atrium to ventricle (antidromic circus movement tachycardia) or, more common, vice versa (orthodromic circus movement tachycardia). Resulting symptoms include dizziness, a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, pre-syncope and syncope. In rare cases, arrhythmias associated with WPW can lead to cardiac arrest and sudden death.</p><p>Wolff&#x02013;Parkinson&#x02013;White affects 1 to 3 in 1000 people worldwide and is the second most common cause of paroxysmal supraventricular tachycardia in most parts of the world. Complications of WPW can occur at any age, although many individuals born with an AP in the heart never experience any health problems associated with the condition.</p></sec><sec><title>Genetics of Wolff&#x02013;Parkinson&#x02013;White</title><sec><title>Non-syndromic cases</title><p>Most cases of WPW occur in people with no apparent family history of the condition. These cases are described as sporadic and are usually not inherited. Familial WPW accounts for only a small percentage of all cases of this condition.<sup><xref rid="euac030-B305" ref-type="bibr">305</xref></sup> The familial form of the disorder typically has an AD pattern of inheritance. No specific genes have been identified for non-syndromic pre-excitation to date.</p></sec><sec><title>Syndromic cases</title><p>Wolff&#x02013;Parkinson&#x02013;White often occurs with other structural abnormalities of the heart or underlying heart disease. The most common heart defect associated with the condition is Ebstein&#x02019;s anomaly, which affects the tricuspid valve and right ventricle. In at least 10% of patients with Ebstein&#x02019;s anomaly, one or more APs are present.<sup><xref rid="euac030-B306" ref-type="bibr">306</xref></sup> Other genetic syndromes associated with APs include hypokalaemic periodic paralysis (a condition that causes episodes of extreme muscle weakness), Pompe disease (a disorder characterized by the storage of excess glycogen), Danon disease (a condition that weakens the heart and skeletal muscles and causes intellectual disability), and tuberous sclerosis complex (a condition that results in the growth of non-cancerous tumours in many parts of the body).</p><p>An important subset of syndromic WPW associates with HCM. The locus for this (combined) condition, consisting of pre-excitation, HCM and (progressive) conduction abnormalities, was first identified in 1995<sup><xref rid="euac030-B307" ref-type="bibr">307</xref></sup> and the gene, <italic toggle="yes">PRKAG2</italic>, encoding for the enzyme AMP-activated protein kinase (AMPK), was identified in 2001, resulting in glycogen storage abnormalities in the heart.<sup><xref rid="euac030-B308" ref-type="bibr">308</xref></sup> In a recent relatively large series one-third of individuals carrying a pathogenic <italic toggle="yes">PRKAG2</italic> variant had evidence of pre-excitation and approximately two-thirds had an increased wall thickness.<sup><xref rid="euac030-B309" ref-type="bibr">309</xref></sup></p><p>In conclusion, only in the presence of the combination of pre-excitation and HCM and/or progressive CCD is genetic testing pertinent (see above and State of genetic testing for cardiomyopathies section). The vast majority of WPW cases, however, will be isolated and not based on a genetic cause.</p></sec></sec></sec></sec><sec><title>State of genetic testing for cardiomyopathies</title><sec><title>Hypertrophic cardiomyopathy</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T38"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">HCM</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">++</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T39"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">For genetic testing in a proband with HCM (including those cases diagnosed post-mortem), the initial tier of genes tested should include genes with definitive or strong evidence of pathogenicity (currently <italic toggle="yes">MYH7, MYBPC3, TNNI3, TPM1, MYL2, MYL3, ACTC1</italic>, and <italic toggle="yes">TNNT2</italic>).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">For genetic testing in a proband with HCM, the initial tier of genes tested may include genes with moderate evidence of pathogenicity (<italic toggle="yes">CSRP3, TNNC1, JPH2</italic>).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B310" ref-type="bibr">310&#x02013;314</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In patients with HCM, genetic testing is recommended for identification of family members at risk of developing HCM.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B315" ref-type="bibr">315&#x02013;318</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In patients with atypical clinical presentation of HCM, or when another genetic condition associated with unexplained hypertrophy is suspected (e.g. HCM phenocopy) genetic testing is recommended.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B253" ref-type="bibr">253</xref>,</sup>
<sup>
<xref rid="euac030-B308" ref-type="bibr">308</xref>,</sup>
<sup>
<xref rid="euac030-B319" ref-type="bibr">319&#x02013;324</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children is recommended in those aged &#x0003e;10&#x02013;12&#x02009;years.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B82" ref-type="bibr">82</xref>,</sup>
<sup>
<xref rid="euac030-B85" ref-type="bibr">85</xref>,</sup>
<sup>
<xref rid="euac030-B318" ref-type="bibr">318</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In patients with HCM who harbour a variant of uncertain significance, the usefulness of genetic testing of phenotype-negative relatives for the purpose of variant reclassification is uncertain.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B315" ref-type="bibr">315</xref>,</sup>
<sup>
<xref rid="euac030-B325" ref-type="bibr">325</xref>
</sup>
</td></tr><tr><td rowspan="2" colspan="1">Predictive genetic testing in related children aged below 10&#x02013;12&#x02009;years may be considered, especially where there is a family history of early-onset disease.</td><td rowspan="2" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B82" ref-type="bibr">82</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B85" ref-type="bibr">85</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In patients with HCM who harbour a variant of uncertain significance, testing of affected family members for the purpose of variant classification may be considered.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">For patients with HCM in whom genetic testing found no LP/P variants, cascade genetic testing of family relatives is not recommended.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B315" ref-type="bibr">315&#x02013;317</xref>,</sup>
<sup>
<xref rid="euac030-B325" ref-type="bibr">325</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Ongoing clinical screening is not recommended in genotype-negative relatives in most families with genotype-positive HCM</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup>
<sup>
<xref rid="euac030-B315" ref-type="bibr">315</xref>,</sup>
<sup>
<xref rid="euac030-B316" ref-type="bibr">316</xref>,</sup>
<sup>
<xref rid="euac030-B325" ref-type="bibr">325</xref>
</sup>
</td></tr></tbody></table></table-wrap><sec><title>Background</title><p>Hypertrophic cardiomyopathy is a relative common inherited cardiac condition characterized by hypertrophy of the LV wall, not explained by other conditions (i.e. hypertension or valvular heart disease). Typically, the hypertrophy is asymmetric and confined to the intraventricular septum. Clinical sequalae of HCM include diastolic dysfunction, heart failure, atrial arrhythmias (with associated thrombogenic events), and malignant ventricular arrhythmias. Genetic testing provides an opportunity to improve care of patients with HCM and their family members. Offspring of carriers have a 50% chance of inheriting the same disease-causing genetic variant.<sup><xref rid="euac030-B16" ref-type="bibr">16</xref>,</sup><sup><xref rid="euac030-B81" ref-type="bibr">81</xref>,</sup><sup><xref rid="euac030-B326" ref-type="bibr">326</xref></sup> It is essential to take a multigenerational family history of HCM including those suspected of dying suddenly. Engaging patients and family members means discussing the role of genetic testing including appropriate pre- and post-test genetic counselling, and its impact on psychological, social, legal, ethical, and professional implications of a positive test. Genetic assessment should ideally be performed in a specialized multidisciplinary HCM centre.<sup><xref rid="euac030-B16" ref-type="bibr">16</xref>,</sup><sup><xref rid="euac030-B326" ref-type="bibr">326</xref></sup> Next-generation sequencing led to an expansion in the number of genes included in diagnostic gene panel. However, inclusion of genes with limited gene-disease association, diminish the efficacy of genetic counselling by adding uncertainty and misinterpretation, among others leading to false positive results.<sup><xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup><sup><xref rid="euac030-B82" ref-type="bibr">82</xref>,</sup><sup><xref rid="euac030-B315" ref-type="bibr">315&#x02013;317</xref>,</sup><sup><xref rid="euac030-B327" ref-type="bibr">327&#x02013;329</xref></sup> Recommendation for genes with a definite, strong or moderate evidence of pathogenicity of HCM and phenocopies are depicted in <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T13" ref-type="table">13</xref></italic>.</p><table-wrap position="float" id="euac030-T13"><label>Table 13</label><caption><p>Genes implicated in hypertrophic cardiomyopathy</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Syndrome</th><th align="left" rowspan="1" colspan="1">Protein (functional effect)</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MYBPC3</italic>
</td><td rowspan="1" colspan="1">11p11.2</td><td rowspan="1" colspan="1">Familial HCM</td><td rowspan="1" colspan="1">&#x02193;contractility due to &#x02193;Ca<sup>2+</sup> sensitivity</td><td rowspan="1" colspan="1">40&#x02013;45%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MYH7</italic>
</td><td rowspan="1" colspan="1">14q11.2-q12</td><td rowspan="1" colspan="1">Familial HCM</td><td rowspan="1" colspan="1">&#x02193;contractility due to &#x02193;Ca<sup>2+</sup> sensitivity</td><td rowspan="1" colspan="1">15&#x02013;25%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TNNI3</italic>
</td><td rowspan="1" colspan="1">19q13.4</td><td rowspan="1" colspan="1">Familial HCM</td><td rowspan="1" colspan="1">Loss of function (inhibitory)</td><td rowspan="1" colspan="1">1&#x02013;7%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TNNT2</italic>
</td><td rowspan="1" colspan="1">1q32.1</td><td rowspan="1" colspan="1">Familial HCM</td><td rowspan="1" colspan="1">Increase oxygen consumption</td><td rowspan="1" colspan="1">1&#x02013;7%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TPM1</italic>
</td><td rowspan="1" colspan="1">15q22.2</td><td rowspan="1" colspan="1">Familial HCM</td><td rowspan="1" colspan="1">Loss-of-function of the thin filament</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">ACTC1</italic>
</td><td rowspan="1" colspan="1">15q.14</td><td rowspan="1" colspan="1">Familial HCM</td><td rowspan="1" colspan="1">Gain-of-function causing high contractile phenotype</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MYL2</italic>
</td><td rowspan="1" colspan="1">12q24.11</td><td rowspan="1" colspan="1">Familial HCM</td><td rowspan="1" colspan="1">Loss-of-function</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MYL3</italic>
</td><td rowspan="1" colspan="1">3p21.31</td><td rowspan="1" colspan="1">Familial HCM</td><td rowspan="1" colspan="1">Loss-of-function</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td colspan="6" rowspan="1">
<bold>Intrinsic cardiomyopathy genes</bold>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">ACTN2</italic>
</td><td rowspan="1" colspan="1">1q43</td><td rowspan="1" colspan="1">LVH, LVNC, DCM, and idiopathic VF</td><td rowspan="1" colspan="1">Loss-of-function</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">PLN</italic>
</td><td rowspan="1" colspan="1">6q22.31</td><td rowspan="1" colspan="1">HCM, DCM, and ARVC</td><td rowspan="1" colspan="1">Loss-of-function of SERCA (Ca<sup>2+</sup> overload) mitochondrial disease</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">JPH2</italic>
</td><td rowspan="1" colspan="1">20q13.12</td><td rowspan="1" colspan="1">Familial HCM/DCM</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">FHOD3</italic>
</td><td rowspan="1" colspan="1">18q12.2</td><td rowspan="1" colspan="1">Familial HCM/DCM</td><td rowspan="1" colspan="1">Actin filament polymerization disruption</td><td rowspan="1" colspan="1">0.5&#x02013;2%</td><td rowspan="1" colspan="1">Not curated by ClinGen</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CSRP3</italic>
</td><td rowspan="1" colspan="1">11p15.1</td><td rowspan="1" colspan="1">Late onset familial HCM, DCM</td><td rowspan="1" colspan="1">Unknown (non-sarcomeric gene)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TNNC1</italic>
</td><td rowspan="1" colspan="1">3p21.1</td><td rowspan="1" colspan="1">Familial HCM</td><td rowspan="1" colspan="1">Disruption of Ca<sup>2+</sup> handling</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td colspan="6" rowspan="1">
<bold>Syndromic genes, where isolated LVH may be seen</bold>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CACNA1C</italic>
</td><td rowspan="1" colspan="1">12p13.33</td><td rowspan="1" colspan="1">Timothy syndrome, BrS, LQTS</td><td rowspan="1" colspan="1">Intracellular Ca (2+) overload</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">DES</italic>
</td><td rowspan="1" colspan="1">2q35</td><td rowspan="1" colspan="1">Desminopathy (DCM), myofibrillar myopathy</td><td rowspan="1" colspan="1">Dysfunction through Z-disk and myofibril disintegration, followed by abnormal accumulation of intracellular proteins</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">FHL1</italic>
</td><td rowspan="1" colspan="1">Xq26.3</td><td rowspan="1" colspan="1">Emery-Dreifuss MD, cardiac conduction abnormalities, arrhythmias, HCM</td><td rowspan="1" colspan="1">Dysfunction through Z-disk and myofibril disintegration, followed by abnormal accumulation of intracellular proteins</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">FLNC</italic>
</td><td rowspan="1" colspan="1">7q32.1</td><td rowspan="1" colspan="1">Myofibrillar myopathy, HCM, RCM, distal myopathy</td><td rowspan="1" colspan="1">Dysfunction through Z-disk and myofibril disintegration, followed by abnormal accumulation of intracellular proteins</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Not curated by ClinGen</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">GLA</italic>
</td><td rowspan="1" colspan="1">Xq22.1</td><td rowspan="1" colspan="1">Fabry disease</td><td rowspan="1" colspan="1">Loss-of-function</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">LAMP2</italic>
</td><td rowspan="1" colspan="1">Xq24</td><td rowspan="1" colspan="1">Danon disease</td><td rowspan="1" colspan="1">Loss-of-function</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">PRKAG2</italic>
</td><td rowspan="1" colspan="1">7q36.1</td><td rowspan="1" colspan="1">PRKAG2 cardiomyopathy</td><td rowspan="1" colspan="1">Dysfunction of AMPK</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">PTPN11</italic>
</td><td rowspan="1" colspan="1">12q24.13</td><td rowspan="1" colspan="1">Noonan syndrome</td><td rowspan="1" colspan="1">RASopathy</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">RAF1</italic>
</td><td rowspan="1" colspan="1">3p25.2</td><td rowspan="1" colspan="1">Noonan syndrome</td><td rowspan="1" colspan="1">RASopathy</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">RIT1</italic>
</td><td rowspan="1" colspan="1">1q22</td><td rowspan="1" colspan="1">Noonan syndrome</td><td rowspan="1" colspan="1">RASopathy</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TTR</italic>
</td><td rowspan="1" colspan="1">18q12.1</td><td rowspan="1" colspan="1">Transthyretin amyloidosis</td><td rowspan="1" colspan="1">Loss-of-function causing amyloid deposition in peripheral nerves and heart</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">ALPK3</italic>
</td><td rowspan="1" colspan="1">15q25.3</td><td rowspan="1" colspan="1">Infant-onset HCM/DCM</td><td rowspan="1" colspan="1">Biallelic loss-of-function</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Strong</td></tr><tr><td colspan="6" rowspan="1">
<bold>Syndromic genes, where LVH is occurs together with other syndromic features</bold>
</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">ABCC9</italic>
</td><td rowspan="1" colspan="1">12p12.1</td><td rowspan="1" colspan="1">Cantu syndrome</td><td rowspan="1" colspan="1">Reduce ATP-mediated potassium channel inhibition (gain-of-function)</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">BAG3</italic>
</td><td rowspan="1" colspan="1">10q26.11</td><td rowspan="1" colspan="1">Myofibrillar myopathy</td><td rowspan="1" colspan="1">Dysfunction through Z-disk and myofibril disintegration, followed by abnormal accumulation of intracellular proteins</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CAV3</italic>
</td><td rowspan="1" colspan="1">3p25.3</td><td rowspan="1" colspan="1">Caveolinopathy</td><td rowspan="1" colspan="1">Disruption of caveolae formation</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">COX15</italic>
</td><td rowspan="1" colspan="1">10q24.2</td><td rowspan="1" colspan="1">Leigh syndrome</td><td rowspan="1" colspan="1">Loss-of-function of SERCA (Ca<sup>2+</sup> overload) mitochondrial disease</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Strong</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">CRYAB</italic>
</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Alpha-B crystallinopathy</td><td rowspan="1" colspan="1">Dysfunction through Z-disk and myofibril disintegration, followed by abnormal accumulation of intracellular proteins</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">FXN</italic>
</td><td rowspan="1" colspan="1">9q21.11</td><td rowspan="1" colspan="1">Friedreich ataxia</td><td rowspan="1" colspan="1">Loss-of-function of mitochondrial protein</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">GAA</italic>
</td><td rowspan="1" colspan="1">17q25.3</td><td rowspan="1" colspan="1">Pompe disease</td><td rowspan="1" colspan="1">Loss-of-function</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">LDB3/ZASP</italic>
</td><td rowspan="1" colspan="1">10q23.2</td><td rowspan="1" colspan="1">Myofibrillar myopathy</td><td rowspan="1" colspan="1">Dysfunction through Z-disk and myofibril disintegration, followed by abnormal accumulation of intracellular proteins</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MYO6</italic>
</td><td rowspan="1" colspan="1">6q14.1</td><td rowspan="1" colspan="1">Bilateral hearing loss</td><td rowspan="1" colspan="1">Disruption of the structural integrity of inner ear hair cells</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">SLC25A4</italic>
</td><td rowspan="1" colspan="1">4q35.1</td><td rowspan="1" colspan="1">Mitochondrial disease</td><td rowspan="1" colspan="1">RASopathy</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definite</td></tr></tbody></table><table-wrap-foot><fn id="tblfn32"><p>ACM, arrhythmogenic cardiomyopathy; BrS, Brugada syndrome; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Diagnostic implications of genetic testing</title><sec><title>Index case</title><p>Hypertrophic cardiomyopathy is predominantly a disease of the sarcomere. First-line genetic testing primarily includes panel testing for genes with strong evidence for being disease-causing in HCM.<sup><xref rid="euac030-B10" ref-type="bibr">10</xref></sup> Gene panels generally (and are recommended to) include 8 sarcomere genes, including <italic toggle="yes">MYH7, MYBPC3, TNNI3, TNNT2, TPM1, MYL2, MYL3</italic>, and <italic toggle="yes">ACTC1</italic>, and typically identify a disease-causing variant in approximately 30% of sporadic and 60% of familial cases.<sup><xref rid="euac030-B10" ref-type="bibr">10</xref>,</sup><sup><xref rid="euac030-B315" ref-type="bibr">315</xref>,</sup><sup><xref rid="euac030-B316" ref-type="bibr">316</xref>,</sup><sup><xref rid="euac030-B328" ref-type="bibr">328&#x02013;330</xref></sup> Variants in <italic toggle="yes">TNNC1</italic> (troponin C1) have moderate evidence of pathogenicity<sup><xref rid="euac030-B310" ref-type="bibr">310</xref>,</sup><sup><xref rid="euac030-B331" ref-type="bibr">331</xref></sup> (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T13" ref-type="table">13</xref></italic>). A number of non-sarcomeric pathogenic variants with moderate to strong evidence of pathogenicity may be included in the initial tier of genes tested, including <italic toggle="yes">CSRP3</italic>, <italic toggle="yes">JPH2</italic>, <italic toggle="yes">ALPK3</italic>, and <italic toggle="yes">FHOD3</italic>.<sup><xref rid="euac030-B311" ref-type="bibr">311&#x02013;314</xref></sup> Expanding to larger panels, including the genes summarized in <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S13</xref></italic>, usually does not add diagnostic value.<sup><xref rid="euac030-B69" ref-type="bibr">69</xref>,</sup><sup><xref rid="euac030-B315" ref-type="bibr">315</xref></sup> Initial genetic testing is usually performed in the index case (proband).<sup><xref rid="euac030-B315" ref-type="bibr">315</xref></sup> In up to 40% of patients with HCM, no sarcomere variant is identified, and there is no family history of disease.<sup><xref rid="euac030-B332" ref-type="bibr">332</xref></sup></p><p>Genes associated with HCM phenocopies may be included in first-tier genetic testing if there is clinical suspicion based on phenotype evaluation of a syndromic disorder, including <italic toggle="yes">PRKAG2</italic> (glycogen storage disease),<sup><xref rid="euac030-B253" ref-type="bibr">253</xref>,</sup><sup><xref rid="euac030-B308" ref-type="bibr">308</xref>,</sup><sup><xref rid="euac030-B319" ref-type="bibr">319</xref></sup><italic toggle="yes">LAMP2</italic> (Danon disease),<sup><xref rid="euac030-B320" ref-type="bibr">320</xref></sup><italic toggle="yes">GLA</italic> (Fabry disease),<sup><xref rid="euac030-B321" ref-type="bibr">321</xref></sup> and relevant genes for transthyretin amyloid cardiomyopathy,<sup><xref rid="euac030-B322" ref-type="bibr">322</xref></sup> and Pompe disease.<sup><xref rid="euac030-B333" ref-type="bibr">333&#x02013;335</xref></sup> In some circumstances, the genetic test result may alter the management of the index case, such as enzyme replacement therapy in patients with Fabry disease or more aggressive clinical management of patients with Danon disease, or increased awareness for sinus bradycardia and AV block in <italic toggle="yes">PRKAG2.</italic><sup><xref rid="euac030-B323" ref-type="bibr">323</xref>,</sup><sup><xref rid="euac030-B324" ref-type="bibr">324</xref></sup></p><p>Postmortem testing for HCM-associated variants using blood or tissue collected at autopsy has been reported, particularly in instances where the family variant is unknown and no other affected family members are still living.<sup><xref rid="euac030-B86" ref-type="bibr">86&#x02013;88</xref></sup> Access to a molecular autopsy as well as considerations related to costs and insurance coverage for this testing can vary between jurisdictions. Nevertheless, identification of a LP/P variant not only confirms the diagnosis of HCM but allows cascade genetic testing of other at-risk relatives as outlined previously.</p></sec><sec><title>Family screening</title><p>After genetic testing, a clinically actionable result (likely-pathogenic or pathogenic) can provide diagnostic clarification in the proband and offers the potential for cascade (predictive) testing of at-risk family members.<sup><xref rid="euac030-B81" ref-type="bibr">81&#x02013;85</xref></sup> Cascade testing involves targeted testing of first-degree relatives for the LP/P variant found in the proband. When cascade testing is performed in an at-risk relative, those who are found not to carry the disease-causing gene variant can be released from further clinical surveillance. Those who are found to carry the disease-causing gene variant should undergo clinical screening at regular intervals. Family members of a patient where genetic testing is not done or is negative (no likely-pathogenic or pathogenic variant is identified) also require clinical screening at regular intervals because there is considerable phenotypic heterogeneity in age of onset and disease progression within members of the same family.</p></sec></sec><sec><title>Prognostic and therapeutic implications of genetic testing</title><p>Although there is some evidence that individuals who carry &#x0003e;1 LP/P variant may have more severe disease, including SCD, the role of the genetic test result in the determination of risk in SCD remains uncertain and is therefore not clinically useful. Similarly, a genetic result <italic toggle="yes">per se</italic> does not influence decisions related to implanting an ICD in patients with HCM. Several studies have reported that patients with HCM who carry LP/P sarcomere variants have a worse prognosis compared to sarcomere variant negative patients. This includes earlier onset of disease, higher incidence of SCD, higher incidence of AFib and ventricular arrhythmias, HF, and overall mortality.<sup><xref rid="euac030-B83" ref-type="bibr">83</xref>,</sup><sup><xref rid="euac030-B329" ref-type="bibr">329</xref>,</sup><sup><xref rid="euac030-B336" ref-type="bibr">336&#x02013;338</xref></sup> However, there remains considerable intra- and inter-familial heterogeneity with variants in the same gene that currently limits the application of genetic information for clinical decision-making, including risk stratification for SCD in the proband.<sup><xref rid="euac030-B318" ref-type="bibr">318</xref>,</sup><sup><xref rid="euac030-B339" ref-type="bibr">339</xref></sup> Early data on polygenic risk scores suggests they may correlate with disease severity.<sup><xref rid="euac030-B29" ref-type="bibr">29</xref>,</sup><sup><xref rid="euac030-B30" ref-type="bibr">30</xref></sup> Discovery of an HCM phenocopy may modify therapeutic options, such as enzyme replacement therapy in Fabry patients.</p></sec></sec><sec><title>Dilated cardiomyopathy</title><p>
<bold>Impact of genetic testing for the index case</bold>
</p><table-wrap position="float" id="T40"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">DCM</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">++</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T41"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Genetic testing is recommended for probands with DCM and family history of DCM, and the initial tier of genes tested should include genes with definitive or strong evidence of pathogenicity (currently <italic toggle="yes">BAG3, DES, FLNC, LMNA, MYH7, PLN, RBM20, SCN5A, TNNC1, TNNT2, TTN, DSP</italic>).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B19" ref-type="bibr">19</xref>,</sup>
<sup>
<xref rid="euac030-B340" ref-type="bibr">340</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">For genetic testing in a proband with DCM, the initial tier of genes tested may include genes with moderate evidence of pathogenicity (<italic toggle="yes">ACTC1, ACTN2, JPH2, NEXN, TNNI3, TPM1, VCL</italic>).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B19" ref-type="bibr">19</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Genetic testing is recommended for patients with DCM and family history of premature unexpected sudden death or in a DCM patient with clinical features suggestive of a particular/rare genetic disease (such as atrioventricular block or sinus dysfunction or creatine phosphokinase elevation).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B340" ref-type="bibr">340</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Genetic testing&#x000a0;can be useful&#x000a0;for patients with apparently sporadic DCM,&#x000a0;particularly in the presence of either severe systolic dysfunction (left ventricular ejection fraction&#x02009;&#x0003c;&#x02009;35%), or a malignant arrhythmia phenotype (e.g. sustained ventricular tachycardia/fibrillation), or particularly at a younger age.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B340" ref-type="bibr">340</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Genetic testing may be considered for patients with DCM related to an acquired or environmental cause that may overlap with a genetic cause (such as peripartum or alcoholic cardiomyopathy).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B341" ref-type="bibr">341</xref>,</sup>
<sup>
<xref rid="euac030-B342" ref-type="bibr">342</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Genetic testing is useful for patients with DCM to improve risk stratification and guide therapy.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B201" ref-type="bibr">201</xref>,</sup>
<sup>
<xref rid="euac030-B343" ref-type="bibr">343&#x02013;348</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant-specific genetic testing is recommended for family members and appropriate relatives following the identification of the disease-causative variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B16" ref-type="bibr">16</xref>,</sup>
<sup>
<xref rid="euac030-B340" ref-type="bibr">340</xref>,</sup>
<sup>
<xref rid="euac030-B349" ref-type="bibr">349</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children is recommended in those aged &#x0003e;10&#x02013;12&#x02009;years.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B16" ref-type="bibr">16</xref>,</sup>
<sup>
<xref rid="euac030-B350" ref-type="bibr">350</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children aged below 10&#x02013;12&#x02009;years may be considered, especially where there is a family history of early-onset disease.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B16" ref-type="bibr">16</xref>,</sup>
<sup>
<xref rid="euac030-B350" ref-type="bibr">350</xref>
</sup>
</td></tr></tbody></table></table-wrap><sec><title>Background</title><p>Dilated cardiomyopathy is defined by the presence of LV or biventricular dilatation and systolic dysfunction in the absence of abnormal loading conditions (hypertension, valve disease) or coronary artery disease sufficient to cause global systolic impairment.<sup><xref rid="euac030-B351" ref-type="bibr">351</xref></sup> A new category of <italic toggle="yes">hypokinetic non-dilated cardiomyopathy</italic> was also proposed<sup><xref rid="euac030-B352" ref-type="bibr">352</xref></sup> to characterize patients with systolic dysfunction but without LV dilatation. Dilated cardiomyopathy encompasses a broad range of genetic or acquired disorders and careful diagnostic work-up should be performed to identify the underlying cause and then consider an aetiology-oriented approach to therapy.<sup><xref rid="euac030-B352" ref-type="bibr">352</xref></sup> In the pre-molecular era, systematic cardiac screening of the relatives of patients with DCM identified probable familial disease in about 20&#x02013;35% of cases.<sup><xref rid="euac030-B353" ref-type="bibr">353&#x02013;355</xref></sup> Subsequently, identification of DCM-related genes and development of high-throughput sequencing technologies led to the identification of pathogenic variants in up to 50% of DCM patients<sup><xref rid="euac030-B340" ref-type="bibr">340</xref>,</sup><sup><xref rid="euac030-B355" ref-type="bibr">355</xref></sup> including a non-marginal yield in sporadic DCM.<sup><xref rid="euac030-B356" ref-type="bibr">356</xref></sup> Moreover, there are more and more situations in which genetic predisposition interacts with extrinsic or environmental factors resulting in mixed genetic/environmental causes, such as myocarditis, as well as peripartum, alcoholic, or chemotherapy-related cardiomyopathies.<sup><xref rid="euac030-B341" ref-type="bibr">341</xref>,</sup><sup><xref rid="euac030-B342" ref-type="bibr">342</xref>,</sup><sup><xref rid="euac030-B357" ref-type="bibr">357</xref>,</sup><sup><xref rid="euac030-B358" ref-type="bibr">358</xref></sup></p><sec><title>Summary of the common dilated cardiomyopathy genes</title><p>About 100 genes have been reported to be possibly related to DCM (main genes in <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T14" ref-type="table">14</xref></italic>). The disease-specific metrics designed by the Clinical Genome Resource (ClinGen), reclassified many of these genes to limited or disputed evidence<sup><xref rid="euac030-B19" ref-type="bibr">19</xref></sup> (<xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S14</xref></italic>). Truncating variants in titin gene (<italic toggle="yes">TTN</italic>) are the most frequent in DCM, accounting for up to 20% of cases.<sup><xref rid="euac030-B24" ref-type="bibr">24</xref></sup> A case&#x02013;control study demonstrated that variants in <italic toggle="yes">TTN, DSP, MYH7, LMNA, BAG3, TNNT2, TNNC1, PLN, ACTC1, NEXN, TPM1,</italic> and <italic toggle="yes">VCL</italic> are significantly enriched in DCM cases.<sup><xref rid="euac030-B359" ref-type="bibr">359</xref></sup> Mutated genes are most often related to sarcomeric genes, z-disc/cytoskeleton, intercalated disc, and ion flux in large series with large panels indicating partial overlap with other cardiomyopathy subtypes [such as ACM (arrhythmogenic right ventricular cardiomyopathy, ARVC)] as well as with channelopathies.<sup><xref rid="euac030-B340" ref-type="bibr">340</xref></sup></p><table-wrap position="float" id="euac030-T14"><label>Table 14</label><caption><p>Genes implicated in dilated cardiomyopathy</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Gene</th><th rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Phenotype&#x02013;syndrome</th><th align="left" rowspan="1" colspan="1">Protein (functional effect)</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TTN</italic>
</td><td rowspan="1" colspan="1">2q31.2</td><td rowspan="1" colspan="1">DCM</td><td rowspan="1" colspan="1">Titin</td><td rowspan="1" colspan="1">&#x0223c;15&#x02013;25%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">LMNA</italic>
</td><td rowspan="1" colspan="1">1q22</td><td rowspan="1" colspan="1">DCM, ACM</td><td rowspan="1" colspan="1">Lamin A/C</td><td rowspan="1" colspan="1">&#x0223c;4&#x02013;7%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MYH7</italic>
</td><td rowspan="1" colspan="1">14q11.2</td><td rowspan="1" colspan="1">HCM</td><td rowspan="1" colspan="1">B&#x000ea;ta Myosin heavy chain</td><td rowspan="1" colspan="1">&#x0223c;3&#x02013;5%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TNNT2</italic>
</td><td rowspan="1" colspan="1">1q32.1</td><td rowspan="1" colspan="1">HCM, DCM</td><td rowspan="1" colspan="1">Troponin T</td><td rowspan="1" colspan="1">&#x0223c;2%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">RBM20</italic>
</td><td rowspan="1" colspan="1">10q25.2</td><td rowspan="1" colspan="1">DCM</td><td rowspan="1" colspan="1">RNA-binding motif protein 20</td><td rowspan="1" colspan="1">&#x0223c;2%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">PLN</italic>
</td><td rowspan="1" colspan="1">6q22.31</td><td rowspan="1" colspan="1">DCM, ACM</td><td rowspan="1" colspan="1">Phospholamban</td><td rowspan="1" colspan="1">&#x0223c;1% (<italic toggle="yes">more in Netherlands)</italic></td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">FLNC</italic>
</td><td rowspan="1" colspan="1">7q32.1</td><td rowspan="1" colspan="1">DCM&#x0226b;BiVACM</td><td rowspan="1" colspan="1">Filamin-C</td><td rowspan="1" colspan="1">&#x0223c;3%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">BAG3</italic>
</td><td rowspan="1" colspan="1">10q26.11</td><td rowspan="1" colspan="1">DCM, myopathy</td><td rowspan="1" colspan="1">BAG family molecular chaperone regulator 3</td><td rowspan="1" colspan="1">&#x0223c;2%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">DSP</italic>
</td><td rowspan="1" colspan="1">6p24.3</td><td rowspan="1" colspan="1">ARVC, DCM</td><td rowspan="1" colspan="1">Desmoplakin</td><td rowspan="1" colspan="1">1&#x02013;3%</td><td rowspan="1" colspan="1">Strong</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TPM1</italic>
</td><td rowspan="1" colspan="1">15q22.1</td><td rowspan="1" colspan="1">HCM, DCM</td><td rowspan="1" colspan="1">alpha-tropomyosin</td><td rowspan="1" colspan="1">&#x0223c;1&#x02013;2%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">ACTC1</italic>
</td><td rowspan="1" colspan="1">15q11q14</td><td rowspan="1" colspan="1">HCM, DCM</td><td rowspan="1" colspan="1">Cardiac alpha-actin</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">ACTN2</italic>
</td><td rowspan="1" colspan="1">1q43</td><td rowspan="1" colspan="1">HCM, DCM, LVNC</td><td rowspan="1" colspan="1">Alpha-actinin-2</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">DES</italic>
</td><td rowspan="1" colspan="1">2q35</td><td rowspan="1" colspan="1">DCM, Myopathy, ACM</td><td rowspan="1" colspan="1">Desmin</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">JPH2</italic>
</td><td rowspan="1" colspan="1">20q13.12</td><td rowspan="1" colspan="1">DCM, HCM</td><td rowspan="1" colspan="1">Junctophilin 2</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">NEXN</italic>
</td><td rowspan="1" colspan="1">1p31.1</td><td rowspan="1" colspan="1">DCM, HCM</td><td rowspan="1" colspan="1">Nexilin</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">SCN5A</italic>
</td><td rowspan="1" colspan="1">3p22.2</td><td rowspan="1" colspan="1">LQTS, Brugada, DCM, ACM</td><td rowspan="1" colspan="1">Sodium channel protein type 5 subunit alpha</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TNNC1</italic>
</td><td rowspan="1" colspan="1">3p21.1</td><td rowspan="1" colspan="1">DCM, HCM</td><td rowspan="1" colspan="1">Cardiac Troponin C</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TNNI3</italic>
</td><td rowspan="1" colspan="1">19q13.4</td><td rowspan="1" colspan="1">HCM, DCM</td><td rowspan="1" colspan="1">Cardiac troponin I</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">VCL</italic>
</td><td rowspan="1" colspan="1">10q22.2</td><td rowspan="1" colspan="1">DCM</td><td rowspan="1" colspan="1">Metavinculin</td><td rowspan="1" colspan="1">&#x0003c;1%</td><td rowspan="1" colspan="1">Moderate</td></tr></tbody></table><table-wrap-foot><fn id="tblfn33"><p>ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy.</p></fn></table-wrap-foot></table-wrap><p>Series also suggest that the single-variant Mendelian disease model is insufficient to explain some DCM cases, since multiple variants (mainly compound heterozygous may be observed in up to 38% in DCM patients).<sup><xref rid="euac030-B340" ref-type="bibr">340</xref></sup> Preliminary data suggest a complex polygenic architecture for some DCM patients with a combination of rare and frequent variants and interactions with environmental factors.<sup><xref rid="euac030-B29" ref-type="bibr">29</xref>,</sup><sup><xref rid="euac030-B30" ref-type="bibr">30</xref>,</sup><sup><xref rid="euac030-B360" ref-type="bibr">360</xref>,</sup><sup><xref rid="euac030-B361" ref-type="bibr">361</xref></sup></p></sec></sec><sec><title>Diagnostic implications of dilated cardiomyopathy genetic testing</title><sec><title>Index cases</title><p>The yield of genetic study in DCM is variable and depends on familial context (familial vs. sporadic DCM, history of SCD), presence of particular associated cardiac or extra-cardiac signs, type of genetic testing selection, and stringency of variant interpretation. It can be grossly estimated to be 20&#x02013;50% and is the highest in DCM with familial forms or with particular associated cardiac or extra-cardiac signs.<sup><xref rid="euac030-B340" ref-type="bibr">340</xref>,</sup><sup><xref rid="euac030-B349" ref-type="bibr">349</xref>,</sup><sup><xref rid="euac030-B356" ref-type="bibr">356</xref></sup> As in other conditions genetic testing in an index patient, and identification of a pathogenic variant, may have several impacts since the information is able to confirm the genetic origin and mode of inheritance, can distinguish DCM from other cardiomyopathies such as ACM and is useful for appropriate aetiology-management of patients. Genetic testing is therefore useful in all DCM patients, is recommended in DCM patients with the highest yield of pathogenic variant screening and should be considered even in the absence of familial context or associated clinical features (&#x0003c;60&#x02009;years of age). High-throughput sequencing with targeted sequencing panels of genes is the most cost-effective approach and recommended technique.<sup><xref rid="euac030-B362" ref-type="bibr">362</xref></sup> Panels should include validated genes in DCM (see <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T14" ref-type="table">14</xref></italic>), with most prevalent genes such as TTN as well as genes with prognostic or therapeutic implications, such as LMNA or FLNC. Genetic testing/panel can be oriented by the presence of a particular extra-cardiac phenotype such as neuromuscular diseases, mitochondrial diseases, congenital syndromes.<sup><xref rid="euac030-B363" ref-type="bibr">363</xref></sup></p></sec><sec><title>Family screening</title><p>Most genetic DCM inheritance follows an AD pattern, although X-linked, recessive, and mitochondrial patterns of inheritance occur (see genetic influences on disease and modes of inheritance section).<sup><xref rid="euac030-B360" ref-type="bibr">360</xref>,</sup><sup><xref rid="euac030-B364" ref-type="bibr">364</xref></sup> Penetrance in AD DCM is age-dependent. Therefore, an individual who carries a disease-causing variant is more likely to show a disease phenotype with increasing age, and a normal phenotypic assessment by echocardiogram and ECG does not exclude the possibility of later onset disease. The identification of a LP/P in the index case allows specific cascade genetic screening to identify gene carriers among relatives.<sup><xref rid="euac030-B16" ref-type="bibr">16</xref>,</sup><sup><xref rid="euac030-B350" ref-type="bibr">350</xref>,</sup><sup><xref rid="euac030-B365" ref-type="bibr">365</xref></sup> Relatives who do not carry the pathogenic variant are reassured and cardiac follow-up is no longer required. Relatives who carry the pathogenic variant must be periodically investigated for early detection of the phenotype, to allow optimal management and prevention of the complications. A genetic diagnosis can be useful for reproductive counselling and planning, including options for prenatal or pre-implantation genetic testing to prevent the transmission of DCM.<sup><xref rid="euac030-B366" ref-type="bibr">366</xref></sup></p></sec></sec><sec><title>Prognostic and therapeutic implications of dilated cardiomyopathy genetic testing</title><p>The identification of a specific genetic substrate can help to manage the patients and guide clinical decisions. Patients with pathogenic LMNA variants have consistently been associated with a poor prognosis, especially with a high risk of SCD related either to conduction defect or ventricular arrhythmia.<sup><xref rid="euac030-B201" ref-type="bibr">201</xref>,</sup><sup><xref rid="euac030-B343" ref-type="bibr">343</xref>,</sup><sup><xref rid="euac030-B344" ref-type="bibr">344</xref></sup> There are, however, exceptions for particular founder pathogenic variants.<sup><xref rid="euac030-B367" ref-type="bibr">367</xref></sup> Preventive pacemaker (PM) or ICD therapy should be considered early in LMNA carriers, and algorithms for ICD implantation include the pathogenic variant mechanism (truncating vs. missense variant) as associated with higher SCD risk.<sup><xref rid="euac030-B201" ref-type="bibr">201</xref>,</sup><sup><xref rid="euac030-B343" ref-type="bibr">343</xref>,</sup><sup><xref rid="euac030-B344" ref-type="bibr">344</xref></sup> Higher risk of SCD is also associated with pathogenic variants, especially truncated variants, in <italic toggle="yes">FLNC, DES, RBM20</italic>, and <italic toggle="yes">PLN</italic> genes,<sup><xref rid="euac030-B345" ref-type="bibr">345&#x02013;348</xref>,</sup><sup><xref rid="euac030-B368" ref-type="bibr">368</xref></sup> so that preventive ICD implantation may also be considered in these patients. Desmosomal pathogenic variants in patients with DCM or biventricular cardiomyopathy are also associated with a greater risk of life-threatening ventricular arrhythmias/SCD.<sup><xref rid="euac030-B369" ref-type="bibr">369</xref></sup> Patients with DCM are also at greater risk for heart failure and heart transplantation when they are carriers of pathogenic variants in <italic toggle="yes">LMNA, RBM20</italic>, and <italic toggle="yes">DSP</italic> genes.<sup><xref rid="euac030-B345" ref-type="bibr">345</xref>,</sup><sup><xref rid="euac030-B369" ref-type="bibr">369</xref></sup> Preventive PM implantation related to conduction defect should also be considered in patients with DCM and muscular dystrophy related to dystrophin, <italic toggle="yes">DES</italic> and <italic toggle="yes">EMD</italic> genes.<sup><xref rid="euac030-B345" ref-type="bibr">345</xref>,</sup><sup><xref rid="euac030-B348" ref-type="bibr">348</xref></sup></p></sec></sec><sec><title>Arrhythmogenic cardiomyopathy</title><p>&#x000a0;
</p><table-wrap position="float" id="T42"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ACM</td><td rowspan="1" colspan="1">+++</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">++</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T43"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendations</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Comprehensive genetic testing is recommended for all patients with consistent phenotypic features of ACM, including those cases diagnosed post-mortem, whatever familial context.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B370" ref-type="bibr">370</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Genetic testing of first tier definitive disease-associated genes (currently <italic toggle="yes">PKP2, DSP, DSG2, DSC2, JUP, TMEM43, PLN, FLNC, DES, LMNA</italic>) is recommended.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B370" ref-type="bibr">370</xref>,</sup>
<sup>
<xref rid="euac030-B371" ref-type="bibr">371</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Owing to the possibility of complex genotypes, in families with multiple affected members, the case with the more severe and/or earlier phenotype may be considered the &#x02018;genetic proband&#x02019; and be tested first.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B362" ref-type="bibr">362</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In patients with a borderline ACM phenotype, comprehensive genetic testing may be considered. The identification of a LP/P genetic variant would be useful to confirm the diagnosis.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B372" ref-type="bibr">372</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant-specific genetic testing is recommended for family members and appropriate relatives following the identification of the disease-causative variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B370" ref-type="bibr">370</xref>,</sup>
<sup>
<xref rid="euac030-B373" ref-type="bibr">373</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children is recommended in those aged &#x0003e;10&#x02013;12&#x02009;years.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B370" ref-type="bibr">370</xref>,</sup>
<sup>
<xref rid="euac030-B374" ref-type="bibr">374</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Predictive genetic testing in related children aged below 10&#x02013;12&#x02009;years may be considered, especially where there is a family history of early-onset disease.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table></table-wrap><sec><title>Background</title><p>Arrhythmogenic cardiomyopathy is mainly characterized by fibro or fibrofatty myocardial replacement which can cause progressive global/regional ventricular dysfunction, and high burden of ventricular arrhythmias.<sup><xref rid="euac030-B375" ref-type="bibr">375</xref></sup> Structural alterations can affect left, right, or both ventricles which lead to three recognized phenotypic variants: the dominant-right (&#x02018;the classic arrhythmogenic right ventricular cardiomyopathy&#x02019;&#x02014;ARVC) variant, the biventricular variant (Biv ACM), and the dominant-left variant (also known as &#x02018;arrhythmogenic left ventricular cardiomyopathy&#x02019;&#x02014;ALVC). The identification of a LP/P genetic variant is a major diagnostic criterion in all types and can be a necessary requirement for the ALVC variant.<sup><xref rid="euac030-B372" ref-type="bibr">372</xref></sup> The most common pattern of inheritance in monogenic ACM is AD. However, Naxos disease and Carvajal syndrome, which lead to the identification of the desmosomal cause of the disease are both recessive conditions.<sup><xref rid="euac030-B373" ref-type="bibr">373</xref></sup></p></sec><sec><title>Diagnostic implications of arrhythmogenic cardiomyopathy genetic testing</title><p>Arrhythmogenic right ventricular cardiomyopathy is predominantly associated with variants in desmosomal genes. Haploinsufficiency is a well-recognized molecular mechanism in these genes, and loss-of-function variants (nonsense, frameshift and splicing site) have the strongest evidence for pathogenicity.<sup><xref rid="euac030-B374" ref-type="bibr">374</xref></sup> The interpretation of missense or in-frame insertion/deletion variants is generally challenging and segregation with the phenotype in the families is usually mandatory for establishing their causality. Nearly 50% of patients with ARVC have one or more desmosomal pathogenic variants, with <italic toggle="yes">PKP2</italic> the most common mutated gene.<sup><xref rid="euac030-B371" ref-type="bibr">371</xref>,</sup><sup><xref rid="euac030-B376" ref-type="bibr">376</xref></sup> The number of variants that could be considered pathogenic in <italic toggle="yes">JUP</italic> is anecdotally besides Naxos disease. Non-desmosomal gene variants represent a minority of ARVC causes, and have been reported in a limited number of cases. Familial segregation studies are limited in some of the new proposed genes and the evidence supporting their causality is limited.</p><p>Biventricular ACM is also frequently associated with desmosomal genetic variants. Specific variants in <italic toggle="yes">PLN</italic> (p.Arg14del) and <italic toggle="yes">TMEM43</italic> (p.Ser358Leu) are highly relevant in some countries where a founder effect has been demonstrated.<sup><xref rid="euac030-B377" ref-type="bibr">377</xref>,</sup><sup><xref rid="euac030-B378" ref-type="bibr">378</xref></sup> The identification of other pathogenic variants in these two genes associated with ACM is quite rare. Initial investigations postulated <italic toggle="yes">RYR2</italic> gene as part of the genetic substrate of ARVC.<sup><xref rid="euac030-B379" ref-type="bibr">379</xref></sup> However, after decades of their initial descriptions, and after investigation of thousands of patients, evidence no longer supports these associations.</p><p>Desmoplakin (<italic toggle="yes">DSP</italic>) is by far the most commonly mutated desmosomal gene in patients with ALVC. <italic toggle="yes">DSG2</italic> and <italic toggle="yes">DSC2</italic> genes variants have also been described in ALVC patients but represent a significantly lower number of cases.<sup><xref rid="euac030-B369" ref-type="bibr">369</xref></sup> Non-desmosomal genes can be more relevant in the left-dominant variant of the disease. Truncations in <italic toggle="yes">FLNC, RBM20</italic>, and some <italic toggle="yes">DES</italic> variants were consistently associated with this phenotype often without overt skeletal myopathy, which is traditionally related to these genes.<sup><xref rid="euac030-B346" ref-type="bibr">346</xref>,</sup><sup><xref rid="euac030-B380" ref-type="bibr">380</xref>,</sup><sup><xref rid="euac030-B381" ref-type="bibr">381</xref></sup> The yield of genetic study in ACM is highly variable and depends on several factors (type of ventricle affected, familial clustering, ethnicity of the cohort and selection criteria, type of genetic testing selection, and the stringency of variant interpretation) but can be grossly estimated in the 50&#x02013;60% range.</p><sec><title>Index cases</title><p>Genetic testing is indicated in a proband with consistent phenotypic features of ACM, including those cases diagnosed post-mortem.<sup><xref rid="euac030-B370" ref-type="bibr">370</xref>,</sup><sup><xref rid="euac030-B375" ref-type="bibr">375</xref>,</sup><sup><xref rid="euac030-B382" ref-type="bibr">382</xref></sup> The identification of a LP/P genetic variant would also be useful to confirm the diagnosis in patients with a borderline phenotype. In those cases with isolated LV compromise, the demonstration of a pathogenic genetic variant could be necessary to link the electrical and/or structural manifestations with the diagnosis of ACM.<sup><xref rid="euac030-B372" ref-type="bibr">372</xref></sup> In families with multiple affected members, the case with the more severe and/or earlier phenotype must be considered the &#x02018;genetic proband&#x02019; and be tested first to enhance the detection of complex genotypes causing the disease (homozygous or compound/double heterozygous situations).<sup><xref rid="euac030-B372" ref-type="bibr">372</xref></sup> Nowadays, the recommended genetic test for ACM must include a minimal number of genes that have clinically demonstrated their association with the disease (see <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T15" ref-type="table">15</xref></italic>). Genes with limited or disputed evidence are summarized in <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>, <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Table S15</xref></italic>. High-throughput sequencing has demonstrated a high level of accuracy and is the recommended technique. Targeted sequencing panels of genes is the most cost-effective approach.<sup><xref rid="euac030-B362" ref-type="bibr">362</xref></sup> Copy number variation&#x02019;s analysis should be included, since this type of variant can be found in 1&#x02013;4% of negative studies.<sup><xref rid="euac030-B371" ref-type="bibr">371</xref></sup> Whole-exome/genome sequencing must assure adequate coverage in causative genes, and its application without filtering against genes of interest should be considered only in research contexts. Owing to the limited yield of genetic testing in ACM, a negative result does not rule out the diagnosis. The high genetic noise based on the prevalence of rare variants in ACM genes (especially missense changes in desmosomal genes) in the general population strengthens the importance of interpretation of the results by experts in cardiovascular molecular genetics.<sup><xref rid="euac030-B374" ref-type="bibr">374</xref></sup></p><table-wrap position="float" id="euac030-T15"><label>Table 15</label><caption><p>Genes implicated in arrhythmogenic cardiomyopathy</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<italic toggle="yes">Gene</italic>
</th><th align="left" rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Phenotype/syndrome</th><th align="left" rowspan="1" colspan="1">Protein (Cellular complex)</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">PKP2</italic>
</td><td rowspan="1" colspan="1">12p11.21</td><td rowspan="1" colspan="1">Classic ARVC. BiVACM and ALVC in a minority of cases.</td><td rowspan="1" colspan="1">Plakophilin 2 (desmosome)</td><td rowspan="1" colspan="1">20&#x02013;45%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">DSP</italic>
</td><td rowspan="1" colspan="1">6p24.3</td><td rowspan="1" colspan="1">Frequent BiVACM and ALVC. Occasional hair and skin features. Rare homozygous variants&#x02014;Carvajal Syndrome.</td><td rowspan="1" colspan="1">Desmoplakin (desmosome)</td><td rowspan="1" colspan="1">2&#x02013;15%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">DSG2</italic>
</td><td rowspan="1" colspan="1">18q12.1</td><td rowspan="1" colspan="1">Frequent BiVACM and ALVC.</td><td rowspan="1" colspan="1">Desmoglein 2 (desmosome)</td><td rowspan="1" colspan="1">4&#x02013;15%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">DSC2</italic>
</td><td rowspan="1" colspan="1">18q12.1</td><td rowspan="1" colspan="1">ARVC. Less frequent BiVACM and ALVC.</td><td rowspan="1" colspan="1">Desmocollin 2 (desmosome)</td><td rowspan="1" colspan="1">2&#x02013;7%</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">FLNC</italic>
</td><td rowspan="1" colspan="1">7q32.1</td><td rowspan="1" colspan="1">ALVC. Right ventricular involvement is rare</td><td rowspan="1" colspan="1">Filamin-C (cytoskeleton)</td><td rowspan="1" colspan="1">3%</td><td rowspan="1" colspan="1">Definite<sup><xref rid="tblfn35" ref-type="table-fn">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">JUP</italic>
</td><td rowspan="1" colspan="1">17q21.2</td><td rowspan="1" colspan="1">Naxos disease (cardioectodermal)</td><td rowspan="1" colspan="1">Plakoglobin (desmosome)</td><td rowspan="1" colspan="1">&#x0003c;1% (higher in Naxos, Greece)</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TMEM43</italic>
</td><td rowspan="1" colspan="1">3p25.1</td><td rowspan="1" colspan="1">ARVC and BiVACM</td><td rowspan="1" colspan="1">Transmembrane protein 43 (nuclear envelope)</td><td rowspan="1" colspan="1">&#x0003c;1% (higher in Newfoundland)</td><td rowspan="1" colspan="1">Definite</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">PLN</italic>
</td><td rowspan="1" colspan="1">6q22.31</td><td rowspan="1" colspan="1">Frequent ALVC/DCM</td><td rowspan="1" colspan="1">Phospholamban (sarcoplasmic reticulum; calcium handling)</td><td rowspan="1" colspan="1">1% (10&#x02013;15% in Netherlands)</td><td rowspan="1" colspan="1">Definite<sup><xref rid="tblfn35" ref-type="table-fn">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">DES</italic>
</td><td rowspan="1" colspan="1">2q35</td><td rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Frequent ALVC. Right ventricular involvement is also possible.</p></list-item><list-item><p>Conduction system abnormalities common. Skeletal myopathy possible.</p></list-item></list>
</td><td rowspan="1" colspan="1">Desmin (cytoskeleton)</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">Moderate</td></tr></tbody></table><table-wrap-foot><fn id="tblfn34"><p>ALVC, arrhythmogenic left ventricular cardiomyopathy; ARVC, arrhythmogenic right ventricular cardiomyopathy; BiVACM, bi-ventricular arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy.</p></fn><fn id="tblfn35"><label>a</label><p>Genes with a clear association with ALVC and included also in the ClinGen classification for DCM.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Family screening</title><p>The identification of a LP/P variant in the index case allows specific cascade genetic screening to identify gene carriers among relatives.<sup><xref rid="euac030-B370" ref-type="bibr">370</xref>,</sup><sup><xref rid="euac030-B373" ref-type="bibr">373</xref></sup> Incomplete penetrance and highly variable clinical expression associated with most ACM-related genes must be considered in the interpretation of the results, genetic counselling and clinical management.<sup><xref rid="euac030-B383" ref-type="bibr">383</xref>,</sup><sup><xref rid="euac030-B384" ref-type="bibr">384</xref></sup> Clinical and genetic evaluations of older generations in the family is also recommended and could be valuable for phenotype delineation associated with a particular genotype. The identification of relatives without the family pathogenic variant allows psychological relief and optimizes the clinical resources. On the other hand, variant-carrier relatives must be investigated periodically should be advised of the benefit of life-style modifications.</p></sec></sec><sec><title>Prognostic and therapeutic implications of arrhythmogenic cardiomyopathy genetic testing</title><p>Arrhythmogenic cardiomyopathy is characterized by highly variable intra/interfamilial phenotype severity and the influence of environmental factors is probably more determinant than in other cardiomyopathies.<sup><xref rid="euac030-B385" ref-type="bibr">385</xref></sup> Some investigations have suggested that ACM patients with an identifiable causative genetic variant do not have significant differences in disease course and prognosis from gene elusive patients.<sup><xref rid="euac030-B383" ref-type="bibr">383</xref></sup> Nevertheless, identification of the specific genetic substrate can guide the clinical decisions in some scenarios. Preventive (early) ICD implantation may be considered in ACM patients with truncations in <italic toggle="yes">FLNC, DSP, LMNA, DES</italic> and <italic toggle="yes">PLN</italic> pathogenic variants, who present with reduced LV systolic function.<sup><xref rid="euac030-B370" ref-type="bibr">370</xref>,</sup><sup><xref rid="euac030-B380" ref-type="bibr">380</xref>,</sup><sup><xref rid="euac030-B381" ref-type="bibr">381</xref></sup> Arrhythmogenic cardiomyopathy patients with cadherin-2 (<italic toggle="yes">CDH2</italic>) pathogenic variants have a higher incidence of ventricular arrhythmias, while development of heart failure is rare.<sup><xref rid="euac030-B386" ref-type="bibr">386</xref></sup> Since the ClinGen curation of genes for ACM, new evidence supports <italic toggle="yes">CDH2</italic> as a disease gene in a small subset of ACM patients.<sup><xref rid="euac030-B387" ref-type="bibr">387</xref></sup> Indeed, in ACM severe ventricular arrhythmias may present before ventricular dysfunction or structural manifestations are evident, that is why the detection of P/LP variant in an index case will allow through familial cascade screening early detection and prompt stratification of arrhythmic risk of those mutation carriers.</p><p>For <italic toggle="yes">LMNA, PLN</italic> and ACM caused by desmosome gene variants (mainly <italic toggle="yes">PKP2</italic>) specific calculators have been developed.<sup><xref rid="euac030-B344" ref-type="bibr">344</xref>,</sup><sup><xref rid="euac030-B388" ref-type="bibr">388</xref>,</sup><sup><xref rid="euac030-B389" ref-type="bibr">389</xref></sup> Those patients initially diagnosed with DCM where a pathogenic desmosomal variant is identified could have a greater risk of life-threatening ventricular arrhythmias and sudden death, regardless of the LV ejection fraction.<sup><xref rid="euac030-B369" ref-type="bibr">369</xref></sup> Patients with complex genotypes (homozygous and compound/double heterozygous) carrying clearly disease-causing variants, have a worse prognosis (considering ventricular arrhythmias and ventricular dysfunction) compared with single pathogenic variant carriers.<sup><xref rid="euac030-B376" ref-type="bibr">376</xref>,</sup><sup><xref rid="euac030-B390" ref-type="bibr">390</xref>,</sup><sup><xref rid="euac030-B391" ref-type="bibr">391</xref></sup> Competitive or high-level leisure sport has been demonstrated to increase penetrance, incidence of ventricular arrhythmias and progression to ventricular dysfunction in carriers of pathogenic desmosomal variants.<sup><xref rid="euac030-B392" ref-type="bibr">392</xref>,</sup><sup><xref rid="euac030-B393" ref-type="bibr">393</xref></sup></p></sec></sec><sec><title>Left ventricular non-compaction cardiomyopathy</title><p>&#x000a0;
</p><table-wrap position="float" id="T44"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">LVNC</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T45"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">LVNC cardiomyopathy genetic testing may be useful for patients in whom a cardiologist has established a clinical diagnosis of LVNC based on examination of the patient&#x02019;s clinical history, family history, and electrocardiographic/echocardiographic/MRI phenotype.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B387" ref-type="bibr">387</xref>,</sup>
<sup>
<xref rid="euac030-B394" ref-type="bibr">394&#x02013;396</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Genetic testing may be useful for patients with a clinical diagnosis of LVNC cardiomyopathy associated with other cardiac or non-cardiac syndromic features.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B397" ref-type="bibr">397&#x02013;399</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Genetic testing should not be performed in isolated (incidental) LVNC with normal LV function, no associated syndromic features and no family history.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B387" ref-type="bibr">387</xref>,</sup>
<sup>
<xref rid="euac030-B394" ref-type="bibr">394</xref>,</sup>
<sup>
<xref rid="euac030-B400" ref-type="bibr">400</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant specific genetic testing may be considered for family members and appropriate relatives following the identification of the disease-causative variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table></table-wrap><sec><title>Background</title><p>Left ventricular non-compaction (LVNC) is a phenotype that can present as a cardiomyopathy characterized by prominent LV trabeculations with deep intertrabecular recesses and thinning of the compact epicardium.<sup><xref rid="euac030-B394" ref-type="bibr">394</xref></sup> In children, LVNC can present with severe heart failure and life threatening arrhythmias. In adults, the clinical presentation and significance is less clear, particularly when the diagnosis is made outside the context of an affected family. Patients with LVNC can present with isolated LV trabeculations with no LV dysfunction, LVNC associated with other cardiomyopathies such as HCM or DCM, or can present with LVNC associated with other cardiac (e.g. conduction disease) or non-cardiac systemic features (e.g. skeletal abnormalities in Holt-Oram syndrome).<sup><xref rid="euac030-B387" ref-type="bibr">387</xref>,</sup><sup><xref rid="euac030-B394" ref-type="bibr">394&#x02013;396</xref>,</sup><sup><xref rid="euac030-B400" ref-type="bibr">400</xref>,</sup><sup><xref rid="euac030-B401" ref-type="bibr">401</xref></sup> Major adverse events in adults include life-threatening arrhythmias, thromboembolism, and heart failure. Genetic testing in LVNC, therefore, is strongly guided by a comprehensive clinical evaluation of the patient and their family. Isolated LVNC, with no LV dysfunction and detected incidentally on MRI will have a very low genetic testing yield compared to LVNC associated with other cardiomyopathies and LV dysfunction, syndromic features, and/or a strong family history where the genetic testing yield will be significantly higher.<sup><xref rid="euac030-B394" ref-type="bibr">394</xref>,</sup><sup><xref rid="euac030-B396" ref-type="bibr">396&#x02013;399</xref>,</sup><sup><xref rid="euac030-B401" ref-type="bibr">401</xref>,</sup><sup><xref rid="euac030-B402" ref-type="bibr">402</xref></sup></p><p>Left ventricular non-compaction is most commonly inherited as an AD trait in families, although AR, X-linked, and mitochondrial inheritance is also seen, often in children. Studies of the genetic causes of LVNC have primarily identified variants in cardiomyopathy genes and specifically sarcomere genes, including <italic toggle="yes">MYH7, MYBPC3</italic>, and <italic toggle="yes">TTN</italic> with reported genetic testing yields between 17% and 41% (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T16" ref-type="table">16</xref></italic>).<sup><xref rid="euac030-B394" ref-type="bibr">394</xref></sup> Other genetic diseases where LVNC is part of a clinical syndrome are also important to consider, such as <italic toggle="yes">LDB3</italic> (LIM-domain binding protein 3) with DCM and myopathy, <italic toggle="yes">TBX5</italic> in Holt&#x02013;Oram syndrome, <italic toggle="yes">NKX2-5</italic> with conduction disease, and <italic toggle="yes">TAZ</italic> (taffazin) associated with Barth syndrome in males<sup><xref rid="euac030-B387" ref-type="bibr">387</xref>,</sup><sup><xref rid="euac030-B394" ref-type="bibr">394&#x02013;399</xref></sup> (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T16" ref-type="table">16</xref></italic>). The choice of which genes to test in LVNC is strongly guided by the clinical phenotype, including presentation (symptomatic vs. incidental finding on cardiac MRI), association with other cardiomyopathies, other systemic cardiac or non-cardiac features, and presence of a family history of LVNC or other inherited cardiomyopathies.<sup><xref rid="euac030-B402" ref-type="bibr">402</xref></sup> There are not many known &#x02018;LVNC only&#x02019; genes, so genetic testing is guided by the other cardiomyopathies such as HCM or DCM (see <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T16" ref-type="table">16</xref></italic>). Most commonly a broad cardiomyopathy panel will represent the first step of genetic testing, with additional selection of genes guided by the phenotype. Left ventricular non-compaction in the setting of physiological changes such as during pregnancy or in athletes, as well as LVNC diagnosed incidentally on imaging studies, has a high prevalence in normal adult populations leading to overdiagnosis of LVNC as a pathogenic entity.<sup><xref rid="euac030-B403" ref-type="bibr">403</xref></sup> Therefore, genetic testing should rarely be considered in these settings and may lead to more harm than benefit related to uncertain genetic findings including variants of uncertain significance.</p><table-wrap position="float" id="euac030-T16"><label>Table 16</label><caption><p>Genes implicated in left ventricular noncompaction in adults</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Syndrome</th><th align="left" rowspan="1" colspan="1">Protein (functional effect)</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MHY7</italic>
</td><td rowspan="1" colspan="1">14q11.2</td><td rowspan="1" colspan="1">LVNC, DCM or HCM</td><td rowspan="1" colspan="1">Beta myosin heavy chain</td><td rowspan="1" colspan="1">10&#x02013;15%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MYBPC3</italic>
</td><td rowspan="1" colspan="1">11p11.2</td><td rowspan="1" colspan="1">LVNC, DCM or HCM</td><td rowspan="1" colspan="1">Myosin binding protein C</td><td rowspan="1" colspan="1">5&#x02013;15%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TTN</italic>
</td><td rowspan="1" colspan="1">2q31.2</td><td rowspan="1" colspan="1">LVNC, DCM</td><td rowspan="1" colspan="1">Titin</td><td rowspan="1" colspan="1">5&#x02013;10%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">ACTC1</italic>
</td><td rowspan="1" colspan="1">15q11.14</td><td rowspan="1" colspan="1">LVNC, DCM or HCM</td><td rowspan="1" colspan="1">Cardiac alpha-actin</td><td rowspan="1" colspan="1">1&#x02013;5%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">RYR2</italic>
</td><td rowspan="1" colspan="1">1q43</td><td rowspan="1" colspan="1">LVNC, DCM</td><td rowspan="1" colspan="1">Ryanodine receptor type 2</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">PRDM16</italic>
</td><td rowspan="1" colspan="1">1p36</td><td rowspan="1" colspan="1">LVNC</td><td rowspan="1" colspan="1">PR domain zinc finger protein 16</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">LBD3</italic>
</td><td rowspan="1" colspan="1">11p15.1</td><td rowspan="1" colspan="1">LVNC, DCM</td><td rowspan="1" colspan="1">LIM domain binding 3</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TBX5</italic>
</td><td rowspan="1" colspan="1">12q24.1</td><td rowspan="1" colspan="1">LVNC, Holt-Oram syndrome</td><td rowspan="1" colspan="1">T-box transcription factor 5</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">NKX2-5</italic>
</td><td rowspan="1" colspan="1">5q35.1</td><td rowspan="1" colspan="1">LVNC, DCM, conduction disease</td><td rowspan="1" colspan="1">Homeobox protein Nkx2-5</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">HCN4</italic>
</td><td rowspan="1" colspan="1">15q24.1</td><td rowspan="1" colspan="1">LVNC, conduction disease</td><td rowspan="1" colspan="1">Hyperpolarization-activated cyclic nucleotide-gated K+ channel 4</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TAZ</italic>
</td><td rowspan="1" colspan="1">Xp28</td><td rowspan="1" colspan="1">LVNC, Barth syndrome</td><td rowspan="1" colspan="1">Tafazzin</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr></tbody></table><table-wrap-foot><fn id="tblfn36"><p>DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left ventricular noncompaction.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Diagnostic implications of left ventricular non-compaction genetic testing</title><p>The main benefit of genetic testing in LVNC is for diagnosis in the index cases and to then use this genetic diagnosis for cascade testing in family members.<sup><xref rid="euac030-B394" ref-type="bibr">394</xref></sup> The identification of a genetic cause may also be useful in guiding reproductive decisions such as pre-implantation genetic diagnosis.</p></sec><sec><title>Prognostic and therapeutic implications</title><p>Currently, no significant genotype-phenotype correlations have been associated with LVNC alone and therefore, little prognostic information is available based on the genetic findings. There are some emerging data suggesting that specific genotypes such as <italic toggle="yes">MYH7</italic> pathogenic variants or multiple pathogenic variants in patients with LVNC and LV dysfunction may be associated with worse clinical outcomes compared to sporadic cases.<sup><xref rid="euac030-B394" ref-type="bibr">394</xref></sup></p></sec></sec><sec><title>Restrictive cardiomyopathy</title><p>&#x000a0;
</p><table-wrap position="float" id="T46"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Disease</th><th rowspan="1" colspan="1">Diagnostic</th><th rowspan="1" colspan="1">Prognostic</th><th rowspan="1" colspan="1">Therapeutic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">RCM</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T47"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendation</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">RCM genetic testing may be considered for patients in whom a cardiologist has established a clinical diagnosis of RCM based on examination of the patient&#x02019;s clinical history, family history, and electrocardiographic/echocardiographic phenotype.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B402" ref-type="bibr">402</xref>,</sup>
<sup>
<xref rid="euac030-B404" ref-type="bibr">404&#x02013;406</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Genetic testing specifically for <italic toggle="yes">TTR</italic> pathogenic variants is recommended for patients with RCM and a clinical diagnosis of cardiac <italic toggle="yes">TTR</italic> amyloidosis.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B407" ref-type="bibr">407</xref>,</sup>
<sup>
<xref rid="euac030-B408" ref-type="bibr">408</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Variant-specific genetic testing may be considered for family members and appropriate relatives following the identification of the disease-causative variant.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table></table-wrap><sec><title>Background</title><p>Restrictive cardiomyopathy (RCM), defined by the presence of impaired LV filling and diminished diastolic volume with normal or near-normal LV wall thickness and ejection fraction, is a relatively rare cardiomyopathy which can have both genetic and non-genetic causes. These causes generally relate to infiltrative (e.g. amyloidosis), non-infiltrative (e.g. myofibrillar myopathies), storage diseases (e.g. Fabry disease), and endomyocardial aetiologies such as carcinoid heart disease.<sup><xref rid="euac030-B404" ref-type="bibr">404</xref></sup> In children, RCM often presents with severe heart failure, and carries a poor prognosis with heart transplant being the only viable long-term treatment option. In adults, there is significant overlap with HCM and DCM, and patients often present with heart failure and life-threatening arrhythmias. While the genetic basis of RCM is still emerging, there are significant commonalities with the genetic causes of HCM and DCM mainly relating to sarcomere and cytoskeletal disease genes.<sup><xref rid="euac030-B402" ref-type="bibr">402</xref>,</sup><sup><xref rid="euac030-B405" ref-type="bibr">405</xref>,</sup><sup><xref rid="euac030-B406" ref-type="bibr">406</xref></sup></p><p>The inheritance pattern of RCM spans AD, AR, X-linked, and mitochondrial forms of transmission. Detailed family history and comprehensive clinical evaluation are essential to establish both cardiac features, as well as potential syndromic manifestations seen in RCM such as skeletal myopathies. Our knowledge of the specific genetic causes of RCM is rapidly growing. Currently, sarcomere and cytoskeletal disease genes include <italic toggle="yes">MYH7, TNNI3, TNNT2, ACTC1, FLNC</italic>, and <italic toggle="yes">TTN</italic>, reflecting the common genetic aetiologies of HCM and DCM<sup><xref rid="euac030-B402" ref-type="bibr">402</xref>,</sup><sup><xref rid="euac030-B405" ref-type="bibr">405</xref>,</sup><sup><xref rid="euac030-B406" ref-type="bibr">406</xref></sup> (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T17" ref-type="table">17</xref></italic>). In practical terms, genetic testing for RCM incorporates gene panels used for HCM and DCM, and relevant phenocopies such as <italic toggle="yes">GLA</italic> gene in suspected Fabry disease (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T17" ref-type="table">17</xref></italic>). The yield of genetic testing in familial RCM is difficult to estimate due to the range of aetiologies and the rare prevalence of disease, but may be up to 60%.<sup><xref rid="euac030-B402" ref-type="bibr">402</xref>,</sup><sup><xref rid="euac030-B405" ref-type="bibr">405</xref></sup> Inherited infiltrative diseases can lead to RCM, with amyloidosis being the most common, caused by pathogenic variants in the <italic toggle="yes">TTR</italic> gene which encodes transthyretin.<sup><xref rid="euac030-B407" ref-type="bibr">407</xref>,</sup><sup><xref rid="euac030-B408" ref-type="bibr">408</xref></sup> Pathological deposition of mis-folded amyloid can occur in many organs such as the liver, kidney, eyes, as well as the heart, so-called cardiac amyloidosis.<sup><xref rid="euac030-B407" ref-type="bibr">407</xref></sup></p><table-wrap position="float" id="euac030-T17"><label>Table 17</label><caption><p>Genes implicated in restrictive cardiomyopathy</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Locus</th><th align="left" rowspan="1" colspan="1">Syndrome</th><th align="left" rowspan="1" colspan="1">Protein (functional effect)</th><th align="left" rowspan="1" colspan="1">Frequency</th><th align="left" rowspan="1" colspan="1">ClinGen classification</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic toggle="yes">MHY7</italic>
</td><td rowspan="1" colspan="1">14q11.2</td><td rowspan="1" colspan="1">RCM</td><td rowspan="1" colspan="1">Beta myosin heavy chain</td><td rowspan="1" colspan="1">10&#x02013;15%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TTN</italic>
</td><td rowspan="1" colspan="1">2q31.2</td><td rowspan="1" colspan="1">RCM</td><td rowspan="1" colspan="1">Titin</td><td rowspan="1" colspan="1">5&#x02013;10%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">ACTC1</italic>
</td><td rowspan="1" colspan="1">15q11.14</td><td rowspan="1" colspan="1">RCM</td><td rowspan="1" colspan="1">Cardiac alpha-actin</td><td rowspan="1" colspan="1">5&#x02013;10%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TNNI3</italic>
</td><td rowspan="1" colspan="1">19q13.4</td><td rowspan="1" colspan="1">RCM</td><td rowspan="1" colspan="1">Cardiac troponin I</td><td rowspan="1" colspan="1">5&#x02013;10%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TTR</italic>
</td><td rowspan="1" colspan="1">18q12.1</td><td rowspan="1" colspan="1">RCM, amyloidosis</td><td rowspan="1" colspan="1">Transthyretin</td><td rowspan="1" colspan="1">1&#x02013;5%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">FLNC</italic>
</td><td rowspan="1" colspan="1">7Q32.1</td><td rowspan="1" colspan="1">RCM</td><td rowspan="1" colspan="1">Filamin-C</td><td rowspan="1" colspan="1">1&#x02013;5%</td><td rowspan="1" colspan="1">NA/major gene</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">TNNT2</italic>
</td><td rowspan="1" colspan="1">1q32.1</td><td rowspan="1" colspan="1">RCM</td><td rowspan="1" colspan="1">Cardiac troponin T</td><td rowspan="1" colspan="1">1&#x02013;2%</td><td rowspan="1" colspan="1">NA/rare gene</td></tr></tbody></table><table-wrap-foot><fn id="tblfn37"><p>RCM, restrictive cardiomyopathy.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Diagnostic implications of restrictive cardiomyopathy genetic testing</title><p>The main benefit of genetic testing in familial RCM is for diagnosis in the index cases and to then use this genetic diagnosis for cascade testing in at-risk family members. The identification of a genetic cause may also be useful in guiding reproductive decisions such as pre-implantation genetic diagnosis.</p></sec><sec><title>Prognostic and therapeutic implications</title><p>The genetic diagnosis may guide clinical management strategies. For example, a genetic diagnosis of Fabry disease may lead to the introduction of enzyme replacement therapy for the deficiency in alpha-galactosidase enzyme.<sup><xref rid="euac030-B409" ref-type="bibr">409</xref></sup> Similarly, a genetic diagnosis of <italic toggle="yes">TTR</italic> cardiac amyloidosis may be amenable to newer targeted treatments that inhibit hepatic synthesis of the TTR protein, stabilize the tetramer, or disrupt fibrils, such as tafamidis.<sup><xref rid="euac030-B407" ref-type="bibr">407</xref>,</sup><sup><xref rid="euac030-B410" ref-type="bibr">410</xref>,</sup><sup><xref rid="euac030-B411" ref-type="bibr">411</xref></sup> As the genetic architecture of RCM is further elucidated and underlying disease mechanisms identified, the impact of the genetic diagnosis in terms of guiding clinical management and informing prognosis will become more prominent.</p></sec></sec></sec><sec><title>State of genetic testing for sudden cardiac death or survivors of unexplained cardiac arrest</title><p>&#x000a0;
</p><table-wrap position="float" id="T48"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendations</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Unexpected sudden deaths should be investigated with a general autopsy, toxicology, and cardiac pathology (where possible).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B6" ref-type="bibr">6</xref>,</sup>
<sup>
<xref rid="euac030-B412" ref-type="bibr">412</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">If a sudden death is likely to be due to a cardiac genetic cause, or remains unexplained after pathological evaluation, EDTA blood, and/or fresh tissue (e.g. liver or spleen) should be retained for potential genetic analysis. Other sources of DNA such as blood spots and tissue stored in suitable media at room temperature may suffice.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B15" ref-type="bibr">15</xref>,</sup>
<sup>
<xref rid="euac030-B413" ref-type="bibr">413&#x02013;416</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">When a SCD could be attributable to a likely genetic cause, post-mortem genetic testing in the deceased individual targeted to the likely cause should be performed.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B414" ref-type="bibr">414</xref>
</sup>, expert opinion</td></tr><tr><td rowspan="1" colspan="1">When a SCD remains unexplained despite an autopsy and toxicology, post-mortem genetic testing in the deceased individual targeted to channelopathy genes&#x000a0;should be performed&#x000a0;when the circumstances and/or family history support a primary electrical disease.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B15" ref-type="bibr">15</xref>,</sup>
<sup>
<xref rid="euac030-B415" ref-type="bibr">415</xref>,</sup>
<sup>
<xref rid="euac030-B416" ref-type="bibr">416</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">When a SCD &#x0003c;50&#x02009;years old remains unexplained despite an autopsy, toxicology and channelopathy&#x000a0;gene panel testing, post-mortem genetic testing in the deceased individual&#x000a0;may be extended&#x000a0;to a wider panel including cardiomyopathy genes.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B15" ref-type="bibr">15</xref>,</sup>
<sup>
<xref rid="euac030-B415" ref-type="bibr">415</xref>,</sup>
<sup>
<xref rid="euac030-B416" ref-type="bibr">416</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In a decedent with unexplained SCD or an UCA survivor, hypothesis-free (post-mortem) genetic testing using exome or genome sequencing&#x000a0;should not be performed.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">In selected UCA survivors with idiopathic VF, genetic testing for founder variants,<sup><xref rid="tblfn38" ref-type="table-fn">a</xref></sup> where relevant, should be considered.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B417" ref-type="bibr">417</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In UCA survivors, genetic testing of channelopathy and cardiomyopathy genes&#x0202f; may be considered.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B418" ref-type="bibr">418&#x02013;421</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In relatives of UCA survivors or SCD decedents in whom a pathogenic variant has been identified, predictive genetic testing should be performed.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B413" ref-type="bibr">413</xref>,</sup>
<sup>
<xref rid="euac030-B422" ref-type="bibr">422</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In relatives of UCA survivors or SCD decedents, clinical evaluation of 1st degree family members should be performed, and targeted to the index case&#x02019;s phenotype if present.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B422" ref-type="bibr">422&#x02013;427</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">In decedents with SCD or survivors with cardiac arrest in whom a non-genetic cause has been identified, genetic testing of the index case and clinical evaluation of relatives should not be performed.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr></tbody></table><table-wrap-foot><fn id="tblfn38"><label>a</label><p>In this setting, a founder variant is a pathogenic variant that has a relatively high prevalence in the population in a particular geographic region&#x000a0;due to the presence of the variant in a single ancestor or small number of ancestors.</p></fn></table-wrap-foot></table-wrap><sec><title>&#x02003;</title><sec><title>Background</title><p>Sudden cardiac death is the most common mode of death due to cardiac disease. Approximately 1&#x02013;3 per 100&#x000a0;000 individuals under 35&#x02009;years old die suddenly and unexpectedly every year within this age group.<sup><xref rid="euac030-B6" ref-type="bibr">6</xref>,</sup><sup><xref rid="euac030-B412" ref-type="bibr">412</xref></sup> A significant minority of decedents will have signs of cardiomyopathy on autopsy that may then receive a molecular diagnosis after post-mortem genetic testing.<sup><xref rid="euac030-B413" ref-type="bibr">413</xref></sup> However, 30&#x02013;40% of cases of SCD in the young remain unexplained despite toxicological assessment and evaluation by an expert cardiac pathologist.<sup><xref rid="euac030-B15" ref-type="bibr">15</xref>,</sup><sup><xref rid="euac030-B414" ref-type="bibr">414</xref>,</sup><sup><xref rid="euac030-B415" ref-type="bibr">415</xref></sup> Many have had an underlying heritable cardiac channelopathy such as CPVT, LQTS, or BrS.<sup><xref rid="euac030-B6" ref-type="bibr">6</xref>,</sup><sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup> Early studies of diagnostic utility of post-mortem genetic testing, the &#x02018;molecular autopsy&#x02019;, in series of sudden arrhythmic death syndrome/sudden unexplained death decedents provided a pathogenic variant yield of 24% in the major channelopathy genes [CPVT1 (<italic toggle="yes">RyR2</italic>); LQT1-3 (<italic toggle="yes">KCNQ1, KCNH2, SCN5A</italic>) and BrS1 (<italic toggle="yes">SCN5A</italic>)].<sup><xref rid="euac030-B415" ref-type="bibr">415</xref></sup> A population-based NGS study then proposed a 27% burden of &#x02018;clinically relevant&#x02019; pathogenic variants by including cardiomyopathy genes and rare subsequently disputed channelopathy genes in the panel.<sup><xref rid="euac030-B416" ref-type="bibr">416</xref></sup> Most recently, a large molecular autopsy series in an extended panel of 77 cardiac genes detected a lower yield (13%) of LP/P variants according to the more stringent ACMG criteria.<sup><xref rid="euac030-B417" ref-type="bibr">417</xref></sup> These variants were immediately useful in guiding family evaluation and they increased the diagnostic yield by 50% when undertaken in families who were also undergoing clinical testing. Furthermore, a proportion of these variants were present in cardiomyopathy genes, indicating a concealed structural cause of SCD.<sup><xref rid="euac030-B417" ref-type="bibr">417</xref>,</sup><sup><xref rid="euac030-B418" ref-type="bibr">418</xref></sup> If focus is placed on younger cases, exertional circumstances of death and the use of exome sequencing in parent and child trios, then yields can increase substantially.<sup><xref rid="euac030-B419" ref-type="bibr">419</xref>,</sup><sup><xref rid="euac030-B420" ref-type="bibr">420</xref></sup></p><p>When individuals survive a cardiac arrest (i.e. non-fatal cardiac arrest), they may present with a range of aetiologies including genetic disorders for which genetic testing is already described in this document. Detailed clinical screening is warranted with emphasis of finding evidence for these aetiologies.<sup><xref rid="euac030-B5" ref-type="bibr">5</xref></sup> If no cause is detectable, the subject is described as UCA, or IVF. Idiopathic ventricular fibrillation is defined as a resuscitated cardiac arrest victim with a normal ECG, preferably with documentation of VF, in whom known cardiac, respiratory, metabolic, and toxicological causes have been excluded through clinical evaluation.<sup><xref rid="euac030-B6" ref-type="bibr">6</xref>,</sup><sup><xref rid="euac030-B15" ref-type="bibr">15</xref></sup> It is estimated to account for &#x0223c;5&#x02013;7% of all out-of-hospital cardiac arrests.<sup><xref rid="euac030-B422" ref-type="bibr">422</xref>,</sup><sup><xref rid="euac030-B423" ref-type="bibr">423</xref></sup></p><p>Genetic investigation of case series of UCA survivors have employed a mixture of cardiac panels and exome sequencing, identifying a yield of channelopathy- and cardiomyopathy-associated putative pathogenic variants ranging from 3% to 27%.<sup><xref rid="euac030-B424" ref-type="bibr">424&#x02013;426</xref></sup> This heterogeneity likely reflects differences in genes studied, adjudication of variant pathogenicity, patient sub-phenotypes and variability in diagnostic conclusions. Importantly, pathogenic variants in cardiomyopathy genes, especially ACM, in UCA survivors without a cardiomyopathic phenotype suggest an underlying concealed structural substrate. Phenotypes may, however, evolve over time in some cases.<sup><xref rid="euac030-B427" ref-type="bibr">427</xref></sup> The most robust genetic finding has been a Dutch founder haplotype at the <italic toggle="yes">DPP6</italic> gene associated with short-coupled-VF. No other genetic defects in or around the <italic toggle="yes">DPP6</italic> gene have been reported in other UCA populations.<sup><xref rid="euac030-B428" ref-type="bibr">428</xref></sup> In other patients with short-coupled-VF <italic toggle="yes">RyR2</italic> variants have been identified and it appears that these variants are characterized by a loss of function phenotype.<sup><xref rid="euac030-B161" ref-type="bibr">161</xref>,</sup><sup><xref rid="euac030-B162" ref-type="bibr">162</xref>,</sup><sup><xref rid="euac030-B429" ref-type="bibr">429</xref>,</sup><sup><xref rid="euac030-B430" ref-type="bibr">430</xref></sup> A term CRDS has been coined for this condition.<sup><xref rid="euac030-B161" ref-type="bibr">161</xref></sup> The role of genetic testing after a sudden unexpected death or cardiac arrest is visualized in <italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F6" ref-type="fig">6</xref></italic>. Recently, WES with virtual panel analysis performed systematically in 228 survivors of cardiac arrest of uncertain aetiology was shown to identify a pathogenic variant in 10% of cases.<sup><xref rid="euac030-B421" ref-type="bibr">421</xref></sup></p><fig position="float" id="euac030-F6"><label>Figure 6</label><caption><p>Flowchart of the work up of a sudden cardiac death or non-fatal cardiac arrest.</p></caption><graphic xlink:href="euac030f6" position="float"/></fig><table-wrap position="float" id="T49"><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Recommendations</th><th align="left" rowspan="1" colspan="1">Consensus statement instruction</th><th align="left" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Genetic testing for patients with congenital heart disease (CHD) should prioritize the personal goals and preferences of the patient, parents or guardian, require pre-test genetic counseling and should be coordinated by multidisciplinary teams with expertise in genetics of CHD.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="3" rowspan="1">
<bold>Antenatal testing</bold>
</td></tr><tr><td rowspan="1" colspan="1">When foetal congenital heart disease (CHD) is identified on antenatal ultrasound examinations, a chromosomal microarray (CMA) or CNV sequencing (CNV seq) of foetal tissue [amniocentesis or chorionic villous sample (CVS)] should be offered.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B431" ref-type="bibr">431&#x02013;433</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Trio WES on amniocentesis or CVS samples may be performed in prenatal cases with syndromic and/or complex CHD.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B431" ref-type="bibr">431&#x02013;433</xref>
</sup>
</td></tr><tr><td colspan="3" rowspan="1">
<bold>
<italic toggle="yes">Neonates and infants</italic> requiring investigation or procedures for complex CHD</bold>
</td></tr><tr><td rowspan="1" colspan="1">CMA or CNV seq is indicated in infants with CHD to identify pathogenic CNVs.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B434" ref-type="bibr">434</xref>
</sup>, Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Standard karyotype analysis may be performed in infants with CHD (or in parents of children with pathogenic CNVs) to identify balanced translocations.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">Expert opinion</td></tr><tr><td rowspan="1" colspan="1">Trio WES or WGS may be performed in infants with complex CHD to identify pathogenic variants/indels, contributing to prognostication for extracardiac outcome and for cardiac outcome.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B435" ref-type="bibr">435</xref>
</sup>, expert opinion</td></tr><tr><td rowspan="1" colspan="1">Targeted CHD gene panels to identify variants in a set of CHD-related genes may be performed in infants with complex CHD.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B436" ref-type="bibr">436</xref>
</sup>, Expert opinion</td></tr><tr><td colspan="3" rowspan="1">
<bold>Patients with CHD and <italic toggle="yes">extracardiac anomalies</italic></bold>
</td></tr><tr><td rowspan="1" colspan="1">CMA or CNV seq is indicated in patients with CHD and extracardiac anomalies to identify pathogenic CNVs.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B437" ref-type="bibr">437</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Trio testing for <italic toggle="yes">de novo</italic> or inherited (autosomal or X-linked recessive) pathogenic variants with either WES or WGS should be performed in patients with CHD and extracardiac anomalies.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B438" ref-type="bibr">438&#x02013;440</xref>
</sup>
</td></tr><tr><td colspan="3" rowspan="1">
<bold>
<italic toggle="yes">Familial forms</italic> of CHD</bold>
</td></tr><tr><td rowspan="1" colspan="1">WES/WGS of the affected family members should be performed in families with at least two first degree relatives with heterotaxy or CHD.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B441" ref-type="bibr">441&#x02013;444</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Targeted analysis of a specific gene may be performed if the CHD type is highly suggestive of a specific gene.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B442" ref-type="bibr">442</xref>
</sup>, Expert opinion</td></tr><tr><td colspan="3" rowspan="1">
<bold>
<italic toggle="yes">Sporadic non-syndromic</italic> CHD (excl. neonates or infants)</bold>
</td></tr><tr><td rowspan="1" colspan="1">CMA or CNV seq for pathogenic CNVs may be performed in older individuals with sporadic non-syndromic CHD.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf2.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B434" ref-type="bibr">434</xref>,</sup>
<sup>
<xref rid="euac030-B445" ref-type="bibr">445</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Trio testing for <italic toggle="yes">de novo</italic> or inherited (autosomal or X-linked recessive) pathogenic variants with either WES or WGS in older patients with sporadic non-syndromic CHD has a low diagnostic yield and limited utility, and should not be performed routinely.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B440" ref-type="bibr">440</xref>
</sup>, Expert opinion</td></tr><tr><td colspan="3" rowspan="1">
<bold>
<italic toggle="yes">Heterotaxy</italic>
</bold>
</td></tr><tr><td rowspan="1" colspan="1">WES/WGS of the affected family members should be performed in families with at least two first degree relatives with CHD.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B446" ref-type="bibr">446</xref>,</sup>
<sup>
<xref rid="euac030-B447" ref-type="bibr">447</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Trio testing for <italic toggle="yes">de novo</italic> or inherited (autosomal or X-linked recessive) pathogenic variants with either WES or WGS should be performed in patients with syndromic heterotaxy (e.g. primary ciliary dyskinesia).</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf1.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B446" ref-type="bibr">446</xref>,</sup>
<sup>
<xref rid="euac030-B448" ref-type="bibr">448</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">Routine trio testing for <italic toggle="yes">de novo</italic> or inherited (autosomal or X-linked recessive) pathogenic variants with either WES or WGS should not be performed in patients with sporadic non-syndromic heterotaxy.</td><td rowspan="1" colspan="1">
<inline-graphic xlink:href="euac030ilf3.jpg"/>
</td><td rowspan="1" colspan="1">
<sup>
<xref rid="euac030-B446" ref-type="bibr">446</xref>
</sup>; expert opinion</td></tr></tbody></table></table-wrap></sec></sec></sec><sec><title>State of genetic testing for congenital heart disease</title><sec><title>&#x02003;</title><sec><title>Background</title><p>Genetic testing in patients with CHD (<italic toggle="yes">Table&#x000a0;<xref rid="euac030-T18" ref-type="table">18</xref></italic>) is moving rapidly, with recent definition of patient subgroups most likely to achieve a genetic diagnosis, beyond well-known causes such as Down syndrome and velocardiofacial syndrome (<italic toggle="yes">Figure&#x000a0;<xref rid="euac030-F7" ref-type="fig">7</xref></italic>).</p><fig position="float" id="euac030-F7"><label>Figure 7</label><caption><p>Genetic causes of congenital heart defects. Non-syndromic (lower panel) and syndromic (upper panel) cohorts. The diagram in the left panel displays the relative prevalence of the three broad CHD subgroups, namely syndromic CHD, sporadic non-syndromic CHD, and familial non-syndromic CHD. The diagrams in the central panel display the current yield of standard karyotyping, CMA and WES/WGS in the non-syndromic (lower panel) and syndromic (upper panel) cohorts, respectively, illustrating the low diagnostic yield in sporadic non-syndromic CHD, compared to the syndromic cohort. The pie diagrams at the right display the most common causes of aneuploidies and of CNVs, and the inheritance pattern of single gene defects. The percentages displayed in the diagrams are based on.<sup><xref rid="euac030-B440" ref-type="bibr">440</xref>,</sup><sup><xref rid="euac030-B441" ref-type="bibr">441</xref>,</sup><sup><xref rid="euac030-B445" ref-type="bibr">445</xref>,</sup><sup><xref rid="euac030-B463" ref-type="bibr">463</xref>,</sup><sup><xref rid="euac030-B464" ref-type="bibr">464</xref></sup> CHD, congenital heart defect; CNV, copy number variant; T13, trisomy 13; T18, Trisomy 18; T21, trisomy 21; WBS, Williams&#x02013;Beuren syndrome.</p></caption><graphic xlink:href="euac030f7" position="float"/></fig><table-wrap position="float" id="euac030-T18"><label>Table 18</label><caption><p>Categories of CHD</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">Category</th><th rowspan="2" align="left" colspan="1">Definition</th><th rowspan="2" align="left" colspan="1">Primary type/s of causative genetic variants</th><th colspan="3" align="left" rowspan="1">Diagnostic yield<sup>a</sup></th></tr><tr><th align="left" rowspan="1" colspan="1">CMA</th><th align="left" rowspan="1" colspan="1">WES</th><th align="left" rowspan="1" colspan="1">WGS<sup><xref rid="tblfn41" ref-type="table-fn">b</xref></sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Syndromic (CHD+ECA)</td><td rowspan="1" colspan="1">CHD seen in conjunction with extracardiac anomalies including (but not limited to) neurological, cranio-facial, limb, growth, skeletal, and genitourinary differences</td><td rowspan="1" colspan="1">
<italic toggle="yes">de novo</italic>
<sup>
<xref rid="tblfn42" ref-type="table-fn">c</xref>
</sup> or inherited CNVs and SNVs</td><td rowspan="1" colspan="1">&#x0223c;3&#x02013;25%</td><td rowspan="1" colspan="1">&#x0223c;25%</td><td rowspan="1" colspan="1">&#x0223c;41%</td></tr><tr><td rowspan="1" colspan="1">Non-syndromic, inherited</td><td rowspan="1" colspan="1">CHD seen without features suggestive of a genetic syndrome, often affecting multiple family members</td><td rowspan="1" colspan="1">Inherited SNVs</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">&#x0223c;31&#x02013;46%</td><td rowspan="1" colspan="1">&#x0223c;36%</td></tr><tr><td rowspan="1" colspan="1">Sporadic</td><td rowspan="1" colspan="1">CHD without a suspected hereditary component and without being associated with a known syndrome</td><td rowspan="1" colspan="1">Multiple variants contributing synergistically</td><td rowspan="1" colspan="1">&#x0223c;3&#x02013;10%</td><td rowspan="1" colspan="1">&#x0223c;2&#x02013;10%<sup><xref rid="tblfn43" ref-type="table-fn">d</xref></sup></td><td rowspan="1" colspan="1">&#x0223c;10%</td></tr></tbody></table><table-wrap-foot><fn id="tblfn40"><label>a</label><p>Based on literature with clinically applicable results, i.e. studies conducting clinical evaluations of variants according to ACMG guidelines.<sup><xref rid="euac030-B69" ref-type="bibr">69</xref></sup></p></fn><fn id="tblfn41"><label>b</label><p>Based on our clinical experience in conjunction with Alankarage <italic toggle="yes">et al</italic>., 2019.<sup><xref rid="euac030-B441" ref-type="bibr">441</xref></sup></p></fn><fn id="tblfn42"><label>c</label><p>
<italic toggle="yes">De novo</italic>, not inherited from either parent.</p></fn><fn id="tblfn43"><label>d</label><p>Based on large cohort-based studies without clinical evaluation of variants. Information presented is collated from research reported in refs<sup><xref rid="euac030-B439" ref-type="bibr">439&#x02013;442</xref>,</sup><sup><xref rid="euac030-B444" ref-type="bibr">444</xref>,</sup><sup><xref rid="euac030-B454" ref-type="bibr">454&#x02013;457</xref></sup> and modified from ref.<sup><xref rid="euac030-B458" ref-type="bibr">458</xref></sup></p></fn><fn id="tblfn39"><p>CHD, congenital heart disease; CMA, chromosome microarray; CNV, copy number variant; ECA, extracardiac anomaly; SNV, single-nucleotide variant; WES, whole-exome sequencing; WGS, whole-genome sequencing.</p></fn></table-wrap-foot></table-wrap><p>A genetic diagnosis usually has little impact on treatment of the CHD itself but may assist in risk stratification<sup><xref rid="euac030-B449" ref-type="bibr">449</xref></sup> and influence priorities during follow-up, such as surveillance for AV block in patients with pathogenic variants in <italic toggle="yes">NKX2.5</italic><sup><xref rid="euac030-B450" ref-type="bibr">450</xref></sup> or <italic toggle="yes">TBX5</italic>, or screening for extracardiac features, such as immune dysfunction in 22q11 deletion syndrome or platelet dysfunction in Noonan syndrome.<sup><xref rid="euac030-B451" ref-type="bibr">451</xref></sup></p><p>Some forms of inherited cardiovascular disease, such as the arrhythmia syndromes, involve a relatively small number of genes, with tight genotype-phenotype relationships, supportive functional data and well-established prognostic implications. In contrast, CHD has a large number of genes that are implicated in the development of CHD, with at least 130 genes identified as having a role in causation of human CHD, presenting either in isolation or in association with extra-cardiac features (see <ext-link xlink:href="http://chdgene.victorchang.edu.au/" ext-link-type="uri">http://chdgene.victorchang.edu.au/</ext-link>). This includes genes associated with heterotaxy syndromes, which are sometimes present in patients with single ventricles and other rare CHD subtypes. Of note, no ClinGen curation yet exists for CHD genes, and for some putative CHD genes, further genomic and functional studies are required to confirm their role in CHD. Even for established CHD genes, variant interpretation is frequently complicated by the fact that CHD often affects singletons, precluding segregation analysis, and when it aggregates in families, is associated with reduced penetrance and variable expressivity. Nevertheless, a molecular diagnosis may be relevant in pre-conception counselling and carries numerous psychological benefits as well.<sup><xref rid="euac030-B452" ref-type="bibr">452</xref></sup></p><p>Indications for genetic testing vary according to age and mode of presentation, such as the severity of a CHD, the type of CHD, the presence of extracardiac features and the presence of non-genetic factors predisposing to CHD. The diagnosis of a monogenic cause of CHD is less likely when environmental factors occur, such as twin-to-twin transfusion, prematurity-associated patent ductus arterious, or maternal risk factors.<sup><xref rid="euac030-B453" ref-type="bibr">453</xref></sup> Extracardiac features, such as developmental delay, growth delay or facial dysmorphic features, are not apparent in foetuses or infants. Early genetic diagnosis can help to differentiate between syndromic and non-syndromic CHD, contributing to prognostication for cardiac and extracardiac outcome in these patients.</p></sec><sec><title>Antenatal testing</title><p>When fetal cardiac anomalies are identified on ultrasound assessments and fetal aneuploidies are excluded, chromosomal microarray (MCA) or copy number sequencing (CNV seq) on DNA derived from amniocentesis specimens or chorionic villous samples (CVS) detect pathogenic chromosomal abnormalities in about 10&#x02013;15% of fetuses with CHD.<sup><xref rid="euac030-B465" ref-type="bibr">465</xref>,</sup><sup><xref rid="euac030-B466" ref-type="bibr">466</xref></sup> In those with normal CMA or CNVseq, a genetic diagnosis is made by subsequent prenatal trio whole exome sequencing (WES) in 5&#x02013;12%.<sup><xref rid="euac030-B441" ref-type="bibr">441</xref></sup> The yield of prenatal CMA or WES varies according to presence of extracardiac anomalies and type of CHD.<sup><xref rid="euac030-B465" ref-type="bibr">465</xref>,</sup><sup><xref rid="euac030-B466" ref-type="bibr">466</xref></sup> Some CHD types have a low positive predictive value for being associated with chromosomal anomalies, while other CHD types have a higher likelihood of being caused by a pathogenic variant in a specific gene for syndromic or isolated CHD.<sup><xref rid="euac030-B465" ref-type="bibr">465</xref></sup> When offering prenatal genetic testing for CHD, expert advice should be sought to counsel on expected yield and on potential risks of amniocentesis or CVS, and personal goals and preferences of the parents should be prioritized.<sup><xref rid="euac030-B467" ref-type="bibr">467</xref></sup> When these conditions are met, prenatal CMA or CNVseq can be offered for fetal CHD.<sup><xref rid="euac030-B439" ref-type="bibr">439&#x02013;441</xref></sup> Trio whole exome sequencing (WES) on amniocentesis or CVS can be considered in prenatal cases with syndromic and/or complex CHD where the anticipated post-natal course carries a high risk of morbidity or mortality.<sup><xref rid="euac030-B439" ref-type="bibr">439&#x02013;441</xref></sup></p></sec><sec><title>Antenatal screening</title><p>Routine antenatal testing on amniocentesis or CVS is focused on the identification of major chromosomal abnormalities including Trisomy 13, 18, 21 and 22q11 deletion, responsible for velocardiofacial syndrome, and should be offered to any patient pursuing invasive prenatal diagnosis without prior knowledge of cardiac or other malformations.<sup><xref rid="euac030-B459" ref-type="bibr">459</xref></sup> Cell-free DNA testing on a maternal blood sample is emerging as a non-invasive means of aneuploidy screening for foetuses with no apparent structural abnormalities although this approach currently lacks resolution in definition of sub-microscopic chromosomal anomalies.<sup><xref rid="euac030-B460" ref-type="bibr">460&#x02013;462</xref></sup></p></sec><sec><title>Neonates and infants requiring investigation or procedures for congenital heart disease</title><p>Testing for pathogenic chromosomal CNVs by CMA or CNV seq should be performed.<sup><xref rid="euac030-B434" ref-type="bibr">434</xref></sup> These techniques have essentially replaced standard karyotype analysis as first line testing, although conventional karyotyping may be performed particularly in assessment of balanced translocations. Testing for SNVs or small insertion/deletions can be considered, although yield in sporadic cases is low.<sup><xref rid="euac030-B435" ref-type="bibr">435</xref></sup> For these variants, WES or WGS are replacing &#x02018;CHD&#x02019; &#x02018;panels&#x02019; (usually comprising 10&#x02013;40 genes<sup><xref rid="euac030-B436" ref-type="bibr">436</xref></sup>) considering the low diagnostic yield of CHD gene panels and the ability to re-interrogate WES/WGS results taking into consideration future findings.</p></sec><sec><title>Patients with congenital heart disease and extracardiac anomalies</title><p>Patients with CHD and extracardiac anomalies, including additional major congenital anomalies (with functional consequences and/or requiring treatment), dysmorphism (association of at least three dysmorphic features), abnormal growth, and neurodevelopmental abnormalities, are regarded as syndromal forms of CHD, and collectivel account for around 20% of the total CHD cohort. Patients with syndromic CHD should undergo CMA or CNV seq,<sup><xref rid="euac030-B437" ref-type="bibr">437</xref></sup> followed by trio testing for <italic toggle="yes">de novo</italic> or inherited (primarily autosomal or X-linked recessive) pathogenic SNVs with either WES or WGS if CMA is not diagnostic, because of the substantial rate of achieving a genetic diagnosis in &#x0223c;25&#x02013;40%.<sup><xref rid="euac030-B438" ref-type="bibr">438</xref></sup> Given its potential to detect both CNVs and SNVs, WGS has shown promise in becoming a first tier analysis in syndromic CHD. <italic toggle="yes">De novo</italic> variants account for &#x0223c;90% of these genetic causes.<sup><xref rid="euac030-B439" ref-type="bibr">439</xref>,</sup><sup><xref rid="euac030-B440" ref-type="bibr">440</xref></sup></p></sec><sec><title>Familial forms of congenital heart disease</title><p>In patients with <italic toggle="yes">familial forms</italic> of CHD (one or more affected first degree relative), inherited single-gene defects may be identified by WES. The diagnostic yield with two affected family members is conventionally thought to be around 10% with a substantially higher yield when three or more are affected.<sup><xref rid="euac030-B441" ref-type="bibr">441</xref></sup> Families with at least two first degree relatives with CHD may benefit from WES/WGS of the affected family members.<sup><xref rid="euac030-B441" ref-type="bibr">441&#x02013;444</xref></sup> In some families, the CHD type is highly suggestive of a specific gene (e.g. <italic toggle="yes">ELN</italic> pathogenic variants in supravalvar aortic stenosis without Williams&#x02013;Beuren syndrome) (see <italic toggle="yes">Table&#x000a0;<xref rid="euac030-T19" ref-type="table">19</xref></italic>). In such families targeted analysis of this specific gene can be considered, followed by WES if this initial investigation is negative.<sup><xref rid="euac030-B442" ref-type="bibr">442</xref></sup></p><table-wrap position="float" id="euac030-T19"><label>Table 19</label><caption><p>Non-exhaustive list of high confident genes for non-syndromic human CHD</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Familial non-syndromic CHD</th><th rowspan="1" colspan="1">Gene</th><th rowspan="1" colspan="1">Inheritance</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Atrial septal defect</td><td rowspan="1" colspan="1">
<italic toggle="yes">GATA4</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1">Atrial septal defect (with or without atrioventricular conduction block)</td><td rowspan="1" colspan="1">
<italic toggle="yes">NKX2.5</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">TBX5</italic>
</td><td rowspan="1" colspan="1">AD<sup><xref rid="tblfn47" ref-type="table-fn">*</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Atrioventricular septal defect</td><td rowspan="1" colspan="1">
<italic toggle="yes">CRELD1</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">NR2F2</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1">Supravalvar aortic stenosis</td><td rowspan="1" colspan="1">
<italic toggle="yes">ELN</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1">Aortic valve stenosis</td><td rowspan="1" colspan="1">
<italic toggle="yes">NOTCH1</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">TAB2</italic>
</td><td rowspan="1" colspan="1">AD<sup><xref rid="tblfn47" ref-type="table-fn">**</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Tetralogy of Fallot</td><td rowspan="1" colspan="1">
<italic toggle="yes">NOTCH1</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">FLT4</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1">Patent ductus arteriosus</td><td rowspan="1" colspan="1">
<italic toggle="yes">TFAP2B</italic>
</td><td rowspan="1" colspan="1">AD<sup><xref rid="tblfn47" ref-type="table-fn">***</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Heterotaxy</td><td rowspan="1" colspan="1">
<italic toggle="yes">ACVR2B</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">CFC1</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">NODAL</italic>
</td><td rowspan="1" colspan="1">AD</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">CCDC11</italic>
</td><td rowspan="1" colspan="1">AR</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">CFAP53</italic>
</td><td rowspan="1" colspan="1">AR</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">PKD1L1</italic>
</td><td rowspan="1" colspan="1">AR</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic toggle="yes">ZIC3</italic>
</td><td rowspan="1" colspan="1">XL</td></tr></tbody></table><table-wrap-foot><fn id="tblfn47"><p>Pathogenic variants in TBX5, TAB2, and TFAP2B can cause non-syndromic CHD, or may be associated with *hand anomalies, **connective tissue disorder, or ***facial dysmorphism.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Sporadic non-syndromic congenital heart disease</title><p>Congenital heart disease with no syndromal or familial pattern should be considered as being of &#x02018;undetermined cause&#x02019; because only a small proportion of these patients will have single-gene variants that may be identified with WGS or WES (&#x0003c;5%).<sup><xref rid="euac030-B434" ref-type="bibr">434</xref>,</sup><sup><xref rid="euac030-B440" ref-type="bibr">440</xref>,</sup><sup><xref rid="euac030-B445" ref-type="bibr">445</xref></sup> Routine testing of such patients remains in the realm of research and is not currently justified in clinical practice. Some apparently non-syndromic infants will later present with syndromic associations including developmental delay, and would be considered for genetic testing, highlighting the difficulty in defining access to testing on the basis of categorization early in life.</p></sec><sec><title>Heterotaxy</title><p>Diagnostic genetic testing strategy for patients with heterotaxy, defined as left-right patterning anomalies of the thoracic and/or abdominal organs, is in line with that proposed for CHD: WES or WGS should be offered to familial heterotaxy and to syndromic patients (e.g. primary ciliary dyskinesia), but is a lower priority for heterotaxy patients with no syndromic appearance or familial occurrence.<sup><xref rid="euac030-B446" ref-type="bibr">446&#x02013;448</xref></sup></p><p>We summarize recommendations for genetic testing in the different categories in the table of recommendations. These recommendations should be applied (1) in consideration of technology availability, access and health insurance issues and sociocultural differences, (2) in the light of shared decision making between a trained healthcare professional and the patient, parents or guardian, and (3) only if adequate pre- and post-test counseling can be guaranteed. Genetic testing in the pediatric domain should be coordinated between cardiology and clinical genetics specialists, with support by genetic counselors and ideally a multidisciplinary clinic for return of results and liaison with genetic pathologists and developmental biologists. Thus, identification of congenital heart disease should prompt a referral to a center specializing in pediatric cardiovascular genetics.</p></sec></sec></sec><sec><title>State of genetic testing for coronary artery disease and heart failure</title><p>Some inherited conditions may lead to coronary artery disease. For example, monogenic predisposition to familial hypercholesterolaemia is a powerful predictor of premature coronary artery disease.<sup><xref rid="euac030-B468" ref-type="bibr">468</xref></sup> The major genes are <italic toggle="yes">APOB, LDLR, PCSK9</italic>. Over the past two decades, a widespread contribution of polygenic risk to coronary artery disease susceptibility has been demonstrated.<sup><xref rid="euac030-B466" ref-type="bibr">469</xref>,</sup><sup><xref rid="euac030-B467" ref-type="bibr">470</xref></sup> Novel genetic susceptibility mechanisms including clonal haematopoiesis of indeterminate potential, a somatic rather than germline genetic process, have also been shown to play a role in coronary artery disease susceptibility recently.<sup><xref rid="euac030-B471" ref-type="bibr">471</xref></sup> Genetic evaluation in clinical practice is currently directed at identifying individuals with an inherited predisposition to coronary artery disease that may enable a mechanistic understanding of the disease, and inform carrier testing. Although research indicates that genetic predisposition may be useful for risk prediction both in primary and secondary prevention settings,<sup><xref rid="euac030-B4" ref-type="bibr">4</xref>,</sup><sup><xref rid="euac030-B63" ref-type="bibr">63</xref>,</sup><sup><xref rid="euac030-B64" ref-type="bibr">64</xref>,</sup><sup><xref rid="euac030-B472" ref-type="bibr">472</xref></sup> the predictive utility of polygenic risk scores for coronary artery disease are debated<sup><xref rid="euac030-B473" ref-type="bibr">473</xref>,</sup><sup><xref rid="euac030-B474" ref-type="bibr">474</xref></sup> and such scores are not routinely used in clinical practice. Data have also emerged to indicate that risk reduction after treatment with statins<sup><xref rid="euac030-B475" ref-type="bibr">475</xref></sup> or proprotein convertase subtulisin/kexin type 9 (PCSK9) inhibitors<sup><xref rid="euac030-B63" ref-type="bibr">63</xref>,</sup><sup><xref rid="euac030-B64" ref-type="bibr">64</xref></sup> may be greatest for individuals with the highest inherited burden of polygenic predisposition to coronary artery disease. Despite rapid innovations in the understanding of both inherited and somatic genetic variation that may underlie coronary artery disease, and despite increasing development of comprehensive polygenic risk assays for coronary artery disease and component clinical risk factors, clinical genetic testing is largely focused on addressing low-density lipoprotein, an underlying treatable clinical risk factor for coronary artery disease.</p><p>Genetic testing for heart failure is in some sense a superset of the earlier sections on genetic testing for cardiomyopathy. In patients with ischaemic cardiomyopathy, testing should be considered according to the recommendations in the paragraph above for coronary artery disease; there is currently no further indication for testing with respect to the presentation of heart failure as a result of coronary artery disease. In cases where patients present with heart failure with preserved or reduced ejection fraction with an apparent explanatory cause such as uncontrolled hypertension or valve disease there is also currently no indication for genetic testing. Heart failure that is unexplained should always lead to a detailed family history and if a Mendelian pattern of inheritance is suggested, then panel testing for cardiomyopathy should proceed as described earlier in this document. In (young) cases of heart failure with no apparent cause and no family history, or in cases where alcohol or pregnancy appear to be co-factors, many would consider Mendelian panel testing, particularly because of the demonstrated contribution from modifying effects of titin loss-of-function variants. While genome wide association studies for heart failure and for LV remodelling are now published, and while this polygenic tail would be expected to modify Mendelian causes of heart failure, such tools have yet to be translated into predictive scores that would provide utility in a clinical setting.</p></sec><sec><title>Conclusion and future directions</title><p>In the past decade, we have seen significant progress in genetic testing of the inherited cardiovascular diseases. Understanding of the genetic basis of disease has improved both in terms of new disease genes, as well as new genetic mechanisms such as oligogenic disease and the emergence of polygenic risk scores. At the present time, cardiovascular genetic testing already offers numerous benefits in terms of more diagnostic precision, influencing therapeutic options, and informing prognosis. Indeed &#x02018;genetic cardiology&#x02019; is recognized as a new field, with such sub-specialty experts needed to facilitate the translation of genetic findings into improved clinical care. While great progress has been made, new challenges and gaps in our knowledge remain, including the accurate classification and interpretation of variants, robust curation of potentially new disease genes, and understanding variable phenotype penetrance both within and between families. Furthermore, understanding the genetic landscape of cardiovascular diseases in other ethnic populations with different genetic backgrounds will be important to ensure the benefits of genetic testing are realized on a truly global scale.</p><p>Looking to the future, with the advances being made in the field of gene therapy, the identification of the patient&#x02019;s fundamental disease-causative substrate may enable not only genotype-guided therapies but also gene-specific, even pathogenic variant-specific therapies.<sup><xref rid="euac030-B23" ref-type="bibr">23</xref>,</sup><sup><xref rid="euac030-B476" ref-type="bibr">476</xref></sup> For AR disorders like TKOS, a molecular diagnosis could permit &#x02018;gene replacement&#x02019; therapies. However, most genetic heart conditions are AD conditions resulting in either haploinsufficiency or a dominant negative state. For some, allele-specific oligonucleotide/short interfering RNA (siRNA) therapies to knock down the mutant allele may be sufficient.<sup><xref rid="euac030-B477" ref-type="bibr">477</xref>,</sup><sup><xref rid="euac030-B478" ref-type="bibr">478</xref></sup> This gene therapy strategy requires a novel therapeutic for each pathogenic variant however. Similarly, gene-editing with CRISPR/Cas9-based strategies requires a unique effort for each pathogenic variant.<sup><xref rid="euac030-B479" ref-type="bibr">479</xref></sup> For those genetic heart diseases with hundreds of unique disease-causative variants within each disease-susceptibility gene, a gene-editing solution may not be feasible. Most recently, proof-of-principle for a gene-specific gene therapy solution has been provided. This therapy, called Suppression-Replacement (SupRep) gene therapy envisions the AAV9 delivery (or some future iteration) of the therapeutic cargo containing a single, gene-specific siRNA to knockdown both the mutant allele and the wild type allele, followed by a bio-engineered complementary DNA (cDNA) of the gene of interest that is immune to siRNA-mediated knockdown.<sup><xref rid="euac030-B480" ref-type="bibr">480</xref></sup> Regardless of the underlying gene therapy strategy being explored, numerous obstacles will need to be overcome before these promising <italic toggle="yes">in vitro</italic> data will be translated into available therapies in humans.</p></sec><sec><title>Funding</title><p>J.B. is supported by a senior clinical investigator fellowship by the FWO &#x02013; Flanders.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data"><label>euac030_Supplementary_Data</label><media xlink:href="euac030_supplementary_data.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list id="ref1"><title>References</title><ref id="euac030-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ackerman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name><surname>Priori</surname><given-names>SG</given-names></string-name>, <string-name><surname>Willems</surname><given-names>S</given-names></string-name>, <string-name><surname>Berul</surname><given-names>C</given-names></string-name>, <string-name><surname>Brugada</surname><given-names>R</given-names></string-name>, <string-name><surname>Calkins</surname><given-names>H</given-names></string-name><etal>et al</etal>; <collab>European Heart Rhythm Association (EHRA)</collab></person-group>. <article-title>HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)</article-title>. <source>Europace</source><year>2011</year>;<volume>13</volume>:<fpage>1077</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">21810866</pub-id></mixed-citation></ref><ref id="euac030-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>George</surname><given-names>AL</given-names></string-name></person-group>
<article-title>Jr. Modifier genes for sudden cardiac death</article-title>. <source>Eur Heart J</source><year>2018</year>;<volume>39</volume>:<fpage>3925</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">30215713</pub-id></mixed-citation></ref><ref id="euac030-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walsh</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Tadros</surname><given-names>R</given-names></string-name>, <string-name><surname>Bezzina</surname><given-names>CR.</given-names></string-name></person-group>
<article-title>When genetic burden reaches threshold</article-title>. <source>Eur Heart J</source><year>2020</year>;<volume>41</volume>:<fpage>3849</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">32350504</pub-id></mixed-citation></ref><ref id="euac030-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Khera</surname>
<given-names>AV</given-names>
</string-name>, <string-name><surname>Chaffin</surname><given-names>M</given-names></string-name>, <string-name><surname>Aragam</surname><given-names>KG</given-names></string-name>, <string-name><surname>Haas</surname><given-names>ME</given-names></string-name>, <string-name><surname>Roselli</surname><given-names>C</given-names></string-name>, <string-name><surname>Choi</surname><given-names>SH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations</article-title>. <source>Nat Genet</source><year>2018</year>;<volume>50</volume>:<fpage>1219</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">30104762</pub-id></mixed-citation></ref><ref id="euac030-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Breithardt</surname><given-names>G</given-names></string-name>, <string-name><surname>Howard</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Julian</surname><given-names>DG</given-names></string-name>, <string-name><surname>Rehnqvist Ahlberg</surname><given-names>N.</given-names></string-name></person-group>
<article-title>Task Force Report: the legal implications of medical guidelines&#x02014;a Task Force of the European Society of Cardiology</article-title>. <source>Eur Heart J</source><year>1999</year>;<volume>20</volume>:<fpage>1152</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">10448023</pub-id></mixed-citation></ref><ref id="euac030-B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stiles</surname>
<given-names>MK</given-names>
</string-name>, <string-name><surname>Wilde</surname><given-names>AAM</given-names></string-name>, <string-name><surname>Abrams</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Albert</surname><given-names>CM</given-names></string-name>, <string-name><surname>Behr</surname><given-names>ER</given-names></string-name><etal>et al</etal></person-group>
<article-title>2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families</article-title>. <source>Heart Rhythm</source><year>2021</year>;<volume>18</volume>:<fpage>e1</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">33091602</pub-id></mixed-citation></ref><ref id="euac030-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cronin</surname>
<given-names>EM</given-names>
</string-name>, <string-name><surname>Bogun</surname><given-names>FM</given-names></string-name>, <string-name><surname>Maury</surname><given-names>P</given-names></string-name>, <string-name><surname>Peichl</surname><given-names>P</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M</given-names></string-name>, <string-name><surname>Namboodiri</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: executive summary</article-title>. <source>J Arrhythm</source><year>2020</year>;<volume>36</volume>:<fpage>1</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">32071620</pub-id></mixed-citation></ref><ref id="euac030-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Musunuru</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Hershberger</surname><given-names>RE</given-names></string-name>, <string-name><surname>Day</surname><given-names>SM</given-names></string-name>, <string-name><surname>Klinedinst</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Landstrom</surname><given-names>AP</given-names></string-name>, <string-name><surname>Parikh</surname><given-names>VN</given-names></string-name><etal>et al</etal>; <collab>American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology</collab></person-group>. <article-title>Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association</article-title>. <source>Circ Genom Precis Med</source><year>2020</year>;<volume>13</volume>:<fpage>e000067</fpage>.<pub-id pub-id-type="pmid">32698598</pub-id></mixed-citation></ref><ref id="euac030-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fellmann</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>van El</surname><given-names>CG</given-names></string-name>, <string-name><surname>Charron</surname><given-names>P</given-names></string-name>, <string-name><surname>Michaud</surname><given-names>K</given-names></string-name>, <string-name><surname>Howard</surname><given-names>HC</given-names></string-name>, <string-name><surname>Boers</surname><given-names>SN</given-names></string-name><etal>et al</etal></person-group>; on behalf of European Society of Human Genetics, European Council of Legal Medicine, European Society of Cardiology working group on myocardial and pericardial diseases, European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Association for European Cardiovascular Pathology. <article-title>European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death</article-title>. <source>Eur J Hum Genet</source><year>2019</year>;<volume>27</volume>:<fpage>1763</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">31235869</pub-id></mixed-citation></ref><ref id="euac030-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ingles</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Goldstein</surname><given-names>J</given-names></string-name>, <string-name><surname>Thaxton</surname><given-names>C</given-names></string-name>, <string-name><surname>Caleshu</surname><given-names>C</given-names></string-name>, <string-name><surname>Corty</surname><given-names>EW</given-names></string-name>, <string-name><surname>Crowley</surname><given-names>SB</given-names></string-name><etal>et al</etal></person-group>
<article-title>Evaluating the clinical validity of hypertrophic cardiomyopathy genes</article-title>. <source>Circ Genom Precis Med</source><year>2019</year>;<volume>12</volume>:<fpage>e002460</fpage>.<pub-id pub-id-type="pmid">30681346</pub-id></mixed-citation></ref><ref id="euac030-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Towbin</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>McKenna</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Abrams</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Calkins</surname><given-names>H</given-names></string-name>, <string-name><surname>Darrieux</surname><given-names>FCC</given-names></string-name><etal>et al</etal></person-group>
<article-title>2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: executive summary</article-title>. <source>Heart Rhythm</source><year>2019</year>;<volume>16</volume>:<fpage>e373</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">31676023</pub-id></mixed-citation></ref><ref id="euac030-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Al-Khatib</surname>
<given-names>SM</given-names>
</string-name>, <string-name><surname>Stevenson</surname><given-names>WG</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Bryant</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Callans</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>AB</given-names></string-name><etal>et al</etal></person-group>
<article-title>2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society</article-title>. <source>Heart Rhythm</source><year>2018</year>;<volume>15</volume>:<fpage>e190</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">29097320</pub-id></mixed-citation></ref><ref id="euac030-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Priori</surname>
<given-names>SG</given-names>
</string-name>, <string-name><surname>Blomstr&#x000f6;m-Lundqvist</surname><given-names>C</given-names></string-name>, <string-name><surname>Mazzanti</surname><given-names>A</given-names></string-name>, <string-name><surname>Blom</surname><given-names>N</given-names></string-name>, <string-name><surname>Borggrefe</surname><given-names>M</given-names></string-name>, <string-name><surname>Camm</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: association for European Paediatric and Congenital Cardiology (AEPC)</article-title>. <source>Eur Heart J</source><year>2015</year>;<volume>36</volume>:<fpage>2793</fpage>&#x02013;<lpage>867</lpage>.<pub-id pub-id-type="pmid">26320108</pub-id></mixed-citation></ref><ref id="euac030-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pedersen</surname>
<given-names>CT</given-names>
</string-name>, <string-name><surname>Kay</surname><given-names>GN</given-names></string-name>, <string-name><surname>Kalman</surname><given-names>J</given-names></string-name>, <string-name><surname>Borggrefe</surname><given-names>M</given-names></string-name>, <string-name><surname>Della-Bella</surname><given-names>P</given-names></string-name>, <string-name><surname>Dickfeld</surname><given-names>T</given-names></string-name><etal>et al</etal>; <collab>EP-Europace,UK</collab></person-group>. <article-title>EHRA/HRS/APHRS expert consensus on ventricular arrhythmias</article-title>. <source>Heart Rhythm</source><year>2014</year>;<volume>11</volume>:<fpage>e166</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">25179489</pub-id></mixed-citation></ref><ref id="euac030-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Priori</surname>
<given-names>SG</given-names>
</string-name>, <string-name><surname>Wilde</surname><given-names>AA</given-names></string-name>, <string-name><surname>Horie</surname><given-names>M</given-names></string-name>, <string-name><surname>Cho</surname><given-names>Y</given-names></string-name>, <string-name><surname>Behr</surname><given-names>ER</given-names></string-name>, <string-name><surname>Berul</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013</article-title>. <source>Heart Rhythm</source><year>2013</year>;<volume>10</volume>:<fpage>1932</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">24011539</pub-id></mixed-citation></ref><ref id="euac030-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Charron</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Arad</surname><given-names>M</given-names></string-name>, <string-name><surname>Arbustini</surname><given-names>E</given-names></string-name>, <string-name><surname>Basso</surname><given-names>C</given-names></string-name>, <string-name><surname>Bilinska</surname><given-names>Z</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases</article-title>. <source>Eur Heart J</source><year>2010</year>;<volume>31</volume>:<fpage>2715</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">20823110</pub-id></mixed-citation></ref><ref id="euac030-B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walsh</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Adler A Amin</surname><given-names>AS</given-names></string-name>, <string-name><surname>Abiusi</surname><given-names>E</given-names></string-name>, <string-name><surname>Care</surname><given-names>M</given-names></string-name>, <string-name><surname>Bikker</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>A multi-centred, evidence-based evaluation of gene validity in sudden arrhythmic death syndromes: CPVT and the short QT syndrome</article-title>. <source>Eur Heart J</source><year>2021</year>;doi:10.1093/eurheartj/ehab687.</mixed-citation></ref><ref id="euac030-B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>James</surname>
<given-names>CA</given-names>
</string-name>, <string-name><surname>Jongbloed</surname><given-names>JDH</given-names></string-name>, <string-name><surname>Hershberger</surname><given-names>RE</given-names></string-name>, <string-name><surname>Morales</surname><given-names>A</given-names></string-name>, <string-name><surname>Judge</surname><given-names>DP</given-names></string-name>, <string-name><surname>Syrris</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework</article-title>. <source>Circ Genom Precis Med</source><year>2021</year>;<volume>14</volume>:<fpage>e003273</fpage>.<pub-id pub-id-type="pmid">33831308</pub-id></mixed-citation></ref><ref id="euac030-B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jordan</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Peterson</surname><given-names>L</given-names></string-name>, <string-name><surname>Ai</surname><given-names>T</given-names></string-name>, <string-name><surname>Asatryan</surname><given-names>B</given-names></string-name>, <string-name><surname>Bronicki</surname><given-names>L</given-names></string-name>, <string-name><surname>Brown</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>Evidence-based assessment of genes in dilated cardiomyopathy</article-title>. <source>Circulation</source><year>2021</year>;<volume>144</volume>:<fpage>7</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">33947203</pub-id></mixed-citation></ref><ref id="euac030-B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Adler</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Novelli</surname><given-names>V</given-names></string-name>, <string-name><surname>Amin</surname><given-names>AS</given-names></string-name>, <string-name><surname>Abiusi</surname><given-names>E</given-names></string-name>, <string-name><surname>Care</surname><given-names>M</given-names></string-name>, <string-name><surname>Nannenberg</surname><given-names>EA</given-names></string-name><etal>et al</etal></person-group>
<article-title>An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome</article-title>. <source>Circulation</source><year>2020</year>;<volume>141</volume>:<fpage>418</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">31983240</pub-id></mixed-citation></ref><ref id="euac030-B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hosseini</surname>
<given-names>SM</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>R</given-names></string-name>, <string-name><surname>Udupa</surname><given-names>S</given-names></string-name>, <string-name><surname>Costain</surname><given-names>G</given-names></string-name>, <string-name><surname>Jobling</surname><given-names>R</given-names></string-name>, <string-name><surname>Liston</surname><given-names>E</given-names></string-name><etal>et al</etal>; <collab>National Institutes of Health Clinical Genome Resource Consortium</collab></person-group>. <article-title>Reappraisal of reported genes for sudden arrhythmic death: evidence-based evaluation of gene validity for Brugada syndrome</article-title>. <source>Circulation</source><year>2018</year>;<volume>138</volume>:<fpage>1195</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">29959160</pub-id></mixed-citation></ref><ref id="euac030-B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mont</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Pelliccia</surname><given-names>A</given-names></string-name>, <string-name><surname>Sharma</surname><given-names>S</given-names></string-name>, <string-name><surname>Biffi</surname><given-names>A</given-names></string-name>, <string-name><surname>Borjesson</surname><given-names>MB</given-names></string-name>, <string-name><surname>Terradellas</surname><given-names>J</given-names></string-name><etal>et al</etal>; <collab>Reviewers</collab></person-group>. <article-title>Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE</article-title>. <source>Eur J Prev Cardiol</source><year>2017</year>;<volume>24</volume>:<fpage>41</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">27815537</pub-id></mixed-citation></ref><ref id="euac030-B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Claussnitzer</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Cho</surname><given-names>JH</given-names></string-name>, <string-name><surname>Collins</surname><given-names>R</given-names></string-name>, <string-name><surname>Cox</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Dermitzakis</surname><given-names>ET</given-names></string-name>, <string-name><surname>Hurles</surname><given-names>ME</given-names></string-name><etal>et al</etal></person-group>
<article-title>A brief history of human disease genetics</article-title>. <source>Nature</source><year>2020</year>;<volume>577</volume>:<fpage>179</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">31915397</pub-id></mixed-citation></ref><ref id="euac030-B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roberts</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Marian</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Dandona</surname><given-names>S</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>AF.</given-names></string-name></person-group>
<article-title>Genomics in cardiovascular disease</article-title>. <source>J Am Coll Cardiol</source><year>2013</year>;<volume>61</volume>:<fpage>2029</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">23524054</pub-id></mixed-citation></ref><ref id="euac030-B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kim</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Devereux</surname><given-names>RB</given-names></string-name>, <string-name><surname>Basson</surname><given-names>CT.</given-names></string-name></person-group>
<article-title>Impact of genetic insights into mendelian disease on cardiovascular clinical practice</article-title>. <source>Circulation</source><year>2011</year>;<volume>123</volume>:<fpage>544</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">21300962</pub-id></mixed-citation></ref><ref id="euac030-B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wordsworth</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Leal</surname><given-names>J</given-names></string-name>, <string-name><surname>Blair</surname><given-names>E</given-names></string-name>, <string-name><surname>Legood</surname><given-names>R</given-names></string-name>, <string-name><surname>Thomson</surname><given-names>K</given-names></string-name>, <string-name><surname>Seller</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model</article-title>. <source>Eur Heart J</source><year>2010</year>;<volume>31</volume>:<fpage>926</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">20299350</pub-id></mixed-citation></ref><ref id="euac030-B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</string-name>, <string-name><surname>Behr</surname><given-names>ER.</given-names></string-name></person-group>
<article-title>Genetic testing for inherited cardiac disease</article-title>. <source>Nat Rev Cardiol</source><year>2013</year>;<volume>10</volume>:<fpage>571</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">23900354</pub-id></mixed-citation></ref><ref id="euac030-B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lahrouchi</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Tadros</surname><given-names>R</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Mizusawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Postema</surname><given-names>PG</given-names></string-name>, <string-name><surname>Beekman</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Transethnic genome-wide association study provides insights in the genetic architecture and heritability of long QT syndrome</article-title>. <source>Circulation</source><year>2020</year>;<volume>142</volume>:<fpage>324</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">32429735</pub-id></mixed-citation></ref><ref id="euac030-B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tadros</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Francis</surname><given-names>C</given-names></string-name>, <string-name><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name><surname>Vermeer</surname><given-names>AMC</given-names></string-name>, <string-name><surname>Harper</surname><given-names>AR</given-names></string-name>, <string-name><surname>Huurman</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect</article-title>. <source>Nat Genet</source><year>2021</year>;<volume>53</volume>:<fpage>128</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">33495596</pub-id></mixed-citation></ref><ref id="euac030-B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Harper</surname>
<given-names>AR</given-names>
</string-name>, <string-name><surname>Goel</surname><given-names>A</given-names></string-name>, <string-name><surname>Grace</surname><given-names>C</given-names></string-name>, <string-name><surname>Thomson</surname><given-names>KL</given-names></string-name>, <string-name><surname>Petersen</surname><given-names>SE</given-names></string-name>, <string-name><surname>Xu</surname><given-names>X</given-names></string-name><etal>et al</etal>; <collab>HCMR Investigators</collab></person-group>. <article-title>Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity</article-title>. <source>Nat Genet</source><year>2021</year>;<volume>53</volume>:<fpage>135</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">33495597</pub-id></mixed-citation></ref><ref id="euac030-B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Conrad</surname>
<given-names>DF</given-names>
</string-name>, <string-name><surname>Keebler</surname><given-names>JE</given-names></string-name>, <string-name><surname>DePristo</surname><given-names>MA</given-names></string-name>, <string-name><surname>Lindsay</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Casals</surname><given-names>F</given-names></string-name><etal>et al</etal>; <collab>1000 Genomes Project</collab></person-group>. <article-title>Variation in genome-wide mutation rates within and between human families</article-title>. <source>Nat Genet</source><year>2011</year>;<volume>43</volume>:<fpage>712</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">21666693</pub-id></mixed-citation></ref><ref id="euac030-B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Abecasis</surname>
<given-names>GR</given-names>
</string-name>, <string-name><surname>Altshuler</surname><given-names>D</given-names></string-name>, <string-name><surname>Auton</surname><given-names>A</given-names></string-name>, <string-name><surname>Brooks</surname><given-names>LD</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>RM</given-names></string-name>, <string-name><surname>Gibbs</surname><given-names>RA</given-names></string-name><etal>et al</etal>; <collab>1000 Genomes Project Consortium</collab></person-group>. <article-title>A map of human genome variation from population-scale sequencing</article-title>. <source>Nature</source><year>2010</year>;<volume>467</volume>:<fpage>1061</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">20981092</pub-id></mixed-citation></ref><ref id="euac030-B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hassold</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Hunt</surname><given-names>P.</given-names></string-name></person-group>
<article-title>To err (meiotically) is human: the genesis of human aneuploidy</article-title>. <source>Nat Rev Genet</source><year>2001</year>;<volume>2</volume>:<fpage>280</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">11283700</pub-id></mixed-citation></ref><ref id="euac030-B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stranger</surname>
<given-names>BE</given-names>
</string-name>, <string-name><surname>Forrest</surname><given-names>MS</given-names></string-name>, <string-name><surname>Dunning</surname><given-names>M</given-names></string-name>, <string-name><surname>Ingle</surname><given-names>CE</given-names></string-name>, <string-name><surname>Beazley</surname><given-names>C</given-names></string-name>, <string-name><surname>Thorne</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>Relative impact of nucleotide and copy number variation on gene expression phenotypes</article-title>. <source>Science</source><year>2007</year>;<volume>315</volume>:<fpage>848</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">17289997</pub-id></mixed-citation></ref><ref id="euac030-B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Gu</surname><given-names>W</given-names></string-name>, <string-name><surname>Hurles</surname><given-names>ME</given-names></string-name>, <string-name><surname>Lupski</surname><given-names>JR.</given-names></string-name></person-group>
<article-title>Copy number variation in human health, disease, and evolution</article-title>. <source>Annu Rev Genomics Hum Genet</source><year>2009</year>;<volume>10</volume>:<fpage>451</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">19715442</pub-id></mixed-citation></ref><ref id="euac030-B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lejeune</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Gautier</surname><given-names>M</given-names></string-name>, <string-name><surname>Turpin</surname><given-names>R.</given-names></string-name></person-group>
<article-title>[Study of somatic chromosomes from 9 mongoloid children]</article-title>. <source>C R Hebd Seances Acad Sci</source><year>1959</year>;<volume>248</volume>:<fpage>1721</fpage>&#x02013;<lpage>2</lpage>.</mixed-citation></ref><ref id="euac030-B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sanger</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Nicklen</surname><given-names>S</given-names></string-name>, <string-name><surname>Coulson</surname><given-names>AR.</given-names></string-name></person-group>
<article-title>DNA sequencing with chain-terminating inhibitors</article-title>. <source>Proc Natl Acad Sci USA</source><year>1977</year>;<volume>74</volume>:<fpage>5463</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">271968</pub-id></mixed-citation></ref><ref id="euac030-B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<collab>International Human Genome Sequencing Consortium</collab>
</person-group>. <article-title>Finishing the euchromatic sequence of the human genome</article-title>. <source>Nature</source><year>2004</year>;<volume>431</volume>:<fpage>931</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">15496913</pub-id></mixed-citation></ref><ref id="euac030-B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Margulies</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Egholm</surname><given-names>M</given-names></string-name>, <string-name><surname>Altman</surname><given-names>WE</given-names></string-name>, <string-name><surname>Attiya</surname><given-names>S</given-names></string-name>, <string-name><surname>Bader</surname><given-names>JS</given-names></string-name>, <string-name><surname>Bemben</surname><given-names>LA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genome sequencing in microfabricated high-density picolitre reactors</article-title>. <source>Nature</source><year>2005</year>;<volume>437</volume>:<fpage>376</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">16056220</pub-id></mixed-citation></ref><ref id="euac030-B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bentley</surname>
<given-names>DR</given-names>
</string-name>, <string-name><surname>Balasubramanian</surname><given-names>S</given-names></string-name>, <string-name><surname>Swerdlow</surname><given-names>HP</given-names></string-name>, <string-name><surname>Smith</surname><given-names>GP</given-names></string-name>, <string-name><surname>Milton</surname><given-names>J</given-names></string-name>, <string-name><surname>Brown</surname><given-names>CG</given-names></string-name><etal>et al</etal></person-group>
<article-title>Accurate whole human genome sequencing using reversible terminator chemistry</article-title>. <source>Nature</source><year>2008</year>;<volume>456</volume>:<fpage>53</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18987734</pub-id></mixed-citation></ref><ref id="euac030-B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Choi</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Scholl</surname><given-names>UI</given-names></string-name>, <string-name><surname>Ji</surname><given-names>W</given-names></string-name>, <string-name><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name><surname>Tikhonova</surname><given-names>IR</given-names></string-name>, <string-name><surname>Zumbo</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic diagnosis by whole exome capture and massively parallel DNA sequencing</article-title>. <source>Proc Natl Acad Sci USA</source><year>2009</year>;<volume>106</volume>:<fpage>19096</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">19861545</pub-id></mixed-citation></ref><ref id="euac030-B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ng</surname>
<given-names>SB</given-names>
</string-name>, <string-name><surname>Turner</surname><given-names>EH</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>PD</given-names></string-name>, <string-name><surname>Flygare</surname><given-names>SD</given-names></string-name>, <string-name><surname>Bigham</surname><given-names>AW</given-names></string-name>, <string-name><surname>Lee</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Targeted capture and massively parallel sequencing of 12 human exomes</article-title>. <source>Nature</source><year>2009</year>;<volume>461</volume>:<fpage>272</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">19684571</pub-id></mixed-citation></ref><ref id="euac030-B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Lupski</surname><given-names>JR.</given-names></string-name></person-group>
<article-title>Non-coding genetic variants in human disease</article-title>. <source>Hum Mol Genet</source><year>2015</year>;<volume>24</volume>:<fpage>R102</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">26152199</pub-id></mixed-citation></ref><ref id="euac030-B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whiffin</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Karczewski</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Chothani</surname><given-names>S</given-names></string-name>, <string-name><surname>Smith</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Evans</surname><given-names>DG</given-names></string-name><etal>et al</etal>; <collab>Genome Aggregation Database Consortium</collab></person-group>. <article-title>Characterising the loss-of-function impact of 5' untranslated region variants in 15,708 individuals</article-title>. <source>Nat Commun</source><year>2020</year>;<volume>11</volume>:<fpage>2523</fpage>.<pub-id pub-id-type="pmid">32461616</pub-id></mixed-citation></ref><ref id="euac030-B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chaisson</surname>
<given-names>MJP</given-names>
</string-name>, <string-name><surname>Sanders</surname><given-names>AD</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name><surname>Malhotra</surname><given-names>A</given-names></string-name>, <string-name><surname>Porubsky</surname><given-names>D</given-names></string-name>, <string-name><surname>Rausch</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Multi-platform discovery of haplotype-resolved structural variation in human genomes</article-title>. <source>Nat Commun</source><year>2019</year>;<volume>10</volume>:<fpage>1784</fpage>.<pub-id pub-id-type="pmid">30992455</pub-id></mixed-citation></ref><ref id="euac030-B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Alkan</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Coe</surname><given-names>BP</given-names></string-name>, <string-name><surname>Eichler</surname><given-names>EE.</given-names></string-name></person-group>
<article-title>Genome structural variation discovery and genotyping</article-title>. <source>Nat Rev Genet</source><year>2011</year>;<volume>12</volume>:<fpage>363</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">21358748</pub-id></mixed-citation></ref><ref id="euac030-B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hindson</surname>
<given-names>CM</given-names>
</string-name>, <string-name><surname>Chevillet</surname><given-names>JR</given-names></string-name>, <string-name><surname>Briggs</surname><given-names>HA</given-names></string-name>, <string-name><surname>Gallichotte</surname><given-names>EN</given-names></string-name>, <string-name><surname>Ruf</surname><given-names>IK</given-names></string-name>, <string-name><surname>Hindson</surname><given-names>BJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Absolute quantification by droplet digital PCR versus analog real-time PCR</article-title>. <source>Nat Methods</source><year>2013</year>;<volume>10</volume>:<fpage>1003</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">23995387</pub-id></mixed-citation></ref><ref id="euac030-B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>LaFramboise</surname>
<given-names>T.</given-names>
</string-name>
</person-group>
<article-title>Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances</article-title>. <source>Nucleic Acids Res</source><year>2009</year>;<volume>37</volume>:<fpage>4181</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">19570852</pub-id></mixed-citation></ref><ref id="euac030-B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kalia</surname>
<given-names>SS</given-names>
</string-name>, <string-name><surname>Adelman</surname><given-names>K</given-names></string-name>, <string-name><surname>Bale</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Chung</surname><given-names>WK</given-names></string-name>, <string-name><surname>Eng</surname><given-names>C</given-names></string-name>, <string-name><surname>Evans</surname><given-names>JP</given-names></string-name><etal>et al</etal></person-group>
<article-title>Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics</article-title>. <source>Genet Med</source><year>2017</year>;<volume>19</volume>:<fpage>249</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">27854360</pub-id></mixed-citation></ref><ref id="euac030-B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Miller</surname>
<given-names>DT</given-names>
</string-name>, <string-name><surname>Lee</surname><given-names>K</given-names></string-name>, <string-name><surname>Chung</surname><given-names>WK</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>AS</given-names></string-name>, <string-name><surname>Herman</surname><given-names>GE</given-names></string-name>, <string-name><surname>Klein</surname><given-names>TE</given-names></string-name><etal>et al</etal>; <collab>ACMG Secondary Findings Working Group</collab></person-group>. <article-title>ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)</article-title>. <source>Genet Med</source><year>2021</year>;<volume>23</volume>:<fpage>1381</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">34012068</pub-id></mixed-citation></ref><ref id="euac030-B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Visscher</surname>
<given-names>PM</given-names>
</string-name>, <string-name><surname>Wray</surname><given-names>NR</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Sklar</surname><given-names>P</given-names></string-name>, <string-name><surname>McCarthy</surname><given-names>MI</given-names></string-name>, <string-name><surname>Brown</surname><given-names>MA</given-names></string-name><etal>et al</etal></person-group>
<article-title>10 years of GWAS discovery: biology, function, and translation</article-title>. <source>Am J Hum Genet</source><year>2017</year>;<volume>101</volume>:<fpage>5</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">28686856</pub-id></mixed-citation></ref><ref id="euac030-B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pe'er</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Yelensky</surname><given-names>R</given-names></string-name>, <string-name><surname>Altshuler</surname><given-names>D</given-names></string-name>, <string-name><surname>Daly</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>Estimation of the multiple testing burden for genomewide association studies of nearly all common variants</article-title>. <source>Genet Epidemiol</source><year>2008</year>;<volume>32</volume>:<fpage>381</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">18348202</pub-id></mixed-citation></ref><ref id="euac030-B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sotoodehnia</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Isaacs</surname><given-names>A</given-names></string-name>, <string-name><surname>de Bakker</surname><given-names>PI</given-names></string-name>, <string-name><surname>Dorr</surname><given-names>M</given-names></string-name>, <string-name><surname>Newton-Cheh</surname><given-names>C</given-names></string-name>, <string-name><surname>Nolte</surname><given-names>IM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction</article-title>. <source>Nat Genet</source><year>2010</year>;<volume>42</volume>:<fpage>1068</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">21076409</pub-id></mixed-citation></ref><ref id="euac030-B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Aung</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Vargas</surname><given-names>JD</given-names></string-name>, <string-name><surname>Yang</surname><given-names>C</given-names></string-name>, <string-name><surname>Cabrera</surname><given-names>CP</given-names></string-name>, <string-name><surname>Warren</surname><given-names>HR</given-names></string-name>, <string-name><surname>Fung</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genome-wide analysis of left ventricular image-derived phenotypes identifies fourteen loci associated with cardiac morphogenesis and heart failure development</article-title>. <source>Circulation</source><year>2019</year>;<volume>140</volume>:<fpage>1318</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">31554410</pub-id></mixed-citation></ref><ref id="euac030-B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Giri</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Hellwege</surname><given-names>JN</given-names></string-name>, <string-name><surname>Keaton</surname><given-names>JM</given-names></string-name>, <string-name><surname>Park</surname><given-names>J</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>C</given-names></string-name>, <string-name><surname>Warren</surname><given-names>HR</given-names></string-name><etal>et al</etal>; <collab>Million Veteran Program</collab></person-group>. <article-title>Trans-ethnic association study of blood pressure determinants in over 750,000 individuals</article-title>. <source>Nat Genet</source><year>2019</year>;<volume>51</volume>:<fpage>51</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">30578418</pub-id></mixed-citation></ref><ref id="euac030-B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nikpay</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Goel</surname><given-names>A</given-names></string-name>, <string-name><surname>Won</surname><given-names>HH</given-names></string-name>, <string-name><surname>Hall</surname><given-names>LM</given-names></string-name>, <string-name><surname>Willenborg</surname><given-names>C</given-names></string-name>, <string-name><surname>Kanoni</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease</article-title>. <source>Nat Genet</source><year>2015</year>;<volume>47</volume>:<fpage>1121</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">26343387</pub-id></mixed-citation></ref><ref id="euac030-B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shah</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Henry</surname><given-names>A</given-names></string-name>, <string-name><surname>Roselli</surname><given-names>C</given-names></string-name>, <string-name><surname>Lin</surname><given-names>H</given-names></string-name>, <string-name><surname>Sveinbjornsson</surname><given-names>G</given-names></string-name>, <string-name><surname>Fatemifar</surname><given-names>G</given-names></string-name><etal>et al</etal>; <collab>Regeneron Genetics Center</collab></person-group>. <article-title>Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure</article-title>. <source>Nat Commun</source><year>2020</year>;<volume>11</volume>:<fpage>163</fpage>.<pub-id pub-id-type="pmid">31919418</pub-id></mixed-citation></ref><ref id="euac030-B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roselli</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Chaffin</surname><given-names>MD</given-names></string-name>, <string-name><surname>Weng</surname><given-names>LC</given-names></string-name>, <string-name><surname>Aeschbacher</surname><given-names>S</given-names></string-name>, <string-name><surname>Ahlberg</surname><given-names>G</given-names></string-name>, <string-name><surname>Albert</surname><given-names>CM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Multi-ethnic genome-wide association study for atrial fibrillation</article-title>. <source>Nat Genet</source><year>2018</year>;<volume>50</volume>:<fpage>1225</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">29892015</pub-id></mixed-citation></ref><ref id="euac030-B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ashar</surname>
<given-names>FN</given-names>
</string-name>, <string-name><surname>Mitchell</surname><given-names>RN</given-names></string-name>, <string-name><surname>Albert</surname><given-names>CM</given-names></string-name>, <string-name><surname>Newton-Cheh</surname><given-names>C</given-names></string-name>, <string-name><surname>Brody</surname><given-names>JA</given-names></string-name>, <string-name><surname>Muller-Nurasyid</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>A comprehensive evaluation of the genetic architecture of sudden cardiac arrest</article-title>. <source>Eur Heart J</source><year>2018</year>;<volume>39</volume>:<fpage>3961</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30169657</pub-id></mixed-citation></ref><ref id="euac030-B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bezzina</surname>
<given-names>CR</given-names>
</string-name>, <string-name><surname>Barc</surname><given-names>J</given-names></string-name>, <string-name><surname>Mizusawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Remme</surname><given-names>CA</given-names></string-name>, <string-name><surname>Gourraud</surname><given-names>JB</given-names></string-name>, <string-name><surname>Simonet</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group>
<article-title>Common variants at <italic toggle="yes">SCN5A-SCN10A</italic> and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death</article-title>. <source>Nat Genet</source><year>2013</year>;<volume>45</volume>:<fpage>1044</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23872634</pub-id></mixed-citation></ref><ref id="euac030-B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Villard</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Perret</surname><given-names>C</given-names></string-name>, <string-name><surname>Gary</surname><given-names>F</given-names></string-name>, <string-name><surname>Proust</surname><given-names>C</given-names></string-name>, <string-name><surname>Dilanian</surname><given-names>G</given-names></string-name>, <string-name><surname>Hengstenberg</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy</article-title>. <source>Eur Heart J</source><year>2011</year>;<volume>32</volume>:<fpage>1065</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">21459883</pub-id></mixed-citation></ref><ref id="euac030-B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lambert</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>Gil</surname><given-names>L</given-names></string-name>, <string-name><surname>Jupp</surname><given-names>S</given-names></string-name>, <string-name><surname>Ritchie</surname><given-names>SC</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Buniello</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation</article-title>. <source><italic toggle="yes">Nat Genet</italic></source><year>2021</year>;<volume>53</volume>:<fpage>420</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">33692568</pub-id></mixed-citation></ref><ref id="euac030-B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Marston</surname>
<given-names>NA</given-names>
</string-name>, <string-name><surname>Kamanu</surname><given-names>FK</given-names></string-name>, <string-name><surname>Nordio</surname><given-names>F</given-names></string-name>, <string-name><surname>Gurmu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Roselli</surname><given-names>C</given-names></string-name>, <string-name><surname>Sever</surname><given-names>PS</given-names></string-name><etal>et al</etal></person-group>
<article-title>Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER trial</article-title>. <source>Circulation</source><year>2020</year>;<volume>141</volume>:<fpage>616</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">31707849</pub-id></mixed-citation></ref><ref id="euac030-B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Damask</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>GG</given-names></string-name>, <string-name><surname>Szarek</surname><given-names>M</given-names></string-name>, <string-name><surname>Hagstrom</surname><given-names>E</given-names></string-name>, <string-name><surname>Badimon</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>; On behalf of the Regeneron Genetics Center and the ODYSSEY OUTCOMES Investigators. <article-title>Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial</article-title>. <source>Circulation</source><year>2020</year>;<volume>141</volume>:<fpage>624</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">31707832</pub-id></mixed-citation></ref><ref id="euac030-B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Marston</surname>
<given-names>NA</given-names>
</string-name>, <string-name><surname>Gurmu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Melloni</surname><given-names>GEM</given-names></string-name>, <string-name><surname>Bonaca</surname><given-names>M</given-names></string-name>, <string-name><surname>Gencer</surname><given-names>B</given-names></string-name>, <string-name><surname>Sever</surname><given-names>PS</given-names></string-name><etal>et al</etal></person-group>
<article-title>The effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibition on the risk of venous thromboembolism</article-title>. <source>Circulation</source><year>2020</year>;<volume>141</volume>:<fpage>1600</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32223429</pub-id></mixed-citation></ref><ref id="euac030-B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tadros</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Tan</surname><given-names>HL</given-names></string-name>, <string-name><surname>El Mathari</surname><given-names>S</given-names></string-name>, <string-name><surname>Kors</surname><given-names>JA</given-names></string-name>, <string-name><surname>Postema</surname><given-names>PG</given-names></string-name>, <string-name><surname>Lahrouchi</surname><given-names>N</given-names></string-name><etal>et al</etal>; <collab>ESCAPE-NET Investigators</collab></person-group>. <article-title>Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores</article-title>. <source>Eur Heart J</source><year>2019</year>;<volume>40</volume>:<fpage>3097</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="pmid">31504448</pub-id></mixed-citation></ref><ref id="euac030-B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wijeyeratne</surname>
<given-names>YD</given-names>
</string-name>, <string-name><surname>Tanck</surname><given-names>MW</given-names></string-name>, <string-name><surname>Mizusawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Batchvarov</surname><given-names>V</given-names></string-name>, <string-name><surname>Barc</surname><given-names>J</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>
<italic toggle="yes">SCN5A</italic> mutation type and a genetic risk score associate variably with Brugada syndrome phenotype in <italic toggle="yes">SCN5A</italic> families</article-title>. <source>Circ Genom Precis Med</source><year>2020</year>;<volume>13</volume>:<fpage>e002911</fpage>.<pub-id pub-id-type="pmid">33164571</pub-id></mixed-citation></ref><ref id="euac030-B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Turkowski</surname>
<given-names>KL</given-names>
</string-name>, <string-name><surname>Dotzler</surname><given-names>SM</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Giudicessi</surname><given-names>JR</given-names></string-name>, <string-name><surname>Bos</surname><given-names>JM</given-names></string-name>, <string-name><surname>Speziale</surname><given-names>AD</given-names></string-name><etal>et al</etal></person-group>
<article-title>Corrected QT interval-polygenic risk score and its contribution to type 1, type 2, and type 3 long-QT syndrome in probands and genotype-positive family members</article-title>. <source>Circ Genom Precis Med</source><year>2020</year>;<volume>13</volume>:<fpage>e002922</fpage>.<pub-id pub-id-type="pmid">32469608</pub-id></mixed-citation></ref><ref id="euac030-B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Richards</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Aziz</surname><given-names>N</given-names></string-name>, <string-name><surname>Bale</surname><given-names>S</given-names></string-name>, <string-name><surname>Bick</surname><given-names>D</given-names></string-name>, <string-name><surname>Das</surname><given-names>S</given-names></string-name>, <string-name><surname>Gastier-Foster</surname><given-names>J</given-names></string-name><etal>et al</etal>; <collab>ACMG Laboratory Quality Assurance Committee</collab></person-group>. <article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source>Genet Med</source><year>2015</year>;<volume>17</volume>:<fpage>405</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation></ref><ref id="euac030-B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Manrai</surname>
<given-names>AK</given-names>
</string-name>, <string-name><surname>Funke</surname><given-names>BH</given-names></string-name>, <string-name><surname>Rehm</surname><given-names>HL</given-names></string-name>, <string-name><surname>Olesen</surname><given-names>MS</given-names></string-name>, <string-name><surname>Maron</surname><given-names>BA</given-names></string-name>, <string-name><surname>Szolovits</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic misdiagnoses and the potential for health disparities</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>375</volume>:<fpage>655</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">27532831</pub-id></mixed-citation></ref><ref id="euac030-B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ackerman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Jones</surname><given-names>GS</given-names></string-name>, <string-name><surname>Will</surname><given-names>ML</given-names></string-name>, <string-name><surname>Burrow</surname><given-names>CR</given-names></string-name>, <string-name><surname>Curran</surname><given-names>ME.</given-names></string-name></person-group>
<article-title>Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome</article-title>. <source>Mayo Clin Proc</source><year>2003</year>;<volume>78</volume>:<fpage>1479</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">14661677</pub-id></mixed-citation></ref><ref id="euac030-B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ackerman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name><surname>Splawski</surname><given-names>I</given-names></string-name>, <string-name><surname>Makielski</surname><given-names>JC</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Will</surname><given-names>ML</given-names></string-name>, <string-name><surname>Timothy</surname><given-names>KW</given-names></string-name><etal>et al</etal></person-group>
<article-title>Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing</article-title>. <source>Heart Rhythm</source><year>2004</year>;<volume>1</volume>:<fpage>600</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15851227</pub-id></mixed-citation></ref><ref id="euac030-B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Giudicessi</surname>
<given-names>JR</given-names>
</string-name>, <string-name><surname>Roden</surname><given-names>DM</given-names></string-name>, <string-name><surname>Wilde</surname><given-names>AAM</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>Classification and reporting of potentially proarrhythmic common genetic variation in long QT syndrome genetic testing</article-title>. <source>Circulation</source><year>2018</year>;<volume>137</volume>:<fpage>619</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">29431662</pub-id></mixed-citation></ref><ref id="euac030-B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Giudicessi</surname>
<given-names>JR</given-names>
</string-name>, <string-name><surname>Wilde</surname><given-names>AAM</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>The genetic architecture of long QT syndrome: a critical reappraisal</article-title>. <source>Trends Cardiovasc Med</source><year>2018</year>;<volume>28</volume>:<fpage>453</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">29661707</pub-id></mixed-citation></ref><ref id="euac030-B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ackerman</surname>
<given-names>JP</given-names>
</string-name>, <string-name><surname>Bartos</surname><given-names>DC</given-names></string-name>, <string-name><surname>Kapplinger</surname><given-names>JD</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Delisle</surname><given-names>BP</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>The Promise and Peril of Precision Medicine</article-title>. <source><italic toggle="yes">Mayo Clin Proc</italic></source><year>2016</year>;<volume>91</volume>:<fpage>1606</fpage>&#x02013;<lpage>16</lpage>.</mixed-citation></ref><ref id="euac030-B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kelly</surname>
<given-names>MA</given-names>
</string-name>, <string-name><surname>Caleshu</surname><given-names>C</given-names></string-name>, <string-name><surname>Morales</surname><given-names>A</given-names></string-name>, <string-name><surname>Buchan</surname><given-names>J</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>Z</given-names></string-name>, <string-name><surname>Harrison</surname><given-names>SM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel</article-title>. <source>Genet Med</source><year>2018</year>;<volume>20</volume>:<fpage>351</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29300372</pub-id></mixed-citation></ref><ref id="euac030-B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Richmond</surname>
<given-names>CM</given-names>
</string-name>, <string-name><surname>James</surname><given-names>PA</given-names></string-name>, <string-name><surname>Pantaleo</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Chong</surname><given-names>B</given-names></string-name>, <string-name><surname>Lunke</surname><given-names>S</given-names></string-name>, <string-name><surname>Tan</surname><given-names>TY</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical and laboratory reporting impact of ACMG-AMP and modified ClinGen variant classification frameworks in MYH7-related cardiomyopathy</article-title>. <source>Genet Med</source><year>2021</year>;<volume>23</volume>:<fpage>1108</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">33568804</pub-id></mixed-citation></ref><ref id="euac030-B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bains</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Dotzler</surname><given-names>SM</given-names></string-name>, <string-name><surname>Krijger</surname><given-names>C</given-names></string-name>, <string-name><surname>Giudicessi</surname><given-names>JR</given-names></string-name>, <string-name><surname>Ye</surname><given-names>D</given-names></string-name>, <string-name><surname>Bikker</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>A phenotype-enhanced variant classification framework to decrease the burden of missense variants of uncertain significance in type 1 long QT syndrome</article-title>. <source>Heart Rhythm</source><year>2022</year>;<volume>19</volume>:<fpage>435</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">34798354</pub-id></mixed-citation></ref><ref id="euac030-B79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kim</surname>
<given-names>YE</given-names>
</string-name>, <string-name><surname>Ki</surname><given-names>CS</given-names></string-name>, <string-name><surname>Jang</surname><given-names>MA.</given-names></string-name></person-group>
<article-title>Challenges and considerations in sequence variant interpretation for mendelian disorders</article-title>. <source>Ann Lab Med</source><year>2019</year>;<volume>39</volume>:<fpage>421</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31037860</pub-id></mixed-citation></ref><ref id="euac030-B80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gelb</surname>
<given-names>BD</given-names>
</string-name>, <string-name><surname>Cav&#x000e9;</surname><given-names>H</given-names></string-name>, <string-name><surname>Dillon</surname><given-names>MW</given-names></string-name>, <string-name><surname>Gripp</surname><given-names>KW</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JA</given-names></string-name>, <string-name><surname>Mason-Suares</surname><given-names>H</given-names></string-name><etal>et al</etal>; <collab>ClinGen RASopathy Working Group</collab></person-group>. <article-title>ClinGen's RASopathy Expert Panel consensus methods for variant interpretation</article-title>. <source>Genet Med</source><year>2018</year>;<volume>20</volume>:<fpage>1334</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">29493581</pub-id></mixed-citation></ref><ref id="euac030-B81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Maron</surname>
<given-names>BJ</given-names>
</string-name>, <string-name><surname>Maron</surname><given-names>MS</given-names></string-name>, <string-name><surname>Semsarian</surname><given-names>C.</given-names></string-name></person-group>
<article-title>Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives</article-title>. <source>J Am Coll Cardiol</source><year>2012</year>;<volume>60</volume>:<fpage>705</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">22796258</pub-id></mixed-citation></ref><ref id="euac030-B82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lafreniere-Roula</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Bolkier</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zahavich</surname><given-names>L</given-names></string-name>, <string-name><surname>Mathew</surname><given-names>J</given-names></string-name>, <string-name><surname>George</surname><given-names>K</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines?</article-title>
<source>Eur Heart J</source>
<year>2019</year>;<volume>40</volume>:<fpage>3672</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">31170284</pub-id></mixed-citation></ref><ref id="euac030-B83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ingles</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Burns</surname><given-names>C</given-names></string-name>, <string-name><surname>Funke</surname><given-names>B.</given-names></string-name></person-group>
<article-title>Pathogenicity of hypertrophic cardiomyopathy variants: a path forward together</article-title>. <source>Circ Cardiovasc Genet</source><year>2017</year>;<volume>10</volume>:<fpage>e001916</fpage>.<pub-id pub-id-type="pmid">28986458</pub-id></mixed-citation></ref><ref id="euac030-B84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ouellette</surname>
<given-names>AC</given-names>
</string-name>, <string-name><surname>Mathew</surname><given-names>J</given-names></string-name>, <string-name><surname>Manickaraj</surname><given-names>AK</given-names></string-name>, <string-name><surname>Manase</surname><given-names>G</given-names></string-name>, <string-name><surname>Zahavich</surname><given-names>L</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical genetic testing in pediatric cardiomyopathy: is bigger better?</article-title>
<source>Clin Genet</source>
<year>2018</year>;<volume>93</volume>:<fpage>33</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">28369760</pub-id></mixed-citation></ref><ref id="euac030-B85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jensen</surname>
<given-names>MK</given-names>
</string-name>, <string-name><surname>Havndrup</surname><given-names>O</given-names></string-name>, <string-name><surname>Christiansen</surname><given-names>M</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>PS</given-names></string-name>, <string-name><surname>Diness</surname><given-names>B</given-names></string-name>, <string-name><surname>Axelsson</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing</article-title>. <source>Circulation</source><year>2013</year>;<volume>127</volume>:<fpage>48</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">23197161</pub-id></mixed-citation></ref><ref id="euac030-B86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Semsarian</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Ingles</surname><given-names>J</given-names></string-name>, <string-name><surname>Wilde</surname><given-names>AA.</given-names></string-name></person-group>
<article-title>Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives</article-title>. <source>Eur Heart J</source><year>2015</year>;<volume>36</volume>:<fpage>1290</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">25765769</pub-id></mixed-citation></ref><ref id="euac030-B87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rueda</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Wagner</surname><given-names>JL</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>TC</given-names></string-name>, <string-name><surname>Topol</surname><given-names>SE</given-names></string-name>, <string-name><surname>Muse</surname><given-names>ED</given-names></string-name>, <string-name><surname>Lucas</surname><given-names>JR</given-names></string-name><etal>et al</etal></person-group>
<article-title>Molecular autopsy for sudden death in the young: is data aggregation the key?</article-title>
<source>Front Cardiovasc Med</source>
<year>2017</year>;<volume>4</volume>:<fpage>72</fpage>.<pub-id pub-id-type="pmid">29181379</pub-id></mixed-citation></ref><ref id="euac030-B88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Torkamani</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Muse</surname><given-names>ED</given-names></string-name>, <string-name><surname>Spencer</surname><given-names>EG</given-names></string-name>, <string-name><surname>Rueda</surname><given-names>M</given-names></string-name>, <string-name><surname>Wagner</surname><given-names>GN</given-names></string-name>, <string-name><surname>Lucas</surname><given-names>JR</given-names></string-name><etal>et al</etal></person-group>
<article-title>Molecular autopsy for sudden unexpected death</article-title>. <source>JAMA</source><year>2016</year>;<volume>316</volume>:<fpage>1492</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">27727376</pub-id></mixed-citation></ref><ref id="euac030-B89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Splawski</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Timothy</surname><given-names>KW</given-names></string-name>, <string-name><surname>Sharpe</surname><given-names>LM</given-names></string-name>, <string-name><surname>Decher</surname><given-names>N</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>P</given-names></string-name>, <string-name><surname>Bloise</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism</article-title>. <source>Cell</source><year>2004</year>;<volume>119</volume>:<fpage>19</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">15454078</pub-id></mixed-citation></ref><ref id="euac030-B90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Crotti</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Johnson</surname><given-names>CN</given-names></string-name>, <string-name><surname>Graf</surname><given-names>E</given-names></string-name>, <string-name><surname>De Ferrari</surname><given-names>GM</given-names></string-name>, <string-name><surname>Cuneo</surname><given-names>BF</given-names></string-name>, <string-name><surname>Ovadia</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Calmodulin mutations associated with recurrent cardiac arrest in infants</article-title>. <source>Circulation</source><year>2013</year>;<volume>127</volume>:<fpage>1009</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">23388215</pub-id></mixed-citation></ref><ref id="euac030-B91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Crotti</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ghidoni</surname><given-names>A</given-names></string-name>, <string-name><surname>Baruteau</surname><given-names>AE</given-names></string-name>, <string-name><surname>Beckmann</surname><given-names>BM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry</article-title>. <source>Eur Heart J</source><year>2019</year>;<volume>40</volume>:<fpage>2964</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">31170290</pub-id></mixed-citation></ref><ref id="euac030-B92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Altmann</surname>
<given-names>HM</given-names>
</string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Will</surname><given-names>ML</given-names></string-name>, <string-name><surname>Middha</surname><given-names>S</given-names></string-name>, <string-name><surname>Evans</surname><given-names>JM</given-names></string-name>, <string-name><surname>Eckloff</surname><given-names>BW</given-names></string-name><etal>et al</etal></person-group>
<article-title>Homozygous/compound heterozygous triadin mutations associated with autosomal-recessive long-QT syndrome and pediatric sudden cardiac arrest: elucidation of the Triadin knockout syndrome</article-title>. <source>Circulation</source><year>2015</year>;<volume>131</volume>:<fpage>2051</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">25922419</pub-id></mixed-citation></ref><ref id="euac030-B93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Clemens</surname>
<given-names>DJ</given-names>
</string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Giudicessi</surname><given-names>JR</given-names></string-name>, <string-name><surname>Bos</surname><given-names>JM</given-names></string-name>, <string-name><surname>Rohatgi</surname><given-names>RK</given-names></string-name>, <string-name><surname>Abrams</surname><given-names>DJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>International Triadin knockout syndrome registry</article-title>. <source>Circ Genom Precis Med</source><year>2019</year>;<volume>12</volume>:<fpage>e002419</fpage>.<pub-id pub-id-type="pmid">30649896</pub-id></mixed-citation></ref><ref id="euac030-B94"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Itoh</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Aiba</surname><given-names>T</given-names></string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name>, <string-name><surname>Denjoy</surname><given-names>I</given-names></string-name>, <string-name><surname>Fressart</surname><given-names>V</given-names></string-name><etal>et al</etal></person-group>
<article-title>The genetics underlying acquired long QT syndrome: impact for genetic screening</article-title>. <source>Eur Heart J</source><year>2016</year>;<volume>37</volume>:<fpage>1456</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">26715165</pub-id></mixed-citation></ref><ref id="euac030-B95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shimizu</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Horie</surname><given-names>M.</given-names></string-name></person-group>
<article-title>Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels</article-title>. <source>Circ Res</source><year>2011</year>;<volume>109</volume>:<fpage>97</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">21700951</pub-id></mixed-citation></ref><ref id="euac030-B96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Crotti</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Odening</surname><given-names>KE</given-names></string-name>, <string-name><surname>Sanguinetti</surname><given-names>MC.</given-names></string-name></person-group>
<article-title>Heritable arrhythmias associated with abnormal function of cardiac potassium channels</article-title>. <source>Cardiovasc Res</source><year>2020</year>;<volume>116</volume>:<fpage>1542</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">32227190</pub-id></mixed-citation></ref><ref id="euac030-B97"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dessertenne</surname>
<given-names>F.</given-names>
</string-name>
</person-group>
<article-title>[Ventricular tachycardia with 2 variable opposing foci]</article-title>. <source>Arch Mal Coeur Vaiss</source><year>1966</year>;<volume>59</volume>:<fpage>263</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">4956181</pub-id></mixed-citation></ref><ref id="euac030-B98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Viskin</surname>
<given-names>S.</given-names>
</string-name>
</person-group>
<article-title>Long QT syndromes and torsade de pointes</article-title>. <source>Lancet</source><year>1999</year>;<volume>354</volume>:<fpage>1625</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">10560690</pub-id></mixed-citation></ref><ref id="euac030-B99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Takenaka</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Ai</surname><given-names>T</given-names></string-name>, <string-name><surname>Shimizu</surname><given-names>W</given-names></string-name>, <string-name><surname>Kobori</surname><given-names>A</given-names></string-name>, <string-name><surname>Ninomiya</surname><given-names>T</given-names></string-name>, <string-name><surname>Otani</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome</article-title>. <source>Circulation</source><year>2003</year>;<volume>107</volume>:<fpage>838</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">12591753</pub-id></mixed-citation></ref><ref id="euac030-B100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sy</surname>
<given-names>RW</given-names>
</string-name>, <string-name><surname>van der Werf</surname><given-names>C</given-names></string-name>, <string-name><surname>Chattha</surname><given-names>IS</given-names></string-name>, <string-name><surname>Chockalingam</surname><given-names>P</given-names></string-name>, <string-name><surname>Adler</surname><given-names>A</given-names></string-name>, <string-name><surname>Healey</surname><given-names>JS</given-names></string-name><etal>et al</etal></person-group>
<article-title>Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands</article-title>. <source>Circulation</source><year>2011</year>;<volume>124</volume>:<fpage>2187</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">22042885</pub-id></mixed-citation></ref><ref id="euac030-B101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Crotti</surname><given-names>L.</given-names></string-name></person-group>
<article-title>QTc behavior during exercise and genetic testing for the long-QT syndrome</article-title>. <source>Circulation</source><year>2011</year>;<volume>124</volume>:<fpage>2181</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">22083145</pub-id></mixed-citation></ref><ref id="euac030-B102"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Stramba-Badiale</surname><given-names>M</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Pedrazzini</surname><given-names>M</given-names></string-name>, <string-name><surname>Besana</surname><given-names>A</given-names></string-name>, <string-name><surname>Bosi</surname><given-names>G</given-names></string-name><etal>et al</etal></person-group>
<article-title>Prevalence of the congenital long-QT syndrome</article-title>. <source>Circulation</source><year>2009</year>;<volume>120</volume>:<fpage>1761</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">19841298</pub-id></mixed-citation></ref><ref id="euac030-B103"><label>103</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Moss</surname>
<given-names>AJ</given-names>
</string-name>, <string-name><surname>Schwartz</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Crampton</surname><given-names>RS</given-names></string-name>, <string-name><surname>Locati</surname><given-names>E</given-names></string-name>, <string-name><surname>Carleen</surname><given-names>E.</given-names></string-name></person-group>
<article-title>The long QT syndrome: a prospective international study</article-title>. <source>Circulation</source><year>1985</year>;<volume>71</volume>:<fpage>17</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">2856865</pub-id></mixed-citation></ref><ref id="euac030-B104"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ.</given-names>
</string-name>
</person-group>
<article-title>Idiopathic long QT syndrome: progress and questions</article-title>. <source>Am Heart J</source><year>1985</year>;<volume>109</volume>:<fpage>399</fpage>&#x02013;<lpage>411</lpage>.<pub-id pub-id-type="pmid">3966369</pub-id></mixed-citation></ref><ref id="euac030-B105"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Bathen</surname><given-names>J</given-names></string-name>, <string-name><surname>Amlie</surname><given-names>JP</given-names></string-name>, <string-name><surname>Timothy</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group>
<article-title>The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome</article-title>. <source>Circulation</source><year>2006</year>;<volume>113</volume>:<fpage>783</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">16461811</pub-id></mixed-citation></ref><ref id="euac030-B106"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roberts</surname>
<given-names>JD</given-names>
</string-name>, <string-name><surname>Asaki</surname><given-names>SY</given-names></string-name>, <string-name><surname>Mazzanti</surname><given-names>A</given-names></string-name>, <string-name><surname>Bos</surname><given-names>JM</given-names></string-name>, <string-name><surname>Tuleta</surname><given-names>I</given-names></string-name>, <string-name><surname>Muir</surname><given-names>AR</given-names></string-name><etal>et al</etal></person-group>
<article-title>An international multicenter evaluation of type 5 long QT syndrome: a low penetrant primary arrhythmic condition</article-title>. <source>Circulation</source><year>2020</year>;<volume>141</volume>:<fpage>429</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">31941373</pub-id></mixed-citation></ref><ref id="euac030-B107"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mazzanti</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Guz</surname><given-names>D</given-names></string-name>, <string-name><surname>Trancuccio</surname><given-names>A</given-names></string-name>, <string-name><surname>Pagan</surname><given-names>E</given-names></string-name>, <string-name><surname>Kukavica</surname><given-names>D</given-names></string-name>, <string-name><surname>Chargeishvili</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Natural history and risk stratification in Andersen-Tawil syndrome type 1</article-title>. <source>J Am Coll Cardiol</source><year>2020</year>;<volume>75</volume>:<fpage>1772</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">32299589</pub-id></mixed-citation></ref><ref id="euac030-B108"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wang</surname>
<given-names>DW</given-names>
</string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Shimizu</surname><given-names>W</given-names></string-name>, <string-name><surname>Pedrazzini</surname><given-names>M</given-names></string-name>, <string-name><surname>Cantu</surname><given-names>FD</given-names></string-name>, <string-name><surname>Filippo</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2008</year>;<volume>1</volume>:<fpage>370</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19808432</pub-id></mixed-citation></ref><ref id="euac030-B109"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Crotti</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Ghidoni</surname><given-names>A</given-names></string-name>, <string-name><surname>Insolia</surname><given-names>R</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>PJ.</given-names></string-name></person-group>
<article-title>The role of the cardiac sodium channel in perinatal early infant mortality</article-title>. <source>Card Electrophysiol Clin</source><year>2014</year>;<volume>6</volume>:<fpage>749</fpage>&#x02013;<lpage>59</lpage>.</mixed-citation></ref><ref id="euac030-B110"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Makita</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Behr</surname><given-names>E</given-names></string-name>, <string-name><surname>Shimizu</surname><given-names>W</given-names></string-name>, <string-name><surname>Horie</surname><given-names>M</given-names></string-name>, <string-name><surname>Sunami</surname><given-names>A</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>The E1784K mutation in <italic toggle="yes">SCN5A</italic> is associated with mixed clinical phenotype of type 3 long QT syndrome</article-title>. <source>J Clin Invest</source><year>2008</year>;<volume>118</volume>:<fpage>2219</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">18451998</pub-id></mixed-citation></ref><ref id="euac030-B111"><label>111</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rocchetti</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Sala</surname><given-names>L</given-names></string-name>, <string-name><surname>Dreizehnter</surname><given-names>L</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Sinnecker</surname><given-names>D</given-names></string-name>, <string-name><surname>Mura</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes</article-title>. <source>Cardiovasc Res</source><year>2017</year>;<volume>113</volume>:<fpage>531</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">28158429</pub-id></mixed-citation></ref><ref id="euac030-B112"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Ackerman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Antzelevitch</surname><given-names>C</given-names></string-name>, <string-name><surname>Bezzina</surname><given-names>CR</given-names></string-name>, <string-name><surname>Borggrefe</surname><given-names>M</given-names></string-name>, <string-name><surname>Cuneo</surname><given-names>BF</given-names></string-name><etal>et al</etal></person-group>
<article-title>Inherited cardiac arrhythmias</article-title>. <source>Nat Rev Dis Primers</source><year>2020</year>;<volume>6</volume>:<fpage>58</fpage>.<pub-id pub-id-type="pmid">32678103</pub-id></mixed-citation></ref><ref id="euac030-B113"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dagradi</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name>, <string-name><surname>Castelletti</surname><given-names>S</given-names></string-name>, <string-name><surname>Pedrazzini</surname><given-names>M</given-names></string-name>, <string-name><surname>Kotta</surname><given-names>MC</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Exercise training-induced repolarization abnormalities masquerading as congenital long QT syndrome</article-title>. <source>Circulation</source><year>2020</year>;<volume>142</volume>:<fpage>2405</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">33073610</pub-id></mixed-citation></ref><ref id="euac030-B114"><label>114</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Priori</surname>
<given-names>SG</given-names>
</string-name>, <string-name><surname>Napolitano</surname><given-names>C</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>PJ.</given-names></string-name></person-group>
<article-title>Low penetrance in the long-QT syndrome: clinical impact</article-title>. <source>Circulation</source><year>1999</year>;<volume>99</volume>:<fpage>529</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">9927399</pub-id></mixed-citation></ref><ref id="euac030-B115"><label>115</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shimizu</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Noda</surname><given-names>T</given-names></string-name>, <string-name><surname>Takaki</surname><given-names>H</given-names></string-name>, <string-name><surname>Kurita</surname><given-names>T</given-names></string-name>, <string-name><surname>Nagaya</surname><given-names>N</given-names></string-name>, <string-name><surname>Satomi</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group>
<article-title>Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome</article-title>. <source>J Am Coll Cardiol</source><year>2003</year>;<volume>41</volume>:<fpage>633</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">12598076</pub-id></mixed-citation></ref><ref id="euac030-B116"><label>116</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Goldenberg</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Horr</surname><given-names>S</given-names></string-name>, <string-name><surname>Moss</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>CM</given-names></string-name>, <string-name><surname>Barsheshet</surname><given-names>A</given-names></string-name>, <string-name><surname>McNitt</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals</article-title>. <source>J Am Coll Cardiol</source><year>2011</year>;<volume>57</volume>:<fpage>51</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21185501</pub-id></mixed-citation></ref><ref id="euac030-B117"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mazzanti</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Maragna</surname><given-names>R</given-names></string-name>, <string-name><surname>Vacanti</surname><given-names>G</given-names></string-name>, <string-name><surname>Monteforte</surname><given-names>N</given-names></string-name>, <string-name><surname>Bloise</surname><given-names>R</given-names></string-name>, <string-name><surname>Marino</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with long QT syndrome</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>;<volume>71</volume>:<fpage>1663</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">29650123</pub-id></mixed-citation></ref><ref id="euac030-B118"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shimizu</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Moss</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Wilde</surname><given-names>AA</given-names></string-name>, <string-name><surname>Towbin</surname><given-names>JA</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>January</surname><given-names>CT</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genotype-phenotype aspects of type 2 long QT syndrome</article-title>. <source>J Am Coll Cardiol</source><year>2009</year>;<volume>54</volume>:<fpage>2052</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">19926013</pub-id></mixed-citation></ref><ref id="euac030-B119"><label>119</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Moreno</surname><given-names>C</given-names></string-name>, <string-name><surname>Kotta</surname><given-names>MC</given-names></string-name>, <string-name><surname>Pedrazzini</surname><given-names>M</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Dagradi</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region</article-title>. <source>Eur Heart J</source><year>2021</year>;<volume>42</volume>:<fpage>4743</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">34505893</pub-id></mixed-citation></ref><ref id="euac030-B120"><label>120</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Moss</surname>
<given-names>AJ</given-names>
</string-name>, <string-name><surname>Shimizu</surname><given-names>W</given-names></string-name>, <string-name><surname>Wilde</surname><given-names>AA</given-names></string-name>, <string-name><surname>Towbin</surname><given-names>JA</given-names></string-name>, <string-name><surname>Zareba</surname><given-names>W</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>JL</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene</article-title>. <source>Circulation</source><year>2007</year>;<volume>115</volume>:<fpage>2481</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17470695</pub-id></mixed-citation></ref><ref id="euac030-B121"><label>121</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Crotti</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Shimizu</surname><given-names>W</given-names></string-name>, <string-name><surname>Denjoy</surname><given-names>I</given-names></string-name>, <string-name><surname>Schulze-Bahr</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification</article-title>. <source>Circulation</source><year>2007</year>;<volume>116</volume>:<fpage>2366</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">17984373</pub-id></mixed-citation></ref><ref id="euac030-B122"><label>122</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</string-name>, <string-name><surname>Moss</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Kaufman</surname><given-names>ES</given-names></string-name>, <string-name><surname>Shimizu</surname><given-names>W</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>DR</given-names></string-name>, <string-name><surname>Benhorin</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical aspects of type 3 long-QT syndrome: an International Multicenter Study</article-title>. <source>Circulation</source><year>2016</year>;<volume>134</volume>:<fpage>872</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">27566755</pub-id></mixed-citation></ref><ref id="euac030-B123"><label>123</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>YK</given-names>
</string-name>, <string-name><surname>Sala</surname><given-names>L</given-names></string-name>, <string-name><surname>Mura</surname><given-names>M</given-names></string-name>, <string-name><surname>Rocchetti</surname><given-names>M</given-names></string-name>, <string-name><surname>Pedrazzini</surname><given-names>M</given-names></string-name>, <string-name><surname>Ran</surname><given-names>X</given-names></string-name><etal>et al</etal></person-group>
<article-title>MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes</article-title>. <source>Cardiovasc Res</source><year>2021</year>;<volume>117</volume>:<fpage>767</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">32173736</pub-id></mixed-citation></ref><ref id="euac030-B124"><label>124</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vincent</surname>
<given-names>GM</given-names>
</string-name>, <string-name><surname>Schwartz</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Denjoy</surname><given-names>I</given-names></string-name>, <string-name><surname>Swan</surname><given-names>H</given-names></string-name>, <string-name><surname>Bithell</surname><given-names>C</given-names></string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment &#x0201c;failures&#x0201d;</article-title>. <source>Circulation</source><year>2009</year>;<volume>119</volume>:<fpage>215</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">19118258</pub-id></mixed-citation></ref><ref id="euac030-B125"><label>125</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Barsheshet</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Goldenberg</surname><given-names>I</given-names></string-name>, <string-name><surname>O-Uchi</surname><given-names>J</given-names></string-name>, <string-name><surname>Moss</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Jons</surname><given-names>C</given-names></string-name>, <string-name><surname>Shimizu</surname><given-names>W</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome</article-title>. <source>Circulation</source><year>2012</year>;<volume>125</volume>:<fpage>1988</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">22456477</pub-id></mixed-citation></ref><ref id="euac030-B126"><label>126</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Priori</surname><given-names>SG</given-names></string-name>, <string-name><surname>Cerrone</surname><given-names>M</given-names></string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name>, <string-name><surname>Odero</surname><given-names>A</given-names></string-name>, <string-name><surname>Napolitano</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome</article-title>. <source>Circulation</source><year>2004</year>;<volume>109</volume>:<fpage>1826</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">15051644</pub-id></mixed-citation></ref><ref id="euac030-B127"><label>127</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dusi</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Pugliese</surname><given-names>L</given-names></string-name>, <string-name><surname>De Ferrari</surname><given-names>GM</given-names></string-name>, <string-name><surname>Odero</surname><given-names>A</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Dagradi</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group>
<article-title>Left cardiac sympathetic denervation for long QT syndrome: 50 years&#x02019; experience provides guidance for management</article-title>. <source>JACC Clin Electrophysiol</source><year>2021</year>;<pub-id pub-id-type="doi">10.1016/j.jacep.2021.09.002</pub-id>.</mixed-citation></ref><ref id="euac030-B128"><label>128</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Etheridge</surname>
<given-names>SP</given-names>
</string-name>, <string-name><surname>Compton</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Tristani-Firouzi</surname><given-names>M</given-names></string-name>, <string-name><surname>Mason</surname><given-names>JW.</given-names></string-name></person-group>
<article-title>A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations</article-title>. <source>J Am Coll Cardiol</source><year>2003</year>;<volume>42</volume>:<fpage>1777</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">14642687</pub-id></mixed-citation></ref><ref id="euac030-B129"><label>129</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Priori</surname><given-names>SG</given-names></string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name>, <string-name><surname>Moss</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Vincent</surname><given-names>GM</given-names></string-name>, <string-name><surname>Napolitano</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias</article-title>. <source>Circulation</source><year>2001</year>;<volume>103</volume>:<fpage>89</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">11136691</pub-id></mixed-citation></ref><ref id="euac030-B130"><label>130</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</string-name>, <string-name><surname>Jongbloed</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Doevendans</surname><given-names>PA</given-names></string-name>, <string-name><surname>D&#x000fc;ren</surname><given-names>DR</given-names></string-name>, <string-name><surname>Hauer</surname><given-names>RN</given-names></string-name>, <string-name><surname>van Langen</surname><given-names>IM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1)</article-title>. <source>J Am Coll Cardiol</source><year>1999</year>;<volume>33</volume>:<fpage>327</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">9973011</pub-id></mixed-citation></ref><ref id="euac030-B131"><label>131</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Khositseth</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Will</surname><given-names>ML</given-names></string-name>, <string-name><surname>Bell</surname><given-names>CM</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome</article-title>. <source>Heart Rhythm</source><year>2004</year>;<volume>1</volume>:<fpage>60</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">15851119</pub-id></mixed-citation></ref><ref id="euac030-B132"><label>132</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Priori</surname><given-names>SG</given-names></string-name>, <string-name><surname>Locati</surname><given-names>EH</given-names></string-name>, <string-name><surname>Napolitano</surname><given-names>C</given-names></string-name>, <string-name><surname>Cantu</surname><given-names>F</given-names></string-name>, <string-name><surname>Towbin</surname><given-names>JA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Long QT syndrome patients with mutations of the <italic toggle="yes">SCN5A</italic> and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy</article-title>. <source>Circulation</source><year>1995</year>;<volume>92</volume>:<fpage>3381</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">8521555</pub-id></mixed-citation></ref><ref id="euac030-B133"><label>133</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mazzanti</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Maragna</surname><given-names>R</given-names></string-name>, <string-name><surname>Faragli</surname><given-names>A</given-names></string-name>, <string-name><surname>Monteforte</surname><given-names>N</given-names></string-name>, <string-name><surname>Bloise</surname><given-names>R</given-names></string-name>, <string-name><surname>Memmi</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3</article-title>. <source>J Am Coll Cardiol</source><year>2016</year>;<volume>67</volume>:<fpage>1053</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26940925</pub-id></mixed-citation></ref><ref id="euac030-B134"><label>134</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Funasako</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Aiba</surname><given-names>T</given-names></string-name>, <string-name><surname>Ishibashi</surname><given-names>K</given-names></string-name>, <string-name><surname>Nakajima</surname><given-names>I</given-names></string-name>, <string-name><surname>Miyamoto</surname><given-names>K</given-names></string-name>, <string-name><surname>Inoue</surname><given-names>Y</given-names></string-name><etal>et al</etal></person-group>
<article-title>Pronounced shortening of QT interval with mexiletine infusion test in patients with type 3 congenital long QT syndrome</article-title>. <source>Circ J</source><year>2016</year>;<volume>80</volume>:<fpage>340</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">26632536</pub-id></mixed-citation></ref><ref id="euac030-B135"><label>135</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bos</surname>
<given-names>JM</given-names>
</string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Rohatgi</surname><given-names>RK</given-names></string-name>, <string-name><surname>Castelletti</surname><given-names>S</given-names></string-name>, <string-name><surname>Dagradi</surname><given-names>F</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>PJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2019</year>;<volume>12</volume>:<fpage>e007280</fpage>.<pub-id pub-id-type="pmid">31006312</pub-id></mixed-citation></ref><ref id="euac030-B136"><label>136</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mehta</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Ramachandra</surname><given-names>CJA</given-names></string-name>, <string-name><surname>Singh</surname><given-names>P</given-names></string-name>, <string-name><surname>Chitre</surname><given-names>A</given-names></string-name>, <string-name><surname>Lua</surname><given-names>CH</given-names></string-name>, <string-name><surname>Mura</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model</article-title>. <source>Eur Heart J</source><year>2018</year>;<volume>39</volume>:<fpage>1446</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">29020304</pub-id></mixed-citation></ref><ref id="euac030-B137"><label>137</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Gnecchi</surname><given-names>M</given-names></string-name>, <string-name><surname>Dagradi</surname><given-names>F</given-names></string-name>, <string-name><surname>Castelletti</surname><given-names>S</given-names></string-name>, <string-name><surname>Parati</surname><given-names>G</given-names></string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2</article-title>. <source>Eur Heart J</source><year>2019</year>;<volume>40</volume>:<fpage>1832</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">30753398</pub-id></mixed-citation></ref><ref id="euac030-B138"><label>138</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Woosley</surname><given-names>RL.</given-names></string-name></person-group>
<article-title>Predicting the unpredictable: drug-induced QT prolongation and Torsades de Pointes</article-title>. <source>J Am Coll Cardiol</source><year>2016</year>;<volume>67</volume>:<fpage>1639</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">27150690</pub-id></mixed-citation></ref><ref id="euac030-B139"><label>139</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>K&#x000e4;&#x000e4;b</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Crawford</surname><given-names>DC</given-names></string-name>, <string-name><surname>Sinner</surname><given-names>MF</given-names></string-name>, <string-name><surname>Behr</surname><given-names>ER</given-names></string-name>, <string-name><surname>Kannankeril</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Wilde</surname><given-names>AA</given-names></string-name><etal>et al</etal></person-group>
<article-title>A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes</article-title>. <source>Circ Cardiovasc Genet</source><year>2012</year>;<volume>5</volume>:<fpage>91</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22100668</pub-id></mixed-citation></ref><ref id="euac030-B140"><label>140</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Strauss</surname>
<given-names>DG</given-names>
</string-name>, <string-name><surname>Vicente</surname><given-names>J</given-names></string-name>, <string-name><surname>Johannesen</surname><given-names>L</given-names></string-name>, <string-name><surname>Blinova</surname><given-names>K</given-names></string-name>, <string-name><surname>Mason</surname><given-names>JW</given-names></string-name>, <string-name><surname>Weeke</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Common genetic variant risk score is associated with drug-induced QT prolongation and Torsade de Pointes risk: a pilot study</article-title>. <source>Circulation</source><year>2017</year>;<volume>135</volume>:<fpage>1300</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">28213480</pub-id></mixed-citation></ref><ref id="euac030-B141"><label>141</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lahat</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Pras</surname><given-names>E</given-names></string-name>, <string-name><surname>Eldar</surname><given-names>M.</given-names></string-name></person-group>
<article-title>A missense mutation in CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel</article-title>. <source>Ann Med</source><year>2004</year>;<volume>36</volume>(Suppl 1):<fpage>87</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">15176429</pub-id></mixed-citation></ref><ref id="euac030-B142"><label>142</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roux-Buisson</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Cacheux</surname><given-names>M</given-names></string-name>, <string-name><surname>Fourest-Lieuvin</surname><given-names>A</given-names></string-name>, <string-name><surname>Fauconnier</surname><given-names>J</given-names></string-name>, <string-name><surname>Brocard</surname><given-names>J</given-names></string-name>, <string-name><surname>Denjoy</surname><given-names>I</given-names></string-name><etal>et al</etal></person-group>
<article-title>Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human</article-title>. <source>Hum Mol Genet</source><year>2012</year>;<volume>21</volume>:<fpage>2759</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">22422768</pub-id></mixed-citation></ref><ref id="euac030-B143"><label>143</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Devalla</surname>
<given-names>HD</given-names>
</string-name>, <string-name><surname>G&#x000e9;linas</surname><given-names>R</given-names></string-name>, <string-name><surname>Aburawi</surname><given-names>EH</given-names></string-name>, <string-name><surname>Beqqali</surname><given-names>A</given-names></string-name>, <string-name><surname>Goyette</surname><given-names>P</given-names></string-name>, <string-name><surname>Freund</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT</article-title>. <source>EMBO Mol Med</source><year>2016</year>;<volume>8</volume>:<fpage>1390</fpage>&#x02013;<lpage>408</lpage>.<pub-id pub-id-type="pmid">27861123</pub-id></mixed-citation></ref><ref id="euac030-B144"><label>144</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Webster</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Aburawi</surname><given-names>EH</given-names></string-name>, <string-name><surname>Chaix</surname><given-names>MA</given-names></string-name>, <string-name><surname>Chandler</surname><given-names>S</given-names></string-name>, <string-name><surname>Foo</surname><given-names>R</given-names></string-name>, <string-name><surname>Islam</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>Life-threatening arrhythmias with autosomal recessive TECRL variants</article-title>. <source>Europace</source><year>2021</year>;<volume>23</volume>:<fpage>781</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">33367594</pub-id></mixed-citation></ref><ref id="euac030-B145"><label>145</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Medeiros-Domingo</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Bhuiyan</surname><given-names>ZA</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Hofman</surname><given-names>N</given-names></string-name>, <string-name><surname>Bikker</surname><given-names>H</given-names></string-name>, <string-name><surname>van Tintelen</surname><given-names>JP</given-names></string-name><etal>et al</etal></person-group>
<article-title>The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis</article-title>. <source>J Am Coll Cardiol</source><year>2009</year>;<volume>54</volume>:<fpage>2065</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">19926015</pub-id></mixed-citation></ref><ref id="euac030-B146"><label>146</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Laurent</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Saal</surname><given-names>S</given-names></string-name>, <string-name><surname>Amarouch</surname><given-names>MY</given-names></string-name>, <string-name><surname>B&#x000e9;ziau</surname><given-names>DM</given-names></string-name>, <string-name><surname>Marsman</surname><given-names>RF</given-names></string-name>, <string-name><surname>Faivre</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Multifocal ectopic Purkinje-related premature contractions: a new <italic toggle="yes">SCN5A</italic>-related cardiac channelopathy</article-title>. <source>J Am Coll Cardiol</source><year>2012</year>;<volume>60</volume>:<fpage>144</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">22766342</pub-id></mixed-citation></ref><ref id="euac030-B147"><label>147</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Swan</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Amarouch</surname><given-names>MY</given-names></string-name>, <string-name><surname>Leinonen</surname><given-names>J</given-names></string-name>, <string-name><surname>Marjamaa</surname><given-names>A</given-names></string-name>, <string-name><surname>Kucera</surname><given-names>JP</given-names></string-name>, <string-name><surname>Laitinen-Forsblom</surname><given-names>PJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Gain-of-function mutation of the <italic toggle="yes">SCN5A</italic> gene causes exercise-induced polymorphic ventricular arrhythmias</article-title>. <source>Circ Cardiovasc Genet</source><year>2014</year>;<volume>7</volume>:<fpage>771</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">25210054</pub-id></mixed-citation></ref><ref id="euac030-B148"><label>148</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tester</surname>
<given-names>DJ</given-names>
</string-name>, <string-name><surname>Ackerman</surname><given-names>JP</given-names></string-name>, <string-name><surname>Giudicessi</surname><given-names>JR</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>NC</given-names></string-name>, <string-name><surname>Cerrone</surname><given-names>M</given-names></string-name>, <string-name><surname>Delmar</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Plakophilin-2 truncation variants in patients clinically diagnosed with catecholaminergic polymorphic ventricular tachycardia and decedents with exercise-associated autopsy negative sudden unexplained death in&#x000a0;the young</article-title>. <source>JACC Clin Electrophysiol</source><year>2019</year>;<volume>5</volume>:<fpage>120</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">30678776</pub-id></mixed-citation></ref><ref id="euac030-B149"><label>149</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hayashi</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Denjoy</surname><given-names>I</given-names></string-name>, <string-name><surname>Extramiana</surname><given-names>F</given-names></string-name>, <string-name><surname>Maltret</surname><given-names>A</given-names></string-name>, <string-name><surname>Buisson</surname><given-names>NR</given-names></string-name>, <string-name><surname>Lupoglazoff</surname><given-names>J-M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>Circulation</source><year>2009</year>;<volume>119</volume>:<fpage>2426</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">19398665</pub-id></mixed-citation></ref><ref id="euac030-B150"><label>150</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van der Werf</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Nederend</surname><given-names>I</given-names></string-name>, <string-name><surname>Hofman</surname><given-names>N</given-names></string-name>, <string-name><surname>van Geloven</surname><given-names>N</given-names></string-name>, <string-name><surname>Ebink</surname><given-names>C</given-names></string-name>, <string-name><surname>Frohn-Mulder</surname><given-names>IM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2012</year>;<volume>5</volume>:<fpage>748</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">22787013</pub-id></mixed-citation></ref><ref id="euac030-B151"><label>151</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Giudicessi</surname>
<given-names>JR</given-names>
</string-name>, <string-name><surname>Lieve</surname><given-names>KVV</given-names></string-name>, <string-name><surname>Rohatgi</surname><given-names>RK</given-names></string-name>, <string-name><surname>Koca</surname><given-names>F</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>van der Werf</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Assessment and validation of a phenotype-enhanced variant classification framework to promote or demote RYR2 missense variants of uncertain significance</article-title>. <source>Circ Genom Precis Med</source><year>2019</year>;<volume>12</volume>:<fpage>e002510</fpage>.<pub-id pub-id-type="pmid">31112425</pub-id></mixed-citation></ref><ref id="euac030-B152"><label>152</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Coumel</surname>
<given-names>P.</given-names>
</string-name>
</person-group>
<article-title>Catecholaminergic-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases</article-title>. <source>Br Heart J</source><year>1978</year>;<volume>40</volume>:<fpage>28</fpage>&#x02013;<lpage>37</lpage>.</mixed-citation></ref><ref id="euac030-B153"><label>153</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leenhardt</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Lucet</surname><given-names>V</given-names></string-name>, <string-name><surname>Denjoy</surname><given-names>I</given-names></string-name>, <string-name><surname>Grau</surname><given-names>F</given-names></string-name>, <string-name><surname>Ngoc</surname><given-names>DD</given-names></string-name>, <string-name><surname>Coumel</surname><given-names>P.</given-names></string-name></person-group>
<article-title>Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients</article-title>. <source>Circulation</source><year>1995</year>;<volume>91</volume>:<fpage>1512</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">7867192</pub-id></mixed-citation></ref><ref id="euac030-B154"><label>154</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tester</surname>
<given-names>DJ</given-names>
</string-name>, <string-name><surname>Spoon</surname><given-names>DB</given-names></string-name>, <string-name><surname>Valdivia</surname><given-names>HH</given-names></string-name>, <string-name><surname>Makielski</surname><given-names>JC</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases</article-title>. <source>Mayo Clin Proc</source><year>2004</year>;<volume>79</volume>:<fpage>1380</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">15544015</pub-id></mixed-citation></ref><ref id="euac030-B155"><label>155</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Krahn</surname>
<given-names>AD</given-names>
</string-name>, <string-name><surname>Healey</surname><given-names>JS</given-names></string-name>, <string-name><surname>Simpson</surname><given-names>CS</given-names></string-name>, <string-name><surname>Chauhan</surname><given-names>VS</given-names></string-name>, <string-name><surname>Birnie</surname><given-names>DH</given-names></string-name>, <string-name><surname>Champagne</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Sentinel symptoms in patients with unexplained cardiac arrest: from the cardiac arrest survivors with preserved ejection fraction registry (CASPER)</article-title>. <source>J Cardiovasc Electrophysiol</source><year>2012</year>;<volume>23</volume>:<fpage>60</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">21955300</pub-id></mixed-citation></ref><ref id="euac030-B156"><label>156</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rucinski</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Winbo</surname><given-names>A</given-names></string-name>, <string-name><surname>Marcondes</surname><given-names>L</given-names></string-name>, <string-name><surname>Earle</surname><given-names>N</given-names></string-name>, <string-name><surname>Stiles</surname><given-names>M</given-names></string-name>, <string-name><surname>Stiles</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>A population-based registry of patients with inherited cardiac conditions and resuscitated cardiac arrest</article-title>. <source>J Am Coll Cardiol</source><year>2020</year>;<volume>75</volume>:<fpage>2698</fpage>&#x02013;<lpage>707</lpage>.<pub-id pub-id-type="pmid">32466885</pub-id></mixed-citation></ref><ref id="euac030-B157"><label>157</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leinonen</surname>
<given-names>JT</given-names>
</string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Djupsj&#x000f6;backa</surname><given-names>A</given-names></string-name>, <string-name><surname>Castelletti</surname><given-names>S</given-names></string-name>, <string-name><surname>Junna</surname><given-names>N</given-names></string-name>, <string-name><surname>Ghidoni</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>The genetics underlying idiopathic ventricular fibrillation: a special role for catecholaminergic polymorphic ventricular tachycardia?</article-title>
<source>Int J Cardiol</source>
<year>2018</year>;<volume>250</volume>:<fpage>139</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">29032884</pub-id></mixed-citation></ref><ref id="euac030-B158"><label>158</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tester</surname>
<given-names>DJ</given-names>
</string-name>, <string-name><surname>Dura</surname><given-names>M</given-names></string-name>, <string-name><surname>Carturan</surname><given-names>E</given-names></string-name>, <string-name><surname>Reiken</surname><given-names>S</given-names></string-name>, <string-name><surname>Wronska</surname><given-names>A</given-names></string-name>, <string-name><surname>Marks</surname><given-names>AR</given-names></string-name><etal>et al</etal></person-group>
<article-title>A mechanism for sudden infant death syndrome (SIDS): stress-induced leak via ryanodine receptors</article-title>. <source>Heart Rhythm</source><year>2007</year>;<volume>4</volume>:<fpage>733</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17556193</pub-id></mixed-citation></ref><ref id="euac030-B159"><label>159</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Priori</surname>
<given-names>SG</given-names>
</string-name>, <string-name><surname>Napolitano</surname><given-names>C</given-names></string-name>, <string-name><surname>Tiso</surname><given-names>N</given-names></string-name>, <string-name><surname>Memmi</surname><given-names>M</given-names></string-name>, <string-name><surname>Vignati</surname><given-names>G</given-names></string-name>, <string-name><surname>Bloise</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>Circulation</source><year>2001</year>;<volume>103</volume>:<fpage>196</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">11208676</pub-id></mixed-citation></ref><ref id="euac030-B160"><label>160</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Laitinen</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Brown</surname><given-names>KM</given-names></string-name>, <string-name><surname>Piippo</surname><given-names>K</given-names></string-name>, <string-name><surname>Swan</surname><given-names>H</given-names></string-name>, <string-name><surname>Devaney</surname><given-names>JM</given-names></string-name>, <string-name><surname>Brahmbhatt</surname><given-names>B</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia</article-title>. <source>Circulation</source><year>2001</year>;<volume>103</volume>:<fpage>485</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">11157710</pub-id></mixed-citation></ref><ref id="euac030-B161"><label>161</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sun</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name><surname>Ni</surname><given-names>M</given-names></string-name>, <string-name><surname>Wei</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhong</surname><given-names>X</given-names></string-name>, <string-name><surname>Guo</surname><given-names>W</given-names></string-name><etal>et al</etal></person-group>
<article-title>Cardiac ryanodine receptor calcium release deficiency syndrome</article-title>. <source>Sci Transl Med</source><year>2021</year>;<volume>13</volume>:<fpage>eaba7287</fpage>.<pub-id pub-id-type="pmid">33536282</pub-id></mixed-citation></ref><ref id="euac030-B162"><label>162</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roston</surname>
<given-names>TM</given-names>
</string-name>, <string-name><surname>Wei</surname><given-names>J</given-names></string-name>, <string-name><surname>Guo</surname><given-names>W</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhong</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical and functional characterization of ryanodine receptor 2 variants implicated in calcium-release deficiency syndrome</article-title>. <source>JAMA Cardiol</source><year>2022</year>;<volume>7</volume>:<fpage>84</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">34730774</pub-id></mixed-citation></ref><ref id="euac030-B163"><label>163</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tester</surname>
<given-names>DJ</given-names>
</string-name>, <string-name><surname>Arya</surname><given-names>P</given-names></string-name>, <string-name><surname>Will</surname><given-names>M</given-names></string-name>, <string-name><surname>Haglund</surname><given-names>CM</given-names></string-name>, <string-name><surname>Farley</surname><given-names>AL</given-names></string-name>, <string-name><surname>Makielski</surname><given-names>JC</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing</article-title>. <source>Heart Rhythm</source><year>2006</year>;<volume>3</volume>:<fpage>800</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">16818210</pub-id></mixed-citation></ref><ref id="euac030-B164"><label>164</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kapplinger</surname>
<given-names>JD</given-names>
</string-name>, <string-name><surname>Pundi</surname><given-names>KN</given-names></string-name>, <string-name><surname>Larson</surname><given-names>NB</given-names></string-name>, <string-name><surname>Callis</surname><given-names>TE</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Bikker</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>Yield of the RYR2 genetic test in suspected catecholaminergic polymorphic ventricular tachycardia and implications for test interpretation</article-title>. <source>Circ Genom Precis Med</source><year>2018</year>;<volume>11</volume>:<fpage>e001424</fpage>.<pub-id pub-id-type="pmid">29453246</pub-id></mixed-citation></ref><ref id="euac030-B165"><label>165</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gray</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Bagnall</surname><given-names>RD</given-names></string-name>, <string-name><surname>Lam</surname><given-names>L</given-names></string-name>, <string-name><surname>Ingles</surname><given-names>J</given-names></string-name>, <string-name><surname>Turner</surname><given-names>C</given-names></string-name>, <string-name><surname>Haan</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>Heart Rhythm</source><year>2016</year>;<volume>13</volume>:<fpage>1652</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">27157848</pub-id></mixed-citation></ref><ref id="euac030-B166"><label>166</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ng</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Titus</surname><given-names>EW</given-names></string-name>, <string-name><surname>Lieve</surname><given-names>KV</given-names></string-name>, <string-name><surname>Roston</surname><given-names>TM</given-names></string-name>, <string-name><surname>Mazzanti</surname><given-names>A</given-names></string-name>, <string-name><surname>Deiter</surname><given-names>FH</given-names></string-name><etal>et al</etal></person-group>
<article-title>An international multicenter evaluation of inheritance patterns, arrhythmic risks, and underlying mechanisms of CASQ2-catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>Circulation</source><year>2020</year>;<volume>142</volume>:<fpage>932</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">32693635</pub-id></mixed-citation></ref><ref id="euac030-B167"><label>167</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van der Werf</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Zwinderman</surname><given-names>AH</given-names></string-name>, <string-name><surname>Wilde</surname><given-names>AA.</given-names></string-name></person-group>
<article-title>Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments</article-title>. <source>Europace</source><year>2012</year>;<volume>14</volume>:<fpage>175</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">21893508</pub-id></mixed-citation></ref><ref id="euac030-B168"><label>168</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kannankeril</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Moore</surname><given-names>JP</given-names></string-name>, <string-name><surname>Cerrone</surname><given-names>M</given-names></string-name>, <string-name><surname>Priori</surname><given-names>SG</given-names></string-name>, <string-name><surname>Kertesz</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Ro</surname><given-names>PS</given-names></string-name><etal>et al</etal></person-group>
<article-title>Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial</article-title>. <source>JAMA Cardiol</source><year>2017</year>;<volume>2</volume>:<fpage>759</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">28492868</pub-id></mixed-citation></ref><ref id="euac030-B169"><label>169</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>De Ferrari</surname>
<given-names>GM</given-names>
</string-name>, <string-name><surname>Dusi</surname><given-names>V</given-names></string-name>, <string-name><surname>Spazzolini</surname><given-names>C</given-names></string-name>, <string-name><surname>Bos</surname><given-names>JM</given-names></string-name>, <string-name><surname>Abrams</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Berul</surname><given-names>CI</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation</article-title>. <source>Circulation</source><year>2015</year>;<volume>131</volume>:<fpage>2185</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">26019152</pub-id></mixed-citation></ref><ref id="euac030-B170"><label>170</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van der Werf</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Lieve</surname><given-names>KV</given-names></string-name>, <string-name><surname>Bos</surname><given-names>JM</given-names></string-name>, <string-name><surname>Lane</surname><given-names>CM</given-names></string-name>, <string-name><surname>Denjoy</surname><given-names>I</given-names></string-name>, <string-name><surname>Roses-Noguer</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group>
<article-title>Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest</article-title>. <source>Eur Heart J</source><year>2019</year>;<volume>40</volume>:<fpage>2953</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">31145795</pub-id></mixed-citation></ref><ref id="euac030-B171"><label>171</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yang</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Hu</surname><given-names>D</given-names></string-name>, <string-name><surname>Sacher</surname><given-names>F</given-names></string-name>, <string-name><surname>Kusano</surname><given-names>KF</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name>, <string-name><surname>Barajas-Martinez</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>Meta-analysis of risk stratification of <italic toggle="yes">SCN5A</italic> with Brugada syndrome: is <italic toggle="yes">SCN5A</italic> always a marker of low risk?</article-title>
<source>Front Physiol</source>
<year>2019</year>;<volume>10</volume>:<fpage>103</fpage>.<pub-id pub-id-type="pmid">30837887</pub-id></mixed-citation></ref><ref id="euac030-B172"><label>172</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walsh</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Lahrouchi</surname><given-names>N</given-names></string-name>, <string-name><surname>Tadros</surname><given-names>R</given-names></string-name>, <string-name><surname>Kyndt</surname><given-names>F</given-names></string-name>, <string-name><surname>Glinge</surname><given-names>C</given-names></string-name>, <string-name><surname>Postema</surname><given-names>PG</given-names></string-name><etal>et al</etal></person-group>
<article-title>Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls</article-title>. <source>Genet Med</source><year>2021</year>;<volume>23</volume>:<fpage>47</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">32893267</pub-id></mixed-citation></ref><ref id="euac030-B173"><label>173</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Postema</surname>
<given-names>PG.</given-names>
</string-name>
</person-group>
<article-title>About Brugada syndrome and its prevalence</article-title>. <source>Europace</source><year>2012</year>;<volume>14</volume>:<fpage>925</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22417721</pub-id></mixed-citation></ref><ref id="euac030-B174"><label>174</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Milman</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Andorin</surname><given-names>A</given-names></string-name>, <string-name><surname>Gourraud</surname><given-names>JB</given-names></string-name>, <string-name><surname>Postema</surname><given-names>PG</given-names></string-name>, <string-name><surname>Sacher</surname><given-names>F</given-names></string-name>, <string-name><surname>Mabo</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS)</article-title>. <source>Heart Rhythm</source><year>2018</year>;<volume>15</volume>:<fpage>716</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">29325976</pub-id></mixed-citation></ref><ref id="euac030-B175"><label>175</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kim</surname>
<given-names>YG</given-names>
</string-name>, <string-name><surname>Oh</surname><given-names>SK</given-names></string-name>, <string-name><surname>Choi</surname><given-names>HY</given-names></string-name>, <string-name><surname>Choi</surname><given-names>JI.</given-names></string-name></person-group>
<article-title>Inherited arrhythmia syndrome predisposing to sudden cardiac death</article-title>. <source>Korean J Intern Med</source><year>2021</year>;<volume>36</volume>:<fpage>527</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">33092314</pub-id></mixed-citation></ref><ref id="euac030-B176"><label>176</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Papadakis</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Papatheodorou</surname><given-names>E</given-names></string-name>, <string-name><surname>Mellor</surname><given-names>G</given-names></string-name>, <string-name><surname>Raju</surname><given-names>H</given-names></string-name>, <string-name><surname>Bastiaenen</surname><given-names>R</given-names></string-name>, <string-name><surname>Wijeyeratne</surname><given-names>Y</given-names></string-name><etal>et al</etal></person-group>
<article-title>The diagnostic yield of Brugada syndrome after sudden death with normal autopsy</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>;<volume>71</volume>:<fpage>1204</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">29544603</pub-id></mixed-citation></ref><ref id="euac030-B177"><label>177</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tadros</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Nannenberg</surname><given-names>EA</given-names></string-name>, <string-name><surname>Lieve</surname><given-names>KV</given-names></string-name>, <string-name><surname>Skoric-Milosavljevic</surname><given-names>D</given-names></string-name>, <string-name><surname>Lahrouchi</surname><given-names>N</given-names></string-name>, <string-name><surname>Lekanne Deprez</surname><given-names>RH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Yield and pitfalls of ajmaline testing in the evaluation of unexplained cardiac arrest and sudden unexplained death: single-center experience with 482 families</article-title>. <source>JACC Clin Electrophysiol</source><year>2017</year>;<volume>3</volume>:<fpage>1400</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">29759671</pub-id></mixed-citation></ref><ref id="euac030-B178"><label>178</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shimizu</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Matsuo</surname><given-names>K</given-names></string-name>, <string-name><surname>Takagi</surname><given-names>M</given-names></string-name>, <string-name><surname>Tanabe</surname><given-names>Y</given-names></string-name>, <string-name><surname>Aiba</surname><given-names>T</given-names></string-name>, <string-name><surname>Taguchi</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms</article-title>. <source>J Cardiovasc Electrophysiol</source><year>2000</year>;<volume>11</volume>:<fpage>396</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">10809492</pub-id></mixed-citation></ref><ref id="euac030-B179"><label>179</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Viskin</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Rosso</surname><given-names>R</given-names></string-name>, <string-name><surname>Friedensohn</surname><given-names>L</given-names></string-name>, <string-name><surname>Havakuk</surname><given-names>O</given-names></string-name>, <string-name><surname>Wilde</surname><given-names>AA.</given-names></string-name></person-group>
<article-title>Everybody has Brugada syndrome until proven otherwise?</article-title>
<source>Heart Rhythm</source>
<year>2015</year>;<volume>12</volume>:<fpage>1595</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25998201</pub-id></mixed-citation></ref><ref id="euac030-B180"><label>180</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Antzelevitch</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Yan</surname><given-names>GX</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Borggrefe</surname><given-names>M</given-names></string-name>, <string-name><surname>Corrado</surname><given-names>D</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>J-Wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge</article-title>. <source>Europace</source><year>2017</year>;<volume>19</volume>:<fpage>665</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">28431071</pub-id></mixed-citation></ref><ref id="euac030-B181"><label>181</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Baranchuk</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Nguyen</surname><given-names>T</given-names></string-name>, <string-name><surname>Ryu</surname><given-names>MH</given-names></string-name>, <string-name><surname>Femenia</surname><given-names>F</given-names></string-name>, <string-name><surname>Zareba</surname><given-names>W</given-names></string-name>, <string-name><surname>Wilde</surname><given-names>AA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Brugada phenocopy: new terminology and proposed classification</article-title>. <source>Ann Noninvasive Electrocardiol</source><year>2012</year>;<volume>17</volume>:<fpage>299</fpage>&#x02013;<lpage>314</lpage>.<pub-id pub-id-type="pmid">23094876</pub-id></mixed-citation></ref><ref id="euac030-B182"><label>182</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Probst</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Veltmann</surname><given-names>C</given-names></string-name>, <string-name><surname>Eckardt</surname><given-names>L</given-names></string-name>, <string-name><surname>Meregalli</surname><given-names>PG</given-names></string-name>, <string-name><surname>Gaita</surname><given-names>F</given-names></string-name>, <string-name><surname>Tan</surname><given-names>HL</given-names></string-name><etal>et al</etal></person-group>
<article-title>Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry</article-title>. <source>Circulation</source><year>2010</year>;<volume>121</volume>:<fpage>635</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">20100972</pub-id></mixed-citation></ref><ref id="euac030-B183"><label>183</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lahrouchi</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Talajic</surname><given-names>M</given-names></string-name>, <string-name><surname>Tadros</surname><given-names>R.</given-names></string-name></person-group>
<article-title>Risk of arrhythmic events in drug-induced Brugada syndrome</article-title>. <source>Heart Rhythm</source><year>2017</year>;<volume>14</volume>:<fpage>1434</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">28666943</pub-id></mixed-citation></ref><ref id="euac030-B184"><label>184</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Postema</surname>
<given-names>PG</given-names>
</string-name>, <string-name><surname>Wolpert</surname><given-names>C</given-names></string-name>, <string-name><surname>Amin</surname><given-names>AS</given-names></string-name>, <string-name><surname>Probst</surname><given-names>V</given-names></string-name>, <string-name><surname>Borggrefe</surname><given-names>M</given-names></string-name>, <string-name><surname>Roden</surname><given-names>DM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (<ext-link xlink:href="http://www.brugadadrugs.org" ext-link-type="uri">www.brugadadrugs.org</ext-link>)</article-title>. <source>Heart Rhythm</source><year>2009</year>;<volume>6</volume>:<fpage>1335</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">19716089</pub-id></mixed-citation></ref><ref id="euac030-B185"><label>185</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Probst</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Wilde</surname><given-names>AA</given-names></string-name>, <string-name><surname>Barc</surname><given-names>J</given-names></string-name>, <string-name><surname>Sacher</surname><given-names>F</given-names></string-name>, <string-name><surname>Babuty</surname><given-names>D</given-names></string-name>, <string-name><surname>Mabo</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>
<italic toggle="yes">SCN5A</italic> mutations and the role of genetic background in the pathophysiology of Brugada syndrome</article-title>. <source>Circ Cardiovasc Genet</source><year>2009</year>;<volume>2</volume>:<fpage>552</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">20031634</pub-id></mixed-citation></ref><ref id="euac030-B186"><label>186</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Peltenburg</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Blom</surname><given-names>NA</given-names></string-name>, <string-name><surname>Vink</surname><given-names>AS</given-names></string-name>, <string-name><surname>Kammeraad</surname><given-names>JAE</given-names></string-name>, <string-name><surname>Breur</surname><given-names>H</given-names></string-name>, <string-name><surname>Rammeloo</surname><given-names>LAJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>In children and adolescents from Brugada syndrome-families, only <italic toggle="yes">SCN5A</italic> mutation carriers develop a type-1 ECG pattern induced by fever</article-title>. <source>Circulation</source><year>2020</year>;<volume>142</volume>:<fpage>89</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">32628552</pub-id></mixed-citation></ref><ref id="euac030-B187"><label>187</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bezzina</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Veldkamp</surname><given-names>MW</given-names></string-name>, <string-name><surname>van Den Berg</surname><given-names>MP</given-names></string-name>, <string-name><surname>Postma</surname><given-names>AV</given-names></string-name>, <string-name><surname>Rook</surname><given-names>MB</given-names></string-name>, <string-name><surname>Viersma</surname><given-names>JW</given-names></string-name><etal>et al</etal></person-group>
<article-title>A single Na(+) channel mutation causing both long-QT and Brugada syndromes</article-title>. <source>Circ Res</source><year>1999</year>;<volume>85</volume>:<fpage>1206</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">10590249</pub-id></mixed-citation></ref><ref id="euac030-B188"><label>188</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sacilotto</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Scanavacca</surname><given-names>MI</given-names></string-name>, <string-name><surname>Olivetti</surname><given-names>N</given-names></string-name>, <string-name><surname>Lemes</surname><given-names>C</given-names></string-name>, <string-name><surname>Pessente</surname><given-names>GD</given-names></string-name>, <string-name><surname>Wulkan</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group>
<article-title>Low rate of life-threatening events and limitations in predicting invasive and noninvasive markers of symptoms in a cohort of type 1 Brugada syndrome patients: data and insights from the GenBra registry</article-title>. <source>J Cardiovasc Electrophysiol</source><year>2020</year>;<volume>31</volume>:<fpage>2920</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32870538</pub-id></mixed-citation></ref><ref id="euac030-B189"><label>189</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yamagata</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Horie</surname><given-names>M</given-names></string-name>, <string-name><surname>Aiba</surname><given-names>T</given-names></string-name>, <string-name><surname>Ogawa</surname><given-names>S</given-names></string-name>, <string-name><surname>Aizawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ohe</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genotype-phenotype correlation of <italic toggle="yes">SCN5A</italic> mutation for the clinical and electrocardiographic characteristics of probands with brugada syndrome: a Japanese Multicenter Registry</article-title>. <source>Circulation</source><year>2017</year>;<volume>135</volume>:<fpage>2255</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">28341781</pub-id></mixed-citation></ref><ref id="euac030-B190"><label>190</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ciconte</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Monasky</surname><given-names>MM</given-names></string-name>, <string-name><surname>Santinelli</surname><given-names>V</given-names></string-name>, <string-name><surname>Micaglio</surname><given-names>E</given-names></string-name>, <string-name><surname>Vicedomini</surname><given-names>G</given-names></string-name>, <string-name><surname>Anastasia</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Brugada syndrome genetics is associated with phenotype severity</article-title>. <source>Eur Heart J</source><year>2021</year>;<volume>42</volume>:<fpage>1082</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">33221895</pub-id></mixed-citation></ref><ref id="euac030-B191"><label>191</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kusumoto</surname>
<given-names>FM</given-names>
</string-name>, <string-name><surname>Schoenfeld</surname><given-names>MH</given-names></string-name>, <string-name><surname>Barrett</surname><given-names>C</given-names></string-name>, <string-name><surname>Edgerton</surname><given-names>JR</given-names></string-name>, <string-name><surname>Ellenbogen</surname><given-names>KA</given-names></string-name>, <string-name><surname>Gold</surname><given-names>MR</given-names></string-name><etal>et al</etal></person-group>
<article-title>2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society</article-title>. <source>Circulation</source><year>2019</year>;<volume>140</volume>:<fpage>e333</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">30586771</pub-id></mixed-citation></ref><ref id="euac030-B192"><label>192</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Surawicz</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Childers</surname><given-names>R</given-names></string-name>, <string-name><surname>Deal</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Gettes</surname><given-names>LS</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Gorgels</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology</article-title>. <source>J Am Coll Cardiol</source><year>2009</year>;<volume>53</volume>:<fpage>976</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">19281930</pub-id></mixed-citation></ref><ref id="euac030-B193"><label>193</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Asatryan</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Medeiros-Domingo</surname><given-names>A.</given-names></string-name></person-group>
<article-title>Molecular and genetic insights into progressive cardiac conduction disease</article-title>. <source>Europace</source><year>2019</year>;<volume>21</volume>:<fpage>1145</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">31087102</pub-id></mixed-citation></ref><ref id="euac030-B194"><label>194</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Neu</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Eiselt</surname><given-names>M</given-names></string-name>, <string-name><surname>Paul</surname><given-names>M</given-names></string-name>, <string-name><surname>Sauter</surname><given-names>K</given-names></string-name>, <string-name><surname>Stallmeyer</surname><given-names>B</given-names></string-name>, <string-name><surname>Isbrandt</surname><given-names>D</given-names></string-name><etal>et al</etal></person-group>
<article-title>A homozygous <italic toggle="yes">SCN5A</italic> mutation in a severe, recessive type of cardiac conduction disease</article-title>. <source>Hum Mutat</source><year>2010</year>;<volume>31</volume>:<fpage>E1609</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">20564468</pub-id></mixed-citation></ref><ref id="euac030-B195"><label>195</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Benson</surname>
<given-names>DW</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>DW</given-names></string-name>, <string-name><surname>Dyment</surname><given-names>M</given-names></string-name>, <string-name><surname>Knilans</surname><given-names>TK</given-names></string-name>, <string-name><surname>Fish</surname><given-names>FA</given-names></string-name>, <string-name><surname>Strieper</surname><given-names>MJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (<italic toggle="yes">SCN5A</italic>)</article-title>. <source>J Clin Invest</source><year>2003</year>;<volume>112</volume>:<fpage>1019</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">14523039</pub-id></mixed-citation></ref><ref id="euac030-B196"><label>196</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kyndt</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Probst</surname><given-names>V</given-names></string-name>, <string-name><surname>Potet</surname><given-names>F</given-names></string-name>, <string-name><surname>Demolombe</surname><given-names>S</given-names></string-name>, <string-name><surname>Chevallier</surname><given-names>JC</given-names></string-name>, <string-name><surname>Baro</surname><given-names>I</given-names></string-name><etal>et al</etal></person-group>
<article-title>Novel <italic toggle="yes">SCN5A</italic> mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family</article-title>. <source>Circulation</source><year>2001</year>;<volume>104</volume>:<fpage>3081</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">11748104</pub-id></mixed-citation></ref><ref id="euac030-B197"><label>197</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fatkin</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>MacRae</surname><given-names>C</given-names></string-name>, <string-name><surname>Sasaki</surname><given-names>T</given-names></string-name>, <string-name><surname>Wolff</surname><given-names>MR</given-names></string-name>, <string-name><surname>Porcu</surname><given-names>M</given-names></string-name>, <string-name><surname>Frenneaux</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease</article-title>. <source>N Engl J Med</source><year>1999</year>;<volume>341</volume>:<fpage>1715</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">10580070</pub-id></mixed-citation></ref><ref id="euac030-B198"><label>198</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Birnie</surname>
<given-names>DH</given-names>
</string-name>, <string-name><surname>Sauer</surname><given-names>WH</given-names></string-name>, <string-name><surname>Bogun</surname><given-names>F</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>JM</given-names></string-name>, <string-name><surname>Culver</surname><given-names>DA</given-names></string-name>, <string-name><surname>Duvernoy</surname><given-names>CS</given-names></string-name><etal>et al</etal></person-group>
<article-title>HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis</article-title>. <source>Heart Rhythm</source><year>2014</year>;<volume>11</volume>:<fpage>1305</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">24819193</pub-id></mixed-citation></ref><ref id="euac030-B199"><label>199</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Akhtar</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Elliott</surname><given-names>PM.</given-names></string-name></person-group>
<article-title>Risk stratification for sudden cardiac death in non-ischaemic dilated cardiomyopathy</article-title>. <source>Curr Cardiol Rep</source><year>2019</year>;<volume>21</volume>:<fpage>155</fpage>.<pub-id pub-id-type="pmid">31768884</pub-id></mixed-citation></ref><ref id="euac030-B200"><label>200</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wahbi</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Ben Yaou</surname><given-names>R</given-names></string-name>, <string-name><surname>Gandjbakhch</surname><given-names>E</given-names></string-name>, <string-name><surname>Anselme</surname><given-names>F</given-names></string-name>, <string-name><surname>Gossios</surname><given-names>T</given-names></string-name>, <string-name><surname>Lakdawala</surname><given-names>NK</given-names></string-name><etal>et al</etal></person-group>
<article-title>Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies</article-title>. <source>Circulation</source><year>2019</year>;<volume>140</volume>:<fpage>293</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">31155932</pub-id></mixed-citation></ref><ref id="euac030-B201"><label>201</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Van Rijsingen</surname>
<given-names>IAW</given-names>
</string-name>, <string-name><surname>Arbustini</surname><given-names>E</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>PM</given-names></string-name>, <string-name><surname>Mogensen</surname><given-names>J</given-names></string-name>, <string-name><surname>Hermans-Van Ast</surname><given-names>JF</given-names></string-name>, <string-name><surname>Van Der Kooi</surname><given-names>AJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers a European cohort study</article-title>. <source>J Am Coll Cardiol</source><year>2012</year>;<volume>59</volume>:<fpage>493</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">22281253</pub-id></mixed-citation></ref><ref id="euac030-B202"><label>202</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nakajima</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Aiba</surname><given-names>T</given-names></string-name>, <string-name><surname>Makiyama</surname><given-names>T</given-names></string-name>, <string-name><surname>Nishiuchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Ohno</surname><given-names>S</given-names></string-name>, <string-name><surname>Kato</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical manifestations and long-term mortality in lamin A/C mutation carriers from a Japanese Multicenter Registry</article-title>. <source>Circ J</source><year>2018</year>;<volume>82</volume>:<fpage>2707</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">30078822</pub-id></mixed-citation></ref><ref id="euac030-B203"><label>203</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tan</surname>
<given-names>RB</given-names>
</string-name>, <string-name><surname>Gando</surname><given-names>I</given-names></string-name>, <string-name><surname>Bu</surname><given-names>L</given-names></string-name>, <string-name><surname>Cecchin</surname><given-names>F</given-names></string-name>, <string-name><surname>Coetzee</surname><given-names>W.</given-names></string-name></person-group>
<article-title>A homozygous <italic toggle="yes">SCN5A</italic> mutation associated with atrial standstill and sudden death</article-title>. <source>Pacing Clin Electrophysiol</source><year>2018</year>;<volume>41</volume>:<fpage>1036</fpage>&#x02013;<lpage>42</lpage>.</mixed-citation></ref><ref id="euac030-B204"><label>204</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Makita</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Sasaki</surname><given-names>K</given-names></string-name>, <string-name><surname>Groenewegen</surname><given-names>WA</given-names></string-name>, <string-name><surname>Yokota</surname><given-names>T</given-names></string-name>, <string-name><surname>Yokoshiki</surname><given-names>H</given-names></string-name>, <string-name><surname>Murakami</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Congenital atrial standstill associated with coinheritance of a novel <italic toggle="yes">SCN5A</italic> mutation and connexin 40 polymorphisms</article-title>. <source>Heart Rhythm</source><year>2005</year>;<volume>2</volume>:<fpage>1128</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">16188595</pub-id></mixed-citation></ref><ref id="euac030-B205"><label>205</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kruse</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Schulze-Bahr</surname><given-names>E</given-names></string-name>, <string-name><surname>Corfield</surname><given-names>V</given-names></string-name>, <string-name><surname>Beckmann</surname><given-names>A</given-names></string-name>, <string-name><surname>Stallmeyer</surname><given-names>B</given-names></string-name>, <string-name><surname>Kurtbay</surname><given-names>G</given-names></string-name><etal>et al</etal></person-group>
<article-title>Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I</article-title>. <source>J Clin Invest</source><year>2009</year>;<volume>119</volume>:<fpage>2737</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">19726882</pub-id></mixed-citation></ref><ref id="euac030-B206"><label>206</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Daumy</surname>
<given-names>X</given-names>
</string-name>, <string-name><surname>Amarouch</surname><given-names>MY</given-names></string-name>, <string-name><surname>Lindenbaum</surname><given-names>P</given-names></string-name>, <string-name><surname>Bonnaud</surname><given-names>S</given-names></string-name>, <string-name><surname>Charpentier</surname><given-names>E</given-names></string-name>, <string-name><surname>Bianchi</surname><given-names>B</given-names></string-name><etal>et al</etal></person-group>
<article-title>Targeted resequencing identifies TRPM4 as a major gene predisposing to progressive familial heart block type I</article-title>. <source>Int J Cardiol</source><year>2016</year>;<volume>207</volume>:<fpage>349</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">26820365</pub-id></mixed-citation></ref><ref id="euac030-B207"><label>207</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kamdar</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Garry</surname><given-names>DJ.</given-names></string-name></person-group>
<article-title>Dystrophin-deficient cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source><year>2016</year>;<volume>67</volume>:<fpage>2533</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">27230049</pub-id></mixed-citation></ref><ref id="euac030-B208"><label>208</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brook</surname>
<given-names>JD</given-names>
</string-name>, <string-name><surname>McCurrach</surname><given-names>ME</given-names></string-name>, <string-name><surname>Harley</surname><given-names>HG</given-names></string-name>, <string-name><surname>Buckler</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Church</surname><given-names>D</given-names></string-name>, <string-name><surname>Aburatani</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member</article-title>. <source>Cell</source><year>1992</year>;<volume>69</volume>:<fpage>385</fpage>.</mixed-citation></ref><ref id="euac030-B209"><label>209</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bonne</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Quijano-Roy</surname><given-names>S.</given-names></string-name></person-group>
<article-title>Emery-Dreifuss muscular dystrophy, laminopathies, and other nuclear envelopathies</article-title>. <source>Handb Clin Neurol</source><year>2013</year>;<volume>113</volume>:<fpage>1367</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">23622360</pub-id></mixed-citation></ref><ref id="euac030-B210"><label>210</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ishikawa</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Mishima</surname><given-names>H</given-names></string-name>, <string-name><surname>Barc</surname><given-names>J</given-names></string-name>, <string-name><surname>Takahashi</surname><given-names>MP</given-names></string-name>, <string-name><surname>Hirono</surname><given-names>K</given-names></string-name>, <string-name><surname>Terada</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>Cardiac emerinopathy: a nonsyndromic nuclear envelopathy with increased risk of thromboembolic stroke due to progressive atrial standstill and left ventricular noncompaction</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2020</year>;<volume>13</volume>:<fpage>e008712</fpage>.<pub-id pub-id-type="pmid">32755394</pub-id></mixed-citation></ref><ref id="euac030-B211"><label>211</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cenacchi</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Papa</surname><given-names>V</given-names></string-name>, <string-name><surname>Pegoraro</surname><given-names>V</given-names></string-name>, <string-name><surname>Marozzo</surname><given-names>R</given-names></string-name>, <string-name><surname>Fanin</surname><given-names>M</given-names></string-name>, <string-name><surname>Angelini</surname><given-names>C.</given-names></string-name></person-group>
<article-title>Review: Danon disease: review of natural history and recent advances</article-title>. <source>Neuropathol Appl Neurobiol</source><year>2020</year>;<volume>46</volume>:<fpage>303</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">31698507</pub-id></mixed-citation></ref><ref id="euac030-B212"><label>212</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Arbustini</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Di Toro</surname><given-names>A</given-names></string-name>, <string-name><surname>Giuliani</surname><given-names>L</given-names></string-name>, <string-name><surname>Favalli</surname><given-names>V</given-names></string-name>, <string-name><surname>Narula</surname><given-names>N</given-names></string-name>, <string-name><surname>Grasso</surname><given-names>M.</given-names></string-name></person-group>
<article-title>Cardiac phenotypes in hereditary muscle disorders: JACC state-of-the-art review</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>;<volume>72</volume>:<fpage>2485</fpage>&#x02013;<lpage>506</lpage>.<pub-id pub-id-type="pmid">30442292</pub-id></mixed-citation></ref><ref id="euac030-B213"><label>213</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hu</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Hu</surname><given-names>D</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Barr</surname><given-names>D</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Balderrabano-Saucedo</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease</article-title>. <source>EBioMedicine</source><year>2020</year>;<volume>54</volume>:<fpage>102723</fpage>.<pub-id pub-id-type="pmid">32259713</pub-id></mixed-citation></ref><ref id="euac030-B214"><label>214</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Theis</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Zimmermann</surname><given-names>MT</given-names></string-name>, <string-name><surname>Larsen</surname><given-names>BT</given-names></string-name>, <string-name><surname>Rybakova</surname><given-names>IN</given-names></string-name>, <string-name><surname>Long</surname><given-names>PA</given-names></string-name>, <string-name><surname>Evans</surname><given-names>JM</given-names></string-name><etal>et al</etal></person-group>
<article-title>TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy</article-title>. <source>Hum Mol Genet</source><year>2014</year>;<volume>23</volume>:<fpage>5793</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="pmid">24925317</pub-id></mixed-citation></ref><ref id="euac030-B215"><label>215</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Seki</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Ishikawa</surname><given-names>T</given-names></string-name>, <string-name><surname>Daumy</surname><given-names>X</given-names></string-name>, <string-name><surname>Mishima</surname><given-names>H</given-names></string-name>, <string-name><surname>Barc</surname><given-names>J</given-names></string-name>, <string-name><surname>Sasaki</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>Progressive atrial conduction defects associated with bone malformation caused by a connexin-45 mutation</article-title>. <source>J Am Coll Cardiol</source><year>2017</year>;<volume>70</volume>:<fpage>358</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">28705318</pub-id></mixed-citation></ref><ref id="euac030-B216"><label>216</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Limongelli</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Masarone</surname><given-names>D</given-names></string-name>, <string-name><surname>Pacileo</surname><given-names>G.</given-names></string-name></person-group>
<article-title>Mitochondrial disease and the heart</article-title>. <source>Heart</source><year>2017</year>;<volume>103</volume>:<fpage>390</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27821705</pub-id></mixed-citation></ref><ref id="euac030-B217"><label>217</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Priori</surname>
<given-names>SG</given-names>
</string-name>, <string-name><surname>Pandit</surname><given-names>SV</given-names></string-name>, <string-name><surname>Rivolta</surname><given-names>I</given-names></string-name>, <string-name><surname>Berenfeld</surname><given-names>O</given-names></string-name>, <string-name><surname>Ronchetti</surname><given-names>E</given-names></string-name>, <string-name><surname>Dhamoon</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene</article-title>. <source>Circ Res</source><year>2005</year>;<volume>96</volume>:<fpage>800</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15761194</pub-id></mixed-citation></ref><ref id="euac030-B218"><label>218</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Templin</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Ghadri</surname><given-names>JR</given-names></string-name>, <string-name><surname>Rougier</surname><given-names>JS</given-names></string-name>, <string-name><surname>Baumer</surname><given-names>A</given-names></string-name>, <string-name><surname>Kaplan</surname><given-names>V</given-names></string-name>, <string-name><surname>Albesa</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6)</article-title>. <source>Eur Heart J</source><year>2011</year>;<volume>32</volume>:<fpage>1077</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">21383000</pub-id></mixed-citation></ref><ref id="euac030-B219"><label>219</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gollob</surname>
<given-names>MH</given-names>
</string-name>, <string-name><surname>Redpath</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>JD.</given-names></string-name></person-group>
<article-title>The short QT syndrome: proposed diagnostic criteria</article-title>. <source>J Am Coll Cardiol</source><year>2011</year>;<volume>57</volume>:<fpage>802</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">21310316</pub-id></mixed-citation></ref><ref id="euac030-B220"><label>220</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Giustetto</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Scrocco</surname><given-names>C</given-names></string-name>, <string-name><surname>Schimpf</surname><given-names>R</given-names></string-name>, <string-name><surname>Maury</surname><given-names>P</given-names></string-name>, <string-name><surname>Mazzanti</surname><given-names>A</given-names></string-name>, <string-name><surname>Levetto</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Usefulness of exercise test in the diagnosis of short QT syndrome</article-title>. <source>Europace</source><year>2015</year>;<volume>17</volume>:<fpage>628</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">25833882</pub-id></mixed-citation></ref><ref id="euac030-B221"><label>221</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brugada</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Hong</surname><given-names>K</given-names></string-name>, <string-name><surname>Dumaine</surname><given-names>R</given-names></string-name>, <string-name><surname>Cordeiro</surname><given-names>J</given-names></string-name>, <string-name><surname>Gaita</surname><given-names>F</given-names></string-name>, <string-name><surname>Borggrefe</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Sudden death associated with short-QT syndrome linked to mutations in HERG</article-title>. <source>Circulation</source><year>2004</year>;<volume>109</volume>:<fpage>30</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">14676148</pub-id></mixed-citation></ref><ref id="euac030-B222"><label>222</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bellocq</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>van Ginneken</surname><given-names>AC</given-names></string-name>, <string-name><surname>Bezzina</surname><given-names>CR</given-names></string-name>, <string-name><surname>Alders</surname><given-names>M</given-names></string-name>, <string-name><surname>Escande</surname><given-names>D</given-names></string-name>, <string-name><surname>Mannens</surname><given-names>MM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mutation in the KCNQ1 gene leading to the short QT-interval syndrome</article-title>. <source>Circulation</source><year>2004</year>;<volume>109</volume>:<fpage>2394</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15159330</pub-id></mixed-citation></ref><ref id="euac030-B223"><label>223</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Thorsen</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Dam</surname><given-names>VS</given-names></string-name>, <string-name><surname>Kjaer-Sorensen</surname><given-names>K</given-names></string-name>, <string-name><surname>Pedersen</surname><given-names>LN</given-names></string-name>, <string-name><surname>Skeberdis</surname><given-names>VA</given-names></string-name>, <string-name><surname>Jurevicius</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>1696</fpage>.<pub-id pub-id-type="pmid">29167417</pub-id></mixed-citation></ref><ref id="euac030-B224"><label>224</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Antzelevitch</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Pollevick</surname><given-names>GD</given-names></string-name>, <string-name><surname>Cordeiro</surname><given-names>JM</given-names></string-name>, <string-name><surname>Casis</surname><given-names>O</given-names></string-name>, <string-name><surname>Sanguinetti</surname><given-names>MC</given-names></string-name>, <string-name><surname>Aizawa</surname><given-names>Y</given-names></string-name><etal>et al</etal></person-group>
<article-title>Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death</article-title>. <source>Circulation</source><year>2007</year>;<volume>115</volume>:<fpage>442</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17224476</pub-id></mixed-citation></ref><ref id="euac030-B225"><label>225</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hancox</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>Whittaker</surname><given-names>DG</given-names></string-name>, <string-name><surname>Du</surname><given-names>C</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>AG</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name></person-group>
<article-title>Emerging therapeutic targets in the short QT syndrome</article-title>. <source>Expert Opin Ther Targets</source><year>2018</year>;<volume>22</volume>:<fpage>439</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">29697308</pub-id></mixed-citation></ref><ref id="euac030-B226"><label>226</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nezu</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Tamai</surname><given-names>I</given-names></string-name>, <string-name><surname>Oku</surname><given-names>A</given-names></string-name>, <string-name><surname>Ohashi</surname><given-names>R</given-names></string-name>, <string-name><surname>Yabuuchi</surname><given-names>H</given-names></string-name>, <string-name><surname>Hashimoto</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter</article-title>. <source>Nat Genet</source><year>1999</year>;<volume>21</volume>:<fpage>91</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">9916797</pub-id></mixed-citation></ref><ref id="euac030-B227"><label>227</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roussel</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Labarthe</surname><given-names>F</given-names></string-name>, <string-name><surname>Thireau</surname><given-names>J</given-names></string-name>, <string-name><surname>Ferro</surname><given-names>F</given-names></string-name>, <string-name><surname>Farah</surname><given-names>C</given-names></string-name>, <string-name><surname>Roy</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Carnitine deficiency induces a short QT syndrome</article-title>. <source>Heart Rhythm</source><year>2016</year>;<volume>13</volume>:<fpage>165</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">26190315</pub-id></mixed-citation></ref><ref id="euac030-B228"><label>228</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>G&#x000e9;linas</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Leach</surname><given-names>E</given-names></string-name>, <string-name><surname>Horvath</surname><given-names>G</given-names></string-name>, <string-name><surname>Laksman</surname><given-names>Z.</given-names></string-name></person-group>
<article-title>Molecular autopsy implicates primary carnitine deficiency in sudden unexplained death and reversible short QT syndrome</article-title>. <source>Can J Cardiol</source><year>2019</year>;<volume>35</volume>:<fpage>1256.e1&#x02013;2</fpage>.</mixed-citation></ref><ref id="euac030-B229"><label>229</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Giustetto</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Schimpf</surname><given-names>R</given-names></string-name>, <string-name><surname>Mazzanti</surname><given-names>A</given-names></string-name>, <string-name><surname>Scrocco</surname><given-names>C</given-names></string-name>, <string-name><surname>Maury</surname><given-names>P</given-names></string-name>, <string-name><surname>Anttonen</surname><given-names>O</given-names></string-name><etal>et al</etal></person-group>
<article-title>Long-term follow-up of patients with short QT syndrome</article-title>. <source>J Am Coll Cardiol</source><year>2011</year>;<volume>58</volume>:<fpage>587</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">21798421</pub-id></mixed-citation></ref><ref id="euac030-B230"><label>230</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hu</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Pfeiffer</surname><given-names>R</given-names></string-name>, <string-name><surname>Gollob</surname><given-names>MH</given-names></string-name>, <string-name><surname>Healey</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>The phenotypic spectrum of a mutation&#x000a0;hotspot responsible for the&#x000a0;short QT syndrome</article-title>. <source>JACC Clin Electrophysiol</source><year>2017</year>;<volume>3</volume>:<fpage>727</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">29759541</pub-id></mixed-citation></ref><ref id="euac030-B231"><label>231</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mazzanti</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Maragna</surname><given-names>R</given-names></string-name>, <string-name><surname>Vacanti</surname><given-names>G</given-names></string-name>, <string-name><surname>Kostopoulou</surname><given-names>A</given-names></string-name>, <string-name><surname>Marino</surname><given-names>M</given-names></string-name>, <string-name><surname>Monteforte</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>Hydroquinidine prevents life-threatening arrhythmic events in patients with short&#x000a0;QT&#x000a0;syndrome</article-title>. <source>J Am Coll Cardiol</source><year>2017</year>;<volume>70</volume>:<fpage>3010</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">29241489</pub-id></mixed-citation></ref><ref id="euac030-B232"><label>232</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Raschwitz</surname>
<given-names>LS</given-names>
</string-name>, <string-name><surname>El-Battrawy</surname><given-names>I</given-names></string-name>, <string-name><surname>Schlentrich</surname><given-names>K</given-names></string-name>, <string-name><surname>Besler</surname><given-names>J</given-names></string-name>, <string-name><surname>Veith</surname><given-names>M</given-names></string-name>, <string-name><surname>Roterberg</surname><given-names>G</given-names></string-name><etal>et al</etal></person-group>
<article-title>Differences in short QT syndrome subtypes: a systematic literature review and pooled analysis</article-title>. <source>Front Genet</source><year>2019</year>;<volume>10</volume>:<fpage>1312</fpage>.<pub-id pub-id-type="pmid">32010184</pub-id></mixed-citation></ref><ref id="euac030-B233"><label>233</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Harrell</surname>
<given-names>DT</given-names>
</string-name>, <string-name><surname>Ashihara</surname><given-names>T</given-names></string-name>, <string-name><surname>Ishikawa</surname><given-names>T</given-names></string-name>, <string-name><surname>Tominaga</surname><given-names>I</given-names></string-name>, <string-name><surname>Mazzanti</surname><given-names>A</given-names></string-name>, <string-name><surname>Takahashi</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome</article-title>. <source>Int J Cardiol</source><year>2015</year>;<volume>190</volume>:<fpage>393</fpage>&#x02013;<lpage>402</lpage>.<pub-id pub-id-type="pmid">25974115</pub-id></mixed-citation></ref><ref id="euac030-B234"><label>234</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Morita</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Kusano-Fukushima</surname><given-names>K</given-names></string-name>, <string-name><surname>Nagase</surname><given-names>S</given-names></string-name>, <string-name><surname>Fujimoto</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hisamatsu</surname><given-names>K</given-names></string-name>, <string-name><surname>Fujio</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome</article-title>. <source>J Am Coll Cardiol</source><year>2002</year>;<volume>40</volume>:<fpage>1437</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">12392834</pub-id></mixed-citation></ref><ref id="euac030-B235"><label>235</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Olson</surname>
<given-names>TM</given-names>
</string-name>, <string-name><surname>Michels</surname><given-names>VV</given-names></string-name>, <string-name><surname>Ballew</surname><given-names>JD</given-names></string-name>, <string-name><surname>Reyna</surname><given-names>SP</given-names></string-name>, <string-name><surname>Karst</surname><given-names>ML</given-names></string-name>, <string-name><surname>Herron</surname><given-names>KJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Sodium channel mutations and susceptibility to heart failure and atrial fibrillation</article-title>. <source>JAMA</source><year>2005</year>;<volume>293</volume>:<fpage>447</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">15671429</pub-id></mixed-citation></ref><ref id="euac030-B236"><label>236</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>McNair</surname>
<given-names>WP</given-names>
</string-name>, <string-name><surname>Ku</surname><given-names>L</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>MR</given-names></string-name>, <string-name><surname>Fain</surname><given-names>PR</given-names></string-name>, <string-name><surname>Dao</surname><given-names>D</given-names></string-name>, <string-name><surname>Wolfel</surname><given-names>E</given-names></string-name><etal>et al</etal>; <collab>Familial Cardiomyopathy Registry Research Group</collab></person-group>. <article-title><italic toggle="yes">SCN5A</italic> mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia</article-title>. <source>Circulation</source><year>2004</year>;<volume>110</volume>:<fpage>2163</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15466643</pub-id></mixed-citation></ref><ref id="euac030-B237"><label>237</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>Q</given-names>
</string-name>, <string-name><surname>Huang</surname><given-names>H</given-names></string-name>, <string-name><surname>Liu</surname><given-names>G</given-names></string-name>, <string-name><surname>Lam</surname><given-names>K</given-names></string-name>, <string-name><surname>Rutberg</surname><given-names>J</given-names></string-name>, <string-name><surname>Green</surname><given-names>MS</given-names></string-name><etal>et al</etal></person-group>
<article-title>Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing</article-title>. <source>Biochem Biophys Res Commun</source><year>2009</year>;<volume>380</volume>:<fpage>132</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">19167345</pub-id></mixed-citation></ref><ref id="euac030-B238"><label>238</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chen</surname>
<given-names>YH</given-names>
</string-name>, <string-name><surname>Xu</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Bendahhou</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>XL</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname><given-names>WY</given-names></string-name><etal>et al</etal></person-group>
<article-title>KCNQ1 gain-of-function mutation in familial atrial fibrillation</article-title>. <source>Science</source><year>2003</year>;<volume>299</volume>:<fpage>251</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">12522251</pub-id></mixed-citation></ref><ref id="euac030-B239"><label>239</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Orr</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Arnaout</surname><given-names>R</given-names></string-name>, <string-name><surname>Gula</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Spears</surname><given-names>DA</given-names></string-name>, <string-name><surname>Leong-Sit</surname><given-names>P</given-names></string-name>, <string-name><surname>Li</surname><given-names>Q</given-names></string-name><etal>et al</etal></person-group>
<article-title>A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation</article-title>. <source>Nat Commun</source><year>2016</year>;<volume>7</volume>:<fpage>11303</fpage>.<pub-id pub-id-type="pmid">27066836</pub-id></mixed-citation></ref><ref id="euac030-B240"><label>240</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kumar</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Baldinger</surname><given-names>SH</given-names></string-name>, <string-name><surname>Gandjbakhch</surname><given-names>E</given-names></string-name>, <string-name><surname>Maury</surname><given-names>P</given-names></string-name>, <string-name><surname>Sellal</surname><given-names>JM</given-names></string-name>, <string-name><surname>Androulakis</surname><given-names>AF</given-names></string-name><etal>et al</etal></person-group>
<article-title>Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers</article-title>. <source>J Am Coll Cardiol</source><year>2016</year>;<volume>68</volume>:<fpage>2299</fpage>&#x02013;<lpage>307</lpage>.<pub-id pub-id-type="pmid">27884249</pub-id></mixed-citation></ref><ref id="euac030-B241"><label>241</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Choi</surname>
<given-names>SH</given-names>
</string-name>, <string-name><surname>Weng</surname><given-names>LC</given-names></string-name>, <string-name><surname>Roselli</surname><given-names>C</given-names></string-name>, <string-name><surname>Lin</surname><given-names>H</given-names></string-name>, <string-name><surname>Haggerty</surname><given-names>CM</given-names></string-name>, <string-name><surname>Shoemaker</surname><given-names>MB</given-names></string-name><etal>et al</etal>; <collab>For the DiscovEHR study and the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium</collab></person-group>. <article-title>Association between titin loss-of-function variants and early-onset atrial fibrillation</article-title>. <source>JAMA</source><year>2018</year>;<volume>320</volume>:<fpage>2354</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">30535219</pub-id></mixed-citation></ref><ref id="euac030-B242"><label>242</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yoneda</surname>
<given-names>ZT</given-names>
</string-name>, <string-name><surname>Anderson</surname><given-names>KC</given-names></string-name>, <string-name><surname>Quintana</surname><given-names>JA</given-names></string-name>, <string-name><surname>O'Neill</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Sims</surname><given-names>RA</given-names></string-name>, <string-name><surname>Glazer</surname><given-names>AM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Early-onset atrial fibrillation and the prevalence of rare variants in cardiomyopathy and arrhythmia genes</article-title>. <source>JAMA Cardiol</source><year>2021</year>;<volume>6</volume>:<fpage>1371</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">34495297</pub-id></mixed-citation></ref><ref id="euac030-B243"><label>243</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Goodyer</surname>
<given-names>WR</given-names>
</string-name>, <string-name><surname>Dunn</surname><given-names>K</given-names></string-name>, <string-name><surname>Caleshu</surname><given-names>C</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>M</given-names></string-name>, <string-name><surname>Wylie</surname><given-names>J</given-names></string-name>, <string-name><surname>Moscarello</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Broad genetic testing in a clinical setting uncovers a high prevalence of titin loss-of-function variants in very early onset atrial fibrillation</article-title>. <source>Circ Genom Precis Med</source><year>2019</year>;<volume>12</volume>:<fpage>e002713</fpage>.<pub-id pub-id-type="pmid">31638414</pub-id></mixed-citation></ref><ref id="euac030-B244"><label>244</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Roberts</surname>
<given-names>R.</given-names>
</string-name>
</person-group>
<article-title>Mechanisms of disease: genetic mechanisms of atrial fibrillation</article-title>. <source>Nat Clin Pract Cardiovasc Med</source><year>2006</year>;<volume>3</volume>:<fpage>276</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">16645668</pub-id></mixed-citation></ref><ref id="euac030-B245"><label>245</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Darbar</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Herron</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Ballew</surname><given-names>JD</given-names></string-name>, <string-name><surname>Jahangir</surname><given-names>A</given-names></string-name>, <string-name><surname>Gersh</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Shen</surname><given-names>WK</given-names></string-name><etal>et al</etal></person-group>
<article-title>Familial atrial fibrillation is a genetically heterogeneous disorder</article-title>. <source>J Am Coll Cardiol</source><year>2003</year>;<volume>41</volume>:<fpage>2185</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">12821245</pub-id></mixed-citation></ref><ref id="euac030-B246"><label>246</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>S&#x000e9;billon</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Bouchier</surname><given-names>C</given-names></string-name>, <string-name><surname>Bidot</surname><given-names>LD</given-names></string-name>, <string-name><surname>Bonne</surname><given-names>G</given-names></string-name>, <string-name><surname>Ahamed</surname><given-names>K</given-names></string-name>, <string-name><surname>Charron</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations</article-title>. <source>J Med Genet</source><year>2003</year>;<volume>40</volume>:<fpage>560</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">12920062</pub-id></mixed-citation></ref><ref id="euac030-B247"><label>247</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mohler</surname>
<given-names>PJ</given-names>
</string-name>, <string-name><surname>Schott</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Gramolini</surname><given-names>AO</given-names></string-name>, <string-name><surname>Dilly</surname><given-names>KW</given-names></string-name>, <string-name><surname>Guatimosim</surname><given-names>S</given-names></string-name>, <string-name><surname>duBell</surname><given-names>WH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death</article-title>. <source>Nature</source><year>2003</year>;<volume>421</volume>:<fpage>634</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">12571597</pub-id></mixed-citation></ref><ref id="euac030-B248"><label>248</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hong</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Piper</surname><given-names>DR</given-names></string-name>, <string-name><surname>Diaz-Valdecantos</surname><given-names>A</given-names></string-name>, <string-name><surname>Brugada</surname><given-names>J</given-names></string-name>, <string-name><surname>Oliva</surname><given-names>A</given-names></string-name>, <string-name><surname>Burashnikov</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>
<italic toggle="yes">De novo</italic> KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome <italic toggle="yes">in utero</italic></article-title>. <source>Cardiovasc Res</source><year>2005</year>;<volume>68</volume>:<fpage>433</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">16109388</pub-id></mixed-citation></ref><ref id="euac030-B249"><label>249</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bhuiyan</surname>
<given-names>ZA</given-names>
</string-name>, <string-name><surname>van den Berg</surname><given-names>MP</given-names></string-name>, <string-name><surname>van Tintelen</surname><given-names>JP</given-names></string-name>, <string-name><surname>Bink-Boelkens</surname><given-names>MT</given-names></string-name>, <string-name><surname>Wiesfeld</surname><given-names>AC</given-names></string-name>, <string-name><surname>Alders</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features</article-title>. <source>Circulation</source><year>2007</year>;<volume>116</volume>:<fpage>1569</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">17875969</pub-id></mixed-citation></ref><ref id="euac030-B250"><label>250</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sy</surname>
<given-names>RW</given-names>
</string-name>, <string-name><surname>Gollob</surname><given-names>MH</given-names></string-name>, <string-name><surname>Klein</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Yee</surname><given-names>R</given-names></string-name>, <string-name><surname>Skanes</surname><given-names>AC</given-names></string-name>, <string-name><surname>Gula</surname><given-names>LJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>Heart Rhythm</source><year>2011</year>;<volume>8</volume>:<fpage>864</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">21315846</pub-id></mixed-citation></ref><ref id="euac030-B251"><label>251</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gillmore</surname>
<given-names>JD</given-names>
</string-name>, <string-name><surname>Booth</surname><given-names>DR</given-names></string-name>, <string-name><surname>Pepys</surname><given-names>MB</given-names></string-name>, <string-name><surname>Hawkins</surname><given-names>PN.</given-names></string-name></person-group>
<article-title>Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man</article-title>. <source>Heart</source><year>1999</year>;<volume>82</volume>:<fpage>e2</fpage>.<pub-id pub-id-type="pmid">10455100</pub-id></mixed-citation></ref><ref id="euac030-B252"><label>252</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gutierrez-Roelens</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>De Roy</surname><given-names>L</given-names></string-name>, <string-name><surname>Ovaert</surname><given-names>C</given-names></string-name>, <string-name><surname>Sluysmans</surname><given-names>T</given-names></string-name>, <string-name><surname>Devriendt</surname><given-names>K</given-names></string-name>, <string-name><surname>Brunner</surname><given-names>HG</given-names></string-name><etal>et al</etal></person-group>
<article-title>A novel CSX/NKX2-5 mutation causes autosomal-dominant AV block: are atrial fibrillation and syncopes part of the phenotype?</article-title>
<source>Eur J Hum Genet</source>
<year>2006</year>;<volume>14</volume>:<fpage>1313</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">16896344</pub-id></mixed-citation></ref><ref id="euac030-B253"><label>253</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gollob</surname>
<given-names>MH</given-names>
</string-name>, <string-name><surname>Seger</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Gollob</surname><given-names>TN</given-names></string-name>, <string-name><surname>Tapscott</surname><given-names>T</given-names></string-name>, <string-name><surname>Gonzales</surname><given-names>O</given-names></string-name>, <string-name><surname>Bachinski</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy</article-title>. <source>Circulation</source><year>2001</year>;<volume>104</volume>:<fpage>3030</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">11748095</pub-id></mixed-citation></ref><ref id="euac030-B254"><label>254</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fuster</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Ryd&#x000e9;n</surname><given-names>LE</given-names></string-name>, <string-name><surname>Cannom</surname><given-names>DS</given-names></string-name>, <string-name><surname>Crijns</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>AB</given-names></string-name>, <string-name><surname>Ellenbogen</surname><given-names>KA</given-names></string-name><etal>et al</etal></person-group>
<article-title>2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society</article-title>. <source>J Am Coll Cardiol</source><year>2011</year>;<volume>57</volume>:<fpage>e101</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">21392637</pub-id></mixed-citation></ref><ref id="euac030-B255"><label>255</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Olson</surname>
<given-names>TM</given-names>
</string-name>, <string-name><surname>Alekseev</surname><given-names>AE</given-names></string-name>, <string-name><surname>Liu</surname><given-names>XK</given-names></string-name>, <string-name><surname>Park</surname><given-names>S</given-names></string-name>, <string-name><surname>Zingman</surname><given-names>LV</given-names></string-name>, <string-name><surname>Bienengraeber</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation</article-title>. <source>Hum Mol Genet</source><year>2006</year>;<volume>15</volume>:<fpage>2185</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">16772329</pub-id></mixed-citation></ref><ref id="euac030-B256"><label>256</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Deo</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Ruan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Pandit</surname><given-names>SV</given-names></string-name>, <string-name><surname>Shah</surname><given-names>K</given-names></string-name>, <string-name><surname>Berenfeld</surname><given-names>O</given-names></string-name>, <string-name><surname>Blaufox</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia</article-title>. <source>Proc Natl Acad Sci USA</source><year>2013</year>;<volume>110</volume>:<fpage>4291</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23440193</pub-id></mixed-citation></ref><ref id="euac030-B257"><label>257</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hong</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Bjerregaard</surname><given-names>P</given-names></string-name>, <string-name><surname>Gussak</surname><given-names>I</given-names></string-name>, <string-name><surname>Brugada</surname><given-names>R.</given-names></string-name></person-group>
<article-title>Short QT syndrome and atrial fibrillation caused by mutation in KCNH2</article-title>. <source>J Cardiovasc Electrophysiol</source><year>2005</year>;<volume>16</volume>:<fpage>394</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15828882</pub-id></mixed-citation></ref><ref id="euac030-B258"><label>258</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>RG</given-names>
</string-name>, <string-name><surname>Xu</surname><given-names>YJ</given-names></string-name>, <string-name><surname>Ye</surname><given-names>WG</given-names></string-name>, <string-name><surname>Li</surname><given-names>YJ</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>XB</given-names></string-name><etal>et al</etal></person-group>
<article-title>Connexin45 (GJC1) loss-of-function mutation contributes to familial atrial fibrillation and conduction disease</article-title>. <source>Heart Rhythm</source><year>2021</year>;<volume>18</volume>:<fpage>684</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">33429106</pub-id></mixed-citation></ref><ref id="euac030-B259"><label>259</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hodgson-Zingman</surname>
<given-names>DM</given-names>
</string-name>, <string-name><surname>Karst</surname><given-names>ML</given-names></string-name>, <string-name><surname>Zingman</surname><given-names>LV</given-names></string-name>, <string-name><surname>Heublein</surname><given-names>DM</given-names></string-name>, <string-name><surname>Darbar</surname><given-names>D</given-names></string-name>, <string-name><surname>Herron</surname><given-names>KJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>359</volume>:<fpage>158</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">18614783</pub-id></mixed-citation></ref><ref id="euac030-B260"><label>260</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kusumoto</surname>
<given-names>FM</given-names>
</string-name>, <string-name><surname>Schoenfeld</surname><given-names>MH</given-names></string-name>, <string-name><surname>Barrett</surname><given-names>C</given-names></string-name>, <string-name><surname>Edgerton</surname><given-names>JR</given-names></string-name>, <string-name><surname>Ellenbogen</surname><given-names>KA</given-names></string-name>, <string-name><surname>Gold</surname><given-names>MR</given-names></string-name><etal>et al</etal></person-group>
<article-title>2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with Bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society</article-title>. <source>Circulation</source><year>2019</year>;<volume>140</volume>:<fpage>e382</fpage>&#x02013;<lpage>482</lpage>.<pub-id pub-id-type="pmid">30586772</pub-id></mixed-citation></ref><ref id="euac030-B261"><label>261</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jensen</surname>
<given-names>MT</given-names>
</string-name>, <string-name><surname>Wod</surname><given-names>M</given-names></string-name>, <string-name><surname>Galatius</surname><given-names>S</given-names></string-name>, <string-name><surname>Hjelmborg</surname><given-names>JB</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>GB</given-names></string-name>, <string-name><surname>Christensen</surname><given-names>K.</given-names></string-name></person-group>
<article-title>Heritability of resting heart rate and association with mortality in middle-aged and elderly twins</article-title>. <source>Heart</source><year>2018</year>;<volume>104</volume>:<fpage>30</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">28637897</pub-id></mixed-citation></ref><ref id="euac030-B262"><label>262</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Holm</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Gudbjartsson</surname><given-names>DF</given-names></string-name>, <string-name><surname>Arnar</surname><given-names>DO</given-names></string-name>, <string-name><surname>Thorleifsson</surname><given-names>G</given-names></string-name>, <string-name><surname>Thorgeirsson</surname><given-names>G</given-names></string-name>, <string-name><surname>Stefansdottir</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>Several common variants modulate heart rate, PR interval and QRS duration</article-title>. <source>Nat Genet</source><year>2010</year>;<volume>42</volume>:<fpage>117</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">20062063</pub-id></mixed-citation></ref><ref id="euac030-B263"><label>263</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Holm</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Gudbjartsson</surname><given-names>DF</given-names></string-name>, <string-name><surname>Sulem</surname><given-names>P</given-names></string-name>, <string-name><surname>Masson</surname><given-names>G</given-names></string-name>, <string-name><surname>Helgadottir</surname><given-names>HT</given-names></string-name>, <string-name><surname>Zanon</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>A rare variant in MYH6 is associated with high risk of sick sinus syndrome</article-title>. <source>Nat Genet</source><year>2011</year>;<volume>43</volume>:<fpage>316</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">21378987</pub-id></mixed-citation></ref><ref id="euac030-B264"><label>264</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ramirez</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Duijvenboden</surname><given-names>SV</given-names></string-name>, <string-name><surname>Ntalla</surname><given-names>I</given-names></string-name>, <string-name><surname>Mifsud</surname><given-names>B</given-names></string-name>, <string-name><surname>Warren</surname><given-names>HR</given-names></string-name>, <string-name><surname>Tzanis</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>Thirty loci identified for heart rate response to exercise and recovery implicate autonomic nervous system</article-title>. <source>Nat Commun</source><year>2018</year>;<volume>9</volume>:<fpage>1947</fpage>.<pub-id pub-id-type="pmid">29769521</pub-id></mixed-citation></ref><ref id="euac030-B265"><label>265</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kusumoto</surname>
<given-names>FM</given-names>
</string-name>, <string-name><surname>Schoenfeld</surname><given-names>MH</given-names></string-name>, <string-name><surname>Barrett</surname><given-names>C</given-names></string-name>, <string-name><surname>Edgerton</surname><given-names>JR</given-names></string-name>, <string-name><surname>Ellenbogen</surname><given-names>KA</given-names></string-name>, <string-name><surname>Gold</surname><given-names>MR</given-names></string-name><etal>et al</etal></person-group>
<article-title>2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with Bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society</article-title>. <source>J Am Coll Cardiol</source><year>2019</year>;<volume>74</volume>:<fpage>932</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">30412710</pub-id></mixed-citation></ref><ref id="euac030-B266"><label>266</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Veldkamp</surname>
<given-names>MW</given-names>
</string-name>, <string-name><surname>Wilders</surname><given-names>R</given-names></string-name>, <string-name><surname>Baartscheer</surname><given-names>A</given-names></string-name>, <string-name><surname>Zegers</surname><given-names>JG</given-names></string-name>, <string-name><surname>Bezzina</surname><given-names>CR</given-names></string-name>, <string-name><surname>Wilde</surname><given-names>AA.</given-names></string-name></person-group>
<article-title>Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families</article-title>. <source>Circ Res</source><year>2003</year>;<volume>92</volume>:<fpage>976</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">12676817</pub-id></mixed-citation></ref><ref id="euac030-B267"><label>267</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chiang</surname>
<given-names>DY</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Valdes</surname><given-names>SO</given-names></string-name>, <string-name><surname>de la Uz</surname><given-names>C</given-names></string-name>, <string-name><surname>Fan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Orcutt</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Loss-of-function <italic toggle="yes">SCN5A</italic> mutations associated with sinus node dysfunction, atrial arrhythmias, and poor pacemaker capture</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2015</year>;<volume>8</volume>:<fpage>1105</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">26111534</pub-id></mixed-citation></ref><ref id="euac030-B268"><label>268</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schulze-Bahr</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Neu</surname><given-names>A</given-names></string-name>, <string-name><surname>Friederich</surname><given-names>P</given-names></string-name>, <string-name><surname>Kaupp</surname><given-names>UB</given-names></string-name>, <string-name><surname>Breithardt</surname><given-names>G</given-names></string-name>, <string-name><surname>Pongs</surname><given-names>O</given-names></string-name><etal>et al</etal></person-group>
<article-title>Pacemaker channel dysfunction in a patient with sinus node disease</article-title>. <source>J Clin Invest</source><year>2003</year>;<volume>111</volume>:<fpage>1537</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">12750403</pub-id></mixed-citation></ref><ref id="euac030-B269"><label>269</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Milano</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Vermeer</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lodder</surname><given-names>EM</given-names></string-name>, <string-name><surname>Barc</surname><given-names>J</given-names></string-name>, <string-name><surname>Verkerk</surname><given-names>AO</given-names></string-name>, <string-name><surname>Postma</surname><given-names>AV</given-names></string-name><etal>et al</etal></person-group>
<article-title>HCN4 mutations in multiple families with bradycardia and left ventricular noncompaction cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source><year>2014</year>;<volume>64</volume>:<fpage>745</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">25145517</pub-id></mixed-citation></ref><ref id="euac030-B270"><label>270</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Stallmeyer</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Ku&#x000df;</surname><given-names>J</given-names></string-name>, <string-name><surname>Kotthoff</surname><given-names>S</given-names></string-name>, <string-name><surname>Zumhagen</surname><given-names>S</given-names></string-name>, <string-name><surname>Vowinkel</surname><given-names>K</given-names></string-name>, <string-name><surname>Rinn&#x000e9;</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>A mutation in the G-protein gene GNB2 causes familial sinus node and atrioventricular conduction dysfunction</article-title>. <source>Circ Res</source><year>2017</year>;<volume>120</volume>:<fpage>e33</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">28219978</pub-id></mixed-citation></ref><ref id="euac030-B271"><label>271</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Righi</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Silvetti</surname><given-names>MS</given-names></string-name>, <string-name><surname>Drago</surname><given-names>F.</given-names></string-name></person-group>
<article-title>Sinus bradycardia, junctional rhythm, and low-rate atrial fibrillation in Short QT syndrome during 20 years of follow-up: three faces of the same genetic problem</article-title>. <source>Cardiol Young</source><year>2016</year>;<volume>26</volume>:<fpage>589</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">26279191</pub-id></mixed-citation></ref><ref id="euac030-B272"><label>272</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Whittaker</surname>
<given-names>DG</given-names>
</string-name>, <string-name><surname>Colman</surname><given-names>MA</given-names></string-name>, <string-name><surname>Ni</surname><given-names>H</given-names></string-name>, <string-name><surname>Hancox</surname><given-names>JC</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name></person-group>
<article-title>Human atrial arrhythmogenesis and sinus bradycardia in KCNQ1-linked short QT syndrome: insights from computational modelling</article-title>. <source>Front Physiol</source><year>2018</year>;<volume>9</volume>:<fpage>1402</fpage>.<pub-id pub-id-type="pmid">30337886</pub-id></mixed-citation></ref><ref id="euac030-B273"><label>273</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ku&#x000df;</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Stallmeyer</surname><given-names>B</given-names></string-name>, <string-name><surname>Goldstein</surname><given-names>M</given-names></string-name>, <string-name><surname>Rinn&#x000e9;</surname><given-names>S</given-names></string-name>, <string-name><surname>Pees</surname><given-names>C</given-names></string-name>, <string-name><surname>Zumhagen</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>Familial sinus node disease caused by a gain of GIRK (G-protein activated inwardly rectifying K(+) channel) channel function</article-title>. <source>Circ Genom Precis Med</source><year>2019</year>;<volume>12</volume>:<fpage>e002238</fpage>.<pub-id pub-id-type="pmid">30645171</pub-id></mixed-citation></ref><ref id="euac030-B274"><label>274</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yamada</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Asano</surname><given-names>Y</given-names></string-name>, <string-name><surname>Fujita</surname><given-names>M</given-names></string-name>, <string-name><surname>Yamazaki</surname><given-names>S</given-names></string-name>, <string-name><surname>Inanobe</surname><given-names>A</given-names></string-name>, <string-name><surname>Matsuura</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mutant KCNJ3 and KCNJ5 potassium channels as novel molecular targets in bradyarrhythmias and atrial fibrillation</article-title>. <source>Circulation</source><year>2019</year>;<volume>139</volume>:<fpage>2157</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">30764634</pub-id></mixed-citation></ref><ref id="euac030-B275"><label>275</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Arbel-Ganon</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Behar</surname><given-names>JA</given-names></string-name>, <string-name><surname>Gomez</surname><given-names>AM</given-names></string-name>, <string-name><surname>Yaniv</surname><given-names>Y.</given-names></string-name></person-group>
<article-title>Distinct mechanisms mediate pacemaker dysfunction associated with catecholaminergic polymorphic ventricular tachycardia mutations: insights from computational modeling</article-title>. <source>J Mol Cell Cardiol</source><year>2020</year>;<volume>143</volume>:<fpage>85</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">32339564</pub-id></mixed-citation></ref><ref id="euac030-B276"><label>276</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Baig</surname>
<given-names>SM</given-names>
</string-name>, <string-name><surname>Koschak</surname><given-names>A</given-names></string-name>, <string-name><surname>Lieb</surname><given-names>A</given-names></string-name>, <string-name><surname>Gebhart</surname><given-names>M</given-names></string-name>, <string-name><surname>Dafinger</surname><given-names>C</given-names></string-name>, <string-name><surname>Nurnberg</surname><given-names>G</given-names></string-name><etal>et al</etal></person-group>
<article-title>Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness</article-title>. <source>Nat Neurosci</source><year>2011</year>;<volume>14</volume>:<fpage>77</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">21131953</pub-id></mixed-citation></ref><ref id="euac030-B277"><label>277</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liaqat</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Schrauwen</surname><given-names>I</given-names></string-name>, <string-name><surname>Raza</surname><given-names>SI</given-names></string-name>, <string-name><surname>Lee</surname><given-names>K</given-names></string-name>, <string-name><surname>Hussain</surname><given-names>S</given-names></string-name>, <string-name><surname>Chakchouk</surname><given-names>I</given-names></string-name><etal>et al</etal>; <collab>University of Washington Center for Mendelian Genomics</collab></person-group>. <article-title>Identification of CACNA1D variants associated with sinoatrial node dysfunction and deafness in additional Pakistani families reveals a clinical significance</article-title>. <source>J Hum Genet</source><year>2019</year>;<volume>64</volume>:<fpage>153</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">30498240</pub-id></mixed-citation></ref><ref id="euac030-B278"><label>278</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lodder</surname>
<given-names>EM</given-names>
</string-name>, <string-name><surname>De Nittis</surname><given-names>P</given-names></string-name>, <string-name><surname>Koopman</surname><given-names>CD</given-names></string-name>, <string-name><surname>Wiszniewski</surname><given-names>W</given-names></string-name>, <string-name><surname>Moura de Souza</surname><given-names>CF</given-names></string-name>, <string-name><surname>Lahrouchi</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>GNB5 mutations cause an autosomal-recessive multisystem syndrome with sinus bradycardia and cognitive disability</article-title>. <source>Am J Hum Genet</source><year>2016</year>;<volume>99</volume>:<fpage>786</fpage>.<pub-id pub-id-type="pmid">27588455</pub-id></mixed-citation></ref><ref id="euac030-B279"><label>279</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chetaille</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Preuss</surname><given-names>C</given-names></string-name>, <string-name><surname>Burkhard</surname><given-names>S</given-names></string-name>, <string-name><surname>Cote</surname><given-names>JM</given-names></string-name>, <string-name><surname>Houde</surname><given-names>C</given-names></string-name>, <string-name><surname>Castilloux</surname><given-names>J</given-names></string-name><etal>et al</etal>; <collab>FORGE Canada Consortium</collab></person-group>. <article-title>Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm</article-title>. <source>Nat Genet</source><year>2014</year>;<volume>46</volume>:<fpage>1245</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25282101</pub-id></mixed-citation></ref><ref id="euac030-B280"><label>280</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kong</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Zhan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Luo</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>A novel mutation of the EMD gene in a family with cardiac conduction abnormalities and a high incidence of sudden cardiac death</article-title>. <source>Pharmgenomics Pers Med</source><year>2019</year>;<volume>12</volume>:<fpage>319</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">31802929</pub-id></mixed-citation></ref><ref id="euac030-B281"><label>281</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wasserburger</surname>
<given-names>RH</given-names>
</string-name>, <string-name><surname>Alt</surname><given-names>WJ.</given-names></string-name></person-group>
<article-title>The normal RS-T segment elevation variant</article-title>. <source>Am J Cardiol</source><year>1961</year>;<volume>8</volume>:<fpage>184</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">13783301</pub-id></mixed-citation></ref><ref id="euac030-B282"><label>282</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tikkanen</surname>
<given-names>JT</given-names>
</string-name>, <string-name><surname>Anttonen</surname><given-names>O</given-names></string-name>, <string-name><surname>Junttila</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Aro</surname><given-names>AL</given-names></string-name>, <string-name><surname>Kerola</surname><given-names>T</given-names></string-name>, <string-name><surname>Rissanen</surname><given-names>HA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Long-term outcome associated with early repolarization on electrocardiography</article-title>. <source>N Engl J Med</source><year>2009</year>;<volume>361</volume>:<fpage>2529</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">19917913</pub-id></mixed-citation></ref><ref id="euac030-B283"><label>283</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rosso</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Kogan</surname><given-names>E</given-names></string-name>, <string-name><surname>Belhassen</surname><given-names>B</given-names></string-name>, <string-name><surname>Rozovski</surname><given-names>U</given-names></string-name>, <string-name><surname>Scheinman</surname><given-names>MM</given-names></string-name>, <string-name><surname>Zeltser</surname><given-names>D</given-names></string-name><etal>et al</etal></person-group>
<article-title>J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance</article-title>. <source>J Am Coll Cardiol</source><year>2008</year>;<volume>52</volume>:<fpage>1231</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18926326</pub-id></mixed-citation></ref><ref id="euac030-B284"><label>284</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ha&#x000ef;ssaguerre</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Derval</surname><given-names>N</given-names></string-name>, <string-name><surname>Sacher</surname><given-names>F</given-names></string-name>, <string-name><surname>Jesel</surname><given-names>L</given-names></string-name>, <string-name><surname>Deisenhofer</surname><given-names>I</given-names></string-name>, <string-name><surname>de Roy</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Sudden cardiac arrest associated with early repolarization</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>358</volume>:<fpage>2016</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">18463377</pub-id></mixed-citation></ref><ref id="euac030-B285"><label>285</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Aizawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Chinushi</surname><given-names>M</given-names></string-name>, <string-name><surname>Hasegawa</surname><given-names>K</given-names></string-name>, <string-name><surname>Naiki</surname><given-names>N</given-names></string-name>, <string-name><surname>Horie</surname><given-names>M</given-names></string-name>, <string-name><surname>Kaneko</surname><given-names>Y</given-names></string-name><etal>et al</etal></person-group>
<article-title>Electrical storm in idiopathic ventricular fibrillation is associated with early repolarization</article-title>. <source>J Am Coll Cardiol</source><year>2013</year>;<volume>62</volume>:<fpage>1015</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23747791</pub-id></mixed-citation></ref><ref id="euac030-B286"><label>286</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nam</surname>
<given-names>GB</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>YH</given-names></string-name>, <string-name><surname>Antzelevitch</surname><given-names>C.</given-names></string-name></person-group>
<article-title>Augmentation of J waves and electrical storms in patients with early repolarization</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>358</volume>:<fpage>2078</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18463391</pub-id></mixed-citation></ref><ref id="euac030-B287"><label>287</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Koncz</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Gurabi</surname><given-names>Z</given-names></string-name>, <string-name><surname>Patocskai</surname><given-names>B</given-names></string-name>, <string-name><surname>Panama</surname><given-names>BK</given-names></string-name>, <string-name><surname>Sz&#x000e9;l</surname><given-names>T</given-names></string-name>, <string-name><surname>Hu</surname><given-names>D</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mechanisms underlying the development of the electrocardiographic and arrhythmic manifestations of early repolarization syndrome</article-title>. <source>J Mol Cell Cardiol</source><year>2014</year>;<volume>68</volume>:<fpage>20</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24378566</pub-id></mixed-citation></ref><ref id="euac030-B288"><label>288</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Cooper</surname><given-names>DH</given-names></string-name>, <string-name><surname>Vijayakumar</surname><given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Pollak</surname><given-names>S</given-names></string-name>, <string-name><surname>Ha&#x000ef;ssaguerre</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Early repolarization associated with sudden death: insights from noninvasive electrocardiographic imaging</article-title>. <source>Heart Rhythm</source><year>2010</year>;<volume>7</volume>:<fpage>534</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">20153422</pub-id></mixed-citation></ref><ref id="euac030-B289"><label>289</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nademanee</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Haissaguerre</surname><given-names>M</given-names></string-name>, <string-name><surname>Hocini</surname><given-names>M</given-names></string-name>, <string-name><surname>Nogami</surname><given-names>A</given-names></string-name>, <string-name><surname>Cheniti</surname><given-names>G</given-names></string-name>, <string-name><surname>Duchateau</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mapping and ablation of ventricular fibrillation associated with early repolarization syndrome</article-title>. <source>Circulation</source><year>2019</year>;<volume>140</volume>:<fpage>1477</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">31542949</pub-id></mixed-citation></ref><ref id="euac030-B290"><label>290</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ha&#x000ef;ssaguerre</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Nademanee</surname><given-names>K</given-names></string-name>, <string-name><surname>Hocini</surname><given-names>M</given-names></string-name>, <string-name><surname>Cheniti</surname><given-names>G</given-names></string-name>, <string-name><surname>Duchateau</surname><given-names>J</given-names></string-name>, <string-name><surname>Frontera</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>Depolarization versus repolarization abnormality underlying inferolateral J-wave syndromes: new concepts in sudden cardiac death with apparently normal hearts</article-title>. <source>Heart Rhythm</source><year>2019</year>;<volume>16</volume>:<fpage>781</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">30391571</pub-id></mixed-citation></ref><ref id="euac030-B291"><label>291</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Boukens</surname>
<given-names>BJ</given-names>
</string-name>, <string-name><surname>Benjacholamas</surname><given-names>V</given-names></string-name>, <string-name><surname>van Amersfoort</surname><given-names>S</given-names></string-name>, <string-name><surname>Meijborg</surname><given-names>VM</given-names></string-name>, <string-name><surname>Schumacher</surname><given-names>C</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>B</given-names></string-name><etal>et al</etal></person-group>
<article-title>Structurally abnormal myocardium underlies ventricular fibrillation storms in a patient diagnosed with the early&#x000a0;repolarization pattern</article-title>. <source>JACC Clin Electrophysiol</source><year>2020</year>;<volume>6</volume>:<fpage>1395</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">33121669</pub-id></mixed-citation></ref><ref id="euac030-B292"><label>292</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Reinhard</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Kaess</surname><given-names>BM</given-names></string-name>, <string-name><surname>Debiec</surname><given-names>R</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>CP</given-names></string-name>, <string-name><surname>Stark</surname><given-names>K</given-names></string-name>, <string-name><surname>Tobin</surname><given-names>MD</given-names></string-name><etal>et al</etal></person-group>
<article-title>Heritability of early repolarization: a population-based study</article-title>. <source>Circ Cardiovasc Genet</source><year>2011</year>;<volume>4</volume>:<fpage>134</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21282333</pub-id></mixed-citation></ref><ref id="euac030-B293"><label>293</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bastiaenen</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Nolte</surname><given-names>IM</given-names></string-name>, <string-name><surname>Munroe</surname><given-names>PB</given-names></string-name>, <string-name><surname>Riese</surname><given-names>H</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>C</given-names></string-name>, <string-name><surname>O'Connor</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>The narrow-sense and common single nucleotide polymorphism heritability of early repolarization</article-title>. <source>Int J Cardiol</source><year>2019</year>;<volume>279</volume>:<fpage>135</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">30297186</pub-id></mixed-citation></ref><ref id="euac030-B294"><label>294</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Honarbakhsh</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Srinivasan</surname><given-names>N</given-names></string-name>, <string-name><surname>Kirkby</surname><given-names>C</given-names></string-name>, <string-name><surname>Firman</surname><given-names>E</given-names></string-name>, <string-name><surname>Tobin</surname><given-names>L</given-names></string-name>, <string-name><surname>Finlay</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Medium-term outcomes of idiopathic ventricular fibrillation survivors and family screening: a multicentre experience</article-title>. <source>Europace</source><year>2017</year>;<volume>19</volume>:<fpage>1874</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">27738067</pub-id></mixed-citation></ref><ref id="euac030-B295"><label>295</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nunn</surname>
<given-names>LM</given-names>
</string-name>, <string-name><surname>Bhar-Amato</surname><given-names>J</given-names></string-name>, <string-name><surname>Lowe</surname><given-names>MD</given-names></string-name>, <string-name><surname>Macfarlane</surname><given-names>PW</given-names></string-name>, <string-name><surname>Rogers</surname><given-names>P</given-names></string-name>, <string-name><surname>McKenna</surname><given-names>WJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Prevalence of J-point elevation in sudden arrhythmic death syndrome families</article-title>. <source>J Am Coll Cardiol</source><year>2011</year>;<volume>58</volume>:<fpage>286</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">21737021</pub-id></mixed-citation></ref><ref id="euac030-B296"><label>296</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mellor</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Nelson</surname><given-names>CP</given-names></string-name>, <string-name><surname>Robb</surname><given-names>C</given-names></string-name>, <string-name><surname>Raju</surname><given-names>H</given-names></string-name>, <string-name><surname>Wijeyeratne</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hengstenberg</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>The prevalence and significance of the early repolarization pattern in sudden arrhythmic death syndrome families</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2016</year>;<volume>9</volume>:<fpage>e003960</fpage>.<pub-id pub-id-type="pmid">27255966</pub-id></mixed-citation></ref><ref id="euac030-B297"><label>297</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Watanabe</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Nogami</surname><given-names>A</given-names></string-name>, <string-name><surname>Ohkubo</surname><given-names>K</given-names></string-name>, <string-name><surname>Kawata</surname><given-names>H</given-names></string-name>, <string-name><surname>Hayashi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ishikawa</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Electrocardiographic characteristics and <italic toggle="yes">SCN5A</italic> mutations in idiopathic ventricular fibrillation associated with early repolarization</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2011</year>;<volume>4</volume>:<fpage>874</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">22028457</pub-id></mixed-citation></ref><ref id="euac030-B298"><label>298</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Giudicessi</surname>
<given-names>JR</given-names>
</string-name>, <string-name><surname>Ye</surname><given-names>D</given-names></string-name>, <string-name><surname>Stutzman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>Prevalence and electrophysiological phenotype of rare <italic toggle="yes">SCN5A</italic> genetic variants identified in unexplained sudden cardiac arrest survivors</article-title>. <source>Europace</source><year>2020</year>;<volume>22</volume>:<fpage>622</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">32091595</pub-id></mixed-citation></ref><ref id="euac030-B299"><label>299</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>ZH</given-names>
</string-name>, <string-name><surname>Barajas-Mart&#x000ed;nez</surname><given-names>H</given-names></string-name>, <string-name><surname>Xia</surname><given-names>H</given-names></string-name>, <string-name><surname>Li</surname><given-names>B</given-names></string-name>, <string-name><surname>Capra</surname><given-names>JA</given-names></string-name>, <string-name><surname>Clatot</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Distinct features of probands with early repolarization and brugada syndromes carrying <italic toggle="yes">SCN5A</italic> pathogenic variants</article-title>. <source>J Am Coll Cardiol</source><year>2021</year>;<volume>78</volume>:<fpage>1603</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">34649698</pub-id></mixed-citation></ref><ref id="euac030-B300"><label>300</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chauveau</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Janin</surname><given-names>A</given-names></string-name>, <string-name><surname>Till</surname><given-names>M</given-names></string-name>, <string-name><surname>Morel</surname><given-names>E</given-names></string-name>, <string-name><surname>Chevalier</surname><given-names>P</given-names></string-name>, <string-name><surname>Millat</surname><given-names>G.</given-names></string-name></person-group>
<article-title>Early repolarization syndrome caused by <italic toggle="yes">de novo</italic> duplication of KCND3 detected by next-generation sequencing</article-title>. <source>HeartRhythm Case Rep</source><year>2017</year>;<volume>3</volume>:<fpage>574</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">29296579</pub-id></mixed-citation></ref><ref id="euac030-B301"><label>301</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Takayama</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Ohno</surname><given-names>S</given-names></string-name>, <string-name><surname>Ding</surname><given-names>WG</given-names></string-name>, <string-name><surname>Ashihara</surname><given-names>T</given-names></string-name>, <string-name><surname>Fukumoto</surname><given-names>D</given-names></string-name>, <string-name><surname>Wada</surname><given-names>Y</given-names></string-name><etal>et al</etal></person-group>
<article-title>A <italic toggle="yes">de novo</italic> gain-of-function KCND3 mutation in early repolarization syndrome</article-title>. <source>Heart Rhythm</source><year>2019</year>;<volume>16</volume>:<fpage>1698</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">31173922</pub-id></mixed-citation></ref><ref id="euac030-B302"><label>302</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Teumer</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Trenkwalder</surname><given-names>T</given-names></string-name>, <string-name><surname>Kessler</surname><given-names>T</given-names></string-name>, <string-name><surname>Jamshidi</surname><given-names>Y</given-names></string-name>, <string-name><surname>van den Berg</surname><given-names>ME</given-names></string-name>, <string-name><surname>Kaess</surname><given-names>B</given-names></string-name><etal>et al</etal></person-group>
<article-title>KCND3 potassium channel gene variant confers susceptibility to electrocardiographic early repolarization pattern</article-title>. <source>JCI Insight</source><year>2019</year>;<volume>4</volume>:<fpage>e131156</fpage>.</mixed-citation></ref><ref id="euac030-B303"><label>303</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Barajas-Mart&#x000ed;nez</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Hu</surname><given-names>D</given-names></string-name>, <string-name><surname>Ferrer</surname><given-names>T</given-names></string-name>, <string-name><surname>Onetti</surname><given-names>CG</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Burashnikov</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8</article-title>. <source>Heart Rhythm</source><year>2012</year>;<volume>9</volume>:<fpage>548</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">22056721</pub-id></mixed-citation></ref><ref id="euac030-B304"><label>304</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Medeiros-Domingo</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Tan</surname><given-names>BH</given-names></string-name>, <string-name><surname>Crotti</surname><given-names>L</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Eckhardt</surname><given-names>L</given-names></string-name>, <string-name><surname>Cuoretti</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes</article-title>. <source>Heart Rhythm</source><year>2010</year>;<volume>7</volume>:<fpage>1466</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">20558321</pub-id></mixed-citation></ref><ref id="euac030-B305"><label>305</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vidaillet</surname>
<given-names>HJ</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name><surname>Pressley</surname><given-names>JC</given-names></string-name>, <string-name><surname>Henke</surname><given-names>E</given-names></string-name>, <string-name><surname>Harrell</surname><given-names>FE</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>German</surname><given-names>LD.</given-names></string-name></person-group>
<article-title>Familial occurrence of accessory atrioventricular pathways (preexcitation syndrome)</article-title>. <source>N Engl J Med</source><year>1987</year>;<volume>317</volume>:<fpage>65</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">3587328</pub-id></mixed-citation></ref><ref id="euac030-B306"><label>306</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Deal</surname>
<given-names>BJ</given-names>
</string-name>, <string-name><surname>Keane</surname><given-names>JF</given-names></string-name>, <string-name><surname>Gillette</surname><given-names>PC</given-names></string-name>, <string-name><surname>Garson</surname><given-names>A</given-names><suffix>Jr.</suffix></string-name></person-group>
<article-title>Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: management and follow-up</article-title>. <source>J Am Coll Cardiol</source><year>1985</year>;<volume>5</volume>:<fpage>130</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">3964800</pub-id></mixed-citation></ref><ref id="euac030-B307"><label>307</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>MacRae</surname>
<given-names>CA</given-names>
</string-name>, <string-name><surname>Ghaisas</surname><given-names>N</given-names></string-name>, <string-name><surname>Kass</surname><given-names>S</given-names></string-name>, <string-name><surname>Donnelly</surname><given-names>S</given-names></string-name>, <string-name><surname>Basson</surname><given-names>CT</given-names></string-name>, <string-name><surname>Watkins</surname><given-names>HC</given-names></string-name><etal>et al</etal></person-group>
<article-title>Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3</article-title>. <source>J Clin Invest</source><year>1995</year>;<volume>96</volume>:<fpage>1216</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">7657794</pub-id></mixed-citation></ref><ref id="euac030-B308"><label>308</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gollob</surname>
<given-names>MH</given-names>
</string-name>, <string-name><surname>Green</surname><given-names>MS</given-names></string-name>, <string-name><surname>Tang</surname><given-names>AS</given-names></string-name>, <string-name><surname>Gollob</surname><given-names>T</given-names></string-name>, <string-name><surname>Karibe</surname><given-names>A</given-names></string-name>, <string-name><surname>Ali Hassan</surname><given-names>AS</given-names></string-name><etal>et al</etal></person-group>
<article-title>Identification of a gene responsible for familial Wolff-Parkinson-White syndrome</article-title>. <source>N Engl J Med</source><year>2001</year>;<volume>344</volume>:<fpage>1823</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">11407343</pub-id></mixed-citation></ref><ref id="euac030-B309"><label>309</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lopez-Sainz</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Dominguez</surname><given-names>F</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>LR</given-names></string-name>, <string-name><surname>Ochoa</surname><given-names>JP</given-names></string-name>, <string-name><surname>Barriales-Villa</surname><given-names>R</given-names></string-name>, <string-name><surname>Climent</surname><given-names>V</given-names></string-name><etal>et al</etal>; <collab>European Genetic Cardiomyopathies Initiative Investigators</collab></person-group>. <article-title>Clinical features and natural history of PRKAG2 variant cardiac glycogenosis</article-title>. <source>J Am Coll Cardiol</source><year>2020</year>;<volume>76</volume>:<fpage>186</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">32646569</pub-id></mixed-citation></ref><ref id="euac030-B310"><label>310</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Landstrom</surname>
<given-names>AP</given-names>
</string-name>, <string-name><surname>Parvatiyar</surname><given-names>MS</given-names></string-name>, <string-name><surname>Pinto</surname><given-names>JR</given-names></string-name>, <string-name><surname>Marquardt</surname><given-names>ML</given-names></string-name>, <string-name><surname>Bos</surname><given-names>JM</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C</article-title>. <source>J Mol Cell Cardiol</source><year>2008</year>;<volume>45</volume>:<fpage>281</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18572189</pub-id></mixed-citation></ref><ref id="euac030-B311"><label>311</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Geier</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Gehmlich</surname><given-names>K</given-names></string-name>, <string-name><surname>Ehler</surname><given-names>E</given-names></string-name>, <string-name><surname>Hassfeld</surname><given-names>S</given-names></string-name>, <string-name><surname>Perrot</surname><given-names>A</given-names></string-name>, <string-name><surname>Hayess</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group>
<article-title>Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy</article-title>. <source>Hum Mol Genet</source><year>2008</year>;<volume>17</volume>:<fpage>2753</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">18505755</pub-id></mixed-citation></ref><ref id="euac030-B312"><label>312</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Landstrom</surname>
<given-names>AP</given-names>
</string-name>, <string-name><surname>Weisleder</surname><given-names>N</given-names></string-name>, <string-name><surname>Batalden</surname><given-names>KB</given-names></string-name>, <string-name><surname>Bos</surname><given-names>JM</given-names></string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ommen</surname><given-names>SR</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans</article-title>. <source>J Mol Cell Cardiol</source><year>2007</year>;<volume>42</volume>:<fpage>1026</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">17509612</pub-id></mixed-citation></ref><ref id="euac030-B313"><label>313</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Al Senaidi</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Joshi</surname><given-names>N</given-names></string-name>, <string-name><surname>Al-Nabhani</surname><given-names>M</given-names></string-name>, <string-name><surname>Al-Kasbi</surname><given-names>G</given-names></string-name>, <string-name><surname>Al Farqani</surname><given-names>A</given-names></string-name>, <string-name><surname>Al-Thihli</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group>
<article-title>Phenotypic spectrum of ALPK3-related cardiomyopathy</article-title>. <source>Am J Med Genet A</source><year>2019</year>;<volume>179</volume>:<fpage>1235</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">31074094</pub-id></mixed-citation></ref><ref id="euac030-B314"><label>314</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ochoa</surname>
<given-names>JP</given-names>
</string-name>, <string-name><surname>Sabater-Molina</surname><given-names>M</given-names></string-name>, <string-name><surname>Garc&#x000ed;a-Pinilla</surname><given-names>JM</given-names></string-name>, <string-name><surname>Mogensen</surname><given-names>J</given-names></string-name>, <string-name><surname>Restrepo-C&#x000f3;rdoba</surname><given-names>A</given-names></string-name>, <string-name><surname>Palomino-Doza</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Formin homology 2 domain containing 3 (FHOD3) is a genetic basis for hypertrophic cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>;<volume>72</volume>:<fpage>2457</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">30442288</pub-id></mixed-citation></ref><ref id="euac030-B315"><label>315</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Alfares</surname>
<given-names>AA</given-names>
</string-name>, <string-name><surname>Kelly</surname><given-names>MA</given-names></string-name>, <string-name><surname>Mcdermott</surname><given-names>G</given-names></string-name>, <string-name><surname>Funke</surname><given-names>BH</given-names></string-name>, <string-name><surname>Lebo</surname><given-names>MS</given-names></string-name>, <string-name><surname>Baxter</surname><given-names>SB</given-names></string-name><etal>et al</etal></person-group>
<article-title>Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity</article-title>. <source>Genet Med</source><year>2015</year>;<volume>17</volume>:<fpage>880</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25611685</pub-id></mixed-citation></ref><ref id="euac030-B316"><label>316</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ingles</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Sarina</surname><given-names>T</given-names></string-name>, <string-name><surname>Yeates</surname><given-names>L</given-names></string-name>, <string-name><surname>Hunt</surname><given-names>L</given-names></string-name>, <string-name><surname>Macciocca</surname><given-names>I</given-names></string-name>, <string-name><surname>McCormack</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy</article-title>. <source>Genet Med</source><year>2013</year>;<volume>15</volume>:<fpage>972</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23598715</pub-id></mixed-citation></ref><ref id="euac030-B317"><label>317</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van Velzen</surname>
<given-names>HG</given-names>
</string-name>, <string-name><surname>Schinkel</surname><given-names>AFL</given-names></string-name>, <string-name><surname>Baart</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Oldenburg</surname><given-names>RA</given-names></string-name>, <string-name><surname>Frohn-Mulder</surname><given-names>IME</given-names></string-name>, <string-name><surname>van Slegtenhorst</surname><given-names>MA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Outcomes of contemporary family screening in hypertrophic cardiomyopathy</article-title>. <source>Circ Genom Precis Med</source><year>2018</year>;<volume>11</volume>:<fpage>e001896</fpage>.<pub-id pub-id-type="pmid">29661763</pub-id></mixed-citation></ref><ref id="euac030-B318"><label>318</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Norrish</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Jager</surname><given-names>J</given-names></string-name>, <string-name><surname>Field</surname><given-names>E</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>E</given-names></string-name>, <string-name><surname>Fell</surname><given-names>H</given-names></string-name>, <string-name><surname>Lord</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives</article-title>. <source>Circulation</source><year>2019</year>;<volume>140</volume>:<fpage>184</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">31006259</pub-id></mixed-citation></ref><ref id="euac030-B319"><label>319</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pena</surname>
<given-names>JLB</given-names>
</string-name>, <string-name><surname>Santos</surname><given-names>WC</given-names></string-name>, <string-name><surname>Siqueira</surname><given-names>MHA</given-names></string-name>, <string-name><surname>Sampaio</surname><given-names>IH</given-names></string-name>, <string-name><surname>Moura</surname><given-names>ICG</given-names></string-name>, <string-name><surname>Sternick</surname><given-names>EB.</given-names></string-name></person-group>
<article-title>Glycogen storage cardiomyopathy (PRKAG2): diagnostic findings of standard and advanced echocardiography techniques</article-title>. <source>Eur Heart J Cardiovasc Imaging</source><year>2021</year>;<volume>22</volume>:<fpage>800</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32747946</pub-id></mixed-citation></ref><ref id="euac030-B320"><label>320</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Maron</surname>
<given-names>BJ</given-names>
</string-name>, <string-name><surname>Roberts</surname><given-names>WC</given-names></string-name>, <string-name><surname>Arad</surname><given-names>M</given-names></string-name>, <string-name><surname>Haas</surname><given-names>TS</given-names></string-name>, <string-name><surname>Spirito</surname><given-names>P</given-names></string-name>, <string-name><surname>Wright</surname><given-names>GB</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy</article-title>. <source>JAMA</source><year>2009</year>;<volume>301</volume>:<fpage>1253</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19318653</pub-id></mixed-citation></ref><ref id="euac030-B321"><label>321</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Elliott</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Baker</surname><given-names>R</given-names></string-name>, <string-name><surname>Pasquale</surname><given-names>F</given-names></string-name>, <string-name><surname>Quarta</surname><given-names>G</given-names></string-name>, <string-name><surname>Ebrahim</surname><given-names>H</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>AB</given-names></string-name><etal>et al</etal>; <collab>ACES study group</collab></person-group>. <article-title>Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey</article-title>. <source>Heart</source><year>2011</year>;<volume>97</volume>:<fpage>1957</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">21890869</pub-id></mixed-citation></ref><ref id="euac030-B322"><label>322</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Benson</surname>
<given-names>MD</given-names>
</string-name>, <string-name><surname>Waddington-Cruz</surname><given-names>M</given-names></string-name>, <string-name><surname>Berk</surname><given-names>JL</given-names></string-name>, <string-name><surname>Polydefkis</surname><given-names>M</given-names></string-name>, <string-name><surname>Dyck</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Wang</surname><given-names>AK</given-names></string-name><etal>et al</etal></person-group>
<article-title>Inotersen treatment for patients with hereditary transthyretin amyloidosis</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>379</volume>:<fpage>22</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">29972757</pub-id></mixed-citation></ref><ref id="euac030-B323"><label>323</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yavari</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Bellahcene</surname><given-names>M</given-names></string-name>, <string-name><surname>Bucchi</surname><given-names>A</given-names></string-name>, <string-name><surname>Sirenko</surname><given-names>S</given-names></string-name>, <string-name><surname>Pinter</surname><given-names>K</given-names></string-name>, <string-name><surname>Herring</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mammalian &#x003b3;2 AMPK regulates intrinsic heart rate</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>1258</fpage>.<pub-id pub-id-type="pmid">29097735</pub-id></mixed-citation></ref><ref id="euac030-B324"><label>324</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sternick</surname>
<given-names>EB</given-names>
</string-name>, <string-name><surname>Oliva</surname><given-names>A</given-names></string-name>, <string-name><surname>Gerken</surname><given-names>LM</given-names></string-name>, <string-name><surname>Magalh&#x000e3;es</surname><given-names>L</given-names></string-name>, <string-name><surname>Scarpelli</surname><given-names>R</given-names></string-name>, <string-name><surname>Correia</surname><given-names>FS</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical, electrocardiographic, and electrophysiologic characteristics of patients with a fasciculoventricular pathway: the role of PRKAG2 mutation</article-title>. <source>Heart Rhythm</source><year>2011</year>;<volume>8</volume>:<fpage>58</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">20888928</pub-id></mixed-citation></ref><ref id="euac030-B325"><label>325</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Das</surname>
<given-names>KJ</given-names>
</string-name>, <string-name><surname>Ingles</surname><given-names>J</given-names></string-name>, <string-name><surname>Bagnall</surname><given-names>RD</given-names></string-name>, <string-name><surname>Semsarian</surname><given-names>C.</given-names></string-name></person-group>
<article-title>Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment</article-title>. <source>Genet Med</source><year>2014</year>;<volume>16</volume>:<fpage>286</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">24113344</pub-id></mixed-citation></ref><ref id="euac030-B326"><label>326</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ahmad</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>McNally</surname><given-names>EM</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Baty</surname><given-names>LC</given-names></string-name>, <string-name><surname>Day</surname><given-names>SM</given-names></string-name>, <string-name><surname>Kullo</surname><given-names>IJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the American Heart Association</article-title>. <source>Circ Genom Precis Med</source><year>2019</year>;<volume>12</volume>:<fpage>e000054</fpage>.<pub-id pub-id-type="pmid">31117808</pub-id></mixed-citation></ref><ref id="euac030-B327"><label>327</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ranthe</surname>
<given-names>MF</given-names>
</string-name>, <string-name><surname>Carstensen</surname><given-names>L</given-names></string-name>, <string-name><surname>&#x000d8;yen</surname><given-names>N</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>MK</given-names></string-name>, <string-name><surname>Axelsson</surname><given-names>A</given-names></string-name>, <string-name><surname>Wohlfahrt</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons</article-title>. <source>Circulation</source><year>2015</year>;<volume>132</volume>:<fpage>1013</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26276887</pub-id></mixed-citation></ref><ref id="euac030-B328"><label>328</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bagnall</surname>
<given-names>RD</given-names>
</string-name>, <string-name><surname>Ingles</surname><given-names>J</given-names></string-name>, <string-name><surname>Dinger</surname><given-names>ME</given-names></string-name>, <string-name><surname>Cowley</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ross</surname><given-names>SB</given-names></string-name>, <string-name><surname>Minoche</surname><given-names>AE</given-names></string-name><etal>et al</etal></person-group>
<article-title>Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>;<volume>72</volume>:<fpage>419</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">30025578</pub-id></mixed-citation></ref><ref id="euac030-B329"><label>329</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ho</surname>
<given-names>CY</given-names>
</string-name>, <string-name><surname>Day</surname><given-names>SM</given-names></string-name>, <string-name><surname>Ashley</surname><given-names>EA</given-names></string-name>, <string-name><surname>Michels</surname><given-names>M</given-names></string-name>, <string-name><surname>Pereira</surname><given-names>AC</given-names></string-name>, <string-name><surname>Jacoby</surname><given-names>D</given-names></string-name><etal>et al</etal>; <collab>For the SHaRe Investigators</collab></person-group>. <article-title>Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)</article-title>. <source>Circulation</source><year>2018</year>;<volume>138</volume>:<fpage>1387</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">30297972</pub-id></mixed-citation></ref><ref id="euac030-B330"><label>330</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Thomson</surname>
<given-names>KL</given-names>
</string-name>, <string-name><surname>Ormondroyd</surname><given-names>E</given-names></string-name>, <string-name><surname>Harper</surname><given-names>AR</given-names></string-name>, <string-name><surname>Dent</surname><given-names>T</given-names></string-name>, <string-name><surname>McGuire</surname><given-names>K</given-names></string-name>, <string-name><surname>Baksi</surname><given-names>J</given-names></string-name><etal>et al</etal>; <collab>NIHR BioResource &#x02013; Rare Diseases Consortium</collab></person-group>. <article-title>Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield</article-title>. <source>Genet Med</source><year>2019</year>;<volume>21</volume>:<fpage>1576</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">30531895</pub-id></mixed-citation></ref><ref id="euac030-B331"><label>331</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vald&#x000e9;s-Mas</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Guti&#x000e9;rrez-Fern&#x000e1;ndez</surname><given-names>A</given-names></string-name>, <string-name><surname>G&#x000f3;mez</surname><given-names>J</given-names></string-name>, <string-name><surname>Coto</surname><given-names>E</given-names></string-name>, <string-name><surname>Astudillo</surname><given-names>A</given-names></string-name>, <string-name><surname>Puente</surname><given-names>DA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mutations in filamin C cause a new form of familial hypertrophic cardiomyopathy</article-title>. <source>Nat Commun</source><year>2014</year>;<volume>5</volume>:<fpage>5326</fpage>.<pub-id pub-id-type="pmid">25351925</pub-id></mixed-citation></ref><ref id="euac030-B332"><label>332</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ingles</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Burns</surname><given-names>C</given-names></string-name>, <string-name><surname>Bagnall</surname><given-names>RD</given-names></string-name>, <string-name><surname>Lam</surname><given-names>L</given-names></string-name>, <string-name><surname>Yeates</surname><given-names>L</given-names></string-name>, <string-name><surname>Sarina</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications</article-title>. <source>Circ Cardiovasc Genet</source><year>2017</year>;<volume>10</volume>:<fpage>e001620</fpage>.<pub-id pub-id-type="pmid">28408708</pub-id></mixed-citation></ref><ref id="euac030-B333"><label>333</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van Capelle</surname>
<given-names>CI</given-names>
</string-name>, <string-name><surname>Poelman</surname><given-names>E</given-names></string-name>, <string-name><surname>Frohn-Mulder</surname><given-names>IM</given-names></string-name>, <string-name><surname>Koopman</surname><given-names>LP</given-names></string-name>, <string-name><surname>van den Hout</surname><given-names>JMP</given-names></string-name>, <string-name><surname>R&#x000e9;gal</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Cardiac outcome in classic infantile Pompe disease after 13&#x0202f;years of treatment with recombinant human acid alpha-glucosidase</article-title>. <source>Int J Cardiol</source><year>2018</year>;<volume>269</volume>:<fpage>104</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">30049495</pub-id></mixed-citation></ref><ref id="euac030-B334"><label>334</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Landstrom</surname>
<given-names>AP</given-names>
</string-name>, <string-name><surname>Adekola</surname><given-names>BA</given-names></string-name>, <string-name><surname>Bos</surname><given-names>JM</given-names></string-name>, <string-name><surname>Ommen</surname><given-names>SR</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing</article-title>. <source>Am Heart J</source><year>2011</year>;<volume>161</volume>:<fpage>165</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">21167350</pub-id></mixed-citation></ref><ref id="euac030-B335"><label>335</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kouz</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Lissewski</surname><given-names>C</given-names></string-name>, <string-name><surname>Spranger</surname><given-names>S</given-names></string-name>, <string-name><surname>Mitter</surname><given-names>D</given-names></string-name>, <string-name><surname>Riess</surname><given-names>A</given-names></string-name>, <string-name><surname>Lopez-Gonzalez</surname><given-names>V</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genotype and phenotype in patients with Noonan syndrome and a RIT1 mutation</article-title>. <source>Genet Med</source><year>2016</year>;<volume>18</volume>:<fpage>1226</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">27101134</pub-id></mixed-citation></ref><ref id="euac030-B336"><label>336</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mathew</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Zahavich</surname><given-names>L</given-names></string-name>, <string-name><surname>Lafreniere-Roula</surname><given-names>M</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>J</given-names></string-name>, <string-name><surname>George</surname><given-names>K</given-names></string-name>, <string-name><surname>Benson</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy</article-title>. <source>Clin Genet</source><year>2018</year>;<volume>93</volume>:<fpage>310</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29053178</pub-id></mixed-citation></ref><ref id="euac030-B337"><label>337</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ingles</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Doolan</surname><given-names>A</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>C</given-names></string-name>, <string-name><surname>Seidman</surname><given-names>J</given-names></string-name>, <string-name><surname>Seidman</surname><given-names>C</given-names></string-name>, <string-name><surname>Semsarian</surname><given-names>C.</given-names></string-name></person-group>
<article-title>Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling</article-title>. <source>J Med Genet</source><year>2005</year>;<volume>42</volume>:<fpage>e59</fpage>.<pub-id pub-id-type="pmid">16199542</pub-id></mixed-citation></ref><ref id="euac030-B338"><label>338</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Miron</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Lafreniere-Roula</surname><given-names>MS</given-names></string-name>, <string-name><surname>Fan</surname><given-names>CP</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>KR</given-names></string-name>, <string-name><surname>Dragulescu</surname><given-names>A</given-names></string-name>, <string-name><surname>Papaz</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy</article-title>. <source>Circulation</source><year>2020</year>;<volume>142</volume>:<fpage>217</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">32418493</pub-id></mixed-citation></ref><ref id="euac030-B339"><label>339</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Christiaans</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Birnie</surname><given-names>E</given-names></string-name>, <string-name><surname>Bonsel</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Mannens</surname><given-names>MM</given-names></string-name>, <string-name><surname>Michels</surname><given-names>M</given-names></string-name>, <string-name><surname>Majoor-Krakauer</surname><given-names>D</given-names></string-name><etal>et al</etal></person-group>
<article-title>Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy</article-title>. <source>Eur Heart J</source><year>2011</year>;<volume>32</volume>:<fpage>1161</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">21459882</pub-id></mixed-citation></ref><ref id="euac030-B340"><label>340</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Haas</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Frese</surname><given-names>KS</given-names></string-name>, <string-name><surname>Peil</surname><given-names>B</given-names></string-name>, <string-name><surname>Kloos</surname><given-names>W</given-names></string-name>, <string-name><surname>Keller</surname><given-names>A</given-names></string-name>, <string-name><surname>Nietsch</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>Atlas of the clinical genetics of human dilated cardiomyopathy</article-title>. <source>Eur Heart J</source><year>2015</year>;<volume>36</volume>:<fpage>1123</fpage>&#x02013;<lpage>35a</lpage>.<pub-id pub-id-type="pmid">25163546</pub-id></mixed-citation></ref><ref id="euac030-B341"><label>341</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ware</surname>
<given-names>JS</given-names>
</string-name>, <string-name><surname>Amor-Salamanca</surname><given-names>A</given-names></string-name>, <string-name><surname>Tayal</surname><given-names>U</given-names></string-name>, <string-name><surname>Govind</surname><given-names>R</given-names></string-name>, <string-name><surname>Serrano</surname><given-names>I</given-names></string-name>, <string-name><surname>Salazar-Mendiguch&#x000ed;a</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic etiology for alcohol-induced cardiac toxicity</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>;<volume>71</volume>:<fpage>2293</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">29773157</pub-id></mixed-citation></ref><ref id="euac030-B342"><label>342</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ware</surname>
<given-names>JS</given-names>
</string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Mazaika</surname><given-names>E</given-names></string-name>, <string-name><surname>Yasso</surname><given-names>CM</given-names></string-name>, <string-name><surname>Desouza</surname><given-names>T</given-names></string-name>, <string-name><surname>Cappola</surname><given-names>TP</given-names></string-name><etal>et al</etal>; <collab>IMAC-2 and IPAC Investigators</collab></person-group>. <article-title>Shared genetic predisposition in peripartum and dilated cardiomyopathies</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>374</volume>:<fpage>233</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">26735901</pub-id></mixed-citation></ref><ref id="euac030-B343"><label>343</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Thuillot</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Maupain</surname><given-names>C</given-names></string-name>, <string-name><surname>Gandjbakhch</surname><given-names>E</given-names></string-name>, <string-name><surname>Waintraub</surname><given-names>X</given-names></string-name>, <string-name><surname>Hidden-Lucet</surname><given-names>F</given-names></string-name>, <string-name><surname>Isnard</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>External validation of risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers</article-title>. <source>Eur J Heart Fail</source><year>2019</year>;<volume>21</volume>:<fpage>253</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">30623531</pub-id></mixed-citation></ref><ref id="euac030-B344"><label>344</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Peters</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>P</given-names></string-name>, <string-name><surname>Kalman</surname><given-names>JM</given-names></string-name>, <string-name><surname>Fatkin</surname><given-names>D.</given-names></string-name></person-group>
<article-title>Arrhythmic genotypes in familial dilated cardiomyopathy: implications for genetic testing and clinical management</article-title>. <source>Heart Lung Circ</source><year>2019</year>;<volume>28</volume>:<fpage>31</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">30482687</pub-id></mixed-citation></ref><ref id="euac030-B345"><label>345</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kayvanpour</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Sedaghat-Hamedani</surname><given-names>F</given-names></string-name>, <string-name><surname>Amr</surname><given-names>A</given-names></string-name>, <string-name><surname>Lai</surname><given-names>A</given-names></string-name>, <string-name><surname>Haas</surname><given-names>J</given-names></string-name>, <string-name><surname>Holzer</surname><given-names>DB</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals</article-title>. <source>Clin Res Cardiol</source><year>2017</year>;<volume>106</volume>:<fpage>127</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">27576561</pub-id></mixed-citation></ref><ref id="euac030-B346"><label>346</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ortiz-Genga</surname>
<given-names>MF</given-names>
</string-name>, <string-name><surname>Cuenca</surname><given-names>S</given-names></string-name>, <string-name><surname>Dal Ferro</surname><given-names>M</given-names></string-name>, <string-name><surname>Zorio</surname><given-names>E</given-names></string-name>, <string-name><surname>Salgado-Aranda</surname><given-names>R</given-names></string-name>, <string-name><surname>Climent</surname><given-names>V</given-names></string-name><etal>et al</etal></person-group>
<article-title>Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies</article-title>. <source>J Am Coll Cardiol</source><year>2016</year>;<volume>68</volume>:<fpage>2440</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">27908349</pub-id></mixed-citation></ref><ref id="euac030-B347"><label>347</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ader</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>De Groote</surname><given-names>P</given-names></string-name>, <string-name><surname>R&#x000e9;ant</surname><given-names>P</given-names></string-name>, <string-name><surname>Rooryck-Thambo</surname><given-names>C</given-names></string-name>, <string-name><surname>Dupin-Deguine</surname><given-names>D</given-names></string-name>, <string-name><surname>Rambaud</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>FLNC pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations</article-title>. <source>Clin Genet</source><year>2019</year>;<volume>96</volume>:<fpage>317</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">31245841</pub-id></mixed-citation></ref><ref id="euac030-B348"><label>348</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wahbi</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>B&#x000e9;hin</surname><given-names>A</given-names></string-name>, <string-name><surname>Charron</surname><given-names>P</given-names></string-name>, <string-name><surname>Dunand</surname><given-names>M</given-names></string-name>, <string-name><surname>Richard</surname><given-names>P</given-names></string-name>, <string-name><surname>Meune</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>High cardiovascular morbidity and mortality in myofibrillar myopathies due to DES gene mutations: a 10-year longitudinal study</article-title>. <source>Neuromuscul Disord</source><year>2012</year>;<volume>22</volume>:<fpage>211</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22153487</pub-id></mixed-citation></ref><ref id="euac030-B349"><label>349</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Heli&#x000f6;</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Elliott</surname><given-names>P</given-names></string-name>, <string-name><surname>Koskenvuo</surname><given-names>JW</given-names></string-name>, <string-name><surname>Gimeno</surname><given-names>JR</given-names></string-name>, <string-name><surname>Tavazzi</surname><given-names>L</given-names></string-name>, <string-name><surname>Tendera</surname><given-names>M</given-names></string-name><etal>et al</etal>; <collab>EORP Cardiomyopathy Registry Investigators Group</collab></person-group>. <article-title>ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients</article-title>. <source>ESC Heart Fail</source><year>2020</year>;<volume>7</volume>:<fpage>3013</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">32767651</pub-id></mixed-citation></ref><ref id="euac030-B350"><label>350</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<collab>European Society of Human Genetics</collab>
</person-group>. <article-title>Genetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics</article-title>. <source>Eur J Hum Genet</source><year>2009</year>;<volume>17</volume>:<fpage>720</fpage>&#x02013;<lpage>1</lpage>.<pub-id pub-id-type="pmid">19277059</pub-id></mixed-citation></ref><ref id="euac030-B351"><label>351</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Elliott</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Andersson</surname><given-names>B</given-names></string-name>, <string-name><surname>Arbustini</surname><given-names>E</given-names></string-name>, <string-name><surname>Bilinska</surname><given-names>Z</given-names></string-name>, <string-name><surname>Cecchi</surname><given-names>F</given-names></string-name>, <string-name><surname>Charron</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases</article-title>. <source>Eur Heart J</source><year>2008</year>;<volume>29</volume>:<fpage>270</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17916581</pub-id></mixed-citation></ref><ref id="euac030-B352"><label>352</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Keren</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Gottlieb</surname><given-names>S</given-names></string-name>, <string-name><surname>Tzivoni</surname><given-names>D</given-names></string-name>, <string-name><surname>Stern</surname><given-names>S</given-names></string-name>, <string-name><surname>Yarom</surname><given-names>R</given-names></string-name>, <string-name><surname>Billingham</surname><given-names>ME</given-names></string-name><etal>et al</etal></person-group>
<article-title>Mildly dilated congestive cardiomyopathy. Use of prospective diagnostic criteria and description of the clinical course without heart transplantation</article-title>. <source>Circulation</source><year>1990</year>;<volume>81</volume>:<fpage>506</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">2297858</pub-id></mixed-citation></ref><ref id="euac030-B353"><label>353</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Grunig</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Tasman</surname><given-names>JA</given-names></string-name>, <string-name><surname>Kucherer</surname><given-names>H</given-names></string-name>, <string-name><surname>Franz</surname><given-names>W</given-names></string-name>, <string-name><surname>Kubler</surname><given-names>W</given-names></string-name>, <string-name><surname>Katus</surname><given-names>HA.</given-names></string-name></person-group>
<article-title>Frequency and phenotypes of familial dilated cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source><year>1998</year>;<volume>31</volume>:<fpage>186</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">9426039</pub-id></mixed-citation></ref><ref id="euac030-B354"><label>354</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mahon</surname>
<given-names>NG</given-names>
</string-name>, <string-name><surname>Murphy</surname><given-names>RT</given-names></string-name>, <string-name><surname>MacRae</surname><given-names>CA</given-names></string-name>, <string-name><surname>Caforio</surname><given-names>AL</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>PM</given-names></string-name>, <string-name><surname>McKenna</surname><given-names>WJ.</given-names></string-name></person-group>
<article-title>Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease</article-title>. <source>Ann Intern Med</source><year>2005</year>;<volume>143</volume>:<fpage>108</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">16027452</pub-id></mixed-citation></ref><ref id="euac030-B355"><label>355</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Michels</surname>
<given-names>VV</given-names>
</string-name>, <string-name><surname>Moll</surname><given-names>PP</given-names></string-name>, <string-name><surname>Miller</surname><given-names>FA</given-names></string-name>, <string-name><surname>Tajik</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Chu</surname><given-names>JS</given-names></string-name>, <string-name><surname>Driscoll</surname><given-names>DJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy</article-title>. <source>N Engl J Med</source><year>1992</year>;<volume>326</volume>:<fpage>77</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">1727235</pub-id></mixed-citation></ref><ref id="euac030-B356"><label>356</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Asselbergs</surname>
<given-names>FW</given-names>
</string-name>, <string-name><surname>Sammani</surname><given-names>A</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>P</given-names></string-name>, <string-name><surname>Gimeno</surname><given-names>JR</given-names></string-name>, <string-name><surname>Tavazzi</surname><given-names>L</given-names></string-name>, <string-name><surname>Tendera</surname><given-names>M</given-names></string-name><etal>et al</etal>; <collab>Cardiomyopathy &#x00026; Myocarditis Registry Investigators Group</collab></person-group>. <article-title>Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy &#x00026; Myocarditis registry</article-title>. <source>ESC Heart Fail</source><year>2021</year>;<volume>8</volume>:<fpage>95</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">33179448</pub-id></mixed-citation></ref><ref id="euac030-B357"><label>357</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Garcia-Pavia</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>Y</given-names></string-name>, <string-name><surname>Restrepo-Cordoba</surname><given-names>MA</given-names></string-name>, <string-name><surname>Lunde</surname><given-names>IG</given-names></string-name>, <string-name><surname>Wakimoto</surname><given-names>H</given-names></string-name>, <string-name><surname>Smith</surname><given-names>AM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic variants associated with cancer therapy-induced cardiomyopathy</article-title>. <source>Circulation</source><year>2019</year>;<volume>140</volume>:<fpage>31</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">30987448</pub-id></mixed-citation></ref><ref id="euac030-B358"><label>358</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kontorovich</surname>
<given-names>AR</given-names>
</string-name>, <string-name><surname>Patel</surname><given-names>N</given-names></string-name>, <string-name><surname>Moscati</surname><given-names>A</given-names></string-name>, <string-name><surname>Richter</surname><given-names>F</given-names></string-name>, <string-name><surname>Peter</surname><given-names>I</given-names></string-name>, <string-name><surname>Purevjav</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>Myopathic cardiac genotypes increase risk for myocarditis</article-title>. <source>JACC Basic Transl Sci</source><year>2021</year>;<volume>6</volume>:<fpage>584</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">34368507</pub-id></mixed-citation></ref><ref id="euac030-B359"><label>359</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mazzarotto</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Tayal</surname><given-names>U</given-names></string-name>, <string-name><surname>Buchan</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Midwinter</surname><given-names>W</given-names></string-name>, <string-name><surname>Wilk</surname><given-names>A</given-names></string-name>, <string-name><surname>Whiffin</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>Reevaluating the genetic contribution of monogenic dilated cardiomyopathy</article-title>. <source>Circulation</source><year>2020</year>;<volume>141</volume>:<fpage>387</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">31983221</pub-id></mixed-citation></ref><ref id="euac030-B360"><label>360</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jordan</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Hershberger</surname><given-names>RE.</given-names></string-name></person-group>
<article-title>Considering complexity in the genetic evaluation of dilated cardiomyopathy</article-title>. <source>Heart</source><year>2021</year>;<volume>107</volume>:<fpage>106</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">33109712</pub-id></mixed-citation></ref><ref id="euac030-B361"><label>361</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Garnier</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Harakalova</surname><given-names>M</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>S</given-names></string-name>, <string-name><surname>Mokry</surname><given-names>M</given-names></string-name>, <string-name><surname>Regitz-Zagrosek</surname><given-names>V</given-names></string-name>, <string-name><surname>Hengstenberg</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23</article-title>. <source>Eur Heart J</source><year>2021</year>;<volume>42</volume>:<fpage>2000</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">33677556</pub-id></mixed-citation></ref><ref id="euac030-B362"><label>362</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mogensen</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>van Tintelen</surname><given-names>JP</given-names></string-name>, <string-name><surname>Fokstuen</surname><given-names>S</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>P</given-names></string-name>, <string-name><surname>van Langen</surname><given-names>IM</given-names></string-name>, <string-name><surname>Meder</surname><given-names>B</given-names></string-name><etal>et al</etal></person-group>
<article-title>The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics</article-title>. <source>Eur Heart J</source><year>2015</year>;<volume>36</volume>:<fpage>1367</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">25845928</pub-id></mixed-citation></ref><ref id="euac030-B363"><label>363</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Peters</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Johnson</surname><given-names>R</given-names></string-name>, <string-name><surname>Birch</surname><given-names>S</given-names></string-name>, <string-name><surname>Zentner</surname><given-names>D</given-names></string-name>, <string-name><surname>Hershberger</surname><given-names>RE</given-names></string-name>, <string-name><surname>Fatkin</surname><given-names>D.</given-names></string-name></person-group>
<article-title>Familial dilated cardiomyopathy</article-title>. <source>Heart Lung Circ</source><year>2020</year>;<volume>29</volume>:<fpage>566</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">31974027</pub-id></mixed-citation></ref><ref id="euac030-B364"><label>364</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pinto</surname>
<given-names>YM</given-names>
</string-name>, <string-name><surname>Elliott</surname><given-names>PM</given-names></string-name>, <string-name><surname>Arbustini</surname><given-names>E</given-names></string-name>, <string-name><surname>Adler</surname><given-names>Y</given-names></string-name>, <string-name><surname>Anastasakis</surname><given-names>A</given-names></string-name>, <string-name><surname>B&#x000f6;hm</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases</article-title>. <source>Eur Heart J</source><year>2016</year>;<volume>37</volume>:<fpage>1850</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26792875</pub-id></mixed-citation></ref><ref id="euac030-B365"><label>365</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hasselberg</surname>
<given-names>NE</given-names>
</string-name>, <string-name><surname>Haland</surname><given-names>TF</given-names></string-name>, <string-name><surname>Saberniak</surname><given-names>J</given-names></string-name>, <string-name><surname>Brekke</surname><given-names>PH</given-names></string-name>, <string-name><surname>Berge</surname><given-names>KE</given-names></string-name>, <string-name><surname>Leren</surname><given-names>TP</given-names></string-name><etal>et al</etal></person-group>
<article-title>Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation</article-title>. <source>Eur Heart J</source><year>2018</year>;<volume>39</volume>:<fpage>853</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">29095976</pub-id></mixed-citation></ref><ref id="euac030-B366"><label>366</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kuliev</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Pomerantseva</surname><given-names>E</given-names></string-name>, <string-name><surname>Polling</surname><given-names>D</given-names></string-name>, <string-name><surname>Verlinsky</surname><given-names>O</given-names></string-name>, <string-name><surname>Rechitsky</surname><given-names>S.</given-names></string-name></person-group>
<article-title>PGD for inherited cardiac diseases</article-title>. <source>Reprod Biomed Online</source><year>2012</year>;<volume>24</volume>:<fpage>443</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">22386593</pub-id></mixed-citation></ref><ref id="euac030-B367"><label>367</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hoorntje</surname>
<given-names>ET</given-names>
</string-name>, <string-name><surname>Bollen</surname><given-names>IA</given-names></string-name>, <string-name><surname>Barge-Schaapveld</surname><given-names>DQ</given-names></string-name>, <string-name><surname>van Tienen</surname><given-names>FH</given-names></string-name>, <string-name><surname>Te Meerman</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Jansweijer</surname><given-names>JA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Lamin A/C-related cardiac disease: late onset with a variable and mild phenotype in a large cohort of patients with the lamin A/C p.(Arg331Gln) founder mutation</article-title>. <source>Circ Cardiovasc Genet</source><year>2017</year>;<volume>10</volume>:<fpage>e001631</fpage>.<pub-id pub-id-type="pmid">28790152</pub-id></mixed-citation></ref><ref id="euac030-B368"><label>368</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Verdonschot</surname>
<given-names>JAJ</given-names>
</string-name>, <string-name><surname>Hazebroek</surname><given-names>MR</given-names></string-name>, <string-name><surname>Derks</surname><given-names>KWJ</given-names></string-name>, <string-name><surname>Barandiar&#x000e1;n Aizpurua</surname><given-names>A</given-names></string-name>, <string-name><surname>Merken</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias</article-title>. <source>Eur Heart J</source><year>2018</year>;<volume>39</volume>:<fpage>864</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">29377983</pub-id></mixed-citation></ref><ref id="euac030-B369"><label>369</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gigli</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Merlo</surname><given-names>M</given-names></string-name>, <string-name><surname>Graw</surname><given-names>SL</given-names></string-name>, <string-name><surname>Barbati</surname><given-names>G</given-names></string-name>, <string-name><surname>Rowland</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Slavov</surname><given-names>DB</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source><year>2019</year>;<volume>74</volume>:<fpage>1480</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">31514951</pub-id></mixed-citation></ref><ref id="euac030-B370"><label>370</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Towbin</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>McKenna</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Abrams</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Calkins</surname><given-names>H</given-names></string-name>, <string-name><surname>Darrieux</surname><given-names>FCC</given-names></string-name><etal>et al</etal></person-group>
<article-title>2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy</article-title>. <source>Heart Rhythm</source><year>2019</year>;<volume>16</volume>:<fpage>e301</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">31078652</pub-id></mixed-citation></ref><ref id="euac030-B371"><label>371</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Van Lint</surname>
<given-names>FHM</given-names>
</string-name>, <string-name><surname>Murray</surname><given-names>B</given-names></string-name>, <string-name><surname>Tichnell</surname><given-names>C</given-names></string-name>, <string-name><surname>Zwart</surname><given-names>R</given-names></string-name>, <string-name><surname>Amat</surname><given-names>N</given-names></string-name>, <string-name><surname>Lekanne Deprez</surname><given-names>RH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Arrhythmogenic right ventricular cardiomyopathy-associated desmosomal variants are rarely <italic toggle="yes">de novo</italic></article-title>. <source>Circ Genom Precis Med</source><year>2019</year>;<volume>12</volume>:<fpage>e002467</fpage>.<pub-id pub-id-type="pmid">31386562</pub-id></mixed-citation></ref><ref id="euac030-B372"><label>372</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Corrado</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Perazzolo Marra</surname><given-names>M</given-names></string-name>, <string-name><surname>Zorzi</surname><given-names>A</given-names></string-name>, <string-name><surname>Beffagna</surname><given-names>G</given-names></string-name>, <string-name><surname>Cipriani</surname><given-names>A</given-names></string-name>, <string-name><surname>Lazzari</surname><given-names>MD</given-names></string-name><etal>et al</etal></person-group>
<article-title>Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria</article-title>. <source>Int J Cardiol</source><year>2020</year>;<volume>319</volume>:<fpage>106</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">32561223</pub-id></mixed-citation></ref><ref id="euac030-B373"><label>373</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ackerman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name><surname>Priori</surname><given-names>SG</given-names></string-name>, <string-name><surname>Willems</surname><given-names>S</given-names></string-name>, <string-name><surname>Berul</surname><given-names>C</given-names></string-name>, <string-name><surname>Brugada</surname><given-names>R</given-names></string-name>, <string-name><surname>Calkins</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)</article-title>. <source>Heart Rhythm</source><year>2011</year>;<volume>8</volume>:<fpage>1308</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">21787999</pub-id></mixed-citation></ref><ref id="euac030-B374"><label>374</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Walsh</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Thomson</surname><given-names>KL</given-names></string-name>, <string-name><surname>Ware</surname><given-names>JS</given-names></string-name>, <string-name><surname>Funke</surname><given-names>BH</given-names></string-name>, <string-name><surname>Woodley</surname><given-names>J</given-names></string-name>, <string-name><surname>McGuire</surname><given-names>KJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples</article-title>. <source>Genet Med</source><year>2017</year>;<volume>19</volume>:<fpage>192</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">27532257</pub-id></mixed-citation></ref><ref id="euac030-B375"><label>375</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Corrado</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>van Tintelen</surname><given-names>PJ</given-names></string-name>, <string-name><surname>McKenna</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Hauer</surname><given-names>RNW</given-names></string-name>, <string-name><surname>Anastastakis</surname><given-names>A</given-names></string-name>, <string-name><surname>Asimaki</surname><given-names>A</given-names></string-name><etal>et al</etal>; <collab>International Experts</collab></person-group>. <article-title>Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis</article-title>. <source>Eur Heart J</source><year>2020</year>;<volume>41</volume>:<fpage>1414</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">31637441</pub-id></mixed-citation></ref><ref id="euac030-B376"><label>376</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fressart</surname>
<given-names>V</given-names>
</string-name>, <string-name><surname>Duthoit</surname><given-names>G</given-names></string-name>, <string-name><surname>Donal</surname><given-names>E</given-names></string-name>, <string-name><surname>Probst</surname><given-names>V</given-names></string-name>, <string-name><surname>Deharo</surname><given-names>JC</given-names></string-name>, <string-name><surname>Chevalier</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy: spectrum of mutations and clinical impact in practice</article-title>. <source>Europace</source><year>2010</year>;<volume>12</volume>:<fpage>861</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20400443</pub-id></mixed-citation></ref><ref id="euac030-B377"><label>377</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van der Zwaag</surname>
<given-names>PA</given-names>
</string-name>, <string-name><surname>van Rijsingen</surname><given-names>IA</given-names></string-name>, <string-name><surname>Asimaki</surname><given-names>A</given-names></string-name>, <string-name><surname>Jongbloed</surname><given-names>JD</given-names></string-name>, <string-name><surname>van Veldhuisen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Wiesfeld</surname><given-names>AC</given-names></string-name><etal>et al</etal></person-group>
<article-title>Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy</article-title>. <source>Eur J Heart Fail</source><year>2012</year>;<volume>14</volume>:<fpage>1199</fpage>&#x02013;<lpage>207</lpage>.<pub-id pub-id-type="pmid">22820313</pub-id></mixed-citation></ref><ref id="euac030-B378"><label>378</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hodgkinson</surname>
<given-names>KA</given-names>
</string-name>, <string-name><surname>Connors</surname><given-names>SP</given-names></string-name>, <string-name><surname>Merner</surname><given-names>N</given-names></string-name>, <string-name><surname>Haywood</surname><given-names>A</given-names></string-name>, <string-name><surname>Young</surname><given-names>TL</given-names></string-name>, <string-name><surname>McKenna</surname><given-names>WJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43</article-title>. <source>Clin Genet</source><year>2013</year>;<volume>83</volume>:<fpage>321</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">22725725</pub-id></mixed-citation></ref><ref id="euac030-B379"><label>379</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tiso</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Stephan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Nava</surname><given-names>A</given-names></string-name>, <string-name><surname>Bagattin</surname><given-names>A</given-names></string-name>, <string-name><surname>Devaney</surname><given-names>JM</given-names></string-name>, <string-name><surname>Stanchi</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group>
<article-title>Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2)</article-title>. <source>Hum Mol Genet</source><year>2001</year>;<volume>10</volume>:<fpage>189</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">11159936</pub-id></mixed-citation></ref><ref id="euac030-B380"><label>380</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Protonotarios</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Brodehl</surname><given-names>A</given-names></string-name>, <string-name><surname>Asimaki</surname><given-names>A</given-names></string-name>, <string-name><surname>Jager</surname><given-names>J</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>E</given-names></string-name>, <string-name><surname>Stanasiuk</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>The novel desmin variant p.Leu115Ile is associated with a unique form of biventricular Arrhythmogenic Cardiomyopathy</article-title>. <source>Can J Cardiol</source><year>2021</year>;<volume>37</volume>:<fpage>857</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">33290826</pub-id></mixed-citation></ref><ref id="euac030-B381"><label>381</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Berm&#x000fa;dez-Jim&#x000e9;nez</surname>
<given-names>FJ</given-names>
</string-name>, <string-name><surname>Carriel</surname><given-names>V</given-names></string-name>, <string-name><surname>Brodehl</surname><given-names>A</given-names></string-name>, <string-name><surname>Alaminos</surname><given-names>M</given-names></string-name>, <string-name><surname>Campos</surname><given-names>A</given-names></string-name>, <string-name><surname>Schirmer</surname><given-names>I</given-names></string-name><etal>et al</etal></person-group>
<article-title>Novel desmin mutation p.Glu401Asp impairs filament formation, disrupts cell membrane integrity, and causes severe arrhythmogenic left ventricular cardiomyopathy/dysplasia</article-title>. <source>Circulation</source><year>2018</year>;<volume>137</volume>:<fpage>1595</fpage>&#x02013;<lpage>610</lpage>.<pub-id pub-id-type="pmid">29212896</pub-id></mixed-citation></ref><ref id="euac030-B382"><label>382</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Marey</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Fressart</surname><given-names>V</given-names></string-name>, <string-name><surname>Rambaud</surname><given-names>C</given-names></string-name>, <string-name><surname>Fornes</surname><given-names>P</given-names></string-name>, <string-name><surname>Martin</surname><given-names>L</given-names></string-name>, <string-name><surname>Grotto</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical impact of post-mortem genetic testing in cardiac death and cardiomyopathy</article-title>. <source>Open Med (Wars)</source><year>2020</year>;<volume>15</volume>:<fpage>435</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">33336002</pub-id></mixed-citation></ref><ref id="euac030-B383"><label>383</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Groeneweg</surname>
<given-names>JA</given-names>
</string-name>, <string-name><surname>Bhonsale</surname><given-names>A</given-names></string-name>, <string-name><surname>James</surname><given-names>CA</given-names></string-name>, <string-name><surname>Te Riele</surname><given-names>AS</given-names></string-name>, <string-name><surname>Dooijes</surname><given-names>D</given-names></string-name>, <string-name><surname>Tichnell</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members</article-title>. <source>Circ Cardiovasc Genet</source><year>2015</year>;<volume>8</volume>:<fpage>437</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">25820315</pub-id></mixed-citation></ref><ref id="euac030-B384"><label>384</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Quarta</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Muir</surname><given-names>A</given-names></string-name>, <string-name><surname>Pantazis</surname><given-names>A</given-names></string-name>, <string-name><surname>Syrris</surname><given-names>P</given-names></string-name>, <string-name><surname>Gehmlich</surname><given-names>K</given-names></string-name>, <string-name><surname>Garcia-Pavia</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria</article-title>. <source>Circulation</source><year>2011</year>;<volume>123</volume>:<fpage>2701</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21606390</pub-id></mixed-citation></ref><ref id="euac030-B385"><label>385</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>James</surname>
<given-names>CA</given-names>
</string-name>, <string-name><surname>Syrris</surname><given-names>P</given-names></string-name>, <string-name><surname>van Tintelen</surname><given-names>JP</given-names></string-name>, <string-name><surname>Calkins</surname><given-names>H.</given-names></string-name></person-group>
<article-title>The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy</article-title>. <source>Eur Heart J</source><year>2020</year>;<volume>41</volume>:<fpage>1393</fpage>&#x02013;<lpage>400</lpage>.<pub-id pub-id-type="pmid">32191298</pub-id></mixed-citation></ref><ref id="euac030-B386"><label>386</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ghidoni</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Elliott</surname><given-names>PM</given-names></string-name>, <string-name><surname>Syrris</surname><given-names>P</given-names></string-name>, <string-name><surname>Calkins</surname><given-names>H</given-names></string-name>, <string-name><surname>James</surname><given-names>CA</given-names></string-name>, <string-name><surname>Judge</surname><given-names>DP</given-names></string-name><etal>et al</etal></person-group>
<article-title>Cadherin 2-related arrhythmogenic cardiomyopathy: prevalence and clinical features</article-title>. <source>Circ Genom Precis Med</source><year>2021</year>;<volume>14</volume>:<fpage>e003097</fpage>.<pub-id pub-id-type="pmid">33566628</pub-id></mixed-citation></ref><ref id="euac030-B387"><label>387</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ross</surname>
<given-names>SB</given-names>
</string-name>, <string-name><surname>Singer</surname><given-names>ES</given-names></string-name>, <string-name><surname>Driscoll</surname><given-names>E</given-names></string-name>, <string-name><surname>Nowak</surname><given-names>N</given-names></string-name>, <string-name><surname>Yeates</surname><given-names>L</given-names></string-name>, <string-name><surname>Puranik</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic architecture of left ventricular noncompaction in adults</article-title>. <source>Hum Genome Var</source><year>2020</year>;<volume>7</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">33082984</pub-id></mixed-citation></ref><ref id="euac030-B388"><label>388</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Verstraelen</surname>
<given-names>TE</given-names>
</string-name>, <string-name><surname>van Lint</surname><given-names>FHM</given-names></string-name>, <string-name><surname>Bosman</surname><given-names>LP</given-names></string-name>, <string-name><surname>de Brouwer</surname><given-names>R</given-names></string-name>, <string-name><surname>Proost</surname><given-names>VM</given-names></string-name>, <string-name><surname>Abeln</surname><given-names>BGS</given-names></string-name><etal>et al</etal></person-group>
<article-title>Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction</article-title>. <source>Eur Heart J</source><year>2021</year>;<volume>42</volume>:<fpage>2842</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">34113975</pub-id></mixed-citation></ref><ref id="euac030-B389"><label>389</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cadrin-Tourigny</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Bosman</surname><given-names>LP</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name><surname>Tadros</surname><given-names>R</given-names></string-name>, <string-name><surname>Bhonsale</surname><given-names>A</given-names></string-name>, <string-name><surname>Bourfiss</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Sudden cardiac death prediction in arrhythmogenic right ventricular cardiomyopathy: a multinational collaboration</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2021</year>;<volume>14</volume>:<fpage>e008509</fpage>.<pub-id pub-id-type="pmid">33296238</pub-id></mixed-citation></ref><ref id="euac030-B390"><label>390</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rigato</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Bauce</surname><given-names>B</given-names></string-name>, <string-name><surname>Rampazzo</surname><given-names>A</given-names></string-name>, <string-name><surname>Zorzi</surname><given-names>A</given-names></string-name>, <string-name><surname>Pilichou</surname><given-names>K</given-names></string-name>, <string-name><surname>Mazzotti</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy</article-title>. <source>Circ Cardiovasc Genet</source><year>2013</year>;<volume>6</volume>:<fpage>533</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">24070718</pub-id></mixed-citation></ref><ref id="euac030-B391"><label>391</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bhonsale</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Groeneweg</surname><given-names>JA</given-names></string-name>, <string-name><surname>James</surname><given-names>CA</given-names></string-name>, <string-name><surname>Dooijes</surname><given-names>D</given-names></string-name>, <string-name><surname>Tichnell</surname><given-names>C</given-names></string-name>, <string-name><surname>Jongbloed</surname><given-names>JDH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers</article-title>. <source>Eur Heart J</source><year>2015</year>;<volume>36</volume>:<fpage>847</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">25616645</pub-id></mixed-citation></ref><ref id="euac030-B392"><label>392</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>James</surname>
<given-names>CA</given-names>
</string-name>, <string-name><surname>Bhonsale</surname><given-names>A</given-names></string-name>, <string-name><surname>Tichnell</surname><given-names>C</given-names></string-name>, <string-name><surname>Murray</surname><given-names>B</given-names></string-name>, <string-name><surname>Russell</surname><given-names>SD</given-names></string-name>, <string-name><surname>Tandri</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers</article-title>. <source>J Am Coll Cardiol</source><year>2013</year>;<volume>62</volume>:<fpage>1290</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23871885</pub-id></mixed-citation></ref><ref id="euac030-B393"><label>393</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sawant</surname>
<given-names>ACT</given-names>
</string-name>, <string-name><surname>Riele</surname><given-names>ASJM</given-names></string-name>, <string-name><surname>Tichnell</surname><given-names>C</given-names></string-name>, <string-name><surname>Murray</surname><given-names>B</given-names></string-name>, <string-name><surname>Bhonsale</surname><given-names>A</given-names></string-name>, <string-name><surname>Tandri</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers</article-title>. <source>Heart Rhythm</source><year>2016</year>;<volume>13</volume>:<fpage>199</fpage>&#x02013;<lpage>207</lpage>.<pub-id pub-id-type="pmid">26321091</pub-id></mixed-citation></ref><ref id="euac030-B394"><label>394</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Van Waning</surname>
<given-names>JI</given-names>
</string-name>, <string-name><surname>Caliskan</surname><given-names>K</given-names></string-name>, <string-name><surname>Hoedemaekers</surname><given-names>YM</given-names></string-name>, <string-name><surname>Van Spaendonck-Zwarts</surname><given-names>KY</given-names></string-name>, <string-name><surname>Baas</surname><given-names>AF</given-names></string-name>, <string-name><surname>Boekholdt</surname><given-names>SM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetics, clinical features, and long-term&#x000a0;outcome of noncompaction&#x000a0;cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>;<volume>71</volume>:<fpage>711</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">29447731</pub-id></mixed-citation></ref><ref id="euac030-B395"><label>395</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Bai</surname><given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Hu</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>Do mitochondria contribute to left ventricular non-compaction cardiomyopathy? New findings from myocardium of patients with left ventricular non-compaction cardiomyopathy</article-title>. <source>Mol Genet Metab</source><year>2013</year>;<volume>109</volume>:<fpage>100</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23465694</pub-id></mixed-citation></ref><ref id="euac030-B396"><label>396</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Richard</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Ader</surname><given-names>F</given-names></string-name>, <string-name><surname>Roux</surname><given-names>M</given-names></string-name>, <string-name><surname>Donal</surname><given-names>E</given-names></string-name>, <string-name><surname>Eicher</surname><given-names>JC</given-names></string-name>, <string-name><surname>Aoutil</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity</article-title>. <source>Clin Genet</source><year>2019</year>;<volume>95</volume>:<fpage>356</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">30471092</pub-id></mixed-citation></ref><ref id="euac030-B397"><label>397</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vanlerberghe</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Jourdain</surname><given-names>A-S</given-names></string-name>, <string-name><surname>Ghoumid</surname><given-names>J</given-names></string-name>, <string-name><surname>Frenois</surname><given-names>F</given-names></string-name>, <string-name><surname>Mezel</surname><given-names>A</given-names></string-name>, <string-name><surname>Vaksmann</surname><given-names>G</given-names></string-name><etal>et al</etal></person-group>
<article-title>Holt-Oram syndrome: clinical and molecular description of 78 patients with TBX5 variants</article-title>. <source>Eur J Hum Genet</source><year>2019</year>;<volume>27</volume>:<fpage>360</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">30552424</pub-id></mixed-citation></ref><ref id="euac030-B398"><label>398</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Maury</surname>
<given-names>P</given-names>
</string-name>, <string-name><surname>Gandjbakhch</surname><given-names>E</given-names></string-name>, <string-name><surname>Baruteau</surname><given-names>A-E</given-names></string-name>, <string-name><surname>Bessi&#x000e8;re</surname><given-names>F</given-names></string-name>, <string-name><surname>Kyndt</surname><given-names>F</given-names></string-name>, <string-name><surname>Bouvagnet</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Cardiac phenotype and long-term follow-up of patients with mutations in NKX2-5 gene</article-title>. <source>J Am Coll Cardiol</source><year>2016</year>;<volume>68</volume>:<fpage>2389</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">27884258</pub-id></mixed-citation></ref><ref id="euac030-B399"><label>399</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ross</surname>
<given-names>SB</given-names>
</string-name>, <string-name><surname>Bagnall</surname><given-names>RD</given-names></string-name>, <string-name><surname>Yeates</surname><given-names>L</given-names></string-name>, <string-name><surname>Sy</surname><given-names>RW</given-names></string-name>, <string-name><surname>Semsarian</surname><given-names>C.</given-names></string-name></person-group>
<article-title>Holt-Oram syndrome in two families diagnosed with left ventricular noncompaction and conduction disease</article-title>. <source>HeartRhythm Case Rep</source><year>2018</year>;<volume>4</volume>:<fpage>146</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">29755943</pub-id></mixed-citation></ref><ref id="euac030-B400"><label>400</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Femia</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Zhu</surname><given-names>D</given-names></string-name>, <string-name><surname>Choudhary</surname><given-names>P</given-names></string-name>, <string-name><surname>Ross</surname><given-names>SB</given-names></string-name>, <string-name><surname>Muthurangu</surname><given-names>V</given-names></string-name>, <string-name><surname>Richmond</surname><given-names>D</given-names></string-name><etal>et al</etal></person-group>
<article-title>Long term clinical outcomes associated with CMR quantified isolated left ventricular non-compaction in adults</article-title>. <source>Int J Cardiol</source><year>2021</year>;<volume>328</volume>:<fpage>235</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">33309759</pub-id></mixed-citation></ref><ref id="euac030-B401"><label>401</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mazzarotto</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Hawley</surname><given-names>MH</given-names></string-name>, <string-name><surname>Beltrami</surname><given-names>M</given-names></string-name>, <string-name><surname>Beekman</surname><given-names>L</given-names></string-name>, <string-name><surname>de Marvao</surname><given-names>A</given-names></string-name>, <string-name><surname>McGurk</surname><given-names>KA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies</article-title>. <source>Genet Med</source><year>2021</year>;<volume>23</volume>:<fpage>856</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">33500567</pub-id></mixed-citation></ref><ref id="euac030-B402"><label>402</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ross</surname>
<given-names>SB</given-names>
</string-name>, <string-name><surname>Semsarian</surname><given-names>C.</given-names></string-name></person-group>
<article-title>Clinical and genetic complexities of left ventricular noncompaction: preventing overdiagnosis in a disease we do not understand</article-title>. <source>JAMA Cardiol</source><year>2018</year>;<volume>3</volume>:<fpage>1033</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">30140926</pub-id></mixed-citation></ref><ref id="euac030-B403"><label>403</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ross</surname>
<given-names>SB</given-names>
</string-name>, <string-name><surname>Jones</surname><given-names>K</given-names></string-name>, <string-name><surname>Blanch</surname><given-names>B</given-names></string-name>, <string-name><surname>Puranik</surname><given-names>R</given-names></string-name>, <string-name><surname>McGeechan</surname><given-names>K</given-names></string-name>, <string-name><surname>Barratt</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults</article-title>. <source>Eur Heart J</source><year>2020</year>;<volume>41</volume>:<fpage>1428</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">31143950</pub-id></mixed-citation></ref><ref id="euac030-B404"><label>404</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gallego-Delgado</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Delgado</surname><given-names>JF</given-names></string-name>, <string-name><surname>Brossa-Loidi</surname><given-names>V</given-names></string-name>, <string-name><surname>Palomo</surname><given-names>J</given-names></string-name>, <string-name><surname>Marzoa-Rivas</surname><given-names>R</given-names></string-name>, <string-name><surname>Perez-Villa</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group>
<article-title>Idiopathic restrictive cardiomyopathy is&#x000a0;primarily a genetic&#x000a0;disease</article-title>. <source>J Am Coll Cardiol</source><year>2016</year>;<volume>67</volume>:<fpage>3021</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">27339502</pub-id></mixed-citation></ref><ref id="euac030-B405"><label>405</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kaski</surname>
<given-names>JP</given-names>
</string-name>, <string-name><surname>Syrris</surname><given-names>P</given-names></string-name>, <string-name><surname>Burch</surname><given-names>M</given-names></string-name>, <string-name><surname>Tome-Esteban</surname><given-names>MT</given-names></string-name>, <string-name><surname>Fenton</surname><given-names>M</given-names></string-name>, <string-name><surname>Christiansen</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes</article-title>. <source>Heart</source><year>2008</year>;<volume>94</volume>:<fpage>1478</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">18467357</pub-id></mixed-citation></ref><ref id="euac030-B406"><label>406</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sen-Chowdhry</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Syrris</surname><given-names>P</given-names></string-name>, <string-name><surname>McKenna</surname><given-names>WJ.</given-names></string-name></person-group>
<article-title>Genetics of restrictive cardiomyopathy</article-title>. <source>Heart Fail Clin</source><year>2010</year>;<volume>6</volume>:<fpage>179</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">20347786</pub-id></mixed-citation></ref><ref id="euac030-B407"><label>407</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ton</surname>
<given-names>V-K</given-names>
</string-name>, <string-name><surname>Mukherjee</surname><given-names>M</given-names></string-name>, <string-name><surname>Judge</surname><given-names>DP.</given-names></string-name></person-group>
<article-title>Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction</article-title>. <source>Clin Med Insights Cardiol</source><year>2014</year>;<volume>8</volume>(Suppl 1):<fpage>39</fpage>&#x02013;<lpage>44</lpage>.</mixed-citation></ref><ref id="euac030-B408"><label>408</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Buxbaum</surname>
<given-names>JN</given-names>
</string-name>, <string-name><surname>Ruberg</surname><given-names>FL.</given-names></string-name></person-group>
<article-title>Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans</article-title>. <source>Genet Med</source><year>2017</year>;<volume>19</volume>:<fpage>733</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">28102864</pub-id></mixed-citation></ref><ref id="euac030-B409"><label>409</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Germain</surname>
<given-names>DP</given-names>
</string-name>, <string-name><surname>Charrow</surname><given-names>J</given-names></string-name>, <string-name><surname>Desnick</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Guffon</surname><given-names>N</given-names></string-name>, <string-name><surname>Kempf</surname><given-names>J</given-names></string-name>, <string-name><surname>Lachmann</surname><given-names>RH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease</article-title>. <source>J Med Genet</source><year>2015</year>;<volume>52</volume>:<fpage>353</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25795794</pub-id></mixed-citation></ref><ref id="euac030-B410"><label>410</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Emdin</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Aimo</surname><given-names>A</given-names></string-name>, <string-name><surname>Rapezzi</surname><given-names>C</given-names></string-name>, <string-name><surname>Fontana</surname><given-names>M</given-names></string-name>, <string-name><surname>Perfetto</surname><given-names>F</given-names></string-name>, <string-name><surname>Seferovic</surname><given-names>PM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Treatment of cardiac transthyretin amyloidosis: an update</article-title>. <source>Eur Heart J</source><year>2019</year>;<volume>40</volume>:<fpage>3699</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">31111153</pub-id></mixed-citation></ref><ref id="euac030-B411"><label>411</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Maurer</surname>
<given-names>MS</given-names>
</string-name>, <string-name><surname>Schwartz</surname><given-names>JH</given-names></string-name>, <string-name><surname>Gundapaneni</surname><given-names>B</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>PM</given-names></string-name>, <string-name><surname>Merlini</surname><given-names>G</given-names></string-name>, <string-name><surname>Waddington-Cruz</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>379</volume>:<fpage>1007</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">30145929</pub-id></mixed-citation></ref><ref id="euac030-B412"><label>412</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Behr</surname>
<given-names>ER</given-names>
</string-name>, <string-name><surname>Casey</surname><given-names>A</given-names></string-name>, <string-name><surname>Sheppard</surname><given-names>M</given-names></string-name>, <string-name><surname>Wright</surname><given-names>M</given-names></string-name>, <string-name><surname>Bowker</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Davies</surname><given-names>MJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Sudden arrhythmic death syndrome: a national survey of sudden unexplained cardiac death</article-title>. <source>Heart</source><year>2007</year>;<volume>93</volume>:<fpage>601</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">17237131</pub-id></mixed-citation></ref><ref id="euac030-B413"><label>413</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lahrouchi</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Raju</surname><given-names>H</given-names></string-name>, <string-name><surname>Lodder</surname><given-names>EM</given-names></string-name>, <string-name><surname>Papatheodorou</surname><given-names>S</given-names></string-name>, <string-name><surname>Miles</surname><given-names>C</given-names></string-name>, <string-name><surname>Ware</surname><given-names>JS</given-names></string-name><etal>et al</etal></person-group>
<article-title>The yield of postmortem genetic testing in sudden death cases with structural findings at autopsy</article-title>. <source>Eur J Hum Genet</source><year>2020</year>;<volume>28</volume>:<fpage>17</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">31534214</pub-id></mixed-citation></ref><ref id="euac030-B414"><label>414</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>de Noronha</surname>
<given-names>SV</given-names>
</string-name>, <string-name><surname>Behr</surname><given-names>ER</given-names></string-name>, <string-name><surname>Papadakis</surname><given-names>M</given-names></string-name>, <string-name><surname>Ohta-Ogo</surname><given-names>K</given-names></string-name>, <string-name><surname>Banya</surname><given-names>W</given-names></string-name>, <string-name><surname>Wells</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group>
<article-title>The importance of specialist cardiac histopathological examination in the investigation of young sudden cardiac deaths</article-title>. <source>Europace</source><year>2014</year>;<volume>16</volume>:<fpage>899</fpage>&#x02013;<lpage>907</lpage>.<pub-id pub-id-type="pmid">24148315</pub-id></mixed-citation></ref><ref id="euac030-B415"><label>415</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tester</surname>
<given-names>DJ</given-names>
</string-name>, <string-name><surname>Medeiros-Domingo</surname><given-names>A</given-names></string-name>, <string-name><surname>Will</surname><given-names>ML</given-names></string-name>, <string-name><surname>Haglund</surname><given-names>CM</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing</article-title>. <source>Mayo Clin Proc</source><year>2012</year>;<volume>87</volume>:<fpage>524</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">22677073</pub-id></mixed-citation></ref><ref id="euac030-B416"><label>416</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bagnall</surname>
<given-names>RD</given-names>
</string-name>, <string-name><surname>Weintraub</surname><given-names>RG</given-names></string-name>, <string-name><surname>Ingles</surname><given-names>J</given-names></string-name>, <string-name><surname>Duflou</surname><given-names>J</given-names></string-name>, <string-name><surname>Yeates</surname><given-names>L</given-names></string-name>, <string-name><surname>Lam</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group>
<article-title>A prospective study of sudden cardiac death among children and young adults</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>374</volume>:<fpage>2441</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">27332903</pub-id></mixed-citation></ref><ref id="euac030-B417"><label>417</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lahrouchi</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Raju</surname><given-names>H</given-names></string-name>, <string-name><surname>Lodder</surname><given-names>EM</given-names></string-name>, <string-name><surname>Papatheodorou</surname><given-names>E</given-names></string-name>, <string-name><surname>Ware</surname><given-names>JS</given-names></string-name>, <string-name><surname>Papadakis</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>Utility of post-mortem genetic testing in cases of sudden arrhythmic death syndrome</article-title>. <source>J Am Coll Cardiol</source><year>2017</year>;<volume>69</volume>:<fpage>2134</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">28449774</pub-id></mixed-citation></ref><ref id="euac030-B418"><label>418</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Isbister</surname>
<given-names>JC</given-names>
</string-name>, <string-name><surname>Nowak</surname><given-names>N</given-names></string-name>, <string-name><surname>Butters</surname><given-names>A</given-names></string-name>, <string-name><surname>Yeates</surname><given-names>L</given-names></string-name>, <string-name><surname>Gray</surname><given-names>B</given-names></string-name>, <string-name><surname>Sy</surname><given-names>RW</given-names></string-name><etal>et al</etal></person-group>
<article-title>"Concealed cardiomyopathy" as a cause of previously unexplained sudden cardiac arrest</article-title>. <source>Int J Cardiol</source><year>2021</year>;<volume>324</volume>:<fpage>96</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">32931854</pub-id></mixed-citation></ref><ref id="euac030-B419"><label>419</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Anderson</surname>
<given-names>JH</given-names>
</string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Will</surname><given-names>ML</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>MJ.</given-names></string-name></person-group>
<article-title>Whole-exome molecular autopsy after exertion-related sudden unexplained death in the young</article-title>. <source>Circ Cardiovasc Genet</source><year>2016</year>;<volume>9</volume>:<fpage>259</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">27114410</pub-id></mixed-citation></ref><ref id="euac030-B420"><label>420</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shanks</surname>
<given-names>GW</given-names>
</string-name>, <string-name><surname>Tester</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>JP</given-names></string-name>, <string-name><surname>Simpson</surname><given-names>MA</given-names></string-name>, <string-name><surname>Behr</surname><given-names>ER</given-names></string-name>, <string-name><surname>White</surname><given-names>SM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Importance of variant interpretation in whole-exome molecular autopsy: population-based case series</article-title>. <source>Circulation</source><year>2018</year>;<volume>137</volume>:<fpage>2705</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">29915097</pub-id></mixed-citation></ref><ref id="euac030-B421"><label>421</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Grondin</surname>
<given-names>SD</given-names>
</string-name>, <string-name><surname>Davies B Cadrin-Tourigny</surname><given-names>J</given-names></string-name>, <string-name><surname>Steinberg</surname><given-names>C</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>CC</given-names></string-name>, <string-name><surname>Jorda</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Importance of genetic testing in unexplained cardiac arrest</article-title>. <source>Eur Heart J</source><year>2022</year>;doi:10.1093/eurheartj/ehac145.</mixed-citation></ref><ref id="euac030-B422"><label>422</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zipes</surname>
<given-names>DP</given-names>
</string-name>, <string-name><surname>Wellens</surname><given-names>HJ.</given-names></string-name></person-group>
<article-title>Sudden cardiac death</article-title>. <source>Circulation</source><year>1998</year>;<volume>98</volume>:<fpage>2334</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">9826323</pub-id></mixed-citation></ref><ref id="euac030-B423"><label>423</label><mixed-citation publication-type="journal">
<article-title>Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States</article-title>. <source>Circulation</source><year>1997</year>;<volume>95</volume>:<fpage>265</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">8994445</pub-id></mixed-citation></ref><ref id="euac030-B424"><label>424</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mellor</surname>
<given-names>G</given-names>
</string-name>, <string-name><surname>Laksman</surname><given-names>ZWM</given-names></string-name>, <string-name><surname>Tadros</surname><given-names>R</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>JD</given-names></string-name>, <string-name><surname>Gerull</surname><given-names>B</given-names></string-name>, <string-name><surname>Simpson</surname><given-names>CS</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic testing in the evaluation of unexplained cardiac arrest: from the CASPER (Cardiac Arrest Survivors With Preserved Ejection Fraction Registry)</article-title>. <source>Circ Cardiovasc Genet</source><year>2017</year>;<volume>10</volume>:<fpage>e001686</fpage>.<pub-id pub-id-type="pmid">28600387</pub-id></mixed-citation></ref><ref id="euac030-B425"><label>425</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Asatryan</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Schaller</surname><given-names>A</given-names></string-name>, <string-name><surname>Seiler</surname><given-names>J</given-names></string-name>, <string-name><surname>Servatius</surname><given-names>H</given-names></string-name>, <string-name><surname>Noti</surname><given-names>F</given-names></string-name>, <string-name><surname>Baldinger</surname><given-names>SH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Usefulness of genetic testing in sudden cardiac arrest survivors with or without previous clinical evidence of heart disease</article-title>. <source>Am J Cardiol</source><year>2019</year>;<volume>123</volume>:<fpage>2031</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">30975432</pub-id></mixed-citation></ref><ref id="euac030-B426"><label>426</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Visser</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Dooijes</surname><given-names>D</given-names></string-name>, <string-name><surname>van der Smagt</surname><given-names>JJ</given-names></string-name>, <string-name><surname>van der Heijden</surname><given-names>JF</given-names></string-name>, <string-name><surname>Doevendans</surname><given-names>PA</given-names></string-name>, <string-name><surname>Loh</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>Next-generation sequencing of a large gene panel in patients initially diagnosed with idiopathic ventricular fibrillation</article-title>. <source>Heart Rhythm</source><year>2017</year>;<volume>14</volume>:<fpage>1035</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">28087426</pub-id></mixed-citation></ref><ref id="euac030-B427"><label>427</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Matassini</surname>
<given-names>MV</given-names>
</string-name>, <string-name><surname>Krahn</surname><given-names>AD</given-names></string-name>, <string-name><surname>Gardner</surname><given-names>M</given-names></string-name>, <string-name><surname>Champagne</surname><given-names>J</given-names></string-name>, <string-name><surname>Sanatani</surname><given-names>S</given-names></string-name>, <string-name><surname>Birnie</surname><given-names>DH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Evolution of clinical diagnosis in patients presenting with unexplained cardiac arrest or syncope due to polymorphic ventricular tachycardia</article-title>. <source>Heart Rhythm</source><year>2014</year>;<volume>11</volume>:<fpage>274</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">24239842</pub-id></mixed-citation></ref><ref id="euac030-B428"><label>428</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Alders</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Koopmann</surname><given-names>TT</given-names></string-name>, <string-name><surname>Christiaans</surname><given-names>I</given-names></string-name>, <string-name><surname>Postema</surname><given-names>PG</given-names></string-name>, <string-name><surname>Beekman</surname><given-names>L</given-names></string-name>, <string-name><surname>Tanck</surname><given-names>MW</given-names></string-name><etal>et al</etal></person-group>
<article-title>Haplotype-sharing analysis implicates chromosome 7q36 harboring DPP6 in familial idiopathic ventricular fibrillation</article-title>. <source>Am J Hum Genet</source><year>2009</year>;<volume>84</volume>:<fpage>468</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">19285295</pub-id></mixed-citation></ref><ref id="euac030-B429"><label>429</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fujii</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Itoh</surname><given-names>H</given-names></string-name>, <string-name><surname>Ohno</surname><given-names>S</given-names></string-name>, <string-name><surname>Murayama</surname><given-names>T</given-names></string-name>, <string-name><surname>Kurebayashi</surname><given-names>N</given-names></string-name>, <string-name><surname>Aoki</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group>
<article-title>A type 2 ryanodine receptor variant associated with reduced Ca(2+) release and short-coupled torsades de pointes ventricular arrhythmia</article-title>. <source>Heart Rhythm</source><year>2017</year>;<volume>14</volume>:<fpage>98</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="pmid">27756708</pub-id></mixed-citation></ref><ref id="euac030-B430"><label>430</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Wei</surname><given-names>J</given-names></string-name>, <string-name><surname>Guo</surname><given-names>W</given-names></string-name>, <string-name><surname>Sun</surname><given-names>B</given-names></string-name>, <string-name><surname>Estillore</surname><given-names>JP</given-names></string-name>, <string-name><surname>Wang</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group>
<article-title>Human RyR2 (Ryanodine Receptor 2) loss-of-function mutations: clinical phenotypes and <italic toggle="yes">in vitro</italic> characterization</article-title>. <source>Circ Arrhythm Electrophysiol</source><year>2021</year>;<volume>14</volume>:<fpage>e010013</fpage>.<pub-id pub-id-type="pmid">34546788</pub-id></mixed-citation></ref><ref id="euac030-B431"><label>431</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mone</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Stott</surname><given-names>BK</given-names></string-name>, <string-name><surname>Hamilton</surname><given-names>S</given-names></string-name>, <string-name><surname>Seale</surname><given-names>AN</given-names></string-name>, <string-name><surname>Quinlan-Jones</surname><given-names>E</given-names></string-name>, <string-name><surname>Allen</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>The diagnostic yield of prenatal genetic technologies in congenital heart disease: a prospective cohort study</article-title>. <source>Fetal Diagn Ther</source><year>2021</year>;<fpage>1</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="euac030-B432"><label>432</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Qiao</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>R</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Comprehensive evaluation of genetic variants in fetuses with congenital heart defect using chromosomal microarray analysis and exome sequencing</article-title>. <source>Ultrasound Obstet Gynecol</source><year>2021</year>;<volume>58</volume>:<fpage>377</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">33142350</pub-id></mixed-citation></ref><ref id="euac030-B433"><label>433</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mone</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Eberhardt</surname><given-names>RY</given-names></string-name>, <string-name><surname>Morris</surname><given-names>RK</given-names></string-name>, <string-name><surname>Hurles</surname><given-names>ME</given-names></string-name>, <string-name><surname>McMullan</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Maher</surname><given-names>ER</given-names></string-name><etal>et al</etal>; <collab>the CODE Study Collaborators</collab></person-group>. <article-title>COngenital heart disease and the Diagnostic yield with Exome sequencing (CODE) study: prospective cohort study and systematic review</article-title>. <source>Ultrasound Obstet Gynecol</source><year>2021</year>;<volume>57</volume>:<fpage>43</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">32388881</pub-id></mixed-citation></ref><ref id="euac030-B434"><label>434</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hanchard</surname>
<given-names>NA</given-names>
</string-name>, <string-name><surname>Umana</surname><given-names>LA</given-names></string-name>, <string-name><surname>D'Alessandro</surname><given-names>L</given-names></string-name>, <string-name><surname>Azamian</surname><given-names>M</given-names></string-name>, <string-name><surname>Poopola</surname><given-names>M</given-names></string-name>, <string-name><surname>Morris</surname><given-names>SA</given-names></string-name><etal>et al</etal></person-group>
<article-title>Assessment of large copy number variants in patients with apparently isolated congenital left-sided cardiac lesions reveals clinically relevant genomic events</article-title>. <source>Am J Med Genet A</source><year>2017</year>;<volume>173</volume>:<fpage>2176</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">28653806</pub-id></mixed-citation></ref><ref id="euac030-B435"><label>435</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hauser</surname>
<given-names>NS</given-names>
</string-name>, <string-name><surname>Solomon</surname><given-names>BD</given-names></string-name>, <string-name><surname>Vilboux</surname><given-names>T</given-names></string-name>, <string-name><surname>Khromykh</surname><given-names>A</given-names></string-name>, <string-name><surname>Baveja</surname><given-names>R</given-names></string-name>, <string-name><surname>Bodian</surname><given-names>DL.</given-names></string-name></person-group>
<article-title>Experience with genomic sequencing in pediatric patients with congenital cardiac defects in a large community hospital</article-title>. <source>Mol Genet Genomic Med</source><year>2018</year>;<volume>6</volume>:<fpage>200</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">29368431</pub-id></mixed-citation></ref><ref id="euac030-B436"><label>436</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brunelli</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Jenkins</surname><given-names>SM</given-names></string-name>, <string-name><surname>Gudgeon</surname><given-names>JM</given-names></string-name>, <string-name><surname>Bleyl</surname><given-names>SB</given-names></string-name>, <string-name><surname>Miller</surname><given-names>CE</given-names></string-name>, <string-name><surname>Tvrdik</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group>
<article-title>Targeted gene panel sequencing for the rapid diagnosis of acutely ill infants</article-title>. <source>Mol Genet Genomic Med</source><year>2019</year>;<volume>7</volume>:<fpage>e00796</fpage>.<pub-id pub-id-type="pmid">31192527</pub-id></mixed-citation></ref><ref id="euac030-B437"><label>437</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Thienpont</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Mertens</surname><given-names>L</given-names></string-name>, <string-name><surname>de Ravel</surname><given-names>T</given-names></string-name>, <string-name><surname>Eyskens</surname><given-names>B</given-names></string-name>, <string-name><surname>Boshoff</surname><given-names>D</given-names></string-name>, <string-name><surname>Maas</surname><given-names>N</given-names></string-name><etal>et al</etal></person-group>
<article-title>Submicroscopic chromosomal imbalances detected by array-CGH are a frequent cause of congenital heart defects in selected patients</article-title>. <source>Eur Heart J</source><year>2007</year>;<volume>28</volume>:<fpage>2778</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">17384091</pub-id></mixed-citation></ref><ref id="euac030-B438"><label>438</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jin</surname>
<given-names>SC</given-names>
</string-name>, <string-name><surname>Homsy</surname><given-names>J</given-names></string-name>, <string-name><surname>Zaidi</surname><given-names>S</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Morton</surname><given-names>S</given-names></string-name>, <string-name><surname>DePalma</surname><given-names>SR</given-names></string-name><etal>et al</etal></person-group>
<article-title>Contribution of rare inherited and <italic toggle="yes">de novo</italic> variants in 2,871 congenital heart disease probands</article-title>. <source>Nat Genet</source><year>2017</year>;<volume>49</volume>:<fpage>1593</fpage>&#x02013;<lpage>601</lpage>.<pub-id pub-id-type="pmid">28991257</pub-id></mixed-citation></ref><ref id="euac030-B439"><label>439</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Homsy</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Zaidi</surname><given-names>S</given-names></string-name>, <string-name><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ware</surname><given-names>JS</given-names></string-name>, <string-name><surname>Samocha</surname><given-names>KE</given-names></string-name>, <string-name><surname>Karczewski</surname><given-names>KJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>
<italic toggle="yes">De novo</italic> mutations in congenital heart disease with neurodevelopmental and other congenital anomalies</article-title>. <source>Science</source><year>2015</year>;<volume>350</volume>:<fpage>1262</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">26785492</pub-id></mixed-citation></ref><ref id="euac030-B440"><label>440</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sifrim</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Hitz</surname><given-names>MP</given-names></string-name>, <string-name><surname>Wilsdon</surname><given-names>A</given-names></string-name>, <string-name><surname>Breckpot</surname><given-names>J</given-names></string-name>, <string-name><surname>Turki</surname><given-names>SH</given-names></string-name>, <string-name><surname>Thienpont</surname><given-names>B</given-names></string-name><etal>et al</etal>; <collab>Deciphering Developmental Disorders Study</collab></person-group>. <article-title>Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing</article-title>. <source>Nat Genet</source><year>2016</year>;<volume>48</volume>:<fpage>1060</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">27479907</pub-id></mixed-citation></ref><ref id="euac030-B441"><label>441</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Alankarage</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Ip</surname><given-names>E</given-names></string-name>, <string-name><surname>Szot</surname><given-names>JO</given-names></string-name>, <string-name><surname>Munro</surname><given-names>J</given-names></string-name>, <string-name><surname>Blue</surname><given-names>GM</given-names></string-name>, <string-name><surname>Harrison</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group>
<article-title>Identification of clinically actionable variants from genome sequencing of families with congenital heart disease</article-title>. <source>Genet Med</source><year>2019</year>;<volume>21</volume>:<fpage>1111</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">30293987</pub-id></mixed-citation></ref><ref id="euac030-B442"><label>442</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jia</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Louw</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Breckpot</surname><given-names>J</given-names></string-name>, <string-name><surname>Callewaert</surname><given-names>B</given-names></string-name>, <string-name><surname>Barrea</surname><given-names>C</given-names></string-name>, <string-name><surname>Sznajer</surname><given-names>Y</given-names></string-name><etal>et al</etal></person-group>
<article-title>The diagnostic value of next generation sequencing in familial nonsyndromic congenital heart defects</article-title>. <source>Am J Med Genet A</source><year>2015</year>;<volume>167a</volume>:<fpage>1822</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25931334</pub-id></mixed-citation></ref><ref id="euac030-B443"><label>443</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Blue</surname>
<given-names>GM</given-names>
</string-name>, <string-name><surname>Kirk</surname><given-names>EP</given-names></string-name>, <string-name><surname>Giannoulatou</surname><given-names>E</given-names></string-name>, <string-name><surname>Dunwoodie</surname><given-names>SL</given-names></string-name>, <string-name><surname>Ho</surname><given-names>JW</given-names></string-name>, <string-name><surname>Hilton</surname><given-names>DC</given-names></string-name><etal>et al</etal></person-group>
<article-title>Targeted next-generation sequencing identifies pathogenic variants in familial congenital heart disease</article-title>. <source>J Am Coll Cardiol</source><year>2014</year>;<volume>64</volume>:<fpage>2498</fpage>&#x02013;<lpage>506</lpage>.<pub-id pub-id-type="pmid">25500235</pub-id></mixed-citation></ref><ref id="euac030-B444"><label>444</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>LaHaye</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Corsmeier</surname><given-names>D</given-names></string-name>, <string-name><surname>Basu</surname><given-names>M</given-names></string-name>, <string-name><surname>Bowman</surname><given-names>JL</given-names></string-name>, <string-name><surname>Fitzgerald-Butt</surname><given-names>S</given-names></string-name>, <string-name><surname>Zender</surname><given-names>G</given-names></string-name><etal>et al</etal></person-group>
<article-title>Utilization of whole exome sequencing to identify causative mutations in familial congenital heart disease</article-title>. <source>Circ Cardiovasc Genet</source><year>2016</year>;<volume>9</volume>:<fpage>320</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27418595</pub-id></mixed-citation></ref><ref id="euac030-B445"><label>445</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Breckpot</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Thienpont</surname><given-names>B</given-names></string-name>, <string-name><surname>Arens</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tranchevent</surname><given-names>LC</given-names></string-name>, <string-name><surname>Vermeesch</surname><given-names>JR</given-names></string-name>, <string-name><surname>Moreau</surname><given-names>Y</given-names></string-name><etal>et al</etal></person-group>
<article-title>Challenges of interpreting copy number variation in syndromic and non-syndromic congenital heart defects</article-title>. <source>Cytogenet Genome Res</source><year>2011</year>;<volume>135</volume>:<fpage>251</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21921585</pub-id></mixed-citation></ref><ref id="euac030-B446"><label>446</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Giguet-Valard</surname><given-names>AG</given-names></string-name>, <string-name><surname>Simonet</surname><given-names>T</given-names></string-name>, <string-name><surname>Szenker-Ravi</surname><given-names>E</given-names></string-name>, <string-name><surname>Lambert</surname><given-names>L</given-names></string-name>, <string-name><surname>Vincent-Delorme</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Next-generation sequencing in a series of 80 fetuses with complex cardiac malformations and/or heterotaxy</article-title>. <source>Hum Mutat</source><year>2020</year>;<volume>41</volume>:<fpage>2167</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">33131162</pub-id></mixed-citation></ref><ref id="euac030-B447"><label>447</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>AH</given-names>
</string-name>, <string-name><surname>Hanchard</surname><given-names>NA</given-names></string-name>, <string-name><surname>Azamian</surname><given-names>M</given-names></string-name>, <string-name><surname>D&#x02019;Alessandro</surname><given-names>LCA</given-names></string-name>, <string-name><surname>Coban-Akdemir</surname><given-names>Z</given-names></string-name>, <string-name><surname>Lopez</surname><given-names>KN</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic architecture of laterality defects revealed by whole exome sequencing</article-title>. <source>Eur J Hum Genet</source><year>2019</year>;<volume>27</volume>:<fpage>563</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">30622330</pub-id></mixed-citation></ref><ref id="euac030-B448"><label>448</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gileles-Hillel</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Mor-Shaked</surname><given-names>H</given-names></string-name>, <string-name><surname>Shoseyov</surname><given-names>D</given-names></string-name>, <string-name><surname>Reiter</surname><given-names>J</given-names></string-name>, <string-name><surname>Tsabari</surname><given-names>R</given-names></string-name>, <string-name><surname>Hevroni</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group>
<article-title>Whole-exome sequencing accuracy in the diagnosis of primary ciliary dyskinesia</article-title>. <source>ERJ Open Res</source><year>2020</year>;<volume>6</volume>:<fpage>00213</fpage>&#x02013;<lpage>2020</lpage>.<pub-id pub-id-type="pmid">33447612</pub-id></mixed-citation></ref><ref id="euac030-B449"><label>449</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Boskovski</surname>
<given-names>MT</given-names>
</string-name>, <string-name><surname>Homsy</surname><given-names>J</given-names></string-name>, <string-name><surname>Nathan</surname><given-names>M</given-names></string-name>, <string-name><surname>Sleeper</surname><given-names>LA</given-names></string-name>, <string-name><surname>Morton</surname><given-names>S</given-names></string-name>, <string-name><surname>Manheimer</surname><given-names>KB</given-names></string-name><etal>et al</etal></person-group>
<article-title>
<italic toggle="yes">De novo</italic> damaging variants, clinical phenotypes, and post-operative outcomes in congenital heart disease</article-title>. <source>Circ Genom Precis Med</source><year>2020</year>;<volume>13</volume>:<fpage>e002836</fpage>.<pub-id pub-id-type="pmid">32812804</pub-id></mixed-citation></ref><ref id="euac030-B450"><label>450</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Elles&#x000f8;e</surname>
<given-names>SG</given-names>
</string-name>, <string-name><surname>Johansen</surname><given-names>MM</given-names></string-name>, <string-name><surname>Bjerre</surname><given-names>JV</given-names></string-name>, <string-name><surname>Hjortdal</surname><given-names>VE</given-names></string-name>, <string-name><surname>Brunak</surname><given-names>S</given-names></string-name>, <string-name><surname>Larsen</surname><given-names>LA.</given-names></string-name></person-group>
<article-title>Familial atrial septal defect and sudden cardiac death: identification of a novel NKX2-5 mutation and a review of the literature</article-title>. <source>Congenit Heart Dis</source><year>2016</year>;<volume>11</volume>:<fpage>283</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">26679770</pub-id></mixed-citation></ref><ref id="euac030-B451"><label>451</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>QY</given-names>
</string-name>, <string-name><surname>Newbury-Ecob</surname><given-names>RA</given-names></string-name>, <string-name><surname>Terrett</surname><given-names>JA</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>DI</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>AR</given-names></string-name>, <string-name><surname>Yi</surname><given-names>CH</given-names></string-name><etal>et al</etal></person-group>
<article-title>Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family</article-title>. <source>Nat Genet</source><year>1997</year>;<volume>15</volume>:<fpage>21</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">8988164</pub-id></mixed-citation></ref><ref id="euac030-B452"><label>452</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Blue</surname>
<given-names>GM</given-names>
</string-name>, <string-name><surname>Smith</surname><given-names>J</given-names></string-name>, <string-name><surname>Sholler</surname><given-names>GF</given-names></string-name>, <string-name><surname>Semsarian</surname><given-names>C</given-names></string-name>, <string-name><surname>Winlaw</surname><given-names>DS</given-names></string-name>; <collab>Australian Genomics Cardiovascular Genetic Disorders Flagship</collab></person-group>. <article-title>Current practice of genetic testing and counselling in congenital heart disease: an Australian perspective</article-title>. <source>Heart Lung Circ</source><year>2020</year>;<volume>29</volume>:<fpage>1733</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">32868177</pub-id></mixed-citation></ref><ref id="euac030-B453"><label>453</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zhang</surname>
<given-names>TN</given-names>
</string-name>, <string-name><surname>Wu</surname><given-names>QJ</given-names></string-name>, <string-name><surname>Liu</surname><given-names>YS</given-names></string-name>, <string-name><surname>Lv</surname><given-names>JL</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name><surname>Chang</surname><given-names>Q</given-names></string-name><etal>et al</etal></person-group>
<article-title>Environmental risk factors and congenital heart disease: an umbrella review of 165 systematic reviews and meta-analyses with more than 120 million participants</article-title>. <source>Front Cardiovasc Med</source><year>2021</year>;<volume>8</volume>:<fpage>640729</fpage>.<pub-id pub-id-type="pmid">33791351</pub-id></mixed-citation></ref><ref id="euac030-B454"><label>454</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Geng</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Picker</surname><given-names>J</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Hisama</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group>
<article-title>Chromosome microarray testing for patients with congenital heart defects reveals novel disease causing loci and high diagnostic yield</article-title>. <source>BMC Genomics</source><year>2014</year>;<volume>15</volume>:<fpage>1127</fpage>.<pub-id pub-id-type="pmid">25516202</pub-id></mixed-citation></ref><ref id="euac030-B455"><label>455</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Szot</surname>
<given-names>JO</given-names>
</string-name>, <string-name><surname>Cuny</surname><given-names>H</given-names></string-name>, <string-name><surname>Blue</surname><given-names>GM</given-names></string-name>, <string-name><surname>Humphreys</surname><given-names>DT</given-names></string-name>, <string-name><surname>Ip</surname><given-names>E</given-names></string-name>, <string-name><surname>Harrison</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group>
<article-title>A screening approach to identify clinically actionable variants causing congenital heart disease in exome data</article-title>. <source>Circ Genom Precis Med</source><year>2018</year>;<volume>11</volume>:<fpage>e001978</fpage>.<pub-id pub-id-type="pmid">29555671</pub-id></mixed-citation></ref><ref id="euac030-B456"><label>456</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lander</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Ware</surname><given-names>SM.</given-names></string-name></person-group>
<article-title>Copy number variation in congenital heart defects</article-title>. <source>Curr Genet Med Rep</source><year>2014</year>;<volume>2</volume>:<fpage>168</fpage>&#x02013;<lpage>78</lpage>.</mixed-citation></ref><ref id="euac030-B457"><label>457</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Powis</surname>
<given-names>Z</given-names>
</string-name>, <string-name><surname>Thrush</surname><given-names>D</given-names></string-name>, <string-name><surname>Davis</surname><given-names>BT</given-names></string-name>, <string-name><surname>Dolinsky</surname><given-names>JS.</given-names></string-name></person-group>
<article-title>Diagnostic exome sequencing in pediatric patients with congenital heart disease</article-title>. <source>J Am Coll Cardiol</source><year>2016</year>;<volume>67</volume>:<fpage>991</fpage><pub-id pub-id-type="pmid">26916490</pub-id></mixed-citation></ref><ref id="euac030-B458"><label>458</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Morrish</surname>
<given-names>AM</given-names>
</string-name>, <string-name><surname>Smith</surname><given-names>J</given-names></string-name>, <string-name><surname>Enriquez</surname><given-names>A</given-names></string-name>, <string-name><surname>Sholler</surname><given-names>GF</given-names></string-name>, <string-name><surname>Mervis</surname><given-names>J</given-names></string-name>, <string-name><surname>Dunwoodie</surname><given-names>SL</given-names></string-name><etal>et al</etal></person-group>
<article-title>A new era of genetic testing in congenital heart disease: a review</article-title>. <source>Trends Cardiovasc Med</source><year>2021</year>;doi: 10.1016/j.tcm2021.04.011.</mixed-citation></ref><ref id="euac030-B459"><label>459</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Richardson</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Ormond</surname><given-names>KE.</given-names></string-name></person-group>
<article-title>Ethical considerations in prenatal testing: genomic testing and medical uncertainty</article-title>. <source>Semin Fetal Neonatal Med</source><year>2018</year>;<volume>23</volume>:<fpage>1</fpage><lpage>61</lpage>.<pub-id pub-id-type="pmid">29033309</pub-id></mixed-citation></ref><ref id="euac030-B460"><label>460</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Iwarsson</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Jacobsson</surname><given-names>B</given-names></string-name>, <string-name><surname>Dagerhamn</surname><given-names>J</given-names></string-name>, <string-name><surname>Davidson</surname><given-names>T</given-names></string-name>, <string-name><surname>Bernab&#x000e9;</surname><given-names>E</given-names></string-name>, <string-name><surname>Heibert Arnlind</surname><given-names>M.</given-names></string-name></person-group>
<article-title>Analysis of cell-free fetal DNA in maternal blood for detection of trisomy 21, 18 and 13 in a general pregnant population and in a high risk population&#x02014;a systematic review and meta-analysis</article-title>. <source>Acta Obstet Gynecol Scand</source><year>2017</year>;<volume>96</volume>:<fpage>7</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">27779757</pub-id></mixed-citation></ref><ref id="euac030-B461"><label>461</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kagan</surname>
<given-names>KO</given-names>
</string-name>, <string-name><surname>Sroka</surname><given-names>F</given-names></string-name>, <string-name><surname>Sonek</surname><given-names>J</given-names></string-name>, <string-name><surname>Abele</surname><given-names>H</given-names></string-name>, <string-name><surname>L&#x000fc;thgens</surname><given-names>K</given-names></string-name>, <string-name><surname>Schmid</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group>
<article-title>First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial</article-title>. <source>Ultrasound Obstet Gynecol</source><year>2018</year>;<volume>51</volume>:<fpage>437</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">28925570</pub-id></mixed-citation></ref><ref id="euac030-B462"><label>462</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Migliorini</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Saccone</surname><given-names>G</given-names></string-name>, <string-name><surname>Silvestro</surname><given-names>F</given-names></string-name>, <string-name><surname>Massaro</surname><given-names>G</given-names></string-name>, <string-name><surname>Arduino</surname><given-names>B</given-names></string-name>, <string-name><surname>D'Alessandro</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group>
<article-title>First-trimester screening based on cell-free DNA vs combined screening: a randomized clinical trial on women's experience</article-title>. <source>Prenat Diagn</source><year>2020</year>;<volume>40</volume>:<fpage>1482</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32683755</pub-id></mixed-citation></ref><ref id="euac030-B463"><label>463</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Russell</surname>
<given-names>MW</given-names>
</string-name>, <string-name><surname>Chung</surname><given-names>WK</given-names></string-name>, <string-name><surname>Kaltman</surname><given-names>JR</given-names></string-name>, <string-name><surname>Miller</surname><given-names>TA.</given-names></string-name></person-group>
<article-title>Advances in the understanding of the genetic determinants of congenital heart disease and their impact on clinical outcomes</article-title>. <source>JAHA</source><year>2018</year>;<volume>7</volume>:<fpage>e006906</fpage>.<pub-id pub-id-type="pmid">29523523</pub-id></mixed-citation></ref><ref id="euac030-B464"><label>464</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zaidi</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Brueckner</surname><given-names>M.</given-names></string-name></person-group>
<article-title>Genetics and genomics of congenital heart disease</article-title>. <source>Circ Res</source><year>2017</year>;<volume>120</volume>:<fpage>923</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">28302740</pub-id></mixed-citation></ref><ref id="euac030-B465"><label>465</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hureaux</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Guterman</surname><given-names>S</given-names></string-name>, <string-name><surname>Herv&#x000e9;</surname><given-names>B</given-names></string-name>, <string-name><surname>Till</surname><given-names>M</given-names></string-name>, <string-name><surname>Jaillard</surname><given-names>S</given-names></string-name>, <string-name><surname>Redon</surname><given-names>S</given-names></string-name><etal>et al</etal></person-group>
<article-title>Chromosomal microarray analysis in fetuses with an isolated congenital heart defect: A retrospective, nationwide, multicenter study in France</article-title>. <source>Prenat Diagn</source><year>2019</year>;<volume>39</volume>:<fpage>464</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">30896039</pub-id></mixed-citation></ref><ref id="euac030-B466"><label>466</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>van Nisselrooij</surname>
<given-names>AEL</given-names>
</string-name>, <string-name><surname>Lugthart</surname><given-names>MA</given-names></string-name>, <string-name><surname>Clur</surname><given-names>SA</given-names></string-name>, <string-name><surname>Linskens</surname><given-names>IH</given-names></string-name>, <string-name><surname>Pajkrt</surname><given-names>E</given-names></string-name>, <string-name><surname>Rammeloo</surname><given-names>LA</given-names></string-name><etal>et al</etal></person-group>
<article-title>The prevalence of genetic diagnoses in fetuses with severe congenital heart defects</article-title>. <source>Genet Med</source><year>2020</year>;<volume>22</volume>:<fpage>1206</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">32341573</pub-id></mixed-citation></ref><ref id="euac030-B467"><label>467</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Landstrom</surname>
<given-names>AP</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Gelb</surname><given-names>BD</given-names></string-name>, <string-name><surname>Helm</surname><given-names>BM</given-names></string-name>, <string-name><surname>Kannankeril</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Semsarian</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic testing for heritable cardiovascular diseases in pediatric patients: a scientific statement from the American Heart Association</article-title>. <source>Circ Genom Precis Med</source><year>2021</year>;<volume>14</volume>:<fpage>e000086</fpage>.<pub-id pub-id-type="pmid">34412507</pub-id></mixed-citation></ref><ref id="euac030-B468"><label>468</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Goldstein</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Brown</surname><given-names>MS.</given-names></string-name></person-group>
<article-title>A century of cholesterol and coronaries: from plaques to genes to statins</article-title>. <source>Cell</source><year>2015</year>;<volume>161</volume>:<fpage>161</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">25815993</pub-id></mixed-citation></ref><ref id="euac030-B469"><label>469</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kathiresan</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Melander</surname><given-names>O</given-names></string-name>, <string-name><surname>Anevski</surname><given-names>D</given-names></string-name>, <string-name><surname>Guiducci</surname><given-names>C</given-names></string-name>, <string-name><surname>Burtt</surname><given-names>NP</given-names></string-name>, <string-name><surname>Roos</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group>
<article-title>Polymorphisms associated with cholesterol and risk of cardiovascular events</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>358</volume>:<fpage>1240</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18354102</pub-id></mixed-citation></ref><ref id="euac030-B470"><label>470</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Myocardial Infarction Genetics</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Kathiresan</surname><given-names>S</given-names></string-name>, <string-name><surname>Voight</surname><given-names>BF</given-names></string-name>, <string-name><surname>Purcell</surname><given-names>S</given-names></string-name>, <string-name><surname>Musunuru</surname><given-names>K</given-names></string-name>, <string-name><surname>Ardissino</surname><given-names>D</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants</article-title>. <source>Nat Genet</source><year>2009</year>;<volume>41</volume>:<fpage>334</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">19198609</pub-id></mixed-citation></ref><ref id="euac030-B471"><label>471</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jaiswal</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Natarajan</surname><given-names>P</given-names></string-name>, <string-name><surname>Silver</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Bick</surname><given-names>AG</given-names></string-name>, <string-name><surname>Shvartz</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group>
<article-title>Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease</article-title>. <source>N Engl J Med</source><year>2017</year>;<volume>377</volume>:<fpage>111</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">28636844</pub-id></mixed-citation></ref><ref id="euac030-B472"><label>472</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Inouye</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Abraham</surname><given-names>G</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>CP</given-names></string-name>, <string-name><surname>Wood</surname><given-names>AM</given-names></string-name>, <string-name><surname>Sweeting</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Dudbridge</surname><given-names>F</given-names></string-name><etal>et al</etal>; <collab>UK Biobank CardioMetabolic Consortium CHD Working Group</collab></person-group>. <article-title>Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>;<volume>72</volume>:<fpage>1883</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">30309464</pub-id></mixed-citation></ref><ref id="euac030-B473"><label>473</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mosley</surname>
<given-names>JD</given-names>
</string-name>, <string-name><surname>Gupta</surname><given-names>DK</given-names></string-name>, <string-name><surname>Tan</surname><given-names>J</given-names></string-name>, <string-name><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name><surname>Wells</surname><given-names>QS</given-names></string-name>, <string-name><surname>Shaffer</surname><given-names>CM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Predictive accuracy of a polygenic risk score compared with a clinical risk score for incident coronary heart disease</article-title>. <source>JAMA</source><year>2020</year>;<volume>323</volume>:<fpage>627</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">32068817</pub-id></mixed-citation></ref><ref id="euac030-B474"><label>474</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Elliott</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Bodinier</surname><given-names>B</given-names></string-name>, <string-name><surname>Bond</surname><given-names>TA</given-names></string-name>, <string-name><surname>Chadeau-Hyam</surname><given-names>M</given-names></string-name>, <string-name><surname>Evangelou</surname><given-names>E</given-names></string-name>, <string-name><surname>Moons</surname><given-names>KGM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Predictive accuracy of a polygenic risk score-enhanced prediction model vs a clinical risk score for coronary artery disease</article-title>. <source>JAMA</source><year>2020</year>;<volume>323</volume>:<fpage>636</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">32068818</pub-id></mixed-citation></ref><ref id="euac030-B475"><label>475</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mega</surname>
<given-names>JL</given-names>
</string-name>, <string-name><surname>Stitziel</surname><given-names>NO</given-names></string-name>, <string-name><surname>Smith</surname><given-names>JG</given-names></string-name>, <string-name><surname>Chasman</surname><given-names>DI</given-names></string-name>, <string-name><surname>Caulfield</surname><given-names>M</given-names></string-name>, <string-name><surname>Devlin</surname><given-names>JJ</given-names></string-name><etal>et al</etal></person-group>
<article-title>Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials</article-title>. <source>Lancet</source><year>2015</year>;<volume>385</volume>:<fpage>2264</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">25748612</pub-id></mixed-citation></ref><ref id="euac030-B476"><label>476</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bongianino</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Priori</surname><given-names>SG.</given-names></string-name></person-group>
<article-title>Gene therapy to treat cardiac arrhythmias</article-title>. <source>Nat Rev Cardiol</source><year>2015</year>;<volume>12</volume>:<fpage>531</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">25917154</pub-id></mixed-citation></ref><ref id="euac030-B477"><label>477</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Matsa</surname>
<given-names>LS</given-names>
</string-name>, <string-name><surname>Sagurthi</surname><given-names>SR</given-names></string-name>, <string-name><surname>Ananthapur</surname><given-names>V</given-names></string-name>, <string-name><surname>Nalla</surname><given-names>S</given-names></string-name>, <string-name><surname>Nallari</surname><given-names>P.</given-names></string-name></person-group>
<article-title>Endothelin 1 gene as a modifier in dilated cardiomyopathy</article-title>. <source>Gene</source><year>2014</year>;<volume>548</volume>:<fpage>256</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">25042451</pub-id></mixed-citation></ref><ref id="euac030-B478"><label>478</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jiang</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Wakimoto</surname><given-names>H</given-names></string-name>, <string-name><surname>Seidman</surname><given-names>JG</given-names></string-name>, <string-name><surname>Seidman</surname><given-names>CE.</given-names></string-name></person-group>
<article-title>Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy</article-title>. <source>Science</source><year>2013</year>;<volume>342</volume>:<fpage>111</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">24092743</pub-id></mixed-citation></ref><ref id="euac030-B479"><label>479</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Anzalone</surname>
<given-names>AV</given-names>
</string-name>, <string-name><surname>Koblan</surname><given-names>LW</given-names></string-name>, <string-name><surname>Liu</surname><given-names>DR.</given-names></string-name></person-group>
<article-title>Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors</article-title>. <source>Nat Biotechnol</source><year>2020</year>;<volume>38</volume>:<fpage>824</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">32572269</pub-id></mixed-citation></ref><ref id="euac030-B480"><label>480</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dotzler</surname>
<given-names>SM</given-names>
</string-name>, <string-name><surname>Kim</surname><given-names>CSJ</given-names></string-name>, <string-name><surname>Gendron</surname><given-names>WAC</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name><surname>Ye</surname><given-names>D</given-names></string-name>, <string-name><surname>Bos</surname><given-names>JM</given-names></string-name><etal>et al</etal></person-group>
<article-title>Suppression-replacement KCNQ1 gene therapy for type 1 long QT syndrome</article-title>. <source>Circulation</source><year>2021</year>;<volume>143</volume>:<fpage>1411</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">33504163</pub-id></mixed-citation></ref></ref-list></back></article>
